<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002047" GROUP_ID="MUSKEL" ID="307799121011143421" MERGED_FROM="" MODIFIED="2010-06-17 05:40:29 +0200" MODIFIED_BY="Elizabeth Tanjong Ghogomu" REVIEW_NO="C048-R" REVMAN_SUB_VERSION="5.0.24" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.2">
<COVER_SHEET MODIFIED="2010-06-16 23:35:37 -0400" MODIFIED_BY="[Empty name]">
<TITLE>Leflunomide for the treatment of rheumatoid arthritis</TITLE>
<CONTACT>
<PERSON ID="14977" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Manathip</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Osiri</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Professor, Division of Rheumatology</POSITION>
<EMAIL_1>Manathip.O@chula.ac.th</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medicine</DEPARTMENT>
<ORGANISATION>Faculty of Medicine</ORGANISATION>
<ADDRESS_1>Chulalongkorn University</ADDRESS_1>
<ADDRESS_2>1873 Rama IV Road, Pathumwan</ADDRESS_2>
<CITY>Bangkok</CITY>
<ZIP>10330</ZIP>
<REGION/>
<COUNTRY CODE="TH">Thailand</COUNTRY>
<PHONE_1>+662-256-4526 ext: 14</PHONE_1>
<PHONE_2/>
<FAX_1>+662-252-8467</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2010-06-16 23:18:11 -0400" MODIFIED_BY="Elizabeth Tanjong Ghogomu">
<PERSON ID="14977" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Manathip</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Osiri</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Professor, Division of Rheumatology</POSITION>
<EMAIL_1>Manathip.O@chula.ac.th</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medicine</DEPARTMENT>
<ORGANISATION>Faculty of Medicine</ORGANISATION>
<ADDRESS_1>Chulalongkorn University</ADDRESS_1>
<ADDRESS_2>1873 Rama IV Road, Pathumwan</ADDRESS_2>
<CITY>Bangkok</CITY>
<ZIP>10330</ZIP>
<REGION/>
<COUNTRY CODE="TH">Thailand</COUNTRY>
<PHONE_1>+662-256-4526 ext: 14</PHONE_1>
<PHONE_2/>
<FAX_1>+662-252-8467</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5440" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Beverley</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Shea</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>bevshea@uottawa.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute of Population Health</DEPARTMENT>
<ORGANISATION>University of Ottawa</ORGANISATION>
<ADDRESS_1>1 Stewart St.</ADDRESS_1>
<ADDRESS_2>Room 312</ADDRESS_2>
<CITY>Ottawa</CITY>
<ZIP>K1N 6N5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 562 5800 ext: 8571</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13312" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Vivian</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Welch</LAST_NAME>
<SUFFIX/>
<POSITION>Research Associate</POSITION>
<EMAIL_1>vivian.welch@uottawa.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre for Global Health, Institute of Population Health</DEPARTMENT>
<ORGANISATION>University of Ottawa</ORGANISATION>
<ADDRESS_1>1 Stewart Street, Room 206</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1N 6N5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 562-5800 ext: 2921</PHONE_1>
<PHONE_2/>
<FAX_1>+1 613 562-5659</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="15002" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Maria</FIRST_NAME>
<MIDDLE_INITIALS>E</MIDDLE_INITIALS>
<LAST_NAME>Suarez-Almazor</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>msalmazor@mdanderson.org</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>General Internal Medicine, Ambulatory Treatment and Emergency Care</DEPARTMENT>
<ORGANISATION>The University of Texas, M.D. Anderson Cancer Center</ORGANISATION>
<ADDRESS_1>1515 Holcombe Blvd</ADDRESS_1>
<ADDRESS_2>Unit 1465</ADDRESS_2>
<CITY>Houston</CITY>
<ZIP>77030</ZIP>
<REGION>Texas</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>1 713 745 4516</PHONE_1>
<PHONE_2/>
<FAX_1>1 713 563 4491</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7073" ROLE="AUTHOR">
<PREFIX>Dr.</PREFIX>
<FIRST_NAME>Vibeke</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Strand</LAST_NAME>
<SUFFIX/>
<POSITION>Professor</POSITION>
<EMAIL_1>vstrand@aol.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Immunology</DEPARTMENT>
<ORGANISATION>Stanford University</ORGANISATION>
<ADDRESS_1>306 Ramona Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Portola Valley</CITY>
<ZIP>94028</ZIP>
<REGION>California</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>650-529-0150</PHONE_1>
<PHONE_2/>
<FAX_1>650-529-0225</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5474" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Peter</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Tugwell</LAST_NAME>
<SUFFIX/>
<POSITION>Director</POSITION>
<EMAIL_1>elacasse@uottawa.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre for Global Health, Institute of Population Health, Department of Medicine</DEPARTMENT>
<ORGANISATION>Ottawa Hospital</ORGANISATION>
<ADDRESS_1>1 Stewart Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1N 6N5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>613-562-5800 ext: 1945</PHONE_1>
<PHONE_2/>
<FAX_1>613-562-5659</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12662" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>George</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Wells</LAST_NAME>
<SUFFIX>PhD, MSc</SUFFIX>
<POSITION>Director</POSITION>
<EMAIL_1>gawells@ottawaheart.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cardiovascular Research Reference Centre</DEPARTMENT>
<ORGANISATION>University of Ottawa Heart Institute</ORGANISATION>
<ADDRESS_1>Room H1-1</ADDRESS_1>
<ADDRESS_2>40 Ruskin Street</ADDRESS_2>
<CITY>Ottawa</CITY>
<ZIP>K1Y 4W7</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 798 5555 x18640</PHONE_1>
<PHONE_2>+1 613 798 5555 x18642</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2009-07-22 12:44:57 -0400" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="20" MONTH="7" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="30" MONTH="6" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="7" MONTH="10" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2003"/>
</DATES>
<WHATS_NEW MODIFIED="2010-06-16 23:35:37 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-05-15 10:34:31 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>CMSG ID C048-R</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-06-16 23:32:48 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-06-16 23:32:48 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="7" YEAR="2009"/>
<DESCRIPTION>
<P>New search with 27 new studies.</P>
<P>Conclusions not changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-07-22 12:42:21 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Department of Medicine, Ottawa General Hospital and the University of Ottawa</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>The Arthritis Society of Canada (Metro A. Ogryzlo Fellowship)</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Faculty of Medicine, Chulalongkorn University, Bangkok</NAME>
<COUNTRY CODE="TH">Thailand</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-06-16 23:31:42 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2009-08-11 20:42:01 -0400" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-05-15 10:37:01 -0400" MODIFIED_BY="[Empty name]">Leflunomide for the treatment of rheumatoid arthritis</TITLE>
<SUMMARY_BODY MODIFIED="2009-08-11 20:42:01 -0400" MODIFIED_BY="[Empty name]">
<P>This summary of a Cochrane review presents what we know from research about the effect of Leflunomide on rheumatoid arthritis. The review shows that in people with rheumatoid arthritis:</P>
<P>- Leflunomide probably improves pain.</P>
<P>-Leflunomide improves number of tender or swollen joints and other outcomes such as pain and disability. <BR/>- Leflunomide causes side effects such as diarrhea, upset stomach, elevated liver function tests, and allergic reactions.  We often do not have precise information about side effects and complications. This is particularly true for rare but serious side effects.</P>
<P>
<B>What is rheumatoid arthritis and what is Leflunomide?</B>
<BR/>When you have rheumatoid arthritis, your immune system, which normally fights infection, becomes over-active and attacks the lining of your joints. This makes your joints swollen, stiff and painful. The small joints of your hands and feet are usually affected first. There is no cure for rheumatoid arthritis at present, so the treatments aim to relieve pain and stiffness and improve your ability to move. </P>
<P>Leflunomide is a disease-modifying antirheumatic drug (DMARD). It works by stabilizing the over-active cells in the immune system that cause inflammation in the joints.  Reducing the inflammation can prevent damage to the joints.  Leflunomide is taken in pill form.  It costs more than other DMARDs, so doctors usually prescribe it if other DMARDs haven&#8217;t worked well.</P>
<P> </P>
<P>
<B>Best estimate of what happens to people with rheumatoid arthritis who take Leflunomide after 6 months:</B>
</P>
<P>
<B>Pain (higher scores mean worse or more severe pain)</B>
</P>
<P>- People who took Leflunomide rated their pain to be10 points lower on a scale of 0 to 100 with Leflunomide (10% absolute improvement).  This may be due to chance.<BR/>- People who took Leflunomide rated their pain to be about 14 points lower on a scale of 0 to 100.<BR/>- People who took a placebo rated their pain to be about 4 points lower on a scale of 0 to 100. </P>
<P> </P>
<P>
<B>ACR 50</B> (number of tender or swollen joints and other outcomes such as pain and disability).</P>
<P>- 19 people out of 100 who took a placebo experienced improvement. (19% absolute improvement)</P>
<P>- 33 more people out of 100 experienced improvement in the symptoms of their rheumatoid arthritis with Leflunomide<BR/>- 14 people out of 100 experienced improvement in the symptoms of their rheumatoid arthritis with a placebo.<BR/>
<BR/>
</P>
<P>
<B>Side effects</B>
<BR/>- 10 more people who took Leflunomide dropped out from the trial because of side effects.  (10% absolute difference)</P>
<P>- 16 people out of 100 who took Leflunomide dropped out from the trial because of side effects</P>
<P>- 6 people out of 100 who used a placebo dropped out from the trial because of side effects.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-08-08 22:56:39 -0400" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2009-08-08 22:43:49 -0400" MODIFIED_BY="[Empty name]">
<P>Rheumatoid arthritis (RA) is a chronic inflammatory joint disease. Leflunomide is one of the more recent oral agents, classified as a disease-modifying antirheumatic drug (DMARD). It has a different mechanism of action than other existing DMARDs.<BR/>
</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-01-04 03:04:08 -0500" MODIFIED_BY="[Empty name]">
<P>To determine the efficacy and toxicity of leflunomide (monotherapy or combined with another DMARD) compared to placebo or other DMARDs in the treatment of RA.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-08-03 22:01:32 -0400" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I>), MEDLINE, EMBASE, and Current Contents for trials (to June 2008). We also handsearched reference lists and consulted content experts.<BR/>
</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-07-22 11:44:33 -0400" MODIFIED_BY="[Empty name]">
<P>Two independent authors selected the trials that met predetermined inclusion criteria.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-08-03 22:02:32 -0400" MODIFIED_BY="[Empty name]">
<P>Two authors independently extracted data and assessed methodologic quality using standardized forms.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-08-08 22:56:39 -0400" MODIFIED_BY="[Empty name]">
<P>Thirty-three trials were included, compared with six trials in the first review. The trials compared the efficacy and safety of leflunomide monotherapy with placebo or another DMARD; leflunomide combined with another DMARD (biologic or non-biologic) with DMARD monotherapy; and for different dosages of leflunomide. The ACR20 improvement criteria, demonstrated a 28% absolute difference in improvement in favour of leflunomide compared to placebo. There was no difference in ACR20 response rate between patients treated with leflunomide and sulfasalazine (SSZ) or methotrexate (MTX), at six and 12 months. Other clinical and radiological outcomes were improved significantly in the leflunomide group compared to placebo but were not different from SSZ or MTX. The efficacy of leflunomide combined with MTX was superior to MTX alone. On the other hand, leflunomide plus SSZ was not better than SSZ alone. Half-dose or weekly administration of leflunomide was shown to be as efficacious as regular doses (20 mg/day).</P>
<P>Withdrawals due to adverse events were 10% greater with leflunomide than placebo. Important adverse events included gastrointestinal symptoms, elevated liver function tests, alopecia, allergic reactions and rashes, and infections. Overall, adverse events and withdrawals with leflunomide monotherapy were not significantly different from SSZ or MTX. However, adverse events were reported more frequently in leflunomide plus MTX than with MTX but withdrawal rates were not significantly different.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-08-03 22:30:22 -0400" MODIFIED_BY="[Empty name]">
<P>Leflunomide appears to improve all clinical outcomes and delay radiologic progression at both six and 12 months of treatment compared to placebo. Its efficacy and adverse events are comparable to MTX, SSZ, and cyclosporin A up to two years of treatment. Combined leflunomide and MTX was more efficacious than MTX alone up to three years of treatment and the adverse events did not increase. Different dosages of leflunomide were similar regarding their effectiveness and toxicity.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-06-16 23:31:42 -0400" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2009-08-11 22:05:22 -0400" MODIFIED_BY="[Empty name]">
<P>Rheumatoid arthritis (RA) is a chronic inflammatory joint disease that causes destruction of the joints. It affects around 1% of the population (<LINK REF="REF-Alarcon-1995" TYPE="REFERENCE">Alarcon 1995</LINK>). RA can cause progressive joint destruction and deformity despite treatment. Several medications, known as disease-modifying antirheumatic drugs (DMARDs), have been shown to decrease inflammation, delay bone erosion, and improve patients' health-related quality of life (HRQoL) (<LINK REF="REF-Wolfe-1991" TYPE="REFERENCE">Wolfe 1991</LINK>; <LINK REF="REF-Egsmose-1995" TYPE="REFERENCE">Egsmose 1995</LINK>; <LINK REF="REF-Fries-1996" TYPE="REFERENCE">Fries 1996</LINK>). DMARDs are more effective if administered within two years of disease occurrence (<LINK REF="REF-Egsmose-1995" TYPE="REFERENCE">Egsmose 1995</LINK>). However, not all RA patients benefit from treatment with DMARDs. A number of patients have progressive bone and joint damage although joint inflammation is well suppressed.</P>
<P>DMARDs may be classified into two groups, traditional DMARDs and biologic DMARDs. Traditional DMARDs contain a diverse group of chemical agents. They include methotrexate, antimalarial drugs (chloroquine and hydroxychloroquine), sulphasalazine, gold (injectable and oral forms), azathioprine, and d-penicillamine (<LINK REF="REF-Weinblatt-1999a" TYPE="REFERENCE">Weinblatt 1999a</LINK>). Newer DMARDs used include cyclosporin A, and leflunomide. These DMARDS may be prescribed either as a single agent or combined. Biologic DMARDs are the new class of DMARDs that act directly on specific mediators of the inflammatory processes in RA. This targeted treatment is more potent than traditional DMARDs and is increasingly prescribed in active RA. However, biologic DMARDs are not effective in all RA patients and may cause serious adverse events. The American College of Rheumatology (ACR) recommends the initiation of traditional DMARDs in all DMARD-naive patients with RA (<LINK REF="REF-Saag-2008" TYPE="REFERENCE">Saag 2008</LINK>).</P>
<P>Leflunomide has a different structure and mechanism of action from the other traditional DMARDs. Leflunomide is an isoxazol derivative and its active metabolite, A77 1726, acts as an inhibitor of pyrimidine synthesis (<LINK REF="REF-Fox-1998" TYPE="REFERENCE">Fox 1998</LINK>; <LINK REF="REF-Rozman-1998" TYPE="REFERENCE">Rozman 1998</LINK>; <LINK REF="REF-Furst-1999" TYPE="REFERENCE">Furst 1999</LINK>). Since pyrimidine is required for the proliferation of activated autoimmune T-lymphocytes, the reduction of pyrimidine synthesis will decrease these T-cells and hence the autoimmune response, which should result in clinical benefits for RA patients (<LINK REF="REF-Fox-1998" TYPE="REFERENCE">Fox 1998</LINK>; <LINK REF="REF-Furst-1999" TYPE="REFERENCE">Furst 1999</LINK>).</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-08-04 03:29:22 -0400" MODIFIED_BY="[Empty name]">
<P>To determine the efficacy and safety of leflunomide in the treatment of RA. The major endpoints included:<BR/>(1) improvement of clinical outcomes, defined by the ACR (<LINK REF="REF-Felson-1995" TYPE="REFERENCE">Felson 1995</LINK>) or the European League Against Rheumatism (EULAR) (<LINK REF="REF-van-der-Heijde-1993" TYPE="REFERENCE">van der Heijde 1993</LINK>; <LINK REF="REF-van-Gestel-1996" TYPE="REFERENCE">van Gestel 1996</LINK>);<BR/>(2) improvement of the patients' HRQoL;<BR/>(3) incidence of side effects.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-08-12 09:14:21 -0400" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2009-08-04 03:37:55 -0400" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2009-08-04 03:30:17 -0400" MODIFIED_BY="[Empty name]">
<P>All randomized controlled trials (RCTs) or controlled clinical trials (CCTs) comparing leflunomide as monotherapy or in combination with another DMARD to placebo or other DMARDs.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-08-04 03:31:34 -0400" MODIFIED_BY="[Empty name]">
<P>Only RCTs or CCTs with patients aged at least 18 years old and clinical diagnosis of RA according to the ACR 1987 revised criteria (<LINK REF="REF-Arnett-1988" TYPE="REFERENCE">Arnett 1988</LINK>) were included. These patients must have active disease as shown in the following outcomes:<BR/>1) number of tender joints;<BR/>2) number of swollen joints;<BR/>3) duration of morning stiffness;<BR/>4) acute phase reactants.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-08-04 03:33:58 -0400" MODIFIED_BY="[Empty name]">
<P>Studies comparing leflunomide treatment (as monotherapy or in combination with other DMARDs) at a dose of 20 to 25 mg/day (with or without a loading daily dose of 100 mg given in the first one to three days) with placebo or other DMARDs were included. The duration of treatment in the trials must have been at least three months (or 12 weeks).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-08-04 03:37:55 -0400" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-08-04 03:37:39 -0400" MODIFIED_BY="[Empty name]">
<P>Primary outcome measures were those defined as the ACR core set of disease activity measures for RA for clinical trials, which were endorsed by EULAR and the Outcome Measures in Rheumatology Clinical Trials (OMERACT) (<LINK REF="REF-Felson-1993" TYPE="REFERENCE">Felson 1993</LINK>; <LINK REF="REF-Felson-1995" TYPE="REFERENCE">Felson 1995</LINK>; <LINK REF="REF-Pincus-1999" TYPE="REFERENCE">Pincus 1999</LINK>). They included:<BR/>(1) number of tender joints;<BR/>(2) number of swollen joints;<BR/>(3) pain level;<BR/>(4) patient global assessment of disease activity;<BR/>(5) physician global assessment of disease activity;<BR/>(6) functional ability;<BR/>(7) acute phase reactants;<BR/>(8) radiographic change of bone and joint damage for trials of at least one year of duration.<BR/>In addition, the numbers of patients who fulfilled the ACR20, ACR50, and ACR 70 response criteria were included.</P>
<P>The EULAR response criteria are measured as the Disease Activity Score (DAS). If the 28-joint assessment method is used, it is called DAS28. The outcomes include mean change in the DAS28 score from baseline; number of patients with remission (DAS28 score &#8804; 2.6); number of patients with low disease activity (2.6 &lt; DAS28 &#8804; 3.2); number of patients with moderate disease activity (3.2 &lt; DAS28 &#8804; 5.1); number of patients with high disease activity (DAS28 &gt; 5.1); number of patients with good response, moderate response, and no response according to the EULAR response criteria (<LINK REF="REF-van-Gestel-1996" TYPE="REFERENCE">van Gestel 1996</LINK>).</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-08-04 03:37:55 -0400" MODIFIED_BY="[Empty name]">
<P>Secondary outcome measures included HRQoL of the patients, reported side effects, total number of patients withdrawn from the studies, and withdrawals due to adverse events.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-08-04 03:41:23 -0400" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library </I>Issue 4, 2008); MEDLINE, EMBASE, HEALTHSTAR (1966 to June 2008) and Current Contents. The search strategy was conducted as recommended by Haynes et al (<LINK REF="REF-Haynes-1994" TYPE="REFERENCE">Haynes 1994</LINK>) and modified for the Cochrane Musculoskeletal Group.</P>
<P>Reference lists were handsearched for further identification of published work and presentations at scientific meetings. Abstracts from the ACR, EULAR, and Asian Pacific League Against Rheumatism (APLAR) Annual Scientific Meetings were manually checked if the information was available. MeSH terms used in the database search included leflunomide, isoxazole, rheumatoid arthritis, and randomized controlled trial. Content experts were also contacted for unpublished data.</P>
<P>The search strategy used in the MEDLINE database is in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.<BR/>
</P>
<P>Our search included articles of all languages.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-08-12 09:14:21 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Data selection and extraction</B>
</P>
<P>All studies were assessed independently by two review authors (MO, BS) to select the trials that fulfilled the inclusion criteria. Differences were resolved by consensus.<BR/>From each selected trial, information regarding the trial design, characteristics of the study population, treatment regimen and duration, and baseline and end-of-study outcome measures was collected. These data were extracted by the same two review authors using standardized forms. Differences in data extraction were resolved by referring back to the original articles and establishing consensus. A third review author (MSA) was consulted to help resolve differences.</P>
<P>
<B>Assessment of risk of bias in included studies</B>
</P>
<P>Assessment of the trial methodological quality was performed using the recommendations from the Cochrane Musculoskeletal Group and a Delphi list (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>, <LINK REF="REF-Verhagen-1998" TYPE="REFERENCE">Verhagen 1998</LINK>). The following criteria were answered as: A (yes), B (not sure), or C (no).</P>
<P>1) Was the allocation concealment adequately generated?</P>
<P>2) Was the allocation sequence adequately concealed?</P>
<P>3) Was knowledge of the allocated interventions adequately prevented during the study?</P>
<P>4) Were incomplete outcome data adequately addressed?</P>
<P>5) Are reports of the study free of suggestions of selective outcome reporting?</P>
<P>6) Was the study apparently free of other problems that could put it at a high risk of bias?</P>
<P>The global quality level was estimated for each study according to the following criteria (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>):</P>
<P>Level A (low risk of bias): all of the individual criteria were met (all of them score A);</P>
<P>Level B (moderate risk of bias): one or more individual criteria partially met (one or more individual criteria scored B);</P>
<P>Level C (high risk of bias): one or more individual criteria not met (one or more criteria scored C).</P>
<P>The quality of the included studies was also assessed using a checklist developed by Jadad (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>) which included the appropriateness of randomization, appropriateness of blinding, and description of dropouts and withdrawals. Quality was assessed independently by two review authors (MO, BS). Differences were resolved by consensus. A third review author (MSA) was consulted, if necessary. Studies were divided into low and high quality, based on the median quality score, to examine the effect of quality on the outcome measures. The maximum score was 5. Studies with quality scores less than 3 were considered low quality studies, while those that scored 3 or higher were high quality studies.</P>
<P>The grading of evidence used in this systematic review and meta-analysis followed the recommendations by the Cochrane Musculoskeletal Group and appear in the Evidence-based Rheumatology book (<LINK REF="REF-Tugwell-2004" TYPE="REFERENCE">Tugwell 2004</LINK>). They are: Platinum, Gold, Silver, and Bronze.</P>
<P>
<B>Platinum level:</B> evidence from a published systematic review that has &#8805; two RCTs, each satisfying the following.</P>
<UL>
<LI>Sample size of &#8805; 50 per group. If no statistically significant difference is found, the sample size are adequately powered for a 20% relative difference in the relevant outcome.</LI>
<LI>Blinding of patients and assessors for outcomes.</LI>
<LI>Handling of withdrawals with &gt; 80% follow up (imputations based on methods such as the last observation carried forward (LOCF) were acceptable).</LI>
<LI>Concealment of treatment allocation.</LI>
</UL>
<P>
<B>Gold level:</B> Evidence from &#8805; one RCT that meets all of the following criteria for the major outcome(s):</P>
<UL>
<LI>Sample size of &#8805; 50 per group. If no statistically significant difference is found, the sample size are adequately powered for a 20% relative difference in the relevant outcome.</LI>
<LI>Blinding of patients and assessors for outcomes</LI>
<LI>Handling of withdrawals &gt;80% follow up (imputations based on methods such as LOCF acceptable)</LI>
<LI>Concealment of treatment allocation</LI>
</UL>
<P>
<B>Silver level:</B> evidence from a systematic review or RCT that does not meet the above criteria. Also includes evidence from &#8805; one non-randomized cohort study or &#8805; one case-control study. Evidence from an RCT with 'head-to-head' comparison of agents is considered Silver level ranking unless a reference is provided to a comparison of one of the agents to placebo showing &#8805; 20% relative difference.</P>
<P>
<B>Bronze level:</B> evidence from &#8805; one case series without controls (including simple before and after studies) or is derived from expert opinion based on clinical experience without reference to any of the foregoing.</P>
<P>In addition, the quality of evidence was assessed by the GRADE approach. The quality of a body of evidence in the GRADE approach is categorized into four levels: high (++++) for RCTs, or double-upgraded observational studies; moderate (+++) for downgraded RCTs, or upgraded observational studies; low (++) for double-downgraded RCTs or observational studies; and very low (+) for triple-downgraded RCTs or downgraded observational studies or case series and case reports (<LINK REF="REF-Sch_x00fc_nemann-2008" TYPE="REFERENCE">Schünemann 2008</LINK>).</P>
<P>
<B>Analysis</B>
<BR/>Data on the outcome measures from each trial were pooled to determine the overall estimate efficacy of leflunomide in RA therapy. Where possible, the analyses were based on the intention-to-treat data from individual trials. A sensitivity analysis was conducted to test the robustness of results based on the trial quality.<BR/>For continuous data, results were present as weighted mean differences (WMD). However, when different scales were used to measure the same outcome standardized mean differences (SMD) were used instead. For dichotomous data, relative risks (RR) were calculated. Homogeneity of the data was calculated using the Chi<SUP>2</SUP> test at n-1 degrees of freedom (n = number of study) with the significance level of P &lt; 0.05. Meta-analysis was conducted according to a fixed-effect model. Where heterogeneity existed, a random-effects model was used.</P>
<P>When necessary, the authors of the primary studies were contacted to obtained additional information.</P>
<P>
<B>Summary of Findings table</B>
</P>
<P>The Summary of Findings (SoF) table for this review presented the efficacy and toxicity outcomes. The efficacy outcome chosen in this SoF table was the ACR 50 response rate, as the ACR50 response represents a clinically relevant change of RA activity (<LINK REF="REF-Felson-1995" TYPE="REFERENCE">Felson 1995</LINK>). In studies that did not report the ACR50 response rate, the EULAR good response rate was used. The toxicity outcome chosen was the withdrawal rate due to treatment adverse events. Both the ACR 50 response rate (or EULAR good response rate) and withdrawals due to adverse events were presented as absolute risk differences and their 95% confidence intervals (CIs). The number needed to treat (NNT) and number needed to harm (NNH) with their 95% CIs were also calculated. Also presented in the SoF table were the different comparisons between leflunomide and comparators, levels of evidence quality, and number of participants and studies for each comparison.</P>
<P>
<B>Absolute and relative differences</B>
<BR/>The absolute and relative differences in changes from baseline of the OMERACT core outcomes are shown in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> (additional tables). The absolute difference was calculated as the difference from baseline in the original units of the outcome measured. The relative difference was calculated as a percentage of the baseline mean of all included trials. The baseline mean is shown in the table also. The 95% CIs of the absolute and relative difference were calculated using the pooled estimates. For tender and swollen joints at six months, standardized mean differences(SMD) were converted back to the original units by multiplying the pooled SMD by the standard deviation, in one study (<LINK REF="STD-Strand-1999a" TYPE="STUDY">Strand 1999a</LINK>).</P>
<P>The number needed to treat was calculated as the inverse of the pooled risk difference (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>).</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-06-16 23:31:42 -0400" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2009-08-04 05:03:42 -0400" MODIFIED_BY="[Empty name]">
<P>The search strategies retrieved 568 articles, of which 26 trials met the inclusion criteria. Handsearching for articles from the ACR, EULAR and APLAR scientific meeting abstract books (to 2008) identified 304 abstracts on leflunomide and RA. Of these, seven abstracts were included in this review. A total of 33 trials were then eligible for systematic review and meta-analysis.</P>
<P>Of these 33 trials, 19 were double-blind RCTs; 2 were single-blind RCTs; nine were open-label RCTs, and the other three were open-label non-randomized CCTs. One study was a phase II study comparing leflunomide at different daily doses (5, 10, 25 mg/day) with placebo (<LINK REF="STD-Mladenovic-1995" TYPE="STUDY">Mladenovic 1995</LINK>). Two phase III studies compared the efficacy of leflunomide with placebo and active control (three-arm studies); one active control was SSZ (<LINK REF="STD-Smolen-1999" TYPE="STUDY">Smolen 1999</LINK>) and the other was MTX (<LINK REF="STD-Strand-1999a" TYPE="STUDY">Strand 1999a</LINK>). Extension studies of both trials were also included in this review where the placebo arm of each trial was switched to active control (SSZ in <LINK REF="STD-Scott-2001" TYPE="STUDY">Scott 2001</LINK> and <LINK REF="STD-Kalden-2001" TYPE="STUDY">Kalden 2001</LINK>; and MTX in <LINK REF="STD-Cohen-2001" TYPE="STUDY">Cohen 2001</LINK>). Eleven trials were head-to-head comparisons between leflunomide and MTX (<LINK REF="STD-Emery-1999" TYPE="STUDY">Emery 1999</LINK>; <LINK REF="STD-Bao-2000" TYPE="STUDY">Bao 2000</LINK>; <LINK REF="STD-Cohen-2001" TYPE="STUDY">Cohen 2001</LINK>; <LINK REF="STD-Hu-2001" TYPE="STUDY">Hu 2001</LINK>; <LINK REF="STD-Jiang-2001" TYPE="STUDY">Jiang 2001</LINK>; <LINK REF="STD-Lao-2001" TYPE="STUDY">Lao 2001</LINK>; <LINK REF="STD-Lau-2002" TYPE="STUDY">Lau 2002</LINK>; <LINK REF="STD-Reece-2002" TYPE="STUDY">Reece 2002</LINK>; <LINK REF="STD-Shuai-2002" TYPE="STUDY">Shuai 2002</LINK>; <LINK REF="STD-Bao-2003" TYPE="STUDY">Bao 2003</LINK>; <LINK REF="STD-Fiehn-2007" TYPE="STUDY">Fiehn 2007</LINK>). Six of them were double-blind RCTs conducted in China (<LINK REF="STD-Bao-2000" TYPE="STUDY">Bao 2000</LINK>; <LINK REF="STD-Jiang-2001" TYPE="STUDY">Jiang 2001</LINK>; <LINK REF="STD-Lao-2001" TYPE="STUDY">Lao 2001</LINK>; <LINK REF="STD-Lau-2002" TYPE="STUDY">Lau 2002</LINK>; <LINK REF="STD-Shuai-2002" TYPE="STUDY">Shuai 2002</LINK>; <LINK REF="STD-Bao-2003" TYPE="STUDY">Bao 2003</LINK>). Three trials compared leflunomide with SSZ (<LINK REF="STD-Kalden-2001" TYPE="STUDY">Kalden 2001</LINK>; <LINK REF="STD-Larsen-2001" TYPE="STUDY">Larsen 2001</LINK>; <LINK REF="STD-Scott-2001" TYPE="STUDY">Scott 2001</LINK>). One three-arm study compared the efficacy and safety of leflunomide with cyclosporin A (CsA) and combined leflunomide and CsA (<LINK REF="STD-Karanikolas-2006" TYPE="STUDY">Karanikolas 2006</LINK>). Four studies compared combined leflunomide and MTX with MTX alone (<LINK REF="STD-Amit-2004" TYPE="STUDY">Amit 2004</LINK>; <LINK REF="STD-Kremer-2002" TYPE="STUDY">Kremer 2002</LINK>; <LINK REF="STD-Lao-2002" TYPE="STUDY">Lao 2002</LINK>; <LINK REF="STD-Amit-2006" TYPE="STUDY">Amit 2006</LINK>) and one trial compared a leflunomide and MTX combination with leflunomide alone (<LINK REF="STD-Antony-2006" TYPE="STUDY">Antony 2006</LINK>). The open-label extension trial of Kremer et al study (<LINK REF="STD-Kremer-2002" TYPE="STUDY">Kremer 2002</LINK>) compared the efficacy and adverse events of combined leflunomide and MTX with the placebo group switched to leflunomide and MTX (<LINK REF="STD-Kremer-2004" TYPE="STUDY">Kremer 2004</LINK>). The <LINK REF="STD-Dougados-2005" TYPE="STUDY">Dougados 2005</LINK> trial was a second-phase double-blind study comparing leflunomide and SSZ with SSZ alone in RA patients who had not responded to leflunomide in the first-phase, open-label study. The <LINK REF="STD-Gao-2004" TYPE="STUDY">Gao 2004</LINK> study was an open-label trial comparing a leflunomide and MTX combination with triple therapy (MTX+CQ+SSZ). Three studies compared the efficacy of different dosages of leflunomide (<LINK REF="STD-Rozman-1994a" TYPE="STUDY">Rozman 1994a</LINK>; <LINK REF="STD-Jakez_x002d_Ocampo-2002" TYPE="STUDY">Jakez-Ocampo 2002</LINK>; <LINK REF="STD-Poor-2004" TYPE="STUDY">Poor 2004</LINK>). Two studies compared leflunomide with anti-tumor necrosis factor agents (anti-TNF) (<LINK REF="STD-Mariette-2004" TYPE="STUDY">Mariette 2004</LINK>; <LINK REF="STD-Wislowska-2007" TYPE="STUDY">Wislowska 2007</LINK>). The <LINK REF="STD-Mariette-2004" TYPE="STUDY">Mariette 2004</LINK> trial was a large cohort study comparing single DMARD, combined DMARDs, adalimumab (ADA), and combined ADA with DMARD. The <LINK REF="STD-Wislowska-2007" TYPE="STUDY">Wislowska 2007</LINK> trial was an open-label, three-arm study that compared leflunomide with MTX and combined anti-TNF with MTX (etanercept and infliximab). With the exception of some Chinese trials, studies reported after the year 2001 were mostly open-label trials with small sample sizes.</P>
<P>Noticeably, several studies included in this review were based on the data from a single trial but outcomes were separately reported by different authors. Strand 1999(a) and Strand 1999(b) reported the data from one trial. The former selectively reported the outcomes in the core set of the ACR response criteria while the latter reported the data on functional ability and quality of life outcomes. <LINK REF="STD-Sharp-2000" TYPE="STUDY">Sharp 2000</LINK> reported the radiographic changes in the population from both Strand trials. This publication pattern was also observed in the extension study of the <LINK REF="STD-Smolen-1999" TYPE="STUDY">Smolen 1999</LINK> trial. Three studies (<LINK REF="STD-Kalden-2001" TYPE="STUDY">Kalden 2001</LINK>; <LINK REF="STD-Larsen-2001" TYPE="STUDY">Larsen 2001</LINK>; <LINK REF="STD-Scott-2001" TYPE="STUDY">Scott 2001</LINK>) reported the data from this extension study with different outcomes. Studies conducted by a group of authors were commonly reported at different time durations. This was evident in the trials by Amit et al (<LINK REF="STD-Amit-2004" TYPE="STUDY">Amit 2004</LINK>; <LINK REF="STD-Amit-2006" TYPE="STUDY">Amit 2006</LINK>), Bao et al (<LINK REF="STD-Bao-2000" TYPE="STUDY">Bao 2000</LINK>; <LINK REF="STD-Bao-2003" TYPE="STUDY">Bao 2003</LINK>), Strand et al (<LINK REF="STD-Strand-1999a" TYPE="STUDY">Strand 1999a</LINK>; <LINK REF="STD-Strand-1999b" TYPE="STUDY">Strand 1999b</LINK>; <LINK REF="STD-Cohen-2001" TYPE="STUDY">Cohen 2001</LINK>), Smolen et al (<LINK REF="STD-Smolen-1999" TYPE="STUDY">Smolen 1999</LINK>; <LINK REF="STD-Kalden-2001" TYPE="STUDY">Kalden 2001</LINK>; <LINK REF="STD-Larsen-2001" TYPE="STUDY">Larsen 2001</LINK>; <LINK REF="STD-Scott-2001" TYPE="STUDY">Scott 2001</LINK>), and Kremer et al (<LINK REF="STD-Kremer-2002" TYPE="STUDY">Kremer 2002</LINK>; <LINK REF="STD-Kremer-2004" TYPE="STUDY">Kremer 2004</LINK>). Thus, this meta-analysis stratified the comparison between leflunomide and comparators by outcomes at different lengths of treatment.</P>
<P>Twenty-four studies were excluded. Most of them were single-arm studies without control groups (<LINK REF="STD-Jevtic-1997" TYPE="STUDY">Jevtic 1997</LINK>; <LINK REF="STD-Mroczkowski-1999" TYPE="STUDY">Mroczkowski 1999</LINK>; <LINK REF="STD-Weinblatt-1999b" TYPE="STUDY">Weinblatt 1999b</LINK>; <LINK REF="STD-Dougados-2003" TYPE="STUDY">Dougados 2003</LINK>; <LINK REF="STD-Kalden-2003" TYPE="STUDY">Kalden 2003</LINK>; <LINK REF="STD-Kuzmanova-2003" TYPE="STUDY">Kuzmanova 2003</LINK>; <LINK REF="STD-Balabanova-2004" TYPE="STUDY">Balabanova 2004</LINK>; <LINK REF="STD-Godinho-2004" TYPE="STUDY">Godinho 2004</LINK>; <LINK REF="STD-Hansen-2004" TYPE="STUDY">Hansen 2004</LINK>; <LINK REF="STD-van-der-Heijde-2004" TYPE="STUDY">van der Heijde 2004</LINK>; <LINK REF="STD-van-Roon-2005" TYPE="STUDY">van Roon 2005</LINK>; <LINK REF="STD-Balabanova-2006" TYPE="STUDY">Balabanova 2006</LINK>; <LINK REF="STD-Litinsky-2006" TYPE="STUDY">Litinsky 2006</LINK>; <LINK REF="STD-Ju-2007" TYPE="STUDY">Ju 2007</LINK>; <LINK REF="STD-Sarunhan_x002d_Direskeneli-2007" TYPE="STUDY">Sarunhan-Direskeneli 2007</LINK>). Some studies were subsets of the included studies (<LINK REF="STD-Kraan-2004" TYPE="STUDY">Kraan 2004</LINK>; <LINK REF="STD-van-der-Kooij-2007" TYPE="STUDY">van der Kooij 2007</LINK>; <LINK REF="STD-Tchetverikov-2008" TYPE="STUDY">Tchetverikov 2008</LINK>) or the outcomes were not clinical-based (<LINK REF="STD-Kraan-2004" TYPE="STUDY">Kraan 2004</LINK>; <LINK REF="STD-Grijalva-2007" TYPE="STUDY">Grijalva 2007</LINK>; <LINK REF="STD-Richards-2007" TYPE="STUDY">Richards 2007</LINK>; <LINK REF="STD-Tchetverikov-2008" TYPE="STUDY">Tchetverikov 2008</LINK>).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-08-04 05:05:01 -0400" MODIFIED_BY="[Empty name]">
<P>From the 33 included studies, according to the global quality level described in the Methods of the review section no trial met level A, 20 trials met level B, and 13 trials met level C.</P>
<P>The median quality score of the included trials was 3. One study scored 0, five scored 1, seven scored 2, 12 scored 3, five scored 4, and three scored 5 using the Jadad score.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-06-16 23:31:42 -0400" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Efficacy of leflunomide compared to placebo</HEADING>
<P>
<I>ACR20, ACR50 and ACR70 response rates</I>
<BR/>RA patients in the leflunomide group were two times more likely to meet the ACR20 response criteria than placebo, at both 6 months (RR 0.51, 95% CI 0.42 to 0.62) and 12 months (RR 0.50, 95% CI 0.36 to 0.70). Similar findings were observed for the patients who met the ACR50 criteria at both 6 months (RR 0.43, 95% CI 0.25 to 0.76) and and 12 months (RR 0.22, 95% CI 0.12 to 0.43) and for the ACR70 at 12 months of treatment (RR 0.21, 95% CI 0.09 to 0.53).</P>
<P>
<I>Joint counts</I>
<BR/>A significant reduction in the number of tender joint count by 26% relative to baseline (SMD -0.57, 95% CI -0.72 to -0.42) was observed in leflunomide-treated patients at 6 months compared to those in the placebo group, and a 13% relative reduction in the number of swollen joint count (SMD -0.49, 95% CI -0.64 to -0.34). The results were similar in the comparison at 12 months with a 29% relative reduction in tender joint count (WMD -4.7 joints, 95% CI -6.59 to -2.81) and a 20% relative reduction in swollen joint count (WMD -8.6 joints, 95% CI -10.05 to -7.15).</P>
<P>
<I>Global assessments</I>
<BR/>Both patient global assessment of disease severity (SMD -0.64, 95% CI -0.79 to -0.49) and physician global assessment (SMD -0.67, 95% CI -0.82 to -0.52) improved significantly in the leflunomide group compared to placebo at 6 months. At 12 months, both patient global assessment in the leflunomide group compared to placebo (WMD -2.2 cm, 95% CI -2.84 to -1.56) and physician global assessment (WMD -1.8 cm, 95% CI -2.41 to -1.19) improved significantly. The relative difference in patient global assessment was 21% and 29% at 6 and 12 months, respectively.</P>
<P>
<I>Erythrocyte sedimentation rate (ESR)</I>
<BR/>ESR decreased significantly more in the leflunomide group than the placebo group, by 15% at 6 months (WMD -7.94 mm/hr, 95% CI -10.96 to -4.92) and by 24% at 12 months (WMD -8.9 mm/hr, 95% CI -13.68 to -4.12) of treatment.</P>
<P>
<I>C-reactive protein (CRP)</I>
<BR/>CRP also decreased significantly in the leflunomide group at both 6 months (WMD -1.24 mg/dl, 95% CI -1.68 to -0.79) and 12 months (WMD -1.09 mg/dl, 95% CI -1.62 to -0.56) of treatment.</P>
<P>
<I>Pain severity</I>
<BR/>Pain severity measured as a visual analog scale in mm improved significantly in the leflunomide group. The relative difference in pain was 23% at 6 months (WMD -13.81 mm, 95% CI -15.91 to -11.71) and 29% at 12 months (WMD -18 mm, 95% CI -24.04 to -11.96).</P>
<P>
<I>Functional status and Health related quality of life</I>
<BR/>1) Health Assessment Questionnaire (HAQ) disability index and modified HAQ (MHAQ) scores<BR/>A significant improvement in the HAQ disability scores in the leflunomide-treated group were observed at 6 months with a relative difference of 39% (WMD -0.43 points, 95% CI -0.52 to -0.33); and a relative difference of 56% at 12 months (WMD - 0.48 points, 95% CI -0.60 to -0.36). The improvements of the MHAQ scores after 6 and 12 months of leflunomide were also significant (WMD -0.35 points, 95% CI -0.46 to -0.24; WMD -0.36 points, 95% CI -0.48 to -0.24, respectively).</P>
<P>2) Problem Elicitation Technique (PET) scores<BR/>The scores of the top 5 items of the PET improved significantly in the leflunomide-treated patients compared to placebo, by 29% relative to baseline (WMD -6.24 points, 95% CI -8.46 to -4.02) at 12 months.</P>
<P>3) Short Form-36 health survey (SF-36)<BR/>A significant improvement in the physical component scores of the SF-36 of 22% relative to baseline was observed in the leflunomide group (WMD -6.6 points, 95% CI -8.91 to -4.29); but not in the mental component (WMD -0.7 points, 95% CI -3.53 to 2.13).</P>
<P>4) Work productivity<BR/>Work productivity scores were also significantly improved in the leflunomide group compared to the placebo group at 12 months of treatment (WMD -9.5 points, 95% CI -14.25 to -4.75).</P>
<P>
<I>Radiographic changes</I>
<BR/>Changes of hand radiographs, measured as a Sharp score, favoured leflunomide treatment in all categories (total score, erosion, and joint space narrowing subscores) at both 6 months (WMD of total Sharp score -4.65 points, 95% CI -7.21 to -2.09) and 12 months (WMD of total score -1.63 points, 95% CI -2.78 to -0.48). Delay in progression of joint damage, as measured by the Larsen score, was also observed when leflunomide was compared to placebo at 6 months (WMD -0.04 points, 95% CI -0.06 to -0.02).</P>
<P>
<B>Evidence level: Gold</B>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Efficacy of leflunomide compared to methotrexate (MTX)</HEADING>
<P>There were 11 clinical trials comparing the efficacy of leflunomide to MTX. The trial duration ranged from 3 months to 2 years. A test of homogeneity showed that the results from several studies were significantly different from the others. Thus, the comparison of outcomes between leflunomide and MTX from more than one study was based on a random-effects model.</P>
<P>
<I>ACR20, ACR50 and ACR70 response rates</I>
<BR/>There was no difference in ACR20 response rates between RA patients treated with leflunomide and those treated with MTX at 3, 4, 6, 12, and 24 months.<BR/>For the ACR50 response rate, no significant difference in the number of ACR50 responders was found between the leflunomide and MTX groups at 12 and 24 months.<BR/>A significantly greater number of patients met the ACR70 response criteria in the leflunomide group compared to MTX at 12 months (RR 0.44, 95% CI 0.26 to 0.77) but not at 2 years (RR 0.72, 95% CI 0.44 to 1.18).</P>
<P>
<I>Joint counts</I>
<BR/>There was no significant difference between leflunomide and MTX in the reduction of tender joint count or swollen joint count at any time point of assessment.</P>
<P>
<I>Global assessments</I>
<BR/>No significant difference between leflunomide and MTX was observed in the change of physician global assessment at 3, 4, 12 months, and 2 years. A significant difference was observed at 6 months for patient and physician global assessment, with a WMD of -0.60 mm (95% CI -0.95 to -0.26) and -0.48 mm (95% CI -0.82 to -0.15), respectively.</P>
<P>
<I>ESR</I>
<BR/>No significant difference in the improvement of ESR after treatment with leflunomide or MTX at any time point of assessment.</P>
<P>
<I>CRP</I>
<BR/>A significant reduction in CRP level was found after 3 months of treatment with leflunomide compared to MTX (WMD -3.02 mg/dl, 95% CI -5.94 to -0.09).</P>
<P>
<I>Pain severity</I>
<BR/>Leflunomide was not significantly different from MTX in pain reduction at any time point of evaluation.</P>
<P>
<I>Functional status and health-related quality of life (HRQoL)</I>
<BR/>1) HAQ disability index and MHAQ scores<BR/>The HAQ scores in the leflunomide-treated group did not improve more than in the MTX group at 3, 6, 12, or 24 months of treatment. The MHAQ scores improved significantly in the leflunomide group compared to MTX at 6, 12, and 24 months, but not at 4 months.</P>
<P>2) PET scores<BR/>The scores of the PET top 5 improved significantly in the leflunomide-treated patients when compared to MTX (WMD -3.5 points, 95% CI -5.62 to -1.38) at 12 months.</P>
<P>3) SF-36 scores<BR/>The changes of the SF-36 scores when leflunomide was compared to MTX were similar to those observe when leflunomide was compared to placebo, that is a significant improvement in the physical component (WMD -3.0 points, 95% CI -5.41 to -0.59) but not the mental component (WMD -0.6 points, 95% CI -3.01 to 1.81).</P>
<P>4) Work productivity<BR/>Work productivity did not improve significantly in the leflunomide group when compared to MTX (WMD -2.3 points, 95% CI -6.37 to 1.77).</P>
<P>5) Disability index in Chinese studies<BR/>The Chinese leflunomide studies compared the disability index between patients taking leflunomide and MTX. A significant difference in the disability index was observed at 3 months (WMD -0.09 points, 95% CI -0.18 to -0.001) but not at 6 months (WMD -0.05 points, 95% CI -0.20 to 0.10).</P>
<P>
<I>Radiographic changes</I>
<BR/>Changes in the total Sharp score were not significant when leflunomide was compared to MTX at 12 and 24 months of treatment. However, a significant change in magnetic resonance imaging (MRI) initial rate of enhancement of the patients' inflamed knee joints was observed in the leflunomide group compared to MTX.</P>
<P>
<I>Treatment response rate in Chinese leflunomide studies</I>
</P>
<P>Therapeutic efficacy of leflunomide compared with MTX in Chinese studies at both three and six months showed that leflunomide was comparable to MTX. No statistical significance in efficacy was detected between groups.</P>
<P>
<I>EULAR response criteria</I>
</P>
<P>The EULAR response criteria measured as Disease Activity Score (DAS) were used for assessing response to treatment in RA. The DAS28 assesses the number of tender and swollen joint on a 28-joint assessment basis as well as patient global assessment of disease activity and ESR or CRP. The mean change of DAS28 score at 4 months of treatment was significantly better for MTX than leflunomide (WMD 0.57 points, 95% CI 0.24 to 0.90). However, the EULAR good and moderate response rates and EULAR remission rate at four months were not significantly different between leflunomide and MTX. At six months, mean changes of DAS28; DAS28 remission rate; number of patients with DAS28 low, moderate, and high disease activity were not significantly different for patients treated with leflunomide and those with MTX.</P>
<P>
<B>Evidence level: Gold</B>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Efficacy of leflunomide compared to sulfsalazine (SSZ)</HEADING>
<P>
<I>ACR20, ACR50 and ACR70 response rates</I>
<BR/>There were no differences in response rates between the RA patients treated with leflunomide and those treated with SSZ at 6 and 12 months. Only at 24 months the ACR20 response rate in the leflunomide group was significantly better than for SSZ (RR 0.73, 95% CI 0.57 to 0.93).<BR/>For the ACR50 response rate, a significantly greater number of patients treated with leflunomide met the ACR50 response criteria compared to SSZ, at 24 months (RR 0.48, 95% CI 0.28 to 0.80).<BR/>The number of ACR70 responders in the leflunomide and SSZ groups were not significantly different at any time point of assessment.</P>
<P>
<I>Joint counts</I>
<BR/>Reductions in the number of tender joint or swollen joint were not significantly different in leflunomide-treated patients compared to SSZ at both 6 and 12 months. However, at 24 months, leflunomide was significantly more efficacious than SSZ in decreasing the number of tender joints (WMD -3.33 joints, 95% CI -5.83 to -0.83) and swollen joints (WMD -2.62 joints, 95% CI -4.67 to -0.57).</P>
<P>
<I>Global assessments</I>
<BR/>No significant differences in the change of patient global and physician global assessments were observed when leflunomide was compared to SSZ at 6 and 12 months. At 24 months, both patient and physician global assessments improved significantly in the leflunomide group (WMD for patient global -0.68 points, 95% CI -1.35 to -0.01; WMD for physician global -0.7 points, 95% CI -1.37 to -0.03) compared to SSZ.</P>
<P>
<I>ESR</I>
<BR/>ESR improved less in the leflunomide group than with SSZ (WMD 9.2 mm/hr, 95% CI 3.47 to 14.93) at 6 months. There was no difference in the change of ESR between leflunomide and SSZ at 12 and 24 months.</P>
<P>
<I>CRP</I>
<BR/>Leflunomide decreased the CRP level significantly at 6, 12, and 24 months of treatment when compared to SSZ. The WMD of CRP changes at 6 months was -1.20 mg/dl (95% CI -1.98 to -0.42). The WMD of CRP changes at 12 and 24 months were -1.10 (95% CI -2.17 to -0.03) and -1.40 (95% CI -2.77 to -0.33), respectively.</P>
<P>
<I>Pain severity</I>
<BR/>Pain severity decreased significantly in the leflunomide group compared to SSZ at all time points. Changes in pain severity measured by VAS at 6, 12, and 24 months in the leflunomide group were better than SSZ with the WMD of -7.5 mm (95% CI -14.21 to -0.79); WMD -11.4 mm (95% CI -20.35 to -2.45); and WMD -15.1 mm (95% CI -25.16 to -5.04), respectively.</P>
<P>
<I>Functional status and health-related quality of life (HRQoL)</I>
<BR/>At 6 and 24 months, leflunomide improved the HAQ disability index significantly when compared to SSZ (WMD -0.25 points, 95% CI -0.42 to -0.08; WMD -0.29 points, 95% CI -0.57 to -0.01, respectively). The difference in HAQ score was not observed at 12 months.<BR/>
<B>
<BR/>
</B>
<I>Radiographic changes</I>
<BR/>Changes in total Sharp score were not significantly different when leflunomide was compared to SSZ, at 6 or 12 months. Larsen scores, both total scores and erosion scores of the hands and feet, were not delayed significantly in the leflunomide group when compared to SSZ at 6, 12, and 24 months.</P>
<P>
<B>Evidence level: Gold</B>
</P>
<P>
<B>Efficacy of leflunomide compared to cyclosporin A (CsA)</B>
</P>
<P>
<I>ACR20, ACR50, and ACR70 response rates</I>
</P>
<P>The ACR20, ACR50, and ACR70 response rates in RA patients receiving leflunomide were not significantly different from those receiving CsA, at 12 months of treatment.</P>
<P>
<I>EULAR response criteria</I>
</P>
<P>The mean change of DAS28 score from baseline was significantly better for patients taking CsA than those taking leflunomide at 12 months of treatment (WMD 0.25 points, 95% CI 0.15 to 0.35). However, the number of patients who met the EULAR low disease activity criteria (DAS28 &lt; 3.2) was not significantly different between the two treatment groups.</P>
<P>
<B>Evidence level: Silver</B>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Efficacy of leflunomide+MTX compared to MTX</HEADING>
<P>
<I>ACR20, ACR50, and ACR70 response rates</I>
<BR/>A significantly greater number of RA patients taking leflunomide+MTX met the ACR20, ACR50, and ACR70 criteria compared to MTX+placebo, at 24 weeks. The RR for ACR20 responders was 0.42 (95% CI 0.29 to 0.63); for ACR50 responders, RR 0.23 (95% CI 0.11 to 0.48); and for ACR70 responders, RR 0.23 (95% CI 0.07 to 0.77). At 48 weeks, the extension study showed that the ACR20, ACR50, and ACR70 response rates for RA patients taking leflunomide+MTX were not significantly different from those taking placebo switched to leflunomide+MTX.</P>
<P>
<I>Joint counts</I>
<BR/>A significant reduction in the number of tender and swollen joints was observed in RA patients treated with leflunomide+MTX compared to MTX+placebo, at 24 weeks. The WMD of tender joint counts was -7.6 joints (95% CI -10.59 to -4.61) and the WMD of swollen joint counts was -3.6 joints (95% CI -5.47 to -1.73). At 48 weeks when patients receiving MTX+placebo were switched to leflunomide+MTX, the changes in joint counts were not different from those receiving leflunomide+MTX at study entry.</P>
<P>
<I>Global assessments</I>
<BR/>Combined leflunomide and MTX improved both patient and physician global assessments more than with MTX, at 24 weeks of treatment. The WMD of patient global assessment measured by VAS was -15.5 mm (95% CI -21.86 to -9.14) and the WMD of physician global assessment was -17.1 mm (95% CI -22.71 to -11.49). At 48 weeks both patient and physician global assessments were not significantly different between the two groups; MTX+placebo was changed to leflunomide+MTX in the control group.</P>
<P>
<I>ESR</I>
<BR/>Improvement of ESR from baseline in the leflunomide+MTX and MTX groups was not significantly different, at both 24 and 48 weeks.</P>
<P>
<I>CRP</I>
<BR/>Leflunomide+MTX decreased the CRP level significantly more at 24 weeks of treatment compared to MTX. The WMD of CRP change was -12.1 mg/l (95% CI -19.84 to -4.36). At 48 weeks, when both groups were assigned leflunomide+MTX treatment, mean changes of CRP in the two groups were not significantly different.</P>
<P>
<I>Pain severity</I>
<BR/>Pain severity decreased significantly in the leflunomide+MTX group compared to MTX, at 24 weeks. The WMD of change in pain severity measured by VAS was -16.9 mm (95% CI -23.7 to -10.1). This difference was not observed in the 48-week extension study when both groups were treated with leflunomide+MTX.</P>
<P>
<I>Functional status and health-related quality of life (HRQoL)</I>
<BR/>At 24 weeks, leflunomide+MTX improved the HAQ disability index significantly when compared to MTX (WMD -0.3 points, 95% CI -0.42 to -0.18). At 48 weeks, when both patient groups were treated with leflunomide+MTX, there were no significant differences in the HAQ score, and SF-36 physical and mental components between the two groups.</P>
<P>
<I>Treatment response rate in Chinese and Indian leflunomide studies</I>
</P>
<P>The number of patients with a remarkable improvement in both clinical and laboratory parameters in a Chinese leflunomide study was significantly higher for leflunomide+MTX treatment than for MTX, at 24 weeks. The RR was 0.43 (95% CI 0.27 to 0.68). In Indian studies, the number of patients with significant improvements was higher for leflunomide+MTX than for MTX at both two and three years. The RR at 2 years was 0.69 (95% CI 0.52 to 0.91) and the RR at 3 years was 0.73 (95% CI 0.62 to 0.86).</P>
<P>
<B>Evidence level: Gold</B>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Efficacy of leflunomide+MTX compared to leflunomide</HEADING>
<P>
<I>EULAR response rate</I>
<BR/>The EULAR good and moderate responders, non responders, and EULAR remission rate at 3 months were not significantly different between RA patients taking leflunomide+MTX and leflunomide alone.</P>
<P>
<B>Evidence level: Silver</B>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Efficacy of leflunomide+SSZ compared to SSZ</HEADING>
<P>
<I>ACR20, ACR50 and ACR70 response rates</I>
<BR/>There was no difference in the ACR20 or ACR50 response rate between the RA patients treated with leflunomide+SSZ and those treated with SSZ, at 24 weeks. The ACR70 response rate in both treatment groups could not be estimated because no patients reached the ACR70 response criteria.</P>
<P>
<I>Joint counts</I>
<BR/>Reductions in the number of tender joints or swollen joints were not significant between leflunomide+SSZ and SSZ groups, at 24 weeks.</P>
<P>
<I>ESR</I>
<BR/>There was no significant difference in ESR after treating with leflunomide+SSZ or SSZ, at 24 weeks.</P>
<P>
<I>CRP</I>
<BR/>Leflunomide+SSZ reduced the CRP but the reduction was not significantly different from the SSZ group, at 24 weeks.</P>
<P>
<I>Pain severity</I>
<BR/>Pain severity did not significantly decrease in the leflunomide+SSZ group compared to SSZ, at 24 weeks.</P>
<P>
<I>Functional status and health-related quality of life (HRQoL)</I>
<BR/>At 24 weeks, changes in HAQ-DI and mean HAQ score were not significantly different between the leflunomide+SSZ group and SSZ group.</P>
<P>
<I>EULAR response criteria</I>
</P>
<P>The number of patients who met the EULAR good and moderate response for both intention-to-treat groups and completers, at 24 weeks, was not significantly different for those treated with leflunomide+SSZ and with SSZ. The mean change of DAS28 scores from baseline was also not different between the two groups.</P>
<P>
<B>Evidence level: Gold</B>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Efficacy of leflunomide+CsA compared to leflunomide</HEADING>
<P>
<I>ACR20, ACR50, and ACR70 response rates</I>
</P>
<P>The ACR20 and ACR50 response rates in RA patients receiving leflunomide+CsA were not significantly different from those in patients receiving leflunomide, at 12 months of treatment. On the other hand, the ACR70 response rate was significantly higher for patients receiving leflunomide+CsA than for those receiving leflunomide alone (RR 1.96, 95% CI 1.12 to 3.44).</P>
<P>
<I>EULAR response criteria</I>
</P>
<P>The mean change of DAS28 score from baseline was significantly better for patients taking leflunomide+CsA than for those taking leflunomide, at 12 months of treatment (WMD 0.46 points, 95% CI 0.35 to 0.57). However, the number of patients who met the EULAR low disease activity criteria (DAS28 &lt; 3.2) was not significantly different between the two treatment groups.</P>
<P>
<B>Evidence level: Gold</B>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Efficacy of leflunomide compared to anti-tumor necrosis factor agents (ANTI-TNF)+MTX</HEADING>
<P>
<I>ACR 20, ACR50, and ACR70 response rates</I>
</P>
<P>The ACR20 and ACR50 response rates in patients taking anti-TNF+MTX were marginally higher than for those taking leflunomide, at 24 weeks, but this difference was not statistical significant. The ACR70 response rate was significantly higher for the anti-TNF+MTX treated group than for the leflunomide group (RR 3.75, 95% CI 1.35 to 10.43).</P>
<P>
<I>Joint counts</I>
</P>
<P>A significant improvement in the number of tender and swollen joints was observed in the combination anti-TNF+MTX group compared with leflunomide, at 24 weeks. The WMD of tender joint counts was 3.3 joints (95% CI 1.88 to 4.72) and the WMD of swollen joint counts was 1.4 joints (95% CI 0.22 to 2.58).</P>
<P>
<I>ESR</I>
</P>
<P>Mean ESR changes from baseline were not significantly different between the two treatment groups.</P>
<P>
<I>Pain severity</I>
</P>
<P>Anti-TNF+MTX reduced the pain intensity measured by VAS more efficiently than leflunomide, at 24 weeks (WMD 11 mm, 95% CI 1.29 to 20.71).</P>
<P>
<I>EULAR response criteria</I>
</P>
<P>Mean change from baseline of the DAS28 score was significantly higher for anti-TNF+MTX treatment group than for the leflunomide group, at 24 weeks (WMD 0.80 points, 95% CI 0.43 to 1.17). The number of patients who met the EULAR remission criteria (DAS28 &lt; 2.6) was not significantly different between the two groups (RR 1.67, 95% CI 0.38 to 7.39). The patients treated with anti-TNF+MTX were significantly more likely to meet the EULAR low disease activity criteria (DAS28 &lt; 3.2) than those treated with leflunomide (RR 3.33, 95% CI 1.17 to 9.51). The number of patients in the leflunomide group who met the EULAR moderate and high disease activity criteria was not significantly different to the number in the anti-TNF+MTX group.</P>
<P>
<B>Evidence level: Silver</B>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Efficacy of leflunomide+adalimumab (ADA) compared to ADA</HEADING>
<P>
<I>ACR20 and ACR50 response rates</I>
</P>
<P>The ACR20 response rate in the leflunomide+ADA group was significantly better than in the ADA group, at 12 weeks (RR 0.83, 95% CI 0.89 to 0.99). There was no significant difference in the ACR50 response rate between the two treatment groups.</P>
<P>
<I>EULAR response criteria</I>
</P>
<P>The number of patients who met the EULAR good response criteria was not significantly different between the two groups, while fewer patients in the leflunomde+ADA group met the EULAR moderate response criteria than in the ADA group (RR 0.83, 95% CI 0.73 to 0.93).</P>
<P>
<B>Evidence level: Silver</B>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Efficacy of leflunomide 10 mg/day compared to leflunomide 20 mg/day</HEADING>
<P>
<I>ACR20, ACR50, and ACR70 response rates</I>
<BR/>There was no significant difference in the ACR20, ACR50, and ACR70 response rate between the RA patients treated with leflunomide 10 mg/day and those treated with leflunomide 20 mg/day, at 24 months.</P>
<P>
<I>Joint counts</I>
<BR/>There was no significant difference in the mean change from baseline of tender and swollen joint counts between leflunomide 10 mg/day and leflunomide 20 mg/day, at 24 months of treatment.<BR/>
<BR/>
<I>Functional status and health-related quality of life (HRQoL)</I>
<BR/>At 24 months, no difference in the change of HAQ scores between leflunomide 10 and 20 mg/day.</P>
<P>
<B>Evidence level: Gold</B>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Efficacy of weekly leflunomide compared to daily leflunomide</HEADING>
<P>ACR20, ACR50, and ACR70 response rates</P>
<P>No significant difference in the ACR20, ACR50, and ACR70 response rate was observed between the two groups at both 6 and 12 months of treatment.</P>
<P>
<B>Evidence level: Silver</B>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Efficacy of leflunomide 100 mg/week compared to leflunomide 200 mg/week</HEADING>
<P>
<I>Joint counts</I>
</P>
<P>There was no significant difference in the mean changes from baseline of the number of tender and swollen joints between the two treatment groups, at 6 months.</P>
<P>
<I>Global assessments</I>
</P>
<P>No significant difference in both patient and physician global assessments at six months of treatment with leflunomide 100 mg/week or 200 mg/week.</P>
<P>
<B>Evidence level: Silver</B>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>1. <B>
<I>Leflunomide monotherapy versus placebo, MTX, SSZ, or CsA</I>
</B>
</P>
<P>An important adverse event with leflunomide is an elevation of liver function test results. The risk ratio of elevated liver function tests as a reported adverse event was significantly higher for leflunomide compared with placebo at 6 months (RR 2.45, 95%CI 1.02 to 5.87), 12 months (RR 5.84, 95% CI 1.81 to 18.8), and 2 years (RR 3.23, 95% CI 1.27 to 8.25). However, this adverse event was not significantly different between leflunomide and MTX or SSZ.</P>
<P>RA patients receiving leflunomide were less likely to discontinue treatment when compared to placebo (RR 0.70, 95% CI 0.59 to 0.83) but was not different from SSZ (RR 0.75, 95% CI 0.53 to 1.07). On the other hand, patients taking leflunomide were more likely to withdraw when compared to MTX (RR 1.26, 95% CI 1.08 to 1.48) at 12 months, but not at 2 years. The withdrawal rate was also significantly higher for leflunomide than for CsA at 12 months of treatment (RR 4.38, 95% CI 1.02 to 18.84). The number of withdrawals due to drug-related adverse events in the leflunomide group was significantly higher than with placebo (RR 2.73, 95% CI 1.67 to 4.47); and MTX at 12 months (RR 1.43, 95% CI 1.13 to 1.83); but not for MTX at 2 years (RR 1.15, 95% CI 0.83 to 1.61) or with SSZ (RR 0.77, 95% CI 0.45 to 1.33) or CsA (RR 8.76, 95% CI 0.49 to 156.85). Withdrawals due to adverse events related to leflunomide were significantly fewer than with MTX at 6 months in the Chinese leflunomide studies (RR 0.24, 95% CI 0.10 to 0.57).</P>
<P>Major reported adverse events from leflunomide included gastrointestinal (GI) symptoms (diarrhea, dyspepsia, nausea and vomiting, abdominal pain, oral ulcers), elevated liver function tests, allergic reactions, alopecia, infections, weight loss, and hypertension. Heterogeneity was significant for several adverse events (random-effects model).</P>
<P>GI symptoms were more likely to occur in the leflunomide group than in the placebo group (RR 1.60, 95% CI 1.28 to 1.99) but less likely to occur compared with the MTX group (RR 0.50, 95% CI 0.28 to 0.92) and not different from SSZ (RR 0.88, 95% CI 0.63 to 1.22).</P>
<P>Elevation of liver function tests, more than 3 times the upper normal values, was more likely in the leflunomide group when compared to placebo (RR 3.74, 95% CI 1.86 to 7.54) but was not different from SSZ (RR 0.60, 95% CI 0.15 to 2.46) or MTX (RR 0.66, 95% CI 0.31 to 1.39).</P>
<P>Mild allergic reactions were more likely to occur in the leflunomide group when compared to placebo (RR 1.72, 95% CI 1.08 to 2.74) or MTX (RR 1.51, 95% CI 1.19 to 1.92) but were not different from SSZ (RR 1.00, 95% CI 0.52 to 1.92).</P>
<P>Reversible alopecia was more likely to occur in the leflunomide group than in the placebo group (RR 6.60, 95% CI 2.36 to 18.44) or MTX group (RR 1.72, 95% CI 1.32 to 2.24) but was no different in the SSZ group (RR 1.57, 95% CI 0.63 to 3.93).</P>
<P>Infection rates and significant weight loss were not significantly different between leflunomide, placebo, SSZ, and MTX.</P>
<P>Hypertension in the leflunomide group was not different from placebo (RR 3.36, 95% CI 0.58 to 19.32) or SSZ (RR 1.00, 95% CI 0.21 to 4.87) but was more likely to occur than in the MTX-treated group (RR 2.29, 95% CI 1.42 to 3.69).</P>
<P>2. <B>
<I>Leflunomide combination with another DMARD compared to DMARD monotherapy</I>
</B>
</P>
<P>The total withdrawal rate and withdrawal rate due to treatment-related adverse events were not significantly different in patients receiving leflunomide+MTX compared with patients receiving MTX, at 24 weeks. A similar result was observed in the 48-week extension study. After the patients in the placebo+MTX group were switched to leflunomide+MTX (without a loading dose of leflunomide), from week 24 to week 48, certain adverse events were observed more frequently in the placebo switched to leflunomide+MTX group than in patients already taking leflunomide+MTX from the beginning of the trial. These adverse events included diarrhea (RR 5.33, 95% CI 1.61 to 17.71) and alopecia (RR 8.0, 95% CI 1.02 to 62.74). The risk of nausea, skin rash, infection, or elevated liver enzymes was not significantly different between the two treatment groups. Serious adverse events were also not different at 48 weeks of treatment. However, the risk of reported adverse events in patients taking leflunomide+MTX was significantly higher than in patients taking MTX as reported by the Chinese Leflunomide Study Group, at 24 weeks (RR 3.5, 95% CI 1.29 to 9.49). The total withdrawal rate and withdrawal rate due to leflunomide+MTX treatment were not significantly higher than in the MTX-treated group at both 24 and 36 months of treatment in the Indian leflunomide studies.</P>
<P>For the adverse events in the trial comparing leflunomide+SSZ with SSZ, at 24 weeks the reported adverse events, serious adverse events, total number of withdrawals, and withdrawal rate from treatment-related adverse events, were not significantly different between the two groups.</P>
<P>Total withdrawals and withdrawals due to treatment-related adverse events in RA patients taking leflunomide+CsA were not significantly different from those in patients taking CsA, at 12 months. Similarly, withdrawals due to adverse events in the leflunomide+MTX were not higher than in the leflunomide group, at three months of treatment.</P>
<P>3. <B>
<I>Comparisons between leflunomide at different doses</I>
</B>
</P>
<P>Reported adverse events and withdrawals due to treatment-related adverse events in RA patients taking leflunomide 10 mg/day and 20 mg/day were not significantly different. Patients taking weekly leflunomide were at a lower risk of developing adverse events and withdrawing from the study due to adverse events compared with patients taking daily leflunomide, but this difference did not reach statistical significance (RR 3.0, 95% CI 0.85 to 10.63; RR 5.0, 95% CI 0.28 to 90.18, respectively). In addition, a study comparing leflunomide at 100 mg/week with 200 mg/week did not show a significant difference in the number of withdrawals due to adverse events, at 6 months of treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Sensitivity analysis</HEADING>
<P>
<I>Methodological quality</I>
<BR/>The median quality scores of the included trials were moderate (Jadad score = 3). Studies with poor blinding quality were compared to those with higher scores in blinding quality. A significant difference in the number of patients who met the ACR20 criteria was observed in studies with blinding quality &gt; 1.</P>
<P>
<I>RA duration</I>
<BR/>Trials including patients with a mean duration of RA less than five years were more likely to report a better response with MTX (RR 1.28, 95% CI 1.15 to 1.43) while the trials involving patients with a mean disease duration of 5 years or more tended to favor leflunomide (RR 0.87, 95% CI 0.72 to 1.05).</P>
<P>
<I>Concomitant steroid use</I>
<BR/>A significant difference in ACR20 response rate between studies with baseline steroid use less than 50% (RR 0.52, 95% CI 0.40 to 0.66) and those with steroid use 50% or more (RR 0.72, 95% CI 0.51 to 1.03) was observed.</P>
<P>
<I>Withdrawal rate</I>
<BR/>Studies with a withdrawal rate of 50% or more did not show a significant difference in ACR20 response rate compared with studies with withdrawal rates less than 50%.<BR/>
</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-08-11 21:03:09 -0400" MODIFIED_BY="[Empty name]">
<P>Leflunomide is a novel DMARD with a different structure and mechanism of action from the other DMARDs. It is an isoxazole derivative that is converted to the active form A77 1726 once ingested. The primary mode of action is to inhibit the enzyme dihydro-orotate dehydrogenase, which activates the rate-limiting step in the pathway for de novo synthesis of pyrimidines (<LINK REF="REF-Fox-1998" TYPE="REFERENCE">Fox 1998</LINK>; <LINK REF="REF-Simon-2000" TYPE="REFERENCE">Simon 2000</LINK>; <LINK REF="REF-Smolen-2000" TYPE="REFERENCE">Smolen 2000</LINK>). Pyrimidine nucleotides are required for the proliferation of T lymphocytes. The autoreactive T lymphocytes are more sensitive to the depletion of pyrimidine pools than other types of lymphocytes and cells in the body (<LINK REF="REF-Fox-1998" TYPE="REFERENCE">Fox 1998</LINK>). This leads to suppression of autoimmune T-cell proliferation with a minimum effect on the other cells. Since most of the cells that infiltrate the RA synovium are activated CD4+ T-cells, leflunomide helps improve the inflammation of synovium in RA patients as well as their clinical symptoms (<LINK REF="REF-Fox-1998" TYPE="REFERENCE">Fox 1998</LINK>; <LINK REF="REF-Simon-2000" TYPE="REFERENCE">Simon 2000</LINK>; <LINK REF="REF-Smolen-2000" TYPE="REFERENCE">Smolen 2000</LINK>).<BR/>
<BR/>Leflunomide was approved by the United States FDA in August 1998 for the treatment of adult RA. It has shown a beneficial result in many RCTs and CCTs. Earlier studies were high quality RCTs evaluating the efficacy and adverse events of leflunomide compared to placebo, MTX, or SSZ. MTX and SSZ are the most widely used DMARDs in North America and Europe, respectively (<LINK REF="STD-Mladenovic-1995" TYPE="STUDY">Mladenovic 1995</LINK>; <LINK REF="STD-Emery-1999" TYPE="STUDY">Emery 1999</LINK>; <LINK REF="STD-Smolen-1999" TYPE="STUDY">Smolen 1999</LINK>; <LINK REF="STD-Strand-1999a" TYPE="STUDY">Strand 1999a</LINK>; <LINK REF="STD-Cohen-2001" TYPE="STUDY">Cohen 2001</LINK>; <LINK REF="STD-Scott-2001" TYPE="STUDY">Scott 2001</LINK>). These six trials had the same objectives and similar primary outcome measures, which included in the core set of disease activity measures for RA clinical trials established by OMERACT and the ACR (<LINK REF="REF-Felson-1993" TYPE="REFERENCE">Felson 1993</LINK>; <LINK REF="REF-Felson-1995" TYPE="REFERENCE">Felson 1995</LINK>; <LINK REF="REF-Pincus-1999" TYPE="REFERENCE">Pincus 1999</LINK>). However, differences in the outcome measures did exist. The Mladenovic study (<LINK REF="STD-Mladenovic-1995" TYPE="STUDY">Mladenovic 1995</LINK>) based the number of joint counts on the evaluation of 66 or 68 joints while the others based the counts on the 28-joint evaluation. In functional evaluation, the Mladenovic 1995 trial used total HAQ scores in their study while the others used the HAQ disability index. There was also a difference in the patients recruited to the studies. The RA patients in Strand 1999(a) had a mean duration of disease at recruitment of 6.5 to 7 years while the patients in Emery 1999 had a shorter duration of disease of 3.7 to 3.8 years. More than 99% of the patients from Strand et al (<LINK REF="STD-Strand-1999a" TYPE="STUDY">Strand 1999a</LINK>) were prescribed folic acid supplement while folic acid was not mandatory in the Emery study (<LINK REF="STD-Emery-1999" TYPE="STUDY">Emery 1999</LINK>). These differences would explain the heterogeneity of the pooled estimates from both studies.</P>
<P>The pooled estimates of the clinical efficacy of leflunomide have shown this agent to be significantly better than placebo at both six months and 12 months, in all outcome measures for disease activity. The pooled relative differences show a relative benefit in change from baseline of over 20%, compared to placebo, for most of the OMERACT core set of outcomes. At six and 12 months, the clinical benefits from leflunomide were not significantly different from SSZ; except for pain severity, which leflunomide significantly improved more than SSZ. At 24 months, leflunomide was shown to be more efficacious than SSZ in improving most of the outcome measures. Thus, the efficacy of leflunomide appeared to be sustained over at least two years of treatment. It might still be efficacious in longer-term treatment, as MTX is. For the comparison between leflunomide and MTX, leflunomide efficacy was not significantly different from MTX in most of the outcome measures, in six trials. However, additional RCTs from China showed that leflunomide was significantly more efficacious than MTX in pooled efficacy outcomes and mean changes of DAS28 scores.</P>
<P>For the functional status and HRQoL, leflunomide improved the health status in almost every aspect for RA patients. The exception was the mental component of the SF-36, for which the treated group did no better than the placebo group. This was also observed when leflunomide was compared to MTX where the improvement of the mental component of the SF-36 was not significant. There may be other factors that influenced the mental component, for example adverse events from the treatment, inability to perform normal social activity, or inadequate length of time to evaluate the improvement of mental status of the patients. The improvement of the MHAQ scores in the RA patients treated with leflunomide was significantly superior to that for the patients treated with MTX but the changes of the HAQ disability index in both groups were not significantly different. This might be explained by the heterogeneity of the results of the included studies. In the study by Strand and colleagues (<LINK REF="STD-Strand-1999b" TYPE="STUDY">Strand 1999b</LINK>) the patients responded better to leflunomide than MTX in term of MHAQ scores, but not the HAQ disability index; while in the study by Emery and colleagues (<LINK REF="STD-Emery-1999" TYPE="STUDY">Emery 1999</LINK>) the patients treated with MTX tended to improve better in the HAQ disability index.</P>
<P>Progression of radiographic changes was also significantly slower in the leflunomide-treated group than the placebo group. The effects of leflunomide in retarding the radiographic changes were not significantly different from those of SSZ or MTX; the results from the study by Strand and colleagues (<LINK REF="STD-Sharp-2000" TYPE="STUDY">Sharp 2000</LINK>) tended to favour leflunomide over MTX and the results from Emery study favoured MTX (<LINK REF="STD-Sharp-2000" TYPE="STUDY">Sharp 2000</LINK>). From the available data to date, leflunomide is not superior to MTX or SSZ in delaying bone erosions or joint damage in RA patients.</P>
<P>Later trials included RCTs and CCTs comparing leflunomide combined with another DMARD (mostly MTX) to DMARD monotherapy, and leflunomide as monotherapy or in combination with biologic agents (anti-TNF agents). These trials comprised heterogeneous groups of trials with low to moderate quality and varied levels of biases. The majority of trials compared the efficacy of leflunomide+MTX with MTX alone (<LINK REF="STD-Kremer-2002" TYPE="STUDY">Kremer 2002</LINK>; <LINK REF="STD-Lao-2002" TYPE="STUDY">Lao 2002</LINK>; <LINK REF="STD-Amit-2004" TYPE="STUDY">Amit 2004</LINK>, <LINK REF="STD-Amit-2006" TYPE="STUDY">Amit 2006</LINK>). Combined leflunomide and MTX was superior to MTX in almost all efficacy outcomes. When placebo was replaced with leflunomide in the 48-week extension study of an RCT, the patients in both treatment groups (leflunomide and leflunomide+MTX, placebo and leflunomide+MTX) responded similarly in all efficacy outcomes (<LINK REF="STD-Kremer-2002" TYPE="STUDY">Kremer 2002</LINK>; <LINK REF="STD-Kremer-2004" TYPE="STUDY">Kremer 2004</LINK>). An open-label, CCT conducted in India showed that the patients' responses to combined leflunomide and MTX were not significantly different from those to leflunomide alone (<LINK REF="STD-Antony-2006" TYPE="STUDY">Antony 2006</LINK>). Although combined leflunomide+MTX was more efficacious than MTX, this combination was no better than leflunomide. This might be explained by the shorter length of the study (three months), small sample size, different patient characteristics and baseline disease activity, or the dose of MTX used in this study (only 5 to 7.5 mg/week) (<LINK REF="STD-Antony-2006" TYPE="STUDY">Antony 2006</LINK>). In an RCT conducted in RA patients with inadequate responses to leflunomide, combined leflunomide and SSZ was superior to SSZ in only one outcome, the number of ACR50 responders art 24 weeks. The other efficacy outcomes were not significantly different between the two groups (<LINK REF="STD-Dougados-2005" TYPE="STUDY">Dougados 2005</LINK>). Thus, when an RA patient needs a combination of DMARDs, leflunomide+MTX is a better combination than leflunomide+SSZ in improving disease activity. Another DMARD combination with leflunomide that was shown to be more efficacious than leflunomide alone was leflunomide+CsA. The ACR50 and ACR70 response rates and mean changes of DAS28 score were significantly better for combined leflunomide and CsA than leflunomide (<LINK REF="STD-Karanikolas-2006" TYPE="STUDY">Karanikolas 2006</LINK>).</P>
<P>Leflunomide efficacy was also compared with that of anti-TNF agents in two studies (<LINK REF="STD-Mariette-2004" TYPE="STUDY">Mariette 2004</LINK>; <LINK REF="STD-Wislowska-2007" TYPE="STUDY">Wislowska 2007</LINK>). ADA+leflunomide was not significantly better than ADA in improving activity outcomes in patients with RA. Anti-TNF agents (etanercept and infliximab) combined with MTX were significantly better than leflunomide in the majority of activity and quality of life outcomes.</P>
<P>Three trials explored the efficacy and safety of different doses and preparations of leflunomide. These included leflunomide 10 mg/day versus 20 mg/day (<LINK REF="STD-Poor-2004" TYPE="STUDY">Poor 2004</LINK>), leflunomide 20 mg/day versus 100 mg/week (<LINK REF="STD-Jakez_x002d_Ocampo-2002" TYPE="STUDY">Jakez-Ocampo 2002</LINK>), and leflunomide 100 mg/week versus 200 mg/week (<LINK REF="STD-Rozman-1994a" TYPE="STUDY">Rozman 1994a</LINK>). The data showed that no significant difference was observed in the efficacy and safety outcomes of these trials. This information suggests that leflunomide may be prescribed as a daily dose (either half or full dose) or weekly dose, which may be suitable for certain patients.</P>
<P>Adverse events in leflunomide-treated patients that were significantly increased compared to placebo included alopecia, gastrointestinal symptoms, and elevated liver function tests. However, infections, hypertension, and weight loss were not significantly different from those in the placebo group. All adverse events in the leflunomide group were not different from those with SSZ. Alopecia, gastrointestinal symptoms, allergic reactions, and hypertension were significantly increased in the leflunomide group compared to MTX. Elevated liver function tests were significantly higher in the MTX group while infection and weight loss were not different between treatment groups.</P>
<P>As expected, the number of withdrawals due to adverse events in the leflunomide group was significantly higher than that in the placebo group. However, the total withdrawal rate in the leflunomide group was lower. This was because the number of withdrawals due to a lack of treatment efficacy was higher in the placebo group. Total withdrawal rates in the SSZ and MTX groups were not different from those in the leflunomide group. Withdrawals due to adverse events were not different between leflunomide and SSZ, but were significantly higher in the leflunomide group compared with the MTX group.</P>
<P>For the year two follow-up studies comparing leflunomide with SSZ and MTX, the adverse events in the leflunomide-treated group were not different from those in the MTX and SSZ groups (<LINK REF="STD-Cohen-2001" TYPE="STUDY">Cohen 2001</LINK>; <LINK REF="STD-Scott-2001" TYPE="STUDY">Scott 2001</LINK>). A follow-up study that extended from the <LINK REF="STD-Mladenovic-1995" TYPE="STUDY">Mladenovic 1995</LINK> trial confirmed leflunomide's efficacy and tolerability after 18 months of treatment (<LINK REF="STD-Rozman-1994b" TYPE="STUDY">Rozman 1994b</LINK>).</P>
<P>The reported adverse events that occurred in patients treated with combined leflunomide and MTX were higher than with MTX alone but the rate of serious adverse events and the number of patients who withdrew from studies because of treatment-related adverse events were not significant different between the two groups. Similarly, reported adverse events, total withdrawal rate, and the withdrawal rate from treatment-related adverse events were not significantly higher for combined leflunomide and another DMARD (MTX, SSZ, or CsA) than for DMARD monotherapy (leflunomide, SSZ, or CsA). These findings suggest that the use of combination DMARDs is more efficacious than single DMARDs and does not result in higher rates of adverse events.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-08-04 09:03:39 -0400" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2009-08-04 09:01:05 -0400" MODIFIED_BY="[Empty name]">
<P>Leflunomide has shown to be efficacious in the treatment of active RA, for up to two years. Patients treated with leflunomide can expect to achieve approximately 20% greater improvements than with placebo in all OMERACT core set outcomes (pain, tender and swollen joints, patient and physician global assessments, function and ESR) relative to baseline. Its efficacy is comparable to SSZ and MTX and is shown to be better than SSZ at 24 months of treatment. Leflunomide is considered a new choice of DMARD therapy in patients with active RA who do not respond to SSZ or MTX, or cannot tolerate these drugs. Leflunomide combined with MTX is more efficacious than MTX alone with additional adverse events. This combination may be recommended in RA patients with active disease despite treatment with DMARD monotherapy. An economic analysis of adding leflunomide to DMARDs for RA treatment showed that leflunomide was cost effective, with the additional cost of 13,000 USD per year of ACR20 response (<LINK REF="REF-Maetzel-2002" TYPE="REFERENCE">Maetzel 2002</LINK>).</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-08-04 09:03:39 -0400" MODIFIED_BY="[Empty name]">
<P>(1) Some studies included in this systematic review did not contain the data essential for pooling in the meta-analysis. Thus, it might be useful to consider including all of the essential data in clinical trials. This would avoid the need to obtain additional data and analyses from the original investigators, which is often hard to obtain after the study is published.</P>
<P>(2) Leflunomide may be a substitute for MTX in RA patients who cannot tolerate or are allergic to MTX. Head-to-head studies of the combination of leflunomide and another DMARD versus MTX and another DMARD (such as antimalarials, SSZ, triple therapy, CsA) should be conducted to evaluate the possibility of using leflunomide instead of MTX.</P>
<P>(3) RCTs on the efficacy of leflunomide+anti-TNF agent should be conducted to assess the additional effect of leflunomide on anti-TNF agent activity, as evident in combined MTX and anti-TNF agent studies.</P>
<P>(4) The efficacy of leflunomide combined with another DMARD should be evaluated compared with combining with biologic agents. Since biologic agents are expensive and may be not affordable in RA patients in developing countries, the need for combination DMARDs with comparable efficacy to anti-TNF agents is crucial for these patients.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-08-03 22:39:13 -0400" MODIFIED_BY="[Empty name]">
<P>We would like to thank Jessie McGowan for her help with the electronic search strategy; Catherine Dorrier for providing additional data on the functional outcomes in the article by Strand et al (<LINK REF="STD-Strand-1999b" TYPE="STUDY">Strand 1999b</LINK>); Barbara Stephenson, Karen Simpson, and Bhakti Kshatriya for providing the data of Strand 1999 (a) study at six months; and the Cochrane Musculoskeletal Editorial team and the Musculoskeletal Consumer group for reviewing our proposal.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-01-03 11:34:03 -0500" MODIFIED_BY="[Empty name]">
<P>MO designed the protocol, searched the literature, extracted data and is responsible for content and updates.</P>
<P>BS extracted data and contributed editorial comments.</P>
<P>VW contributed analysis for additional tables.</P>
<P>VS contributed editorial comments.</P>
<P>GW and PT contributed methodological and statistical guidance.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2009-01-04 02:51:18 -0500" MODIFIED_BY="[Empty name]">
<P>None</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-08-12 09:19:34 -0400" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2009-08-12 09:19:34 -0400" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2009-08-12 09:19:34 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Amit-2004" MODIFIED="2008-12-17 12:22:47 -0500" MODIFIED_BY="[Empty name]" NAME="Amit 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-12-17 12:22:47 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Amit M</AU>
<TI>A comparative 2-year clinical study of combined leflunomide and methotrexate vs methotrexate alone as DMARD in rheumatoid arthritis</TI>
<SO>Abstract book, the 11th APLAR meeting, Jeju, South Korea</SO>
<YR>Sep 2004</YR>
<PG>93</PG>
<CY>Seoul</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Amit-2006" MODIFIED="2009-08-03 22:53:51 -0400" MODIFIED_BY="[Empty name]" NAME="Amit 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-08-03 22:53:51 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amit M, Rakhee M</AU>
<TI>A comparative 3-year clinical study of combined leflunomide and methotrexate vs methotrexate alone as DMARD in rheumatoid arthritis</TI>
<SO>The Journal of Rheumatology</SO>
<YR>2006</YR>
<VL>9 Suppl 1</VL>
<PG>A190</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Antony-2006" MODIFIED="2009-08-03 22:51:38 -0400" MODIFIED_BY="[Empty name]" NAME="Antony 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-08-03 22:51:38 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Antony T, Jose VM, Paul BJ, Thomas T</AU>
<TI>Efficacy and safety of leflunomide alone and in combination with methotrexate in the treatment of refractory rheumatoid arthritis</TI>
<SO>Indian Journal of Medical Sciences</SO>
<YR>2006</YR>
<VL>60</VL>
<NO>8</NO>
<PG>318-26</PG>
<IDENTIFIERS MODIFIED="2008-12-28 02:38:28 -0500" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bao-2000" MODIFIED="2008-12-28 02:42:53 -0500" MODIFIED_BY="[Empty name]" NAME="Bao 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-12-28 02:42:53 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bao CD, Huang WQ, Chen SL, Gu YY</AU>
<TI>Treatment of rheumatoid arthritis with leflunomide: a double blind, randomised controlled study</TI>
<SO>China Journal of Rheumatology</SO>
<YR>2000</YR>
<VL>4</VL>
<PG>44-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bao-2003" MODIFIED="2009-08-03 22:55:58 -0400" MODIFIED_BY="[Empty name]" NAME="Bao 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-08-03 22:55:58 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bao C, Chen S, Gu Y, Lao Z, Ni L, Yu Q, et al</AU>
<TI>Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial</TI>
<SO>Chinese Medical Journal</SO>
<YR>2003</YR>
<VL>116</VL>
<NO>8</NO>
<PG>1228-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-2001" MODIFIED="2009-08-03 22:57:57 -0400" MODIFIED_BY="[Empty name]" NAME="Cohen 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-08-03 22:57:57 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, et al, for the Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group, Strand V</AU>
<TI>Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2001</YR>
<VL>44</VL>
<NO>9</NO>
<PG>1984-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dougados-2005" MODIFIED="2009-08-03 22:59:18 -0400" MODIFIED_BY="[Empty name]" NAME="Dougados 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-08-03 22:59:18 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dougados M, Emery P, Lemmel EM, Zerbini CAF, Brin S, van Riel P</AU>
<TI>When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2005</YR>
<VL>64</VL>
<NO>5</NO>
<PG>44-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Emery-1999" MODIFIED="2009-08-03 23:01:18 -0400" MODIFIED_BY="[Empty name]" NAME="Emery 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-08-03 23:00:09 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Emery P, Breedveld FC, Jubb RW, Sorensen H, Oed C, Loew-Friedrich I</AU>
<TI>Efficacy and safety of leflunomide vs. methotrexate in rheumatoid arthritis (RA): results of a double-blind, randomized, 2-year trial</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1999</YR>
<VL>42 Suppl</VL>
<NO>9</NO>
<PG>271</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-08-03 23:01:18 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gomor B, et al</AU>
<TI>A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis</TI>
<SO>Rheumatology</SO>
<YR>2000</YR>
<VL>39</VL>
<NO>6</NO>
<PG>655-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Emery P, Breedveld FC, Lemmel EM, et al</AU>
<TI>A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis</TI>
<SO>Data on file, Hoechst Marion Roussel (Bridgewater)</SO>
<YR>Nov 2, 1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-22 12:28:40 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>United States Food and Drug Administration</AU>
<TI>Summary basis of approval, leflunomide: NDA 20-905</TI>
<SO>Summary basis of approval, United States Department of Health and Human Services</SO>
<YR>1997</YR>
<VL>ND 20-905</VL>
<PG>2-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fiehn-2007" MODIFIED="2009-08-03 23:01:54 -0400" MODIFIED_BY="[Empty name]" NAME="Fiehn 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-08-03 23:01:54 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fiehn C, Jacki S, Heilig B, Lampe M, Wiesmuller G, Richter C, et al</AU>
<TI>Eight versus 16-week re-evaluation period in rheumatoid arthritis patients treated with leflunomide or methotrexate accompanied by moderate dose prednisone</TI>
<SO>Rheumatology International</SO>
<YR>2007</YR>
<VL>27</VL>
<NO>10</NO>
<PG>975-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gao-2004" MODIFIED="2008-12-17 12:21:35 -0500" MODIFIED_BY="[Empty name]" NAME="Gao 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-12-17 12:21:22 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Gao JS, Wu H, Chen YJ, Li F, Tian J, Xie X</AU>
<TI>Observation on the short-term curative effect and safety on combination use of LEF plus MTX in the treatment of active and severe RA</TI>
<SO>Abstract book, the 11th APLAR meeting, Jeju, South Korea</SO>
<YR>Sep 2004</YR>
<PG>92</PG>
<CY>Seoul</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hu-2001" MODIFIED="2008-12-28 02:44:29 -0500" MODIFIED_BY="[Empty name]" NAME="Hu 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-12-28 02:44:29 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hu Y, Tu S, Liu P</AU>
<TI>A randomized, controlled, single-blind trial of leflunomide in the treatment of rheumatoid arthritis</TI>
<SO>Journal of Tongji Medical University</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>1</NO>
<PG>72-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jakez_x002d_Ocampo-2002" MODIFIED="2009-08-03 23:45:37 -0400" MODIFIED_BY="[Empty name]" NAME="Jakez-Ocampo 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-08-03 23:45:37 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jakez-Ocampo J, Richaud-Patin Y, Simón A, Llorente L</AU>
<TI>Weekly dose of leflunomide for the treatment of refractory rheumatoid arthritis: an open pilot comparative study</TI>
<SO>Joint, Bone, Spine: Revue du Rhumatisme</SO>
<YR>2002</YR>
<VL>69</VL>
<PG>307-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jiang-2001" MODIFIED="2009-08-12 09:17:44 -0400" MODIFIED_BY="[Empty name]" NAME="Jiang 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-08-12 09:17:44 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jiang LD, Yu Q, and Mei ZW</AU>
<TI>Efficacy in Active Rheumatoid Arthritis Treated by Leflunomide in Comparison with Methotrexate: A Randomized and Controlled Trial</TI>
<SO>Clinical Medical Journal of China</SO>
<YR>2001</YR>
<VL>8</VL>
<NO>2</NO>
<PG>157-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kalden-2001" MODIFIED="2009-08-12 09:19:05 -0400" MODIFIED_BY="[Empty name]" NAME="Kalden 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-08-12 09:19:05 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kalden JR, Scott DL, Smolen JS, Schattenkirchner M, Rozman B, Williams BD, et al, for the Eurpoean Leflunomide Study Group</AU>
<TI>Improved functional ability in patients with rheumatoid arthritis - long term treatment with leflunomide versus sulfasalazine</TI>
<SO>The Journal of Rheumatology</SO>
<YR>2001</YR>
<VL>28</VL>
<NO>9</NO>
<PG>1983-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karanikolas-2006" MODIFIED="2009-08-03 23:48:09 -0400" MODIFIED_BY="[Empty name]" NAME="Karanikolas 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-08-03 23:48:09 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karanikolas G, Charalambopoulos D, Andrianakos A, Antoniades C, Katsilambros N</AU>
<TI>Combination of cyclosporine and leflunomide versus single therapy in severe rheumatoid arthritis</TI>
<SO>The Journal of Rheumatology</SO>
<YR>2006</YR>
<VL>33</VL>
<NO>3</NO>
<PG>486-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kremer-2002" MODIFIED="2009-08-03 23:48:44 -0400" MODIFIED_BY="[Empty name]" NAME="Kremer 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-08-03 23:48:44 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, et al</AU>
<TI>Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2002 Nov 5</YR>
<VL>137</VL>
<NO>9</NO>
<PG>726-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kremer-2004" MODIFIED="2009-08-03 23:49:44 -0400" MODIFIED_BY="[Empty name]" NAME="Kremer 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-08-03 23:49:44 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kremer J, Genovese M, Cannon GW, Caldwell J, Cush J, Furst DE, et al</AU>
<TI>Combination leflunomide and methotrexate therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial</TI>
<SO>The Journal of Rheumatology</SO>
<YR>2004</YR>
<VL>31</VL>
<NO>8</NO>
<PG>1521-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lao-2001" MODIFIED="2008-12-29 11:50:47 -0500" MODIFIED_BY="[Empty name]" NAME="Lao 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-12-29 11:50:47 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lao ZY, Ni LQ, Zhang ZF, Zhou JL, et al</AU>
<TI>Leflunomide in treating rheumatoid arthritis: a double-blind study</TI>
<SO>Chinese Journal of New Drugs and Clinical Remedies</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>2</NO>
<PG>94-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lao-2002" MODIFIED="2008-12-03 10:51:10 -0500" MODIFIED_BY="[Empty name]" NAME="Lao 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-12-03 10:51:10 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lao ZY, Chen JH</AU>
<TI>Leflunomide combined with MTX in the treatment of rheumatoid arthritis</TI>
<SO>Abstract book, the 10th APLAR congress, Bangkok, Thailand</SO>
<YR>Dec 2002</YR>
<PG>140</PG>
<CY>Bangkok</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Larsen-2001" MODIFIED="2009-08-03 23:50:25 -0400" MODIFIED_BY="[Empty name]" NAME="Larsen 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-08-03 23:50:25 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Larsen A, Kvien T, Schattenkirchner M, Rau R, Scott DL, Smolen JS, et al, European Leflunomide Study Group</AU>
<TI>Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine</TI>
<SO>Scandinavian Journal of Rheumatology</SO>
<YR>2001</YR>
<VL>30</VL>
<NO>3</NO>
<PG>135-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lau-2002" MODIFIED="2008-12-17 12:25:26 -0500" MODIFIED_BY="[Empty name]" NAME="Lau 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-12-17 12:25:26 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lau CS, on behalf of the ARAVA Asia Study Group</AU>
<TI>Leflunomide (LEF) versus low dose methotrexate (MTX) in adult Asian patients with active rheumatoid arthritis (RA)</TI>
<SO>Abstract book, the 10th APLAR congress, Bangkok, Thailand</SO>
<YR>Dec 2002</YR>
<PG>141</PG>
<CY>Bangkok</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mariette-2004" MODIFIED="2009-08-03 23:51:09 -0400" MODIFIED_BY="[Empty name]" NAME="Mariette 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-08-03 23:51:09 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mariette X, Bijlsma JWJ, Herold M, Eiselstein J, Spencer-Green GT, Kupper H</AU>
<TI>Efficacy evaluation of adalimumab (Humira<SUP>®</SUP>) in combination with single and multiple disease modifying antirheumatic drugs in the REACT trial</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2004</YR>
<VL>63 Suppl 1</VL>
<PG>278</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mladenovic-1995" MODIFIED="2009-08-03 23:51:39 -0400" MODIFIED_BY="[Empty name]" NAME="Mladenovic 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-08-03 23:51:39 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mladenovic V, Domljan Z, Rozman B, Jajic I, Mihajlovic D, Dordevic J, Popovic M, et al</AU>
<TI>Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1995</YR>
<VL>38</VL>
<NO>11</NO>
<PG>1595-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poor-2004" MODIFIED="2009-07-22 12:10:37 -0400" MODIFIED_BY="[Empty name]" NAME="Poor 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-12-28 02:52:27 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poor G for the Leflunomide Multinational Study Group, Strand V</AU>
<TI>Efficacy and safety of leflunomide 10 mg vs 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomized trial</TI>
<SO>Rheumatology (Oxford)</SO>
<YR>2004</YR>
<VL>43</VL>
<NO>6</NO>
<PG>744-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reece-2002" MODIFIED="2009-08-03 23:52:19 -0400" MODIFIED_BY="[Empty name]" NAME="Reece 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-08-03 23:52:19 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reece RJ, Kraan MC, Radjenovic A, Veale DJ, O'Connor PJ, Ridgway JP, et al</AU>
<TI>Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2002</YR>
<VL>46</VL>
<NO>2</NO>
<PG>366-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rozman-1994a" MODIFIED="2009-08-03 23:53:07 -0400" MODIFIED_BY="[Empty name]" NAME="Rozman 1994a" YEAR="1994">
<REFERENCE MODIFIED="2009-08-03 23:53:07 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rozman B, Domijan Z, Popovic M, Mladenovic V, Mihajlovic D, Jajic I, Zivkovic M, Leflunomide Study Group, Croatia, Slovenia and Yugoslavia, Low-Friedrich I, Oed Ch, Seifert H, Strand V</AU>
<TI>Weekly administration of leflunomide to patients with active rheumatoid arthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1994</YR>
<VL>37 Suppl 9</VL>
<PG>339</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scott-2001" MODIFIED="2008-12-28 02:51:57 -0500" MODIFIED_BY="[Empty name]" NAME="Scott 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-12-28 02:51:57 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scott DL, Smolen JS, Kalden JR, van de Putte LBA, Larsen A, Kvien TK, et al for the European Leflunomide Study Group</AU>
<TI>Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2001</YR>
<VL>60</VL>
<NO>10</NO>
<PG>913-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharp-2000" MODIFIED="2009-08-03 23:54:59 -0400" MODIFIED_BY="[Empty name]" NAME="Sharp 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-08-03 23:54:59 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I, on behalf of the Leflunomide Rheumatoid Arthritis Investigators Group</AU>
<TI>Treatment with leflunomide slows radiographic progression of rheumatoid arthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2000</YR>
<VL>43</VL>
<NO>3</NO>
<PG>495-505</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shuai-2002" MODIFIED="2009-08-03 23:55:49 -0400" MODIFIED_BY="[Empty name]" NAME="Shuai 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-08-03 23:55:49 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shuai ZW, Liu S, Shun GH, Xue JH, Xue SY</AU>
<TI>The phase II clinical trial of leflunomide in treatment of rheumatoid arthritis</TI>
<SO>Acta Universitatis Medicinalis Anhui</SO>
<YR>2002</YR>
<VL>37</VL>
<NO>1</NO>
<PG>41-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smolen-1999" MODIFIED="2009-08-12 09:19:34 -0400" MODIFIED_BY="[Empty name]" NAME="Smolen 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-08-12 09:19:34 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al</AU>
<TI>Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>353</VL>
<PG>259-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Strand-1999a" MODIFIED="2009-08-03 23:56:48 -0400" MODIFIED_BY="[Empty name]" NAME="Strand 1999a" YEAR="1999">
<REFERENCE MODIFIED="2009-08-03 23:56:48 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al</AU>
<TI>Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate</TI>
<SO>Archives in Internal Medicine</SO>
<YR>1999</YR>
<VL>159</VL>
<PG>2542-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strand-1999b" MODIFIED="2009-08-03 23:57:18 -0400" MODIFIED_BY="[Empty name]" NAME="Strand 1999b" YEAR="1999">
<REFERENCE MODIFIED="2009-08-03 23:57:18 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strand V, Tugwell P, Bombardier C, Maetzel A, Crawford B, Dorrier C, et al</AU>
<TI>Function and health-related quality of life: results form a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1999</YR>
<VL>42</VL>
<NO>9</NO>
<PG>1870-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wislowska-2007" MODIFIED="2009-08-03 23:58:09 -0400" MODIFIED_BY="[Empty name]" NAME="Wislowska 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-08-03 23:58:09 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wislowska M, Jakubicz D</AU>
<TI>Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-&#945; blocker plus methotrexate versus methotrexate or leflunomide alone</TI>
<SO>Rheumatology International</SO>
<YR>2007</YR>
<VL>27</VL>
<PG>641-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-08-04 00:21:38 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Balabanova-2004" MODIFIED="2009-08-04 00:01:30 -0400" MODIFIED_BY="[Empty name]" NAME="Balabanova 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-08-04 00:01:30 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Balabanova RM, Makolkin VI, Shostak NA, Chichasova NV, Olyunin YuA, Goryachev DV, et al</AU>
<TI>Changes in indices of inflammatory activity in patients with rheumatoid arthritis during early stages of basic therapy with leflunomide</TI>
<SO>Terapevticheskii Arkhiv</SO>
<YR>2004</YR>
<VL>76</VL>
<NO>5</NO>
<PG>28-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Balabanova-2006" MODIFIED="2008-12-09 22:30:11 -0500" MODIFIED_BY="[Empty name]" NAME="Balabanova 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-12-09 22:30:08 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Balabanova RM, Kashevarov RIu, Oliunin IuA, Smirnov AV, Aleksandrova EN</AU>
<TI>An antidestructive effect of leflunomide in early rheumatoid arthritis</TI>
<SO>Terapevticheskii Arkhiv</SO>
<YR>2006</YR>
<VL>78</VL>
<NO>6</NO>
<PG>6-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dougados-2003" MODIFIED="2009-08-04 00:02:06 -0400" MODIFIED_BY="[Empty name]" NAME="Dougados 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-08-04 00:02:06 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dougados M, Emery P, Lemmel EM, de la Serna R, Zerbini CA, Brin S, van Riel P</AU>
<TI>Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIEF 6-month data</TI>
<SO>The Journal of Rheumatology</SO>
<YR>2003</YR>
<VL>30</VL>
<NO>12</NO>
<PG>2572-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Godinho-2004" MODIFIED="2009-08-04 00:03:31 -0400" MODIFIED_BY="[Empty name]" NAME="Godinho 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-08-04 00:03:31 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Godinho F, Godfrin B, El Mahou S, Navaux F, Zabraniecki L, Cantagrel A</AU>
<TI>Safety of leflunomide plus infliximab combination therapy in rheumatoid arthritis</TI>
<SO>Clinical and Experimental Rheumatology</SO>
<YR>2004</YR>
<VL>22</VL>
<NO>3</NO>
<PG>328-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grijalva-2007" MODIFIED="2009-08-04 00:04:50 -0400" MODIFIED_BY="[Empty name]" NAME="Grijalva 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-08-04 00:04:50 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grijalva CG, Chung CP, Arbogast PG, Stein CM, Mitchel EF Jr, Griffin MR</AU>
<TI>Assessment of adherence to and persistence on disease- modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis</TI>
<SO>Medical Care</SO>
<YR>2007</YR>
<VL>45 Suppl 2</VL>
<NO>10</NO>
<PG>66-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hansen-2004" MODIFIED="2009-08-04 00:06:40 -0400" MODIFIED_BY="[Empty name]" NAME="Hansen 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-08-04 00:06:40 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hansen KE, Cush J, SInghal A, Cooley DA, Cohen S, Patel SR, et al</AU>
<TI>The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2004</YR>
<VL>51</VL>
<NO>2</NO>
<PG>228-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jevtic-1997" MODIFIED="2009-08-04 00:08:01 -0400" MODIFIED_BY="[Empty name]" NAME="Jevtic 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-08-04 00:08:01 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jevtic V, Watt I, Rozman B, Kos-Golja M, Praprotnik S, Logar D, et al</AU>
<TI>Contrast enhanced Gd-DTPA magnetic resonance imaging in the evaluation of rheumatoid arthritis during a clinical trial with DMARDs. A prospective two-year follow-up study on hand joints in 31 patients</TI>
<SO>Clinical and Experimental Rheumatology</SO>
<YR>1997</YR>
<VL>15</VL>
<PG>151-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ju-2007" MODIFIED="2009-08-04 00:08:35 -0400" MODIFIED_BY="[Empty name]" NAME="Ju 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-08-04 00:08:35 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ju JH, Kim SI, Lee JH, Lee SI, Yoo WH, Choe JY, et al</AU>
<TI>Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2007 Jun</YR>
<VL>56</VL>
<NO>6</NO>
<PG>2094-6</PG>
<IDENTIFIERS MODIFIED="2008-12-28 02:54:44 -0500" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kalden-2003" MODIFIED="2009-08-04 00:09:06 -0400" MODIFIED_BY="[Empty name]" NAME="Kalden 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-08-04 00:09:06 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kalden JR, Schattenkirchner M, Sorensen H, Emery P, Deighton C, Rozman B</AU>
<TI>The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2003</YR>
<VL>48</VL>
<NO>6</NO>
<PG>1513-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kraan-2004" MODIFIED="2009-08-04 00:10:11 -0400" MODIFIED_BY="[Empty name]" NAME="Kraan 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-08-04 00:10:11 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kraan MC, Smeets TJ, van Loon MJ, Breedveld FC, Dijkmans BA, Tak PP</AU>
<TI>Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2004</YR>
<VL>63</VL>
<NO>9</NO>
<PG>1056-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuzmanova-2003" MODIFIED="2008-12-09 23:03:56 -0500" MODIFIED_BY="[Empty name]" NAME="Kuzmanova 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-12-09 23:03:53 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuzmanova SI, Solakov PT, Batalov AZ, Staikova ND, Andreev SA, Russafov PB</AU>
<TI>Leflunomide in the treatment of refractory rheumatoid arthritis</TI>
<SO>Folia Medica (Plovdiv)</SO>
<YR>2003</YR>
<VL>45</VL>
<NO>3</NO>
<PG>43-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Litinsky-2006" MODIFIED="2009-08-04 00:10:56 -0400" MODIFIED_BY="[Empty name]" NAME="Litinsky 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-08-04 00:10:56 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Litinsky I, Paran D, Levartovsky D, Wigler I, Kaufman I, Yaron I, et al</AU>
<TI>The effect of leflunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1, and MMP-3 in patients with resistant rheumatoid arthritis</TI>
<SO>Cytokine</SO>
<YR>2006</YR>
<VL>33</VL>
<NO>2</NO>
<PG>106-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mroczkowski-1999" MODIFIED="2009-08-04 00:11:36 -0400" MODIFIED_BY="[Empty name]" NAME="Mroczkowski 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-08-04 00:11:36 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;No control group&lt;/p&gt;" NOTES_MODIFIED="2009-08-04 00:11:36 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mroczkowski PJ, Weinblatt ME, Kremer JM</AU>
<TI>Methotrexate and leflunomide combination therapy for patients with active rheumatoid arthritis</TI>
<SO>Clinical and Experimental Rheumatology</SO>
<YR>1999</YR>
<VL>17 Suppl 18</VL>
<NO>6</NO>
<PG>66-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Popovic-1998" MODIFIED="2009-08-04 00:12:49 -0400" MODIFIED_BY="[Empty name]" NAME="Popovic 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-08-04 00:12:49 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Popovic M, Stefanovic D, Pejnovic N, Popovic R, Glisic B, Obradovic S, et al</AU>
<TI>Comparative study of the clinical efficacy of four DMARDs (leflunomide, methotrexate, cyclosporin, and levamisole) in patients with rheumatoid arthritis</TI>
<SO>Transplantation Proceedings</SO>
<YR>1998</YR>
<VL>30</VL>
<NO>8</NO>
<PG>4135-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Richards-2007" MODIFIED="2009-08-04 00:15:02 -0400" MODIFIED_BY="[Empty name]" NAME="Richards 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-08-04 00:15:02 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Richards BL, Spies J, McGill N, Richards GW, Vaile J, Bleasel JF, Youssef PP</AU>
<TI>Effect of leflunomide on the peripheral nerves in rheumatoid arthritis</TI>
<SO>Internal Medicine Journal</SO>
<YR>2007</YR>
<VL>37</VL>
<NO>2</NO>
<PG>101-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rozman-1994b" MODIFIED="2009-08-04 00:15:51 -0400" MODIFIED_BY="[Empty name]" NAME="Rozman 1994b" YEAR="1994">
<REFERENCE MODIFIED="2009-08-04 00:15:51 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rozman B, Domljan Z, Popovic M, Mladenovic D, Mihajlovic I, Jajic M, Zivkovic M, Leflunomide Study Group, Croatia, Slovenia and Yugoslavia, Low-Friedrich I, Oed Ch, Seifert H, Strand V</AU>
<TI>Long term administration of leflunomide to patients with rheumatoid arthritis (RA)</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1994</YR>
<VL>37 Suppl</VL>
<NO>9</NO>
<PG>339</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sarunhan_x002d_Direskeneli-2007" MODIFIED="2009-08-04 00:16:30 -0400" MODIFIED_BY="[Empty name]" NAME="Sarunhan-Direskeneli 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-08-04 00:16:30 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saruhan-Direskeneli G, Inanc M, Fresko I, Akkoc N, Dalkilic E, Erken E, et al</AU>
<TI>The role of HLA-DRB1 shared epitope alleles in predicting short-term response to leflunomide in rheumatoid arthritis</TI>
<SO>Rheumatology</SO>
<YR>2007</YR>
<VL>46</VL>
<NO>12</NO>
<PG>1842-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strand-2005" MODIFIED="2009-08-04 00:17:12 -0400" MODIFIED_BY="[Empty name]" NAME="Strand 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-08-04 00:17:12 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strand V, Scott DL, Emery P, Kalden JR, Smolen JS, Cannon GW, et al, Leflunomide Rheumatoid Arthritis Investigators Groups</AU>
<TI>Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis</TI>
<SO>The Journal of Rheumatology</SO>
<YR>2005</YR>
<VL>32</VL>
<NO>4</NO>
<PG>590-601</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tchetverikov-2008" MODIFIED="2009-08-04 00:18:17 -0400" MODIFIED_BY="[Empty name]" NAME="Tchetverikov 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-08-04 00:18:17 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tchetverikov I, Kraan MC, van El B, Hanemaaijer R, DeGroot J, Huizinga TW</AU>
<TI>Leflunomide and methotrexate reduce levels of activated matrix metalloproteinases in complexes with alpha2 macroglobulin in serum of rheumatoid arthritis patients</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2008</YR>
<VL>67</VL>
<NO>1</NO>
<PG>128-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-der-Heijde-2004" MODIFIED="2008-12-09 22:57:29 -0500" MODIFIED_BY="[Empty name]" NAME="van der Heijde 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-12-09 22:57:29 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van der Heijde D, Kalden J, Scott D, Smolen J, Strand V</AU>
<TI>Long term evaluation of radiographic disease progression in a subset of patients with rheumatoid arthritis treated with leflunomide beyond 2 years</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2004 Jun</YR>
<VL>63</VL>
<NO>6</NO>
<PG>737-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-der-Kooij-2007" MODIFIED="2009-08-04 00:19:13 -0400" MODIFIED_BY="[Empty name]" NAME="van der Kooij 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-08-04 00:19:13 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, van Zeben D, Kerstens PJ, Gerards AH, et al</AU>
<TI>Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2007</YR>
<VL>66</VL>
<NO>10</NO>
<PG>1356-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Riel-2003" MODIFIED="2009-08-04 00:20:24 -0400" MODIFIED_BY="[Empty name]" NAME="van Riel 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-08-04 00:20:24 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Riel P</AU>
<TI>Lelfunomide improves the clinical response in patients with active rheumatoid arthritis treated with methotrexate</TI>
<SO>Clinical and Experimental Rheumatology</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>6</NO>
<PG>695-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Roon-2005" MODIFIED="2009-08-04 00:21:04 -0400" MODIFIED_BY="[Empty name]" NAME="van Roon 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-08-04 00:21:04 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Roon EN, Jansen TL, van de Laar MA, Janssen M, Yska JP, Keuper R, et al</AU>
<TI>Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2005 Apr</YR>
<VL>64</VL>
<NO>4</NO>
<PG>569-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weinblatt-1999b" MODIFIED="2009-08-04 00:21:38 -0400" MODIFIED_BY="[Empty name]" NAME="Weinblatt 1999b" YEAR="1999">
<REFERENCE MODIFIED="2009-08-04 00:21:38 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;No control group&lt;/p&gt;" NOTES_MODIFIED="2009-08-04 00:21:38 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weinblatt ME, Kremer JM, Coblyn JS, Maier AL, Helfgott SM, Morrell M, et al</AU>
<TI>Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1999</YR>
<VL>42</VL>
<NO>7</NO>
<PG>1322-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-08-04 00:24:52 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Raczkiewicz_x002d_Papierska2007" MODIFIED="2009-08-04 00:24:09 -0400" MODIFIED_BY="[Empty name]" NAME="Raczkiewicz-Papierska2007" YEAR="2007">
<REFERENCE MODIFIED="2009-08-04 00:24:09 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raczkiewicz-Papierska A, Dudek A, Bachta A, Thustochowicz M, Zawadyl B, Sulek M</AU>
<TI>Leflunomide as a second choice treatment in patients with rheumatoid arthritis</TI>
<SO>Polski Merkuriusz Lekarski</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>132</NO>
<PG>547-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shevchuk-2003" MODIFIED="2009-08-04 00:24:34 -0400" MODIFIED_BY="[Empty name]" NAME="Shevchuk 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-08-04 00:24:34 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shevchuk SV, Stanislavchuk MA, Pentiuk OO</AU>
<TI>Efficacy and safety of treatment with methotrexate, leflunomide, detralex, and their combination of patients with rheumatoid arthritis</TI>
<SO>Likarska Sprava</SO>
<YR>2003</YR>
<NO>3-4</NO>
<PG>34-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2004" MODIFIED="2009-08-04 00:24:52 -0400" MODIFIED_BY="[Empty name]" NAME="Zhang 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-08-04 00:24:52 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang X, Cui Y, Luo Q, Yao RY, Zhou H</AU>
<TI>Methotrexate combined with leflunomide or hydroxychloroquine in the treatment of rheumatoid arthritis</TI>
<SO>Zhonghua Yi Xue Za Zhi</SO>
<YR>2004</YR>
<VL>84</VL>
<NO>12</NO>
<PG>1038-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-2006" MODIFIED="2008-11-07 11:42:40 -0500" MODIFIED_BY="[Empty name]" NAME="Zhao 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-11-07 11:42:26 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao YX, Liu Y</AU>
<TI>Clinical observation on effects of leflunomide and total glucosides of paeony on rheumatoid arthritis</TI>
<SO>Chinese Journal of Integrated Traditional and Western Medicine</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>4</NO>
<PG>355-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-11-07 11:35:03 -0500" MODIFIED_BY="[Empty name]"/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2008-12-17 12:36:40 -0500" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-08-11 20:59:53 -0400" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2009-08-11 20:59:53 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Alarcon-1995" MODIFIED="2009-08-04 00:27:34 -0400" MODIFIED_BY="[Empty name]" NAME="Alarcon 1995" TYPE="JOURNAL_ARTICLE">
<AU>Alarcon GS</AU>
<TI>Epidemiology of rheumatoid arthritis</TI>
<SO>Rheumatic Diseases Clinics of North America</SO>
<YR>1995</YR>
<VL>21</VL>
<PG>589-604</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Arnett-1988" MODIFIED="2009-08-04 00:28:02 -0400" MODIFIED_BY="[Empty name]" NAME="Arnett 1988" TYPE="JOURNAL_ARTICLE">
<AU>Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al</AU>
<TI>The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1988</YR>
<VL>31</VL>
<PG>315-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egsmose-1995" MODIFIED="2009-08-04 00:28:29 -0400" MODIFIED_BY="[Empty name]" NAME="Egsmose 1995" TYPE="JOURNAL_ARTICLE">
<AU>Egsmose C, Lund B, Borg G, Pettersson H, Berg E, Brodin U, et al</AU>
<TI>Patients with rheumatoid arthritis benefit from early second line therapy: 5-year follow up of a prospective, double blind, placebo controlled study</TI>
<SO>The Journal of Rheumatology</SO>
<YR>1995</YR>
<VL>22</VL>
<PG>2208-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Felson-1993" MODIFIED="2009-08-04 00:28:46 -0400" MODIFIED_BY="[Empty name]" NAME="Felson 1993" TYPE="JOURNAL_ARTICLE">
<AU>Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al</AU>
<TI>The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1993</YR>
<VL>36</VL>
<PG>729-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Felson-1995" MODIFIED="2008-12-29 11:48:42 -0500" MODIFIED_BY="[Empty name]" NAME="Felson 1995" TYPE="JOURNAL_ARTICLE">
<AU>Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith D, et al</AU>
<TI>American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1995</YR>
<VL>38</VL>
<PG>727-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fox-1998" MODIFIED="2009-08-04 00:29:27 -0400" MODIFIED_BY="[Empty name]" NAME="Fox 1998" TYPE="JOURNAL_ARTICLE">
<AU>Fox RI</AU>
<TI>Mechanism of action of leflunomide in rheumatoid arthritis</TI>
<SO>The Journal of Rheumatology</SO>
<YR>1998</YR>
<VL>25 Suppl</VL>
<NO>53</NO>
<PG>20-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fries-1996" MODIFIED="2009-08-04 00:29:49 -0400" MODIFIED_BY="[Empty name]" NAME="Fries 1996" TYPE="JOURNAL_ARTICLE">
<AU>Fries JF, Williams CA, Morfield D, Singh G, Sibley J</AU>
<TI>Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1996</YR>
<VL>39</VL>
<PG>616-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Furst-1999" MODIFIED="2009-08-04 00:30:11 -0400" MODIFIED_BY="[Empty name]" NAME="Furst 1999" TYPE="JOURNAL_ARTICLE">
<AU>Furst DE</AU>
<TI>Leflunomide, mycophenolic acid and matrix metalloproteinase inhibitors</TI>
<SO>Rheumatology</SO>
<YR>1999</YR>
<VL>38 Suppl 2</VL>
<PG>14-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haynes-1994" MODIFIED="2009-08-04 00:31:37 -0400" MODIFIED_BY="[Empty name]" NAME="Haynes 1994" TYPE="JOURNAL_ARTICLE">
<AU>Haynes R, Wilczynski N, McKibbon KA, Walker CJ, Sinclair JC</AU>
<TI>Developing optimal search strategies for detecting clinically sound studies in MEDLINE</TI>
<SO>Journal of the American Medical Informatics Association</SO>
<YR>1994</YR>
<VL>1</VL>
<PG>447-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2009-07-22 12:15:43 -0400" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2009-08-04 00:32:29 -0400" MODIFIED_BY="[Empty name]" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad A, Moore A, Carrol D</AU>
<TI>Assessing the quality of randomized trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maetzel-2002" MODIFIED="2009-08-04 00:33:31 -0400" MODIFIED_BY="[Empty name]" NAME="Maetzel 2002" TYPE="JOURNAL_ARTICLE">
<AU>Maetzel A, Strand V, Tugwell P, Wells G, Bombardier C</AU>
<TI>Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2002</YR>
<VL>47</VL>
<NO>6</NO>
<PG>655-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pincus-1999" MODIFIED="2009-08-04 00:33:12 -0400" MODIFIED_BY="[Empty name]" NAME="Pincus 1999" TYPE="JOURNAL_ARTICLE">
<AU>Pincus T, Stein CM</AU>
<TI>ACR20: clinical or statistical significance?</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1999</YR>
<VL>42</VL>
<NO>8</NO>
<PG>1572-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rozman-1998" MODIFIED="2009-08-04 00:34:02 -0400" MODIFIED_BY="[Empty name]" NAME="Rozman 1998" TYPE="JOURNAL_ARTICLE">
<AU>Rozman B for the Leflunomide Investigators Group</AU>
<TI>Clinical experience with leflunomide in rheumatoid arthritis</TI>
<SO>The Journal of Rheumatology</SO>
<YR>1998</YR>
<VL>25 Suppl</VL>
<NO>53</NO>
<PG>27-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saag-2008" MODIFIED="2009-08-04 00:35:10 -0400" MODIFIED_BY="[Empty name]" NAME="Saag 2008" TYPE="JOURNAL_ARTICLE">
<AU>Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al</AU>
<TI>American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2008</YR>
<VL>59</VL>
<NO>6</NO>
<PG>762-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2008" MODIFIED="2009-03-07 00:54:07 -0500" MODIFIED_BY="[Empty name]" NAME="Schünemann 2008" TYPE="BOOK_SECTION">
<AU>Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, and Guyatt GH on behalf of the Cochrane Applicability and Recommendations Methods Group</AU>
<TI>Chapter 12: Interpreting results and drawing conclusions</TI>
<SO>Cochrane handbook for systematic reviews of interventions</SO>
<YR>Updated Sep 2008</YR>
<EN>Version 5.0.1</EN>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simon-2000" MODIFIED="2009-08-11 20:59:53 -0400" MODIFIED_BY="[Empty name]" NAME="Simon 2000" TYPE="JOURNAL_ARTICLE">
<AU>Simon LS, Yocum D</AU>
<TI>New and future drug therapies for rheumatoid arthritis</TI>
<SO>Rheumatology (Oxford)</SO>
<YR>2000</YR>
<VL>39 Suppl 1</VL>
<PG>36-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smolen-2000" MODIFIED="2009-08-11 20:59:38 -0400" MODIFIED_BY="[Empty name]" NAME="Smolen 2000" TYPE="JOURNAL_ARTICLE">
<AU>Smolen JS, Emery P</AU>
<TI>Efficacy and safety of leflunomide in active rheumatoid arthritis</TI>
<SO>Rheumatology (Oxford)</SO>
<YR>2000</YR>
<VL>39 Suppl 1</VL>
<PG>48-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tugwell-2004" MODIFIED="2009-08-04 00:36:35 -0400" MODIFIED_BY="[Empty name]" NAME="Tugwell 2004" TYPE="BOOK">
<AU>Tugwell P, Shea B, Boers M, Brooks P, Simon L, Strand V, Wells G (editors)</AU>
<SO>Evidence-based Rheumatology</SO>
<YR>2004</YR>
<PB>BMJ Books</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-der-Heijde-1993" MODIFIED="2009-08-04 00:36:56 -0400" MODIFIED_BY="[Empty name]" NAME="van der Heijde 1993" TYPE="JOURNAL_ARTICLE">
<AU>van der Heijde DM, van Hof M, van Riel PL, van de Putte LB</AU>
<TI>Development of a disease activity score based on judgment in clinical practice by rheumatologists</TI>
<SO>The Journal of Rheumatology</SO>
<YR>1993</YR>
<VL>20</VL>
<PG>573-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Gestel-1996" MODIFIED="2009-08-04 00:37:38 -0400" MODIFIED_BY="[Empty name]" NAME="van Gestel 1996" TYPE="JOURNAL_ARTICLE">
<AU>van Gestel AM, Prevoo ML, van Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL</AU>
<TI>Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1996</YR>
<VL>39</VL>
<PG>34-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Verhagen-1998" MODIFIED="2009-01-04 11:19:42 -0500" MODIFIED_BY="[Empty name]" NAME="Verhagen 1998" TYPE="JOURNAL_ARTICLE">
<AU>Verhagen AP, de Vet HCW, de Bie RA, Kessels AGH, Boers M, Bouter LM, Knipschild PG</AU>
<TI>The Delphi list: a criteria list for quality assessment of randomized controlled trials for conducting systematic review developed by Delphi consensus</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1998</YR>
<VL>51</VL>
<NO>12</NO>
<PG>1235-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weinblatt-1999a" MODIFIED="2009-08-04 00:38:19 -0400" MODIFIED_BY="[Empty name]" NAME="Weinblatt 1999a" TYPE="JOURNAL_ARTICLE">
<AU>Weinblatt ME</AU>
<TI>The role of current strategies in the future treatment of rheumatoid arthritis</TI>
<SO>Rheumatology</SO>
<YR>1999</YR>
<VL>38 Suppl 2</VL>
<PG>19-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wolfe-1991" MODIFIED="2009-08-04 00:38:34 -0400" MODIFIED_BY="[Empty name]" NAME="Wolfe 1991" TYPE="JOURNAL_ARTICLE">
<AU>Wolfe F, Hawley DJ, Cathey MA</AU>
<TI>Clinical and health status measures over time: prognosis and outcome assessment in rheumatoid arthritis</TI>
<SO>The Journal of Rheumatology</SO>
<YR>1991</YR>
<VL>18</VL>
<PG>1290-7</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2009-08-04 00:38:55 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Osiri-2003a" MODIFIED="2009-08-04 00:38:55 -0400" MODIFIED_BY="[Empty name]" NAME="Osiri 2003a" TYPE="JOURNAL_ARTICLE">
<AU>Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V, Tugwell P, Wells G</AU>
<TI>Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis</TI>
<SO>The Journal of Rheumatology</SO>
<YR>2003</YR>
<VL>30</VL>
<NO>6</NO>
<PG>1182-90</PG>
<IDENTIFIERS MODIFIED="2009-01-04 11:42:51 -0500" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Osiri-2003b" MODIFIED="2009-07-22 12:17:16 -0400" MODIFIED_BY="[Empty name]" NAME="Osiri 2003b" TYPE="COCHRANE_REVIEW">
<AU>Osiri M, Shea B, Welch V, Suarez-Almazor ME, Strand V, Tugwell P, Wells GA</AU>
<TI>Leflunomide for the treatment of rheumatoid arthritis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-07-22 12:17:16 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-22 12:17:16 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002047"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-08-12 09:16:05 -0400" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-08-12 09:16:05 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-08-04 01:15:25 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Amit-2004">
<CHAR_METHODS MODIFIED="2009-08-04 01:15:25 -0400" MODIFIED_BY="[Empty name]">
<P>Open-label, randomized, active controlled, parallel group clinical trial</P>
<P>Sample size at entry: total 166, Lef+MTX 83, MTX 83</P>
<P>WIthdrawals: Lef+MTX 8, MTX 10</P>
<P>Trial duration: 24 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-12-04 10:55:22 -0500" MODIFIED_BY="[Empty name]">
<P>Patients who met the ACR classification criteria of RA were included</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-04 01:15:09 -0400" MODIFIED_BY="[Empty name]">
<P>Group A: MTX 7.5 mg/week + folic acid 5 mg/week + Lef 20 mg/d</P>
<P>Group B: MTX 7.5 mg/week + folic acid 5 mg/week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-12-09 21:46:14 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: improvement of each item of ACR core set</P>
<P>Secondary outcomes: duration of morning stiffness, grip strength, RF, ESR, CRP, CBC, LFT, hands X-Ray</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-12-04 11:27:45 -0500" MODIFIED_BY="[Empty name]">
<P>Quality score = 1 (R0, B0,W1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-04 01:14:54 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Amit-2006">
<CHAR_METHODS MODIFIED="2009-08-04 01:14:54 -0400" MODIFIED_BY="[Empty name]">
<P>Open-label, randomized, active controlled, parallel group clinical trial</P>
<P>Sample size at entry: total 466, Lef+MTX 233, MTX 233</P>
<P>WIthdrawals: Lef+MTX 20, MTX 15</P>
<P>Trial duration: 36 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-21 09:33:10 -0500" MODIFIED_BY="[Empty name]">
<P>Patients who met the ACR classification criteria of RA were included</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-21 09:37:01 -0500" MODIFIED_BY="[Empty name]">
<P>Group A: MTX 10 mg/week + folic acid 5 mg/week + Lef 20 mg/day</P>
<P>Group B: MTX 10 mg/week + folic acid 5 mg/week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-12-09 21:46:41 -0500" MODIFIED_BY="[Empty name]">
<P>Improvement of each item of ACR core set</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-21 09:40:24 -0500" MODIFIED_BY="[Empty name]">
<P>Quality score = 2 (R1, B0, W1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-04 01:14:43 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Antony-2006">
<CHAR_METHODS MODIFIED="2009-08-04 01:14:43 -0400" MODIFIED_BY="[Empty name]">
<P>Open-label, non-randomized, active controlled, parallel group clinical trial</P>
<P>Sample size at entry: total 60, Lef 49, Lef+MTX 11</P>
<P>WIthdrawals: Lef 4, Lef+MTX 0</P>
<P>Trial duration: total 6 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-19 10:56:55 -0500" MODIFIED_BY="[Empty name]">
<P>Patients, aged 18-65 years old, with active RA not responded to antimalarials, SSZ, MTX after 3-6 months of treatment.</P>
<P>Excluded patients with:</P>
<P>1. uncontrolled HT</P>
<P>2. hepatic, renal, pulmonary and hematologic diseases</P>
<P>3. overlap syndrome</P>
<P>4. pregnancy and lactation</P>
<P>4. reproductive age with unwilling to use contraception</P>
<P>Wash-out period: 2 weeks</P>
<P>Stable dose of prednisolone &#8804; 10 mg/day of prednisolone</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-04 01:14:29 -0400" MODIFIED_BY="[Empty name]">
<P>All patients received leflunomide loading dose of 100 mg/day for 3 days then 20 mg/day. After 3 months of treatment, if improvement was observed, the patients continued taking leflunomide until 6 months. If no significant improvement was not seen, MTX 5-7.5 mg/week was added on baseline leflunomide</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-19 11:04:50 -0500" MODIFIED_BY="[Empty name]">
<P>1. DAS28 response criteria</P>
<P>2. Physician and patient global assessment of disease activity</P>
<P>3. Remission rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-19 11:05:40 -0500" MODIFIED_BY="[Empty name]">
<P>Quality score = 1 (R0, B0, W1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-04 01:14:21 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bao-2000">
<CHAR_METHODS MODIFIED="2009-08-04 01:14:21 -0400" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, active controlled, parallel group trial</P>
<P>Sample size at entry: total 60, leflunomide 30, MTX 30</P>
<P>Withdrawals: leflunomide: 0, MTX: 4 (serious GI symptoms)</P>
<P>Trial duration: 6 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-04 01:14:10 -0400" MODIFIED_BY="[Empty name]">
<P>Patients who were 18-65 years of age, met the ACR criteria with active RA</P>
<P>Active RA, at least 4 of 5:<BR/>1) 5 or more tender joints<BR/>2) 3 or more swollen joints<BR/>3) morning stiffness lasted at least 1 hour<BR/>4) Westergren ESR at least 28 mm/hr 5) Moderate resting pain</P>
<P>Exclusion criteria:<BR/>1. taking other DMARDs during the last 6 months<BR/>2. serious hepatic, renal, hematologic disorders<BR/>3. history of gastrointestinal ulcer<BR/>4. women who were pregnant, breastfeeding<BR/>5. history of allergy to drugs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Leflunomide: 20 mg once daily (no loading dose)</P>
<P>MTX: 15 mg/ week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-04 01:13:55 -0400" MODIFIED_BY="[Empty name]">
<P>1. pain level<BR/>2. duration of morning stiffness (min)<BR/>3. grip strength (Kpa)<BR/>4. tender joint count<BR/>5. swollen joint count<BR/>6. HAQ<BR/>7. patient global assessment of disease activity<BR/>8. physician global assessment of disease activity<BR/>9. ESR (mm/h)<BR/>10. CRP (ug/ml)</P>
<P>Improvement of each of the 10 indices = (value before treatment-value after treatment)/value before treatment x100%</P>
<P>Response rate = average of improvement of the ten indices</P>
<P>Ineffective = improvement &lt;30%<BR/>Effective = improvement 30-50%<BR/>Improvement = improvement 51-75%<BR/>Remarkable improvement = improvement &gt;75%</P>
<P>Total response rate = (number of patients with effective+improvement+ remarkable improvement)/total patientsx100%</P>
<P>Obvious response rate = (number of patients with improvement+ remarkable improvement)/total patientsx100%</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score = 4 <BR/>(R1, B2, W1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-04 01:13:06 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bao-2003">
<CHAR_METHODS MODIFIED="2008-11-20 11:11:06 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, active controlled, parallel group, multicenter trial</P>
<P>Sample size at entry: total 566, Lef 323, MTX 243</P>
<P>Withdrawals: Lef 32, MTX 30</P>
<P>Trial duration: 24 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-04 01:13:06 -0400" MODIFIED_BY="[Empty name]">
<P>Patients who were &#8805;18 years old, met the ACR criteria with active RA</P>
<P>Active RA: at least 4 of 5:<BR/>1) moderate resting pain 2) morning stiffness &#8805; 1 hour<BR/>3) 3 or more swollen joints 4) 5 or more tender joints<BR/>5) Westergren ESR at least 28 mm/hr</P>
<P>Exclusion criteria:</P>
<P>1. any acute or chronic illness in heart, liver, renal, GI and other vital organs 2. history of sensitivity to trial drugs or allergies 3. pregnant women or breast-feeding women 4. previous treatment with gold</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-20 11:27:20 -0500" MODIFIED_BY="[Empty name]">
<P>Leflunomide: 20 mg once daily (no loading dose)</P>
<P>MTX: 15 mg/ week </P>
<P>NSAIDs (Neptlung 0.4 g/day) was permitted in the first 4-6 weeks of the trial</P>
<P>Glucocorticoids and other DMARDs were not allowed in the trial and the washout period was at least 1 month</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-04 01:12:48 -0400" MODIFIED_BY="[Empty name]">
<P>1. resting pain level<BR/>2. duration of morning stiffness (min)<BR/>3. grip strength (Kpa)<BR/>4. tender joint count<BR/>5. swollen joint count<BR/>6. HAQ<BR/>7. patient global assessment of disease activity<BR/>8. physician global assessment of disease activity<BR/>9. ESR (mm/h)<BR/>10. CRP (ug/ml)</P>
<P>Improvement of each of the 10 indices = (value before treatment-value after treatment)/ value before treatment x100%</P>
<P>General effective rate Ineffective = improvement &lt;30%<BR/>Effective = improvement 30 to &lt;50%<BR/>Remarkable improvement = improvement &#8805;50%</P>
<P>Total response rate = (number of patients with effective+ remarkable improvement) / total patients x100%</P>
<P>ACR20 response rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-20 11:44:31 -0500" MODIFIED_BY="[Empty name]">
<P>Quality score = 4<BR/>(R1, B2, W1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-04 01:12:17 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cohen-2001">
<CHAR_METHODS>
<P>Randomized, double-blind, active controlled, parallel group, multinational trial</P>
<P>Sample size at entry; total 199, leflunomide 98, MTX 101.</P>
<P>Withdrawals: leflunomide 15, MTX 21</P>
<P>Trial duration: 12 months (year 2 extension from Strand 1999 (a) study<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-04 01:12:17 -0400" MODIFIED_BY="[Empty name]">
<P>Patients who were 18-75 years of age, met the ACR criteria for 6 months or more, with active RA and never been treated with MTX.<BR/>Active RA, at least 3 of 4:<BR/>1) 9 or more tender joints<BR/>2) 6 or more swollen joints<BR/>3) morning stiffness lasted at least 45 minutes<BR/>4) Westergren ESR at least 28 mm/hr</P>
<P>No other DMARD treatment within the last 30 days</P>
<P>Stable dose of NSAID and/or prednisone (not more than 10 mg/day) for at least 30 days</P>
<P>Required contraceptions during the study and continued at least 6 months after the study ended</P>
<P>All patients who continued treatment into the second year and received at least 1 dose of study medication and attended 1 follow-up visit after week 52 were included in the year-2 cohort, regardless of the ACR responder status</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-04 01:11:38 -0400" MODIFIED_BY="[Empty name]">
<P>Leflunomide: 20 mg/day if the problems with tolerability occurred, the dose was reduced to 10 mg/day</P>
<P>MTX: 15-17.5-20 mg/week<BR/>Almost all patients received 1-2 mg folate daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-04 01:11:20 -0400" MODIFIED_BY="[Empty name]">
<P>Tender and swollen joint counts (28 joints), patient global and physician global assessments using 10 cm VAS, patient assessment of pain on 10-cm VAS, modified HAQ score, Westergren ESR, CRP, HAQ DI, PET, SF-36, work productivity index</P>
<P>Hands and feet X-ray: modified Sharp score</P>
<P>Number of patients met the ACR20, ACR50, ACR70 response criteria</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score = 3<BR/>(R1, B1, W1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-12-09 10:51:23 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dougados-2005">
<CHAR_METHODS MODIFIED="2008-12-09 10:51:23 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, active controlled, parallel group, multinational trial</P>
<P>Sample size at entry: total 106, leflunomide+SSZ 56, placebo+SSZ 50</P>
<P>Withdrawals:<BR/>leflunomide+SSZ 32 (57%)<BR/>placebo+SSZ 27 (54%)</P>
<P>Trial duration: 24 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Patients who were 18-75 years of age, with active RA as defined by a DAS28 &gt;3.2 and ARA functional class I,II, or III. </P>
<P>FIrst open label phase: No other DMARD treatment for at least 4 weeks. Stable NSAIDs dose and prednisone dose &lt;=10 mg/day. No intraarticular steroid injection within 4 weeks.</P>
<P>Second double blind phase: Patients not responded to leflunomide after 24 weeks of the first open label phase</P>
<P>Stable dose of NSAID and/or prednisone (not more than 10 mg/day) for at least 30 days.</P>
<P>Required contraceptions.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>First open label phase: leflunomide loading 100 mg/d for 3 days followed by 20 mg/d for 24 weeks in all patients</P>
<P>Second double blind phase: Patients not responded adequately to leflunomide 20 mg/d (DAS28 &gt; 3.2) were randomized to received either leflunomide 20 mg/d plus SSZ 2 g/d or SSZ 2 g/d plus placebo for 24 weeks</P>
<P>Second open label phase: Patients who were good or moderate responders in the first open label phase entered a second open label phase of 24 weeks leflunomide monotherapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. DAS28 response rate (sum of good and moderate responders) every 4 weeks<BR/>2. number of patients with sustained DAS28 responders at week 24<BR/>3. ACR20, 50, and 70 response rates every 4 weeks<BR/>4. Sustained responders for ACR criteria at week 24</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score = 3 (R1, B1, W1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-12 09:16:05 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Emery-1999">
<CHAR_METHODS MODIFIED="2008-12-09 10:54:41 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, active controlled, parallel group, multinational trial</P>
<P>Sample size at entry: total 999, leflunomide 501, MTX 498</P>
<P>Withdrawals: leflunomide 152, MTX 111</P>
<P>Trial duration: 52 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-12 09:16:05 -0400" MODIFIED_BY="[Empty name]">
<P>Patients who met the 1987 ACR criteria for RA, had active disease as defined by all of the followings:<BR/>6 or more tender joints; 6 or more swollen joints; patient global assessment of RA condition as fair, poor, or very poor; physician global assessment as fair, poor, or very poor; CRP.2.0 mg/dl or ESR.28 mm/hr</P>
<P>Excluded: women who were pregnant, breastfeeding, or of childbearing potential; men wishing to father a child; previous therapy with leflunomide or MTX at any time</P>
<P>Total 1244 patients were enrolled, 999 were randomized<BR/>Patients completed treatment phase: leflunomide 349, MTX 387</P>
<P>Mean (SD) age:<BR/>lef 58.3 (10.12), MTX 57.79 (10.8)</P>
<P>Men/women:<BR/>lef 354/147, MTX 348/150</P>
<P>Mean (SD) duration of RA in years:<BR/>lef 3.7 (3.16), MTX 3.8 (3.49)</P>
<P>Mean (SD) at RA onset:<BR/>lef 54.6 (10.64), MTX 54.0 (11.21)</P>
<P>Mean (SD) number of DMARDs failed:<BR/>lef 1.1 (1.09), MTX 1.1 (1.12)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Leflunomide: loading 100 mg once daily for 3 days followed by a 20-mg daily maintenance dose <BR/>MTX: single doses of 7.5 mg on days 1, 8, 15, and 22 followed by 10 mg/week and increase to 15 mg/week on or after week 12</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: tender joint count, swollen joint count, patient global assessment, physician global assessment<BR/>Secondary outcomes: responder rates defined as Paulus criteria and ACR20 criteria, joint tenderness score, swollen joint score, duration of morning stiffness, pain intensity, HAQ, X-ray of both hands and feet, ESR, CRP, RF,<BR/>Safety outcomes: standard adverse events, laboratory and clinical safety variables</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score = 3<BR/>(R1, B1, W1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-04 01:09:49 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fiehn-2007">
<CHAR_METHODS MODIFIED="2008-11-07 12:03:13 -0500" MODIFIED_BY="[Empty name]">
<P>Prospective, open-label, randomized controlled trial</P>
<P>Sample size at entry: leflunomide 19, MTX 21</P>
<P>Withdrawals: leflunomide 3, MTX 4</P>
<P>Trial duration: 16 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-04 01:09:49 -0400" MODIFIED_BY="[Empty name]">
<P>Patients who fulfilled the ACR criteria of RA and were MTX-naive with age less than 70 years old</P>
<P>All received prednisone at the initial dose of 20 mg/d with weekly dose reduction by 5 mg/d to 10 mg/d, then prednisone dose was reduced by 2.5 mg/d every week</P>
<P>Allowed previously used DMARDs included sulfasalazine and hydroxychloroquine</P>
<P>Exclusion criteria: renal insufficiency, liver disease, hypertension, and other severe organ disease</P>
<P>Mean (SD) age in years: leflunomide 53 (13), MTX 56 (12)</P>
<P>Female gender: leflunomide 17, MTX 14</P>
<P>Mean disease duration in years: leflunomide 2.46, MTX 2.43</P>
<P>Baseline mean (SD) DAS28: leflunomide 5.46 (0.8), MTX 5.36 (0.8)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-04 01:09:34 -0400" MODIFIED_BY="[Empty name]">
<P>Leflunomide loading dose 100 mg/d for 3 days and then 20 mg/d</P>
<P>MTX 25 mg/week intramuscularly</P>
<P>All patients received oral prednisone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-07 12:12:16 -0500" MODIFIED_BY="[Empty name]">
<P>Disease activity score (DAS)28 at 8 and 16 weeks</P>
<P>Serum C-reactive protein (CRP) level at 8 and 16 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-07 12:13:44 -0500" MODIFIED_BY="[Empty name]">
<P>Quality score = 3 (R2, B0, W1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-04 01:09:15 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gao-2004">
<CHAR_METHODS MODIFIED="2009-08-04 01:09:15 -0400" MODIFIED_BY="[Empty name]">
<P>Randomized, open-label, active-controlled, parallel group, clinical trial</P>
<P>Sample size at entry: 162, MTX+Lef 84, MTX+CQ+SSZ 78</P>
<P>Withdrawals: not mentioned</P>
<P>Trial duration: 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-12-04 10:32:47 -0500" MODIFIED_BY="[Empty name]">
<P>Chinese patients with active and severe RA </P>
<P>Definition of active and severe RA: rest pain VAS &#8805; 8.0 cm, ESR &gt; 60 mm/hr, duration of morning stiffness &gt; 1 hour, Steinbrocker damage score &#8805; grade III, tender joint count &gt; 8, swollen joint count &#8805; 3</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-04 01:09:02 -0400" MODIFIED_BY="[Empty name]">
<P>Active treatment group: MTX + Lef</P>
<P>Control group: MTX+CQ+SSZ</P>
<P>Doses were not mentioned</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-12-04 10:45:41 -0500" MODIFIED_BY="[Empty name]">
<P>Rest pain, duration of morning stiffness, grip strength, tender joint count, tender joint index, swollen joint count, swollen joint index, patient global assessment, physician global assessment, functional class, ESR, CRP, RF, CBC, liver function, renal function</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-12-04 10:47:05 -0500" MODIFIED_BY="[Empty name]">
<P>Quality score = 1 (R1, B0, W0)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-04 01:08:48 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hu-2001">
<CHAR_METHODS MODIFIED="2009-08-04 01:08:48 -0400" MODIFIED_BY="[Empty name]">
<P>Randomized, single-blind, active controlled, parallel group trial</P>
<P>Sample size at entry: total 81 leflunomide 56, MTX 25</P>
<P>Withdrawals: leflunomide: 1, MTX: 0</P>
<P>Trial duration: 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-04 01:08:25 -0400" MODIFIED_BY="[Empty name]">
<P>Patients who were 18-65 years of age, met the ACR criteria with active RA and FC I, II</P>
<P>Exclusion criteria:<BR/>1. Taking other DMARDs during the last 1 month<BR/>2. Clinical evidence of cardiac, hepatic, renal, stomach or duodenal disorders<BR/>3. Previous use of gold salts<BR/>4. Women who were pregnant, breastfeeding<BR/>5. History of allergy to drugs</P>
<P>Oxaprozin 0.4 g/d was allowed for 4-6 weeks after study entry</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Leflunomide: 20 mg once daily (no loading dose)</P>
<P>MTX: 15 mg/ week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-04 01:08:10 -0400" MODIFIED_BY="[Empty name]">
<P>Efficacy outcomes:<BR/>1. resting pain<BR/>2. morning stiffness<BR/>3. swollen joint count<BR/>4. swollen joint score<BR/>5. tender joint count<BR/>6. tender joint score<BR/>7. grip strength<BR/>8. joint function<BR/>9. activity of daily living<BR/>10. physician global assessment<BR/>11. patient global assessment<BR/>12. ESR<BR/>13. CRP<BR/>14. rheumatoid factor<BR/>15. improvement rate (IR)<BR/>16. general therapeutic efficacy</P>
<P>Improvement of each of the 10 indices (IR) = (value before treatment-value after treatment)/ value before treatment x100%</P>
<P>Response rate = average of improvement rate of the 10 indices</P>
<P>Ineffective = improvement &lt;30%<BR/>Effective = improvement 30-&lt;50%<BR/>Improvement = improvement 50-&lt;75%<BR/>Remarkable improvement = improvement &#8805;75%</P>
<P>Total response rate = (number of patients with effective+improvement+ remarkable improvement) / total patientsx100%</P>
<P>Adverse reactions assessment:<BR/>1. slight<BR/>2. mild<BR/>3. severe<BR/>4. dangerous<BR/>5. side reaction rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score = 3 (R1, B1, W1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-21 10:28:45 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jakez_x002d_Ocampo-2002">
<CHAR_METHODS MODIFIED="2008-11-21 10:13:34 -0500" MODIFIED_BY="[Empty name]">
<P>Open-label, randomized, active control, parallel group, clinical trial</P>
<P>Sample size at entry: total 16, weekly Lef 8, daily Lef 8<BR/>
</P>
<P>Withdrawals: weekly Lef 1, daily Lef 2</P>
<P>Trial duration: 12 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-21 10:25:40 -0500" MODIFIED_BY="[Empty name]">
<P>Patients who fulfilled the ACR classification criteria for RA</P>
<P>All had positive rheumatoid factor</P>
<P>Active disease: 1. TJC &#8805; 8 2. SJC &#8805; 8 3. duration of morning stiffness &#8805; 45 minutes 4. ESR &#8805; 28 mm/hr</P>
<P>Refractory to &#8805; 4 DMARDs (chloroquine, d-penicillamine, cyclophosphamide, MTX, SSZ, and glucocorticoids) at a conventional dosage for &#8805; 8 months</P>
<P>Exclusion criteria: pregnancy, nursing, hypertension, infection, abnormal LFT, HIV positive test, hepatitis B and C, GI disturbance, and presence of other inflammatory and/or chronic diseases</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-21 10:26:51 -0500" MODIFIED_BY="[Empty name]">
<P>Weekly Lef: Lef 100 mg/week without loading dose</P>
<P>Daily Lef: Lef 100 mg/day for 3 days then Lef 20 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-21 10:27:36 -0500" MODIFIED_BY="[Empty name]">
<P>ACR20,/50/70 response criteria</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-21 10:28:45 -0500" MODIFIED_BY="[Empty name]">
<P>Quality score = 2 (R1, B0, W1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-04 01:06:49 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jiang-2001">
<CHAR_METHODS MODIFIED="2009-08-04 01:06:49 -0400" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, active controlled, parallel group, trial</P>
<P>Sample size at entry: total 60 leflunomide 30, MTX 30</P>
<P>Withdrawals: none</P>
<P>Trial duration: 3 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-04 01:06:35 -0400" MODIFIED_BY="[Empty name]">
<P>Patients who were 18-65 years of age, met the ACR criteria with active RA</P>
<P>Active RA: at least 4 of 5:<BR/>1) 5 or more tender joints<BR/>2) 3 or more swollen joints<BR/>3) morning stiffness lasted at least 1 hour<BR/>4) Westergren ESR at least 28 mm/hr</P>
<P>Exclusion criteria:<BR/>1. taking other DMARDs during the last 6 months<BR/>2. serious hepatic, renal, hematologic disorders<BR/>3. history of gastrointestinal ulcer<BR/>4. women who were pregnant, breastfeeding<BR/>5. history of allergy to drugs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Leflunomide: 20 mg once daily (no loading dose)</P>
<P>MTX: 15 mg/ week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. pain level <BR/>2. duration of morning stiffness (min)<BR/>3. grip strength (Kpa)<BR/>4. tender joint count<BR/>5. tender joint score<BR/>6. swollen joint count<BR/>7. swollen joint score<BR/>8. HAQ<BR/>9. patient global assessment of disease activity<BR/>10. physician global assessment of disease activity<BR/>11. ESR (mm/h)<BR/>12. CRP (ug/ml)<BR/>15. RF</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score = 3<BR/>(R1, B1, W1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-04 01:06:08 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kalden-2001">
<CHAR_METHODS MODIFIED="2009-08-04 01:06:08 -0400" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, active controlled, parallel group, multicenter study</P>
<P>Sample size at entry (6-12 months): total 197, leflunomide 80, placebo-switch-to-SSZ 41, sulphasalazine 76</P>
<P>Withdrawals (6-12 months): lef 9, pl-SSZ 12, SSZ 8</P>
<P>Sample size at entry (12-24 months): total 146, leflunomide 60, pl-SSZ 26, sulphasalazine 60</P>
<P>Withdrawals (12-24 months): lef 11, pl-SSZ 5, SSZ 14</P>
<P>Trial duration: 18 months (month 6 to 24 extension of Smolen study)</P>
<P>(complementary data with Scott 2001 study)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-04 01:05:50 -0400" MODIFIED_BY="[Empty name]">
<P>Patients aged at least 18 years with active RA based on ACR criteria and ACR functional class I, II, III<BR/>Tender joint count at least 6; swollen joint count at least 6; patient and doctor global assessment as fair, poor, or very poor; CRP more than 20 mg/l or ESR more than 28 mm/hr</P>
<P>Excluded women who were pregnant, breast feeding, or of childbearing potential not taking oral contraceptives</P>
<P>Permitted concomitant stable dose of NSAIDs, oral prednisone (less than 10 mg/day), not more than 3 IA injections or 60 mg of triamcinolone. No IA steroid injection within the first six months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-27 09:58:37 -0500" MODIFIED_BY="[Empty name]">
<P>Leflunomide 20 mg/day, SSZ 2 g/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-04 01:05:30 -0400" MODIFIED_BY="[Empty name]">
<P>Tender joint counts, swollen joint counts, patient global assessment and doctor global assessment, pain intensity, duration of morning stiffness, Westergren ESR, CRP, RF, functional disability (HAQ-DI and mean HAQ score), number of patients met the ACR20, ACR50 and ACR 70 response criteria</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score = 3<BR/>(R1, B1, W1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-04 01:05:15 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karanikolas-2006">
<CHAR_METHODS MODIFIED="2008-11-17 09:22:17 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized, open-label, active controlled, parallel group, 2-center trial</P>
<P>Sample size at entry: total 106</P>
<P>Lef 36, CsA 35, Lef+CsA 35</P>
<P>Withdrawals: Lef 9, CsA 2, Lef+CsA 4</P>
<P>Trial duration: 12 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-17 09:24:20 -0500" MODIFIED_BY="[Empty name]">
<P>Patients with RA refractory to at least one DMARD (MTX compulsorily)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-04 01:05:15 -0400" MODIFIED_BY="[Empty name]">
<P>Leflunomide (Lef) 20 mg/day (with 100-mg loading dose for 3 days)</P>
<P>Cyclosporin (CsA) 2.5-5 mg/kg/day</P>
<P>Combination Lef and CsA dose as above, not mentioned whether loading dose of Lef were prescribed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-17 09:39:57 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: ACR20, ACR50, ACR70 response rate at 12 months</P>
<P>Secondary outcomes: </P>
<P>Assessed at 12 months</P>
<P>1. DAS28 remission rate </P>
<P>2. Change in DAS28 index at 12 months</P>
<P>Assessed at 6 and 12 months </P>
<P>1. Number of tender joints</P>
<P>2. Number of swollen joints</P>
<P>3. Patient global assessment of disease activity</P>
<P>4. Physician global assessment of disease activity</P>
<P>5. Pain score</P>
<P>6. Disability</P>
<P>7. Duration of morning stiffness</P>
<P>8. Hemoglobin</P>
<P>9. ESR</P>
<P>10. CRP</P>
<P>Adverse events and withdrawal rates due to adverse events at 12 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-17 09:41:02 -0500" MODIFIED_BY="[Empty name]">
<P>Quality score = 2 (R1, B0, W1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-04 01:04:40 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kremer-2002">
<CHAR_METHODS MODIFIED="2008-12-28 02:29:57 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, active controlled, parallel group, multinational trial</P>
<P>Sample size at entry: total 263, Lef+MTX 130, MTX 133</P>
<P>Withdrawals: Lef+MTX 30, MTX 33</P>
<P>Trial duration: 24 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-04 01:04:40 -0400" MODIFIED_BY="[Empty name]">
<P>Patients who were 18-75 years of age, met the ACR criteria, with active RA despite &#8805; 6 months of MTX treatment.</P>
<P>Active RA: at least 3 of 4:<BR/>1) 9 or more tender joints<BR/>2) 6 or more swollen joints<BR/>3) morning stiffness lasted at least 45 minutes<BR/>4) Westergren ESR at least 28 mm/hr.</P>
<P>Stable dose of MTX for &#8805; 8 weeks<BR/>Stable dose of NSAID and/or prednisone (not more than 10 mg/day) for at least 30 days.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Leflunomide: loading 100 mg once daily for 2 days followed by 10-20 mg/day if the problems with tolerability occurred, the dose was reduced to 10 mg alternate day.</P>
<P>MTX: 10-15-20 mg/week<BR/>Almost all patients received 1-2 mg folate daily.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-17 09:33:29 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcomes:<BR/>ACR20 response rate at the end of study<BR/>Secondary outcomes:<BR/>1. ACR50 response rate at week 24<BR/>2. ACR70 response rate at week 24<BR/>3. Changes from baseline to week 24 in each component of the ACR response criteria<BR/>4. Changes from baseline to week 24 in RF levels </P>
<P>5. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score = 5<BR/>(R2, B2, W1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-12-06 23:01:57 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kremer-2004">
<CHAR_METHODS>
<P>Open-label extension of study Kremer 2002</P>
<P>Sample size at entry: total 192 <BR/>Lef/Lef+MTX 96,<BR/>Plc/Lef+MTX 96</P>
<P>Withdrawals:<BR/>Lef/Lef+MTX 10<BR/>Plc/Lef+MTX 14</P>
<P>Trial duration: 24 weeks<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Patients who completed the Kremer 2002 study at 24 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-06 23:01:44 -0500" MODIFIED_BY="[Empty name]">
<P>Leflunomide: 10 mg/day at study initiation then adjusted between 10 mg qid and 20 mg/ day+stable MTX dose</P>
<P>Placebo+MTX: placebo was switched to leflunomide 10 mg/day. Leflunomide dosage was adjusted between 10 mg qid and 20 mg/ day + stable dose of MTX</P>
<P>No loading dose of Lef</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Same as Kremer 2002 study</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-12-06 23:01:57 -0500" MODIFIED_BY="[Empty name]">
<P>Quality score = 2<BR/>(R1, B0, W1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-04 01:03:12 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lao-2001">
<CHAR_METHODS MODIFIED="2008-12-27 10:07:45 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, active controlled, parallel group, trial</P>
<P>Sample size at entry: total 80 leflunomide 40, MTX 40</P>
<P>Withdrawals: leflunomide: 4, MTX: 5</P>
<P>Trial duration: 6 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-04 01:03:12 -0400" MODIFIED_BY="[Empty name]">
<P>Patients who were 18-65 years of age, met the ACR criteria with active RA</P>
<P>Active RA: at least 4 of 5:<BR/>1) 5 or more tender joints<BR/>2) 3 or more swollen joints<BR/>3) morning stiffness lasted at least 1 hour<BR/>4) Westergren ESR at least 28 mm/hr.</P>
<P>Exclusion criteria:<BR/>1. taking other DMARDs during the last 6 months<BR/>2. serious hepatic, renal, hematologic disorders<BR/>3. history of gastrointestinal ulcer<BR/>4. women who were pregnant, breastfeeding<BR/>5. history of allergy to drugs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Leflunomide: 20 mg once daily (no loading dose)</P>
<P>MTX: 15 mg/ week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. pain level <BR/>2. duration of morning stiffness (min)<BR/>3. grip strength (Kpa)<BR/>4. tender joint count<BR/>5. tender joint score<BR/>6. swollen joint count<BR/>7. swollen joint score<BR/>8. HAQ<BR/>9. patient global assessment of disease activity<BR/>10. physician global assessment of disease activity<BR/>11. ESR (mm/h)<BR/>12. CRP (ug/ml)<BR/>15. RF</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score = 3<BR/>(R1, B1, W1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-12-06 23:03:28 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lao-2002">
<CHAR_METHODS MODIFIED="2008-12-06 23:03:28 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized, open-label, active controlled, parallel group, clinical trial</P>
<P>Sample size at entry: 64, Lef+MTX 32, MTX 32</P>
<P>Withdrawals: not mentioned</P>
<P>Trial duration: 24 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-12-03 11:07:19 -0500" MODIFIED_BY="[Empty name]">
<P>Patients with RA</P>
<P>Group I: female gender 23, male 9; mean (SD) age 45.88 (12.22) years; mean (SD) disease duration 61.25 (45.08) months</P>
<P>Group II: female gender 25, male 7; mean (SD) age 44.31 (8.39) years; mean (SD) disease duration 40.22 (42.42) months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-03 11:11:36 -0500" MODIFIED_BY="[Empty name]">
<P>NSAIDs were withdrawn one week before starting treatment</P>
<P>Group I: Lef 20 mg/d + MTX 7.5 mg/week, four weeks later, Lef dose was reduced to 10 mg/d</P>
<P>No data on the loading dose of Lef</P>
<P>Group II: MTX 15 mg/week</P>
<P>One NSAID was allowed as needed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-12-03 11:14:41 -0500" MODIFIED_BY="[Empty name]">
<P>Morning stiffness, grip strength, tender joint count, swollen joint count, rest pain, activity of daily living, patient's and physician's global assessment of disease activity, CBC, UA, LFT, Cr, ESR, CRP, RF</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-12-04 09:50:01 -0500" MODIFIED_BY="[Empty name]">
<P>Quality score = 1 (R1, B0, W0)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-04 01:02:13 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Larsen-2001">
<CHAR_METHODS MODIFIED="2009-08-04 01:02:12 -0400" MODIFIED_BY="[Empty name]">
<P>Randomized, open-label, active controlled, parallel group, multinational trial</P>
<P>Sample size at entry: 358<BR/>leflunomide<BR/>n = 133 at 6 mos<BR/>n = 80 at 12 mos<BR/>n = 60 at 24 mos<BR/>SSZ<BR/>n = 133 at 6 mos<BR/>n = 76 at 12 mos<BR/>n = 60 at 24 mos<BR/>Placebo<BR/>n = 92 at 6 mos<BR/>Plc --&gt; SSZ<BR/>n = 41 at 12 mos<BR/>n = 26 at 24 mos</P>
<P>Withdrawals:<BR/>leflunomide 28%, 11%, 18% at 6, 12, 24 mos<BR/>SSZ 38%, 11%, 23% at 6, 12, 24 mos</P>
<P>Trial duration: 6, 12, 24 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-04 01:01:36 -0400" MODIFIED_BY="[Empty name]">
<P>Consenting patients aged = or &gt; 18 years who fulfilled the ACR criteria with active RA and ARA FC I, II, III<BR/>1. tender joint count &#8805;6<BR/>2. swollen joint count &#8805;6<BR/>3. patient and physician global assessment fair, poor or very poor<BR/>4. CRP &gt; 2.0 g/dl<BR/>or ESR &gt; 28 mm/hr</P>
<P>Excluded women who were pregnant or breast feeding, or of childbearing potential without appropriate contraceptions</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Leflunomide loading 100 mg once daily for 3 days followed by 20 mg once daily<BR/>SSZ 0.5 g--&gt;1.0 g --&gt; 1.5 g --&gt; 2.0 g per day <BR/>Patients receiving placebo in the first 24 weeks were switched to SSZ after 24 weeks until study completion.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-04 01:00:49 -0400" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: radiographic analysis of both hands and feet in the intention-to-treat population.<BR/>Larsen scores<BR/>Erosion scores</P>
<P>Secondary outcomes:<BR/>ACR response rate, physician and patient global assessments, pain intensity, duration of morning stiffness, HAQ, ESR, CRP, RF and safety</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-12-06 23:05:13 -0500" MODIFIED_BY="[Empty name]">
<P>Quality score = 2 (R1, B0, W1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-12-04 09:58:16 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lau-2002">
<CHAR_METHODS MODIFIED="2008-12-04 09:23:06 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-controlled, multicenter study</P>
<P>Sample size at entry: 301, Lef 151, MTX 150</P>
<P>Withdrawals: not mentioned (no withdrawals due to alopecia)</P>
<P>Trial duration: 16 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-12-04 09:24:02 -0500" MODIFIED_BY="[Empty name]">
<P>Adult Asian patients with active RA (DAS28 of &gt; 3.2)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-04 09:27:00 -0500" MODIFIED_BY="[Empty name]">
<P>Leflunomide 20 mg/d (loading dose was not mentioned)</P>
<P>MTX 7.5-10 mg/week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-12-04 09:56:28 -0500" MODIFIED_BY="[Empty name]">
<P>EULAR response criteria, tender joint count, swollen joint count, patient's global assessment of disease activity, physician global assessment of disease activity, duration of morning stiffness, general health assessment, pain, ESR, clinical and laboratory adverse reactions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-12-04 09:58:16 -0500" MODIFIED_BY="[Empty name]">
<P>Quality score = 2 (R1, B1, W0)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-21 08:02:35 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mariette-2004">
<CHAR_METHODS MODIFIED="2008-11-21 07:52:42 -0500" MODIFIED_BY="[Empty name]">
<P>Open-label, non-randomized, active controlled, parallel group, multicenter, clinical trial</P>
<P>Sample size at entry: Lef+ADA 115, ADA 242</P>
<P>Withdrawals: not mentioned</P>
<P>Trial duration: 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-21 07:56:23 -0500" MODIFIED_BY="[Empty name]">
<P>Patients with long-standing, moderate to severe RA, despite their concomitant DMARDs</P>
<P>Mean age at study entry: 53 years, mean disease duration 11 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-21 07:59:35 -0500" MODIFIED_BY="[Empty name]">
<P>Adalimumab 40 mg sc every other week</P>
<P>Leflunomide 20 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-21 08:01:43 -0500" MODIFIED_BY="[Empty name]">
<P>1. ACR20 response rate</P>
<P>2. ACR50 response rate</P>
<P>3. EULAR moderate response rate</P>
<P>4. EULAR good response rate</P>
<P>5. Mean change of DAS28</P>
<P>6. Mean change of tender joint count</P>
<P>7. Mean change of swollen joint count</P>
<P>8. Mean change of HAQ </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-21 08:02:35 -0500" MODIFIED_BY="[Empty name]">
<P>Quality score =0 (R0, B0, W0)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-04 00:59:55 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mladenovic-1995">
<CHAR_METHODS MODIFIED="2009-08-04 00:59:55 -0400" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, phase II study</P>
<P>Sample size at entry:<BR/>placebo 102, leflunomide 5mg/day 95, leflunomide 10 mg/day 101, leflunomide 25 mg/day 104</P>
<P>Withdrawals: placebo 13, lef5 8, lef10 11, lef25 13</P>
<P>Trial duration: 24 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-04 00:59:42 -0400" MODIFIED_BY="[Empty name]">
<P>Patients who met the ACR classification criteria for RA,<BR/>active disease: 3 in 4 of<BR/>1) tender joints &#8805;8<BR/>2) swollen joints &#8805;8<BR/>3) morning stiffness &#8805;45 minutes<BR/>4) Westergren ESR &#8805;40 mm/hr</P>
<P>With stable dose of NSAIDs &#8805;4 weeks and/or stable corticosteroid dose at &#8804; 10 mg/day prednisone or equivalent for &#8805;8 weeks</P>
<P>Stop gold, methotrexate, azathioprine &#8805; 3 months</P>
<P>Mean age: 51 years (20-76)<BR/>Male/female: 68/334<BR/>Mean RA duration: 8.3 years (0.8-37.8)<BR/>Mean number of failed DMARDs: 1.1<BR/>NSAIDs used: 95%<BR/>Steroid used: 35%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-04 00:57:33 -0400" MODIFIED_BY="[Empty name]">
<P>Leflunomide loading 50 mg once and then 5 mg/day</P>
<P>Leflunomide loading 100 mg once and then 10 mg/day</P>
<P>Leflunomide 100 mg loading once and then 25 mg/day</P>
<P>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: tender joint count, swollen joint count, tender joint score, swollen joint score, patient global assessment, physician global assessment</P>
<P>Secondary outcomes: duration of morning stiffness, grip strength, HAQ, pain score (VAS), ESR, CRP, Paulus criteria &gt;20%, ACR 20 <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score =4 (R2, B1, W1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-04 00:57:08 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Poor-2004">
<CHAR_METHODS MODIFIED="2008-12-28 02:33:29 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, active controlled, parallel group, multinational trial</P>
<P>Sample size at entry: total 402, Lef10: 202, Lef20: 200</P>
<P>Withdrawals: Lef10: 50, Lef20: 36</P>
<P>Trial duration: 24 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-04 00:57:08 -0400" MODIFIED_BY="[Empty name]">
<P>Patients who were 18-75 years of age, met the ACR criteria, with active RA</P>
<P>Active RA: at least 3 of 4:<BR/>1) 6 or more tender joints<BR/>2) 6 or more swollen joints<BR/>3) physician and patient global assessment not better than 'fair'<BR/>4) Westergren ESR &gt; 28 mm/hr or CRP &gt; 2.0mg/dl</P>
<P>Stable dose of NSAID and/or prednisone (not more than 10 mg/day) for at least 4 weeks.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Leflunomide loading 100 mg once daily for 3 days followed by 10 or 20 mg once daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: tender joint count, swollen joint count, HAQ-DI</P>
<P>Secondary outcomes: ACR20, ACR50, ACR70 response rates and adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score =4 (R2, B1, W1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-04 00:56:41 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reece-2002">
<CHAR_METHODS MODIFIED="2009-08-04 00:56:41 -0400" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, active controlled, parallel group trial</P>
<P>Sample size at entry: total 39<BR/>Leflunomide 18, MTX 21</P>
<P>Withdrawals:<BR/>Lef 0<BR/>MTX 1 (died from acute MI)<BR/>paired MRI scans were available in 34 patients (data lost in 4)</P>
<P>Trial duration: 4 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-04 00:56:17 -0400" MODIFIED_BY="[Empty name]">
<P>Patients aged &#8805;18 years, met the 1987 ACR revised criteria, with active RA were enrolled from 2 centers</P>
<P>Active RA: &#8805; 6 swollen or tender joints and moderate or worse patient and physician global assessment. At least 1 knee joint with active disease, defined by clinically detectable synovitis</P>
<P>Stable dose of NSAID and/or prednisone (not more than 10 mg/day) for at least 4 weeks. No IA steroid injection was allowed during the trial period</P>
<P>No previous treatment with MTX or leflunomide. Other DMARD therapy had to be stopped at least 28 days<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Leflunomide loading 100 mg/d for 3 days followed by 20 mg/d<BR/>MTX initial dose of 7.5 mg/week and was increased to 15 mg/week over 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-01-03 11:22:20 -0500" MODIFIED_BY="[Empty name]">
<P>Clinical assessment:<BR/>1. swollen and tender joint counts (28-joint assessment)<BR/>2. Duration of morning stiffness<BR/>3. Patient and physician global assessment of disease activity (VAS)<BR/>4. Patient pain (VAS)<BR/>5. ESR<BR/>6. CRP<BR/>7. RF level<BR/>8. modified Health Assessment Questionnaire (mHAQ)<BR/>9. ACR20 response rate</P>
<P>Dynamic MRI scans (DEMRI): Measurement of inflamed synovium at knee joint<BR/>1. Initial rate of enhancement (IRE)<BR/>2. Maximal signal intensity enhancement (ME)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score = 3<BR/>(R1, B1, W1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-12-28 02:35:00 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rozman-1994a">
<CHAR_METHODS MODIFIED="2008-12-28 02:35:00 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized, single blind, active controlled, parallel group, clinical trial</P>
<P>Sample size at entry: 49, Lef 100mg/week 24, Lef 200 mg/week 23</P>
<P>Withdrawals: 2</P>
<P>Trial duration: 6 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-12-17 12:52:04 -0500" MODIFIED_BY="[Empty name]">
<P>Patients with active RA with 3 of 4 of the following:</P>
<P>1) &#8805; 8 tender joints</P>
<P>2) &#8805; 8 swollen joints</P>
<P>3) Duration of morning stiffness &#8805; 45 minutes</P>
<P>4) ESR &#8805; 40 mm/hr</P>
<P>47 patients were enrolled, with 15 men and 34 women</P>
<P>Mean disease duration: 9.6 years</P>
<P>Mean number of failed DMARDs: 1.1</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-17 12:52:47 -0500" MODIFIED_BY="[Empty name]">
<P>Leflunomide 100 mg weekly and 200 mg weekly</P>
<P>A loading dose of 200 mg was given</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-12-17 12:54:05 -0500" MODIFIED_BY="[Empty name]">
<P>Number of tender joints, number of swollen joints, patient assessment of disease activity, physician assessment of disease activity, Paulus20 response rate, adverse events, number of withdrawals due to adverse events and lack of efficacy</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-12-17 12:54:27 -0500" MODIFIED_BY="[Empty name]">
<P>Quality score=3 (R1, B1, W1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-04 00:54:57 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Scott-2001">
<CHAR_METHODS MODIFIED="2009-08-04 00:54:57 -0400" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, active controlled, parallel group, multicenter study</P>
<P>Sample size at entry (6-12 months): total 197, leflunomide 80, placebo-switch-to-SSZ 41, sulphasalazine 76</P>
<P>Withdrawals (6-12 months): lef 9, pl-SSZ 12, SSZ 8</P>
<P>Sample size at entry (12-24 months): total 146, leflunomide 60, pl-SSZ 26, sulphasalazine 60</P>
<P>Withdrawals (12-24 months): lef 11, pl-SSZ 5, SSZ 14</P>
<P>Trial duration: 18 months (month 6 to 24 extension of Smolen study)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-04 00:54:42 -0400" MODIFIED_BY="[Empty name]">
<P>Patients aged at least 18 years with active RA based on ACR criteria and ACR functional class I, II, III.<BR/>Tender joint count at least 6; swollen joint count at least 6; patient and doctor global assessment as fair, poor, or very poor; CRP more than 20 mg/l or ESR more than 28 mm/hr</P>
<P>Excluded women who were pregnant, breast feeding, or of childbearing potential not taking oral contraceptives</P>
<P>Permitted concomitant stable dose of NSAIDs, oral prednisone (less than 10 mg/day), not more than 3 IA injections or 60 mg of triamcinolone. No IA steroid injection within the first six months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Leflunomide 20 mg/day, SSZ 2 g/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-04 00:54:46 -0400" MODIFIED_BY="[Empty name]">
<P>Tender joint counts, swollen joint counts, patient global assessment and doctor global assessment, pain intensity, duration of morning stiffness, Westergren ESR, CRP, RF, functional disability (HAQ-DI and mean HAQ score), number of patients met the ACR20, ACR50 and ACR 70 response criteria</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score = 3<BR/>(R1, B1, W1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-12 09:12:18 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sharp-2000">
<CHAR_METHODS>
<P>Combined data from the studies Smolen 1999, Strand 1999 (a), and FDA 1997 (or MN302)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>All patients from the studies Smolen 1999, Strand 1999 (a), and FDA 1997</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-04 00:54:21 -0400" MODIFIED_BY="[Empty name]">
<P>In all 3 studies, a 3-day loading dose of leflunomide (100 mg/day) was followed by 20-mg daily doses.<BR/>Smolen 1999: sulphasalazine was started at 500 mg/day and increased to 2000 mg/day in weekly increment of 500 mg<BR/>Strand 1999 (a): MTX was started at 7.5 mg/week and increased to 15 mg/week over week 6-9 in 60% of the patients<BR/>FDA1997: MTX was initiated at 7.5 mg/week, increased to 10 mg/week at week 4 and to 15 mg/week at week 12, in 53% of the patients</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-12 09:12:18 -0400" MODIFIED_BY="[Empty name]">
<P>Sharp scores obtained from the radiographs of hands and feet at baseline and follow-up (6 months, 12 months, or at early exit)<BR/>- total Sharp score (summation of erosion and joint space narrowing subscores)<BR/>- erosion subscore (34 hand joints and 12 foot joints, on a scale of 0-5)<BR/>- joint space narrowing subscore ( 36 hand joints and 12 foot joints, on a scale of 0-4)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score = 2<BR/>(R1, B1, W0)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-04 00:54:02 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shuai-2002">
<CHAR_METHODS MODIFIED="2009-08-04 00:54:02 -0400" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, active controlled, parallel group, trial</P>
<P>Sample size at entry: total 80 leflunomide 40, MTX 40</P>
<P>Withdrawals:<BR/>leflunomide: 0<BR/>MTX: 2</P>
<P>Trial duration: 6 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Patients who were 18-65 years of age, met the ACR criteria with active RA </P>
<P>Active RA: at least 4 of 5:<BR/>1) 5 or more tender joints<BR/>2) 3 or more swollen joints<BR/>3) morning stiffness lasted at least 1 hour<BR/>4) Westergren ESR at least 28 mm/hr.</P>
<P>Exclusion criteria<BR/>1. taking other DMARDs during the last 6 months<BR/>2. serious hepatic, renal, hematologic disorders<BR/>3. history of gastrointestinal ulcer<BR/>4. women who were pregnant, breastfeeding<BR/>5. history of allergy to drugs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Leflunomide: 20 mg once daily (no loading dose)</P>
<P>MTX: 15 mg/ week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-15 10:30:12 -0400" MODIFIED_BY="[Empty name]">
<P>1. pain level<BR/>2. duration of morning stiffness (min)<BR/>3. grip strength (Kpa)<BR/>4. tender joint count<BR/>5. tender joint score<BR/>6. swollen joint count<BR/>7. swollen joint score<BR/>8. HAQ<BR/>9. patient global assessment of disease activity<BR/>10. physician global assessment of disease activity<BR/>11. ESR (mm/h)<BR/>12. CRP (ug/ml)<BR/>15. RF</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score = 3<BR/>(R1, B1, W1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-04 00:53:37 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smolen-1999">
<CHAR_METHODS MODIFIED="2009-08-04 00:53:37 -0400" MODIFIED_BY="[Empty name]">
<P>Double-blind, randomized controlled, multicenter study</P>
<P>Sample size at entry: leflunomide 133,<BR/>placebo 92, sulphasalazine 132</P>
<P>Withdrawals: lef 37, placebo 41, SSZ 50</P>
<P>Trial duration: 24 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-04 00:53:18 -0400" MODIFIED_BY="[Empty name]">
<P>Met the ACR classification criteria for RA,<BR/>ACR functional class I, II, III,<BR/>Active disease: 1) tender joints &#8805;6<BR/>2) swollen joints &#8805;6<BR/>3) global assessment of fair, poor, or very poor<BR/>4) CRP &#8805;20 or ESR &#8805;28 mm/hr</P>
<P>Age =&gt;18 years, if women must have adequate contraception, and not pregnant</P>
<P>Stable doses of NSAIDs and/or corticosteroid (&#8804;10 mg/day of prednisolone) for &#8805;30 days</P>
<P>Discontinue SSZ &#8805;1 year or other DMARDs =&gt; 28 days</P>
<P>Mean (SD) age: lef 58.3 (10.6), placebo 58.8 (12.2), SSZ 58.9 (11.4)</P>
<P>Male/female: lef 32/101, placebo 23/69, SSZ 41/92</P>
<P>Mean (SD) RA duration: lef 7.6 (8.6), placebo 5.7 (6.5), SSZ 7.4 (10.0)</P>
<P>% never used DMARDs: lef 40, placebo 53, SSZ 51</P>
<P>% NSAIDs used: lef 85, placebo 83, SSZ 82</P>
<P>% corticosteroid used: lef 29, placebo 25, SSZ 28</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Leflunomide 100 mg loading for 3 days, follow by 20 mg/day</P>
<P>SSZ 0.5, 1.0, 1.5 g OD or bid on week 1,2,3 and then 2 g/day</P>
<P>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-04 00:51:38 -0400" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: tender joint count, swollen joint count, patient global assessment, physician global assessment, ACR20, ACR50, Paulus criteria &#8805;20%<BR/>Other outcomes:<BR/>tender joint score, swollen joint score, duration of morning stiffness, pain (VAS), ESR, CRP, RF, HAQ, radiographic changes using Larsen method, and safety</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score = 5 (R2, B2, W1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-04 00:51:11 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Strand-1999a">
<CHAR_METHODS MODIFIED="2009-08-04 00:51:11 -0400" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo and active controlled, multicentre study</P>
<P>Sample size at entry: leflunomide 182, placebo 118, methotrexate 182</P>
<P>Withdrawals: lef 86, placebo 81, MTX 77</P>
<P>Trial duration: 12 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-04 00:51:00 -0400" MODIFIED_BY="[Empty name]">
<P>Met the ACR classification criteria for RA &#8805;6 months,</P>
<P>Active disease: 3 in 4 of<BR/>1) tender joints &#8805;9<BR/>2) swollen joints &#8805;6<BR/>3) morning stiffness &#8805;45 minutes<BR/>4) ESR &#8805;28 mm/hr</P>
<P>Age &#8805;18 years, must have adequate contraception 6 months before and after the trial</P>
<P>Stable doses of NSAIDs and/or corticosteroid (&#8804;10 mg/day of prednisolone) for &#8805;30 days</P>
<P>No previous MTX use or discontinue other DMARDs &#8805; 30 days</P>
<P>No history or clinical of drug or alcohol abuse or take &gt; 1 alcoholic drink/day.</P>
<P>Laboratory: Hb &#8805; 10 or Hct &#8805; 30, WBC &#8805; 3,000, platelet &#8805; 100,000, Cr &lt; 2UNL, albumin &#8805; 3.5 g/dl, normal LFT (AST, ALT, AP, bilirubin &#8804;1.2 UNL for &#8805; 3 times)</P>
<P>Mean (SD) age: lef 54.1 (12.0), placebo 54.6 (10.7), MTX 53.5 (11.8)</P>
<P>% female: lef 72.5, placebo 70.3, MTX 75.3</P>
<P>Mean (SD) RA duration: lef 7.0 (8.6), placebo 6.9 (8.0), MTX 6.5 (8.1)</P>
<P>% no previous DMARDs used: lef 44.5, placebo 39.8, MTX 44.0</P>
<P>% with NSAIDs use: lef 75.2, placebo 65.2, MTX 69.7</P>
<P>% with corticosteroid use: lef 53.8, placebo 55.1, MTX 52.7</P>
<P>Mean (SD) number of failed DMARDs: lef 0.8 (1.0), placebo 0.9 (0.9), MTX 0.9 (1.0)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-04 00:45:21 -0400" MODIFIED_BY="[Empty name]">
<P>Leflunomide 100 mg loading for 3 days and then 20 mg/day</P>
<P>MTX increased to 15 mg/week in week 7-9</P>
<P>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: ACR20 and complete 52 weeks of initial therapy (ACR success), ACR50, ACR70 at 12 months</P>
<P>Secondary outcomes: mean change of tender joint count, swollen joint count, patient global, physician global, pain (VAS), ESR, hand and feet X-Ray films, physical function and quality of life (HAQ, PET, SF-36), duration of morning stiffness, RF titers</P>
<P>Adverse events will also be reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score = 5 (R2, B2, W1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-04 00:44:47 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Strand-1999b">
<CHAR_METHODS>
<P>Same as Strand 1999 (a)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Same as Strand 1999 (a)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Same as Strand 1999 (a)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-04 00:44:47 -0400" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: tender joint count, swollen joint count, patient and physician global assessments of disease activity, pain intensity (VAS), MHAQ scores, Westergren ESR, CRP</P>
<P>Physical function and HRQoL measures: HAQ, PET top-5, SF-36, and questionnaire related to work productivity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality = 4<BR/>(R1, B2, W1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-12-30 08:47:00 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wislowska-2007">
<CHAR_METHODS MODIFIED="2008-12-30 08:47:00 -0500" MODIFIED_BY="[Empty name]">
<P>Open-label, controlled clinical trial</P>
<P>Sample size at entry: MTX 30, Lef 30, anti-TNF+MTX 18</P>
<P>Withdrawals: 1</P>
<P>Trial duration: 24 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-11 12:10:03 -0500" MODIFIED_BY="[Empty name]">
<P>Met the ACR classification criteria for RA,</P>
<P>Steinbrocker stage II, III, IV</P>
<P>Stable doses of NSAIDs and/or corticosteroid (&lt;=10 mg/day of prednisolone) </P>
<P>Exclude patients with concomitant other connective tissue diseases or contraindications to treatment interventions</P>
<P>Mean (SD) age: MTX 61.0 (11.8), Lef 56.6 (9.9), anti-TNF 52.9 (13.2) years</P>
<P>Number (%) female: MTX 25 (83), Lef 27 (90%), anti-TNF 11 (61)</P>
<P>Mean (SD) RA duration: MTX 14.6 (7.5), Lef 12.6 (10.1), anti-TNF 13.0 (9.0) years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-11 12:15:04 -0500" MODIFIED_BY="[Empty name]">
<P>Group I: MTX 15 mg/week</P>
<P>Group II: Lef 20 mg/d</P>
<P>Group III: MTX 15 mg/week + Anti-TNF (infliximab 3 mg/kg week 0, 2, 6 and then every 8 weeks in 12 patients; etanercept 25 mg twice weekly in 6 patients)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-11 12:18:43 -0500" MODIFIED_BY="[Empty name]">
<P>Tender joint count, swollen joint count, duration of morning stiffness, HAQ, pain intensity (VAS), patient and physician global assessment of disease activity (VAS), ESR, CRP, DAS28, ACR20/ACR50/ACR70 response rate, X-Ray of hands and feet</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-11 12:19:45 -0500" MODIFIED_BY="[Empty name]">
<P>Quality = 1 </P>
<P>(R0, B0, W1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-08-03 22:44:28 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Balabanova-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Single-arm study, no comparator</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 22:43:08 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Balabanova-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 22:43:08 -0400" MODIFIED_BY="[Empty name]">
<P>Single-arm study without control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-09 23:10:20 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dougados-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-09 23:10:20 -0500" MODIFIED_BY="[Empty name]">
<P>Open-label, single-arm study, no comparator</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-09 22:56:02 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Godinho-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-09 22:56:02 -0500" MODIFIED_BY="[Empty name]">
<P>Retrospective, single-arm study without control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-09 22:15:05 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grijalva-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-09 22:15:05 -0500" MODIFIED_BY="[Empty name]">
<P>Outcomes do not meet the inclusion criteria of the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-09 23:01:07 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hansen-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-09 23:01:07 -0500" MODIFIED_BY="[Empty name]">
<P>Retrospective, single-arm study without control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jevtic-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open-label study, no comparator</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-09 22:24:08 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ju-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-09 22:24:08 -0500" MODIFIED_BY="[Empty name]">
<P>Retrospective study without control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 22:43:22 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kalden-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 22:43:22 -0400" MODIFIED_BY="[Empty name]">
<P>Single-arm study without control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-09 22:52:34 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kraan-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-09 22:52:34 -0500" MODIFIED_BY="[Empty name]">
<P>Subset of Emery 1999 study and outcomes are not clinical-based ones</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 22:43:31 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuzmanova-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 22:43:31 -0400" MODIFIED_BY="[Empty name]">
<P>Single-arm study without control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 22:43:35 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Litinsky-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 22:43:35 -0400" MODIFIED_BY="[Empty name]">
<P>Single-arm study without control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 22:42:44 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mroczkowski-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 22:42:44 -0400" MODIFIED_BY="[Empty name]">
<P>Single-arm study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 22:42:49 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Popovic-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 22:42:49 -0400" MODIFIED_BY="[Empty name]">
<P>Contained pool data from open and/or double-blind studies with different duration of studies and dosages of treatment. (28 patients were treated with leflunomide 10-25 mg per day for 30 weeks. 81 patients were treated with MTX 7.5-15 mg per week for 12-84 weeks)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-21 11:22:50 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Richards-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-21 11:22:50 -0500" MODIFIED_BY="[Empty name]">
<P>Outcomes were neurophysiologic findings from nerve conduction velocity</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-03 11:55:02 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rozman-1994b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-03 11:55:02 -0500" MODIFIED_BY="[Empty name]">
<P>Open-label study comparing the adverse events from different doses of leflunomide (5-25 mg/day)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 22:43:51 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sarunhan_x002d_Direskeneli-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 22:43:51 -0400" MODIFIED_BY="[Empty name]">
<P>Single-arm study, no control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 22:44:00 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Strand-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 22:44:00 -0400" MODIFIED_BY="[Empty name]">
<P>Pooled data on year 2 extension studies from 3 RCTs comparing leflunomide with sulfasalazine or methotrexate. These data were already presented in included studies</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 22:44:07 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tchetverikov-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 22:44:07 -0400" MODIFIED_BY="[Empty name]">
<P>Subset of Emery 1999 trial with non-clinical based outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 22:42:34 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-der-Heijde-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 22:42:34 -0400" MODIFIED_BY="[Empty name]">
<P>Single-arm study, no control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-09 22:20:09 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-der-Kooij-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-09 22:20:09 -0500" MODIFIED_BY="[Empty name]">
<P>Subset of BeSt study without direct comparison between leflunomide and other options</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 22:44:28 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-Riel-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 22:44:28 -0400" MODIFIED_BY="[Empty name]">
<P>Comments on Kremer 2002 study (Evidence-based Rheumatology)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 22:42:29 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-Roon-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 22:42:29 -0400" MODIFIED_BY="[Empty name]">
<P>Single-arm study without control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 22:42:38 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weinblatt-1999b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 22:42:38 -0400" MODIFIED_BY="[Empty name]">
<P>Single-arm study, no comparator</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-08-04 00:43:57 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2009-08-04 00:43:57 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Raczkiewicz_x002d_Papierska2007">
<CHAR_METHODS MODIFIED="2008-11-11 11:33:42 -0500" MODIFIED_BY="[Empty name]">
<P>Open-label, controlled clinical trial</P>
<P>Sample size at entry: MTX+Lef 49, Lef 32</P>
<P>Trial duration: 5 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-04 00:43:57 -0400" MODIFIED_BY="[Empty name]">
<P>Met the ACR criteria for the classification of RA</P>
<P>Mean (SD) age 57.6 (11.7) years, mean (SD) disease duration 7.7 (7.1) years</P>
<P>Active disease: Disease activity score (DAS)28 &gt; 3.2</P>
<P>With contraindication to MTX or inadequate response to MTX for &#8805; 3 months</P>
<P>66 (77.7%) were prescribed stable dose of prednisolone (daily dose 5-15 mg)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-11 11:43:27 -0500" MODIFIED_BY="[Empty name]">
<P>MTX (mean (SD) weekly dose 17 (4.2) mg) + Lef 20 mg/d (without loading dose)</P>
<P>Lef 100 mg/d for 3 days then 20 mg/d </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-04 00:43:00 -0400" MODIFIED_BY="[Empty name]">
<P>Tender joint count, swollen joint count, pain score (VAS), global assessments of disease activity (VAS), ESR, CRP, blood count, aminotransferase level, adverse events</P>
<P>The assessment was performed monthly until 5 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-11 11:47:57 -0500" MODIFIED_BY="[Empty name]">
<P>Await for data from full article</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2008-12-30 08:40:48 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shevchuk-2003">
<CHAR_METHODS MODIFIED="2008-12-30 08:33:00 -0500" MODIFIED_BY="[Empty name]">
<P>Open-label, controlled clinical trial</P>
<P>Sample size at entry: 189</P>
<P>Withdrawals:</P>
<P>Trial duration: 6 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-12-30 08:33:27 -0500" MODIFIED_BY="[Empty name]">
<P>Patients with RA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-30 08:37:34 -0500" MODIFIED_BY="[Empty name]">
<P>1) Leflunomide 20 mg/day (with loading dose?)</P>
<P>2) MTX 7.5-10 mg/week</P>
<P>3) Combined MTX and leflunomide</P>
<P>4) Combined MTX and detralex</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-12-30 08:38:56 -0500" MODIFIED_BY="[Empty name]">
<P>Efficacy: clinical and laboratory outcomes</P>
<P>Functional ability: HAQ</P>
<P>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-12-30 08:40:48 -0500" MODIFIED_BY="[Empty name]">
<P>Await data from full article and authors</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2009-08-04 00:42:41 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2004">
<CHAR_METHODS MODIFIED="2008-11-10 09:22:42 -0500" MODIFIED_BY="[Empty name]">
<P>Open-label, randomized controlled trial</P>
<P>Sample size at entry: MTX+Lef 20, MTX+HCQ 20</P>
<P>Withdrawals: MTX+Lef 0, MTX+HCQ 1</P>
<P>Trial duration: 12 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-04 00:42:41 -0400" MODIFIED_BY="[Empty name]">
<P>Met the ACR criteria for the classification of RA</P>
<P>Age 19-65 years, RA disease duration &lt; 2 years</P>
<P>Active disease: at least 3 out of 4 activity indices</P>
<P>1) tender joint count &gt; 5</P>
<P>2) swollen joint count &gt; 3</P>
<P>3) ESR &gt; 30 mm/hr</P>
<P>4) morning stiffness duration &gt; 30 minutes</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-11 11:11:19 -0500" MODIFIED_BY="[Empty name]">
<P>MTX 10-15 mg/week + Lef 20 mg/d (with loading dose?)</P>
<P>MTX 10-15 mg/week + HCQ 400 mg/d</P>
<P>NSAIDs or low dose prednisolone (&lt;10 mg/d) was administered in the first 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-11 11:21:11 -0500" MODIFIED_BY="[Empty name]">
<P>Tender joint count, tender joint score, swollen joint count, swollen joint score, patient global assessment of disease activity, physician global assessment of disease activity, pain score, HAQ, duration of morning stiffness, grip strength, ESR, CRP, ACR20, ACR50</P>
<P>Assessment at baseline, 3, 6, and 12 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-11 11:22:15 -0500" MODIFIED_BY="[Empty name]">
<P>Await for data from full article </P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2009-08-04 00:42:19 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhao-2006">
<CHAR_METHODS MODIFIED="2008-11-10 09:21:23 -0500" MODIFIED_BY="[Empty name]">
<P>Open-label, randomized controlled trial</P>
<P>Sample size at entry: leflunomide 40, leflunomide + total glycosides of paeony (TGP) 40</P>
<P>Withdrawals: await for data from full article</P>
<P>Trial duration: 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-07 11:17:14 -0500" MODIFIED_BY="[Empty name]">
<P>Await for data from full article</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-07 11:17:58 -0500" MODIFIED_BY="[Empty name]">
<P>Leflunomide</P>
<P>Leflunomide +TGP</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-12-06 23:36:49 -0500" MODIFIED_BY="[Empty name]">
<P>Total effectiveness</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-04 00:42:19 -0400" MODIFIED_BY="[Empty name]">
<P>Await data from full article</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2008-12-17 12:36:40 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-08-04 01:09:25 -0400" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2008-12-27 09:59:54 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:48:04 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Amit-2004">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:48:53 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Amit-2006">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:49:44 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Antony-2006">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:50:40 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bao-2000">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:51:34 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bao-2003">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:52:18 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohen-2001">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:53:19 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dougados-2005">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:54:02 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Emery-1999">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:54:58 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fiehn-2007">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:58:52 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gao-2004">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:55:46 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hu-2001">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:57:03 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jakez_x002d_Ocampo-2002">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:58:00 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jiang-2001">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-27 09:59:54 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kalden-2001">
<DESCRIPTION>
<P>A-adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:00:12 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Karanikolas-2006">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:01:04 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kremer-2002">
<DESCRIPTION>
<P>A-adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:02:12 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kremer-2004">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:02:54 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lao-2001">
<DESCRIPTION>
<P>A-adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:03:49 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lao-2002">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:05:21 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Larsen-2001">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:06:09 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lau-2002">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:06:52 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mariette-2004">
<DESCRIPTION>
<P>C-no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:07:31 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mladenovic-1995">
<DESCRIPTION>
<P>A-adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:24:12 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poor-2004">
<DESCRIPTION>
<P>A-adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:25:02 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Reece-2002">
<DESCRIPTION>
<P>A-adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-17 12:54:38 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rozman-1994a">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:26:44 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Scott-2001">
<DESCRIPTION>
<P>A-adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:27:28 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sharp-2000">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:28:12 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shuai-2002">
<DESCRIPTION>
<P>A-adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:28:58 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smolen-1999">
<DESCRIPTION>
<P>A-adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:34:13 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Strand-1999a">
<DESCRIPTION>
<P>A-adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:34:55 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Strand-1999b">
<DESCRIPTION>
<P>A-adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:35:42 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wislowska-2007">
<DESCRIPTION>
<P>C-no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-08-04 01:09:25 -0400" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:48:11 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Amit-2004">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:48:58 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Amit-2006">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:50:00 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Antony-2006">
<DESCRIPTION>
<P>C-no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:50:45 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bao-2000">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:51:41 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bao-2003">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:52:32 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohen-2001">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:53:26 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dougados-2005">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:54:17 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Emery-1999">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-04 01:09:25 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fiehn-2007">
<DESCRIPTION>
<P>A-adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:59:00 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gao-2004">
<DESCRIPTION>
<P>A-adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:55:52 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hu-2001">
<DESCRIPTION>
<P>A-adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:57:16 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jakez_x002d_Ocampo-2002">
<DESCRIPTION>
<P>A-adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:58:09 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jiang-2001">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-27 10:00:00 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kalden-2001">
<DESCRIPTION>
<P>A-adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:00:21 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karanikolas-2006">
<DESCRIPTION>
<P>A-adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:01:10 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kremer-2002">
<DESCRIPTION>
<P>A-adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:02:17 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kremer-2004">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:03:04 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lao-2001">
<DESCRIPTION>
<P>A-adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:04:02 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lao-2002">
<DESCRIPTION>
<P>A-adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:05:28 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Larsen-2001">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:06:15 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lau-2002">
<DESCRIPTION>
<P>A-adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:06:56 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mariette-2004">
<DESCRIPTION>
<P>C-no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:07:35 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mladenovic-1995">
<DESCRIPTION>
<P>A-adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:24:14 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poor-2004">
<DESCRIPTION>
<P>A-adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:25:11 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Reece-2002">
<DESCRIPTION>
<P>A-adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-17 12:54:45 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rozman-1994a">
<DESCRIPTION>
<P>A-adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:26:49 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Scott-2001">
<DESCRIPTION>
<P>A-adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:27:36 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharp-2000">
<DESCRIPTION>
<P>A-adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:28:18 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shuai-2002">
<DESCRIPTION>
<P>A-adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:29:02 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smolen-1999">
<DESCRIPTION>
<P>A-adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:34:16 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Strand-1999a">
<DESCRIPTION>
<P>A-adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:35:04 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Strand-1999b">
<DESCRIPTION>
<P>A-adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:35:50 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wislowska-2007">
<DESCRIPTION>
<P>C-no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2008-12-17 12:54:50 -0500" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-06 22:48:17 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Amit-2004">
<DESCRIPTION>
<P>C-no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-06 22:49:02 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Amit-2006">
<DESCRIPTION>
<P>C-no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-06 22:49:55 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Antony-2006">
<DESCRIPTION>
<P>C-no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-06 22:50:53 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bao-2000">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-06 22:51:47 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bao-2003">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-06 22:52:42 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohen-2001">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-06 22:53:31 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dougados-2005">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-06 22:54:22 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Emery-1999">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-06 22:55:05 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fiehn-2007">
<DESCRIPTION>
<P>C-no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-06 22:59:04 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gao-2004">
<DESCRIPTION>
<P>C-no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-06 22:55:59 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hu-2001">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-06 22:57:22 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jakez_x002d_Ocampo-2002">
<DESCRIPTION>
<P>C-no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-06 22:58:16 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jiang-2001">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-06 22:59:42 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kalden-2001">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-06 23:00:27 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Karanikolas-2006">
<DESCRIPTION>
<P>C-no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-06 23:01:18 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kremer-2002">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-06 23:02:23 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kremer-2004">
<DESCRIPTION>
<P>C-no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-06 23:03:10 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lao-2001">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-06 23:04:07 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lao-2002">
<DESCRIPTION>
<P>C-no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-06 23:05:32 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Larsen-2001">
<DESCRIPTION>
<P>C-no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-06 23:06:19 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lau-2002">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-06 23:06:58 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mariette-2004">
<DESCRIPTION>
<P>C-no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-06 23:22:37 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mladenovic-1995">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-06 23:24:19 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poor-2004">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-06 23:25:17 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Reece-2002">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-17 12:54:50 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rozman-1994a">
<DESCRIPTION>
<P>A-Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-06 23:26:57 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Scott-2001">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-06 23:27:43 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharp-2000">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-06 23:28:25 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shuai-2002">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-06 23:29:06 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smolen-1999">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-06 23:34:22 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Strand-1999a">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-06 23:35:10 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Strand-1999b">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-06 23:35:57 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wislowska-2007">
<DESCRIPTION>
<P>C-no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2008-12-17 12:54:55 -0500" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-06 22:48:21 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Amit-2004">
<DESCRIPTION>
<P>C-no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-06 22:49:09 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Amit-2006">
<DESCRIPTION>
<P>C-no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-06 22:50:10 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Antony-2006">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-06 22:51:04 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bao-2000">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-11-20 11:54:17 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bao-2003">
<DESCRIPTION>
<P>B - unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-06 22:52:50 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cohen-2001">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-06 22:53:39 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dougados-2005">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-06 22:54:28 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emery-1999">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-06 22:55:19 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fiehn-2007">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-06 22:59:08 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gao-2004">
<DESCRIPTION>
<P>C-no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-06 22:56:03 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hu-2001">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-06 22:57:35 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jakez_x002d_Ocampo-2002">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-06 22:58:21 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jiang-2001">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-06 22:59:48 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kalden-2001">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-06 23:00:33 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Karanikolas-2006">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-06 23:01:23 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kremer-2002">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-06 23:02:29 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kremer-2004">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-06 23:03:15 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lao-2001">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-06 23:04:13 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lao-2002">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-06 23:05:41 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Larsen-2001">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-06 23:06:27 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lau-2002">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-06 23:07:02 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mariette-2004">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-06 23:22:47 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mladenovic-1995">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-06 23:24:33 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poor-2004">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-06 23:25:22 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reece-2002">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-17 12:54:55 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rozman-1994a">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-06 23:27:02 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Scott-2001">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-06 23:27:49 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sharp-2000">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-06 23:28:31 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shuai-2002">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-06 23:29:13 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smolen-1999">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-06 23:34:31 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Strand-1999a">
<DESCRIPTION>
<P>A-yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-06 23:35:18 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Strand-1999b">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-06 23:36:01 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wislowska-2007">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2008-12-17 12:54:59 -0500" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:48:27 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Amit-2004">
<DESCRIPTION>
<P>C-no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:49:20 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Amit-2006">
<DESCRIPTION>
<P>C-no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:50:14 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Antony-2006">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:51:07 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bao-2000">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-20 11:54:19 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bao-2003">
<DESCRIPTION>
<P>B - unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:52:54 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cohen-2001">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:53:44 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dougados-2005">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:54:31 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emery-1999">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:55:22 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fiehn-2007">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:59:11 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gao-2004">
<DESCRIPTION>
<P>C-no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:56:12 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hu-2001">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:57:38 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jakez_x002d_Ocampo-2002">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:58:29 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jiang-2001">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:59:51 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kalden-2001">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:00:38 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Karanikolas-2006">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:01:27 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kremer-2002">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:02:32 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kremer-2004">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:03:18 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lao-2001">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:04:18 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lao-2002">
<DESCRIPTION>
<P>C-no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:05:45 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Larsen-2001">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:06:33 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lau-2002">
<DESCRIPTION>
<P>C-no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:07:06 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mariette-2004">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:23:21 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mladenovic-1995">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:24:37 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poor-2004">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:25:25 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reece-2002">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-17 12:54:59 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rozman-1994a">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:27:05 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Scott-2001">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:27:52 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sharp-2000">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:28:34 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shuai-2002">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:29:19 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smolen-1999">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:34:37 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Strand-1999a">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:35:22 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Strand-1999b">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:36:06 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wislowska-2007">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2008-12-17 12:55:07 -0500" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:48:33 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Amit-2004">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:49:24 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Amit-2006">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:50:19 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Antony-2006">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:51:10 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bao-2000">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-20 11:54:21 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bao-2003">
<DESCRIPTION>
<P>B - unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:52:59 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cohen-2001">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:53:47 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dougados-2005">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:54:35 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emery-1999">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:55:25 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fiehn-2007">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:59:16 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gao-2004">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:56:16 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hu-2001">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:57:41 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jakez_x002d_Ocampo-2002">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:58:33 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jiang-2001">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 22:59:55 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kalden-2001">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:00:41 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Karanikolas-2006">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:01:30 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kremer-2002">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:02:36 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kremer-2004">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:03:21 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lao-2001">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:04:22 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lao-2002">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:05:48 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Larsen-2001">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:06:38 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lau-2002">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:07:10 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mariette-2004">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:23:38 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mladenovic-1995">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:24:42 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poor-2004">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:25:30 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reece-2002">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-17 12:55:07 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rozman-1994a">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:27:08 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Scott-2001">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:27:55 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sharp-2000">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:28:38 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shuai-2002">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:29:22 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smolen-1999">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:34:40 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Strand-1999a">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:35:26 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Strand-1999b">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-06 23:36:10 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wislowska-2007">
<DESCRIPTION>
<P>B-unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2009-08-12 09:11:02 -0400" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2009-08-12 09:09:44 -0400" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-08-03 22:45:10 -0400" MODIFIED_BY="[Empty name]">Summary of findings: leflunomide versus placebo, 6 months</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>Leflunomide for rheumatoid arthritis versus placebo, 6 months</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>adult patients with rheumatoid arthritis</P>
<P>
<B>Settings: </B>randomized controlled trials</P>
<P>
<B>Intervention:</B> leflunomide ± DMARDs</P>
<P>
<B>Comparison: </B>comparator (placebo or active treatment)</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P/>
<P/>
<P>For outcome</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="MIDDLE">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Absolute differences and</P>
<P>NNTs (95% CI)</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Assumed risk</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Control</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Leflunomide +/- DMARDs</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ACR 50 response</P>
<P>at 6 months</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>143 per 1000</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>331 per 1000 (189 to 579)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>RR 2.32</P>
<P>(1.32 to 4.05)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>221<BR/>(1 study)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>++++<BR/>high</P>
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Absolute risk difference: 19% <BR/>(8 to 30%)</P>
<P>NNT: 6<BR/>(4 to 13)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>HAQ change</P>
<P>(0-3 scale)</P>
<P>6 months</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Mean change in HAQ score in control groups ranged from 8.1 to 0.07 units lower</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>The mean change in HAQ score in the LEF was 0.43 lower (0.52 to 0.33 lower)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>679<BR/>(3 studies)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>++++<BR/>high</P>
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pain change</P>
<P>(0-100 mm VAS)</P>
<P>6 months</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>The mean change in pain (0-100 mm VAS) in control groups ranged from 8.8 mm lower to 3 mm higher</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>The mean change in pain (0-100 mm VAS) in the LEF groups was 13.81 mm lower (15.91 to 11.71 mm lower)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>724<BR/>(3 studies)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>++++<BR/>high</P>
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Radiographic change (Change in Sharp score)</P>
<P>12 months</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Mean change in Sharp score in control group was  5.88</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>The mean change in Sharp score in the intervention groups was 1.63 lower (2.78 to 0.48 lower)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>RR 1.23</P>
<P>(0.91 to 1.66)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>380<BR/>(1 study)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>++++<BR/>high</P>
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Withdrawals due to adverse events</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>58 per 1000</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>158 per 1000</P>
<P>(97 to 259)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>2.73</P>
<P>(1.67 to 4.47)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>727</P>
<P>(3 studies)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>++++<BR/>high</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Absolute risk difference: 10% <BR/>(6 to 15%)</P>
<P>NNH: 10 <BR/>(7 to 17)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: Confidence interval; RR: Risk ratio; NNT: Number needed to treat; MTX: Methotrexate; Lef: Leflunomide; Plc: Placebo; ; GRADE: GRADE Working Group grades of evidence (see explanations)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>GRADE Working Group grades of evidance<BR/>
<B>High quality (++++):</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality (+++O):</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality (++OO):</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality (+OOO):</B> We are very uncertain about the estimate.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2009-08-12 09:11:02 -0400" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-08-03 22:46:27 -0400" MODIFIED_BY="[Empty name]">Summary of findings: leflunomide + methotrexate versus methotrexate, 6 months</TITLE>
<TABLE COLS="7" ROWS="10">
<TR>
<TD COLSPAN="7">
<P>
<B>Leflunomide + MTX vs MTX for rheumatoid arthritis, 6 months</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>adult patients with rheumatoid arthritis</P>
<P>
<B>Settings: </B>randomized controlled trials</P>
<P>
<B>Intervention:</B> leflunomide + MTX</P>
<P>
<B>Comparison: </B>MTX</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P/>
<P/>
<P>For outcome</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="MIDDLE">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Absolute differences and</P>
<P>NNTs (95% CI)</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Assumed risk</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Control</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Leflunomide +/- DMARDs</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ACR 50</P>
<P>at 6 months</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>60 per 1000</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>261 per 1000</P>
<P>(125 to 542)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>RR 4.35</P>
<P>(2.09 to 9.03)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>263<BR/>(1 study)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>++++<BR/>high</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Absolute risk difference: 20% <BR/>(7 to 48%)</P>
<P>NNT: 5<BR/>(4 to 9)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>HAQ change</P>
<P>Range of HAQ: 0-3 scale</P>
<P>(6 months)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>The mean change in HAQ score in the LEF group was 0.1 units lower</P>
<P> </P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>The mean change in HAQ scores in the LEF+MTX groups was<BR/>0.3 lower<BR/>[0.42 to 0.18 lower]</P>
<P> </P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P> </P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>263</P>
<P>(1 study)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>++++<BR/>high </P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Change in pain</P>
<P>(0-100 mm VAS)</P>
<P>6 months</P>
<P> </P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>The mean change in the control group was 8.3 mm lower</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>The mean change in LEF+MTX group was 16.9 mm lower (from 10.10 to 23.7 mm lower)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P> </P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P> 263</P>
<P>(1 study)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P> ++++<BR/>high</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Withdrawals due to adverse events</P>
<P>(6 months)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>68 per 1000</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>124 per 1000</P>
<P>(56 to 270)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1.82 (0.83 to 3.97)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>263</P>
<P>(1 study)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>+++</P>
<P>Moderate</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Absolute risk difference: 5%<BR/>(1 to 20%)<BR/>
</P>
<P>NNH: 17<BR/>(not statistically significant)</P>
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: Confidence interval; RR: Risk ratio; NNT: Number needed to treat; MTX: Methotrexate; Lef: Leflunomide; Plc: Placebo; ; GRADE: GRADE Working Group grades of evidence (see explanations)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality (++++):</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality (+++O):</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality (++OO):</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality (+OOO):</B> We are very uncertain about the estimate.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2009-08-11 20:35:13 -0400" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2009-08-11 20:35:13 -0400" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-08-03 22:46:58 -0400" MODIFIED_BY="[Empty name]">Absolute and relative benefit table of ACR core set outcomes: leflunomide versus placebo</TITLE>
<TABLE COLS="5" ROWS="17">
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Time point</P>
</TH>
<TH>
<P>Scale</P>
</TH>
<TH>
<P>Absolute benefit</P>
</TH>
<TH>
<P>Absolute 95% CI</P>
</TH>
</TR>
<TR>
<TD>
<P>Tender joint count</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>28 joints</P>
</TD>
<TD>
<P>5.0 joints</P>
</TD>
<TD>
<P>3.7 to 6.3 joints</P>
</TD>
</TR>
<TR>
<TD>
<P>Tender joint count</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>28 joints</P>
</TD>
<TD>
<P>4.7 joints</P>
</TD>
<TD>
<P>2.8 to 6.6 joints</P>
</TD>
</TR>
<TR>
<TD>
<P>Swollen joint count</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>28 joints</P>
</TD>
<TD>
<P>3.3 joints</P>
</TD>
<TD>
<P>2.3 to 4.4 joints</P>
</TD>
</TR>
<TR>
<TD>
<P>Swollen joint count</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>28 joints</P>
</TD>
<TD>
<P>8.6 joints</P>
</TD>
<TD>
<P>7.2 to 10.1 joints</P>
</TD>
</TR>
<TR>
<TD>
<P>Patient global</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>5-point scale</P>
<P>and 100 mm VAS</P>
</TD>
<TD>
<P>0.64 (SMD)</P>
</TD>
<TD>
<P>0.49 to 0.79</P>
</TD>
</TR>
<TR>
<TD>
<P>Patient global</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>100 mm VAS</P>
</TD>
<TD>
<P>22.0 mm</P>
</TD>
<TD>
<P>15.6 to 28.4 mm</P>
</TD>
</TR>
<TR>
<TD>
<P>Physician global</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>5 point scale</P>
<P>and 100 mm VAS</P>
</TD>
<TD>
<P>0.67 (SMD)</P>
</TD>
<TD>
<P>0.52 to 0.82</P>
</TD>
</TR>
<TR>
<TD>
<P>Physician global</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>100 mm VAS</P>
</TD>
<TD>
<P>18.0 mm</P>
</TD>
<TD>
<P>11.9 to 24.1 mm</P>
</TD>
</TR>
<TR>
<TD>
<P>Pain</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>100 mm VAS</P>
</TD>
<TD>
<P>13.8 mm</P>
</TD>
<TD>
<P>11.7 to 15.9 mm</P>
</TD>
</TR>
<TR>
<TD>
<P>Pain</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>100 mm VAS</P>
</TD>
<TD>
<P>18.0 mm</P>
</TD>
<TD>
<P>12.0 to 24.0 mm</P>
</TD>
</TR>
<TR>
<TD>
<P>ESR</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>mm/hr</P>
</TD>
<TD>
<P>7.9 mm/hr</P>
</TD>
<TD>
<P>4.9 to 11.0 mm</P>
</TD>
</TR>
<TR>
<TD>
<P>ESR</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>mm/hr</P>
</TD>
<TD>
<P>8.9 mm/hr</P>
</TD>
<TD>
<P>4.1 to 13.7 mm/hr</P>
</TD>
</TR>
<TR>
<TD>
<P>HAQ</P>
</TD>
<TD>
<P>6 month</P>
</TD>
<TD>
<P>0-3 scale</P>
</TD>
<TD>
<P>0.43</P>
</TD>
<TD>
<P>0.33 to 0.52</P>
</TD>
</TR>
<TR>
<TD>
<P>HAQ</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>0-3 scale</P>
</TD>
<TD>
<P>0.48</P>
</TD>
<TD>
<P>0.36 to 0.6</P>
</TD>
</TR>
<TR>
<TD>
<P>SF-36 physical</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>6.6</P>
</TD>
<TD>
<P>4.3 to 8.9</P>
</TD>
</TR>
<TR>
<TD>
<P>PET</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>6.24</P>
</TD>
<TD>
<P>4.0 to 8.5</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2009-08-04 00:41:55 -0400" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-08-04 00:41:55 -0400" MODIFIED_BY="[Empty name]">Responder criteria, number needed to treat: leflunomide versus placebo</TITLE>
<TABLE COLS="5" ROWS="12">
<TR>
<TH>
<P>Criteria</P>
</TH>
<TH>
<P>Time point</P>
</TH>
<TH>
<P>Comparator</P>
</TH>
<TH>
<P>Absolute risk diff</P>
</TH>
<TH>
<P>NNT</P>
</TH>
</TR>
<TR>
<TD>
<P>ACR 20</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>28% (21 to 35%)</P>
</TD>
<TD>
<P>3.6 (2.9 to 4.8)</P>
</TD>
</TR>
<TR>
<TD>
<P>ACR 20</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>26% (15 to 37%)</P>
</TD>
<TD>
<P>3.9 (2.7 to 6.7)</P>
</TD>
</TR>
<TR>
<TD>
<P>ACR 20</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>SSZ</P>
</TD>
<TD>
<P>1% (-13 to 11%)</P>
</TD>
<TD>
<P>100 (cannot calculate 95% CI)</P>
</TD>
</TR>
<TR>
<TD>
<P>ACR20</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>MTX</P>
</TD>
<TD>
<P>5% (-15 to 25%)</P>
</TD>
<TD>
<P>20 (cannot calculate 95% CI)</P>
</TD>
</TR>
<TR>
<TD>
<P>ACR50</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>19% (8 to 30%)</P>
</TD>
<TD>
<P>5.3 (3.3 to 12.5)</P>
</TD>
</TR>
<TR>
<TD>
<P>ACR50</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>26% (18 to 35%)</P>
</TD>
<TD>
<P>3.85 (2.9 to 5.6)</P>
</TD>
</TR>
<TR>
<TD>
<P>ACR50</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>SSZ</P>
</TD>
<TD>
<P>3% (-8 to 14%)</P>
</TD>
<TD>
<P>33 (cannot calculate 95% CI)</P>
</TD>
</TR>
<TR>
<TD>
<P>ACR 50</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>MTX</P>
</TD>
<TD>
<P>3% (-12 to 18%)</P>
</TD>
<TD>
<P>33 (cannot calculate 95% CI)</P>
</TD>
</TR>
<TR>
<TD>
<P>ACR 70</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>16% (9 to 22%)</P>
</TD>
<TD>
<P>6.3 (4.5 to 11.1)</P>
</TD>
</TR>
<TR>
<TD>
<P>ACR70</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>SSZ</P>
</TD>
<TD>
<P>3% (-3 to 10%)</P>
</TD>
<TD>
<P>33 (cannot calculate 95% CI)</P>
</TD>
</TR>
<TR>
<TD>
<P>ACR70</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>MTX</P>
</TD>
<TD>
<P>11% (4 to 18%)</P>
</TD>
<TD>
<P>9.1 (5.6 to 25)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-06-16 23:23:49 -0400" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2009-03-31 21:15:49 -0400" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Treatment responder - ACR20</NAME>
<DICH_OUTCOME CHI2="0.08164961887174922" CI_END="0.6153430784765349" CI_START="0.41578074720075997" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5058140023306883" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="232" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.21088268008544966" LOG_CI_START="-0.3811356246198835" LOG_EFFECT_SIZE="-0.2960091523526666" METHOD="MH" MODIFIED="2009-01-03 22:25:42 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9599972985982314" P_Q="0.0" P_Z="9.403012649803655E-12" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="311" TOTAL_2="413" WEIGHT="100.0" Z="6.8153567539399225">
<NAME>leflunomide vs. placebo, at 6 months</NAME>
<GROUP_LABEL_1>placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7152113269311353" CI_START="0.3659560295851551" EFFECT_SIZE="0.5116013071895424" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="60" LOG_CI_END="-0.14556561615741917" LOG_CI_START="-0.4365710928998727" LOG_EFFECT_SIZE="-0.291068354528646" ORDER="34299" O_E="0.0" SE="0.1709380575388592" STUDY_ID="STD-Mladenovic-1995" TOTAL_1="102" TOTAL_2="101" VAR="0.02921981951515834" WEIGHT="30.418586532136704"/>
<DICH_DATA CI_END="0.7503402220134416" CI_START="0.36473353095230193" EFFECT_SIZE="0.5231388329979879" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="71" LOG_CI_END="-0.12474177255518132" LOG_CI_START="-0.43802430896984695" LOG_EFFECT_SIZE="-0.28138304076251414" ORDER="34300" O_E="0.0" SE="0.18402371266354045" STUDY_ID="STD-Smolen-1999" TOTAL_1="91" TOTAL_2="130" VAR="0.0338647268224733" WEIGHT="29.49790094015575"/>
<DICH_DATA CI_END="0.67507969459288" CI_START="0.35373735584937394" EFFECT_SIZE="0.48867259607316665" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="101" LOG_CI_END="-0.1706449547557922" LOG_CI_START="-0.45131907481178224" LOG_EFFECT_SIZE="-0.3109820147837872" ORDER="34301" O_E="0.0" SE="0.1648693674801901" STUDY_ID="STD-Strand-1999a" TOTAL_1="118" TOTAL_2="182" VAR="0.027181908333317968" WEIGHT="40.083512527707555"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.7019715692279246" CI_START="0.3608572336380819" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.503300624442462" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="95" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.1536804770118852" LOG_CI_START="-0.4426645845393663" LOG_EFFECT_SIZE="-0.2981725307756257" METHOD="MH" MODIFIED="2009-01-03 22:26:25 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="5.2420490519882514E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="118" TOTAL_2="182" WEIGHT="100.0" Z="4.044564432968432">
<NAME>leflunomide vs. placebo, at 12 months</NAME>
<GROUP_LABEL_1>placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7019715692279247" CI_START="0.3608572336380819" EFFECT_SIZE="0.503300624442462" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="95" LOG_CI_END="-0.15368047701188517" LOG_CI_START="-0.4426645845393663" LOG_EFFECT_SIZE="-0.2981725307756257" ORDER="34302" O_E="0.0" SE="0.16975069525604536" STUDY_ID="STD-Strand-1999a" TOTAL_1="118" TOTAL_2="182" VAR="0.02881529853991078" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0971285213405868" CI_START="0.8412749643541392" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9607219981257386" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="202" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.040257505277219996" LOG_CI_START="-0.0750620351360119" LOG_EFFECT_SIZE="-0.017402264929395946" METHOD="MH" MODIFIED="2009-03-31 21:14:46 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.5541615456475906" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="243" TOTAL_2="323" WEIGHT="100.0" Z="0.591535699653672">
<NAME>leflunomide vs. methotrexate, at 3 months</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0971285213405868" CI_START="0.8412749643541392" EFFECT_SIZE="0.9607219981257386" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="202" LOG_CI_END="0.040257505277219996" LOG_CI_START="-0.0750620351360119" LOG_EFFECT_SIZE="-0.017402264929395946" MODIFIED="2008-11-21 05:31:35 -0500" MODIFIED_BY="[Empty name]" ORDER="457" O_E="0.0" SE="0.06773926887966387" STUDY_ID="STD-Bao-2003" TOTAL_1="243" TOTAL_2="323" VAR="0.004588608548351399" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8132673198095044" CI_START="0.500218290237172" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9523809523809523" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.2584618344099575" LOG_CI_START="-0.3008404325498337" LOG_EFFECT_SIZE="-0.021189299069938095" METHOD="MH" MODIFIED="2009-03-31 21:14:57 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.8819423455684119" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="21" TOTAL_2="18" WEIGHT="100.0" Z="0.14850740105336419">
<NAME>leflunomide vs. methotrexate, at 4 months</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8132673198095044" CI_START="0.500218290237172" EFFECT_SIZE="0.9523809523809523" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.2584618344099575" LOG_CI_START="-0.3008404325498337" LOG_EFFECT_SIZE="-0.021189299069938095" ORDER="34304" O_E="0.0" SE="0.3285369202030541" STUDY_ID="STD-Reece-2002" TOTAL_1="21" TOTAL_2="18" VAR="0.10793650793650794" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.561630868771761" CI_END="1.0615754796382435" CI_START="0.8715405070333511" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9618763079409367" ESTIMABLE="YES" EVENTS_1="271" EVENTS_2="334" I2="64.03932502550852" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.0259508786009245" LOG_CI_START="-0.059712423158416524" LOG_EFFECT_SIZE="-0.016880772278745987" METHOD="MH" MODIFIED="2009-03-31 21:15:07 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.06198798486479373" P_Q="0.0" P_Z="0.4398424689018139" Q="0.0" RANDOM="NO" SCALE="8.88" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="453" TOTAL_2="535" WEIGHT="100.0" Z="0.7724592682760207">
<NAME>leflunomide vs. methotrexate, at 6months (24 weeks)</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0885060370614963" CI_START="0.8409951695079767" EFFECT_SIZE="0.9567801832965548" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="207" LOG_CI_END="0.03683084206358449" LOG_CI_START="-0.07520649868729044" LOG_EFFECT_SIZE="-0.01918782831185299" MODIFIED="2008-11-21 05:33:33 -0500" MODIFIED_BY="[Empty name]" ORDER="458" O_E="0.0" SE="0.06581128855084503" STUDY_ID="STD-Bao-2003" TOTAL_1="243" TOTAL_2="323" VAR="0.004331125700722587" WEIGHT="58.33651489967806"/>
<DICH_DATA CI_END="1.1173454932185867" CI_START="0.759177260501588" EFFECT_SIZE="0.921012101210121" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="101" LOG_CI_END="0.04818748161894343" LOG_CI_START="-0.11965680872958057" LOG_EFFECT_SIZE="-0.03573466355531858" ORDER="34306" O_E="0.0" SE="0.09859256699335987" STUDY_ID="STD-Strand-1999a" TOTAL_1="180" TOTAL_2="182" VAR="0.009720494266340154" WEIGHT="32.96595038947851"/>
<DICH_DATA CI_END="1.3397508337679778" CI_START="0.9887440768307858" EFFECT_SIZE="1.150943396226415" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="26" LOG_CI_END="0.12702403599049122" LOG_CI_START="-0.004916105170535247" LOG_EFFECT_SIZE="0.06105396540997798" MODIFIED="2008-11-11 12:23:23 -0500" MODIFIED_BY="[Empty name]" ORDER="818" O_E="0.0" SE="0.07750229203221896" STUDY_ID="STD-Wislowska-2007" TOTAL_1="30" TOTAL_2="30" VAR="0.0060066052702473505" WEIGHT="8.697534710843435"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.606228599060355" CI_END="1.5525890418678157" CI_START="0.7474804607872387" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0772789668551839" ESTIMABLE="YES" EVENTS_1="401" EVENTS_2="345" I2="89.5900874137243" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.19105651659930697" LOG_CI_START="-0.12640015535562832" LOG_EFFECT_SIZE="0.03232818062183934" METHOD="MH" MODIFIED="2009-01-03 22:33:47 -0500" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0019392045353953113" P_Q="0.0" P_Z="0.6897564367580685" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.06253048616751908" TOTALS="YES" TOTAL_1="671" TOTAL_2="677" WEIGHT="100.0" Z="0.3991856231234313">
<NAME>leflunomide vs. methotrexate, at 12 months</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.431288752059266" CI_START="1.1510758129384389" EFFECT_SIZE="1.283558282208589" ESTIMABLE="YES" EVENTS_1="317" EVENTS_2="250" LOG_CI_END="0.15572725834084816" LOG_CI_START="0.06110392837047647" LOG_EFFECT_SIZE="0.10841559335566235" ORDER="34307" O_E="0.0" SE="0.05558221241763383" STUDY_ID="STD-Emery-1999" TOTAL_1="489" TOTAL_2="495" VAR="0.0030893823372389684" WEIGHT="52.99181154877934"/>
<DICH_DATA CI_END="1.0904522777924728" CI_START="0.716976130702748" EFFECT_SIZE="0.8842105263157894" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="95" LOG_CI_END="0.03760666400467908" LOG_CI_START="-0.1444953024586114" LOG_EFFECT_SIZE="-0.05344431922696612" ORDER="34308" O_E="0.0" SE="0.10696759651980872" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="182" VAR="0.011442066705224595" WEIGHT="47.00818845122067"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.5686461442356965" CI_END="1.3738064324071297" CI_START="0.8075584172382853" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0532943312039977" ESTIMABLE="YES" EVENTS_1="332" EVENTS_2="285" I2="82.04231380305723" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.13792554548952093" LOG_CI_START="-0.09282605182460667" LOG_EFFECT_SIZE="0.0225497468324571" METHOD="MH" NO="7" P_CHI2="0.018285004936242966" P_Q="0.0" P_Z="0.7016698912706922" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.030464329442783985" TOTALS="YES" TOTAL_1="504" TOTAL_2="476" WEIGHT="100.0" Z="0.38306726511579586">
<NAME>leflunomide vs. methotrexate, at 2 years</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours leflunomide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1120095431232828" CI_START="0.7446878537338171" EFFECT_SIZE="0.91" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="100" LOG_CI_END="0.046108514321576345" LOG_CI_START="-0.12802572967938916" LOG_EFFECT_SIZE="-0.040958607678906384" ORDER="34309" O_E="0.0" SE="0.10228731690457672" STUDY_ID="STD-Cohen-2001" TOTAL_1="190" TOTAL_2="190" VAR="0.010462695199537308" WEIGHT="44.890502102843406"/>
<DICH_DATA CI_END="1.3179863563848913" CI_START="1.068199779367716" EFFECT_SIZE="1.1865381304871752" ESTIMABLE="YES" EVENTS_1="241" EVENTS_2="185" LOG_CI_END="0.11991091452398193" LOG_CI_START="0.028652483931383473" LOG_EFFECT_SIZE="0.07428169922768268" ORDER="34310" O_E="0.0" SE="0.05360565386660931" STUDY_ID="STD-Emery-1999" TOTAL_1="314" TOTAL_2="286" VAR="0.0028735661264667257" WEIGHT="55.109497897156594"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2760288510455133" CI_START="0.8257053343849237" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0264618011096884" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="71" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.10586049390568614" LOG_CI_START="-0.08317490967991055" LOG_EFFECT_SIZE="0.011342792112887806" METHOD="MH" MODIFIED="2009-01-03 22:27:19 -0500" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.81404611135612" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="132" TOTAL_2="130" WEIGHT="100.0" Z="0.23520952799001488">
<NAME>leflunomide vs. sulfasalazine, at 6 months</NAME>
<GROUP_LABEL_1>SSZ</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2760288510455133" CI_START="0.8257053343849237" EFFECT_SIZE="1.0264618011096884" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="71" LOG_CI_END="0.10586049390568614" LOG_CI_START="-0.08317490967991055" LOG_EFFECT_SIZE="0.011342792112887806" ORDER="34311" O_E="0.0" SE="0.1110403318065187" STUDY_ID="STD-Smolen-1999" TOTAL_1="132" TOTAL_2="130" VAR="0.012329955287701769" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2871062437819107" CI_START="0.8303191106230083" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0337837837837838" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="52" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.10961439708606277" LOG_CI_START="-0.08075496624077991" LOG_EFFECT_SIZE="0.014429715422641409" METHOD="MH" MODIFIED="2009-03-31 21:15:20 -0400" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="0.7663712874957459" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="74" TOTAL_2="78" WEIGHT="100.0" Z="0.29712472680788254">
<NAME>leflunomide vs. sulfasalazine, at 12 months</NAME>
<GROUP_LABEL_1>SSZ</GROUP_LABEL_1>
<GROUP_LABEL_2>Leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2871062437819107" CI_START="0.8303191106230083" EFFECT_SIZE="1.0337837837837838" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="52" LOG_CI_END="0.10961439708606277" LOG_CI_START="-0.08075496624077991" LOG_EFFECT_SIZE="0.014429715422641409" ORDER="34312" O_E="0.0" SE="0.11182390636173375" STUDY_ID="STD-Scott-2001" TOTAL_1="74" TOTAL_2="78" VAR="0.0125045860339978" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9330529751778172" CI_START="0.5717578834660774" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7303974221267454" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="49" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-0.030093697974537936" LOG_CI_START="-0.24278783857567465" LOG_EFFECT_SIZE="-0.13644076827510632" METHOD="MH" MODIFIED="2008-12-31 11:38:49 -0500" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="0.01191717957326695" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="57" TOTAL_2="60" WEIGHT="100.0" Z="2.514587295036696">
<NAME>leflunomide vs. sulfasalazine, at 24 months</NAME>
<GROUP_LABEL_1>SSZ</GROUP_LABEL_1>
<GROUP_LABEL_2>Leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9330529751778172" CI_START="0.5717578834660773" EFFECT_SIZE="0.7303974221267454" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="49" LOG_CI_END="-0.030093697974537936" LOG_CI_START="-0.24278783857567476" LOG_EFFECT_SIZE="-0.13644076827510632" ORDER="34313" O_E="0.0" SE="0.1249375910420839" STUDY_ID="STD-Scott-2001" TOTAL_1="57" TOTAL_2="60" VAR="0.015609401655399004" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.6265815684325445" CI_START="0.2863188904240985" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.42355889724310775" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="60" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="-0.2030223845034222" LOG_CI_START="-0.5431499976427272" LOG_EFFECT_SIZE="-0.3730861910730747" METHOD="MH" MODIFIED="2009-03-31 21:15:31 -0400" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="1.7097435187866662E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="130" WEIGHT="100.0" Z="4.299771435099364">
<NAME>leflunomide+MTX vs MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6265815684325445" CI_START="0.2863188904240985" EFFECT_SIZE="0.42355889724310775" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="60" LOG_CI_END="-0.2030223845034222" LOG_CI_START="-0.5431499976427272" LOG_EFFECT_SIZE="-0.3730861910730747" ORDER="34314" O_E="0.0" SE="0.19979264361686652" STUDY_ID="STD-Kremer-2002" TOTAL_1="133" TOTAL_2="130" VAR="0.03991710044341623" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0581971181918692" CI_START="0.7310307506855259" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8795309168443497" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="112" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.024566574475311027" LOG_CI_START="-0.13606435413358975" LOG_EFFECT_SIZE="-0.055748889829139364" METHOD="MH" MODIFIED="2009-01-01 04:19:00 -0500" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="0.0" P_Z="0.1736850339198393" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="201" TOTAL_2="198" WEIGHT="100.0" Z="1.360458003816208">
<NAME>leflunomide10mg vs leflunomide 20 mg, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef10</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef20</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef10</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0581971181918692" CI_START="0.731030750685526" EFFECT_SIZE="0.8795309168443497" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="112" LOG_CI_END="0.024566574475311027" LOG_CI_START="-0.1360643541335897" LOG_EFFECT_SIZE="-0.055748889829139364" ORDER="34315" O_E="0.0" SE="0.0943554026007887" STUDY_ID="STD-Poor-2004" TOTAL_1="201" TOTAL_2="198" VAR="0.008902941999956924" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8763265886990554" CI_START="0.4911724886012451" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.96" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.27330843283054834" LOG_CI_START="-0.30876596675141155" LOG_EFFECT_SIZE="-0.017728766960431602" METHOD="MH" MODIFIED="2008-12-31 22:27:16 -0500" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="0.0" P_Z="0.9049641692404886" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="56" WEIGHT="100.0" Z="0.11939279500251199">
<NAME>leflunomide+SSZ vs. placebo+SSZ, at 24 weeks</NAME>
<GROUP_LABEL_1>Plc+SSZ</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef+SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8763265886990554" CI_START="0.4911724886012451" EFFECT_SIZE="0.96" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.27330843283054834" LOG_CI_START="-0.30876596675141155" LOG_EFFECT_SIZE="-0.017728766960431602" ORDER="34316" O_E="0.0" SE="0.3419133836291904" STUDY_ID="STD-Dougados-2005" TOTAL_1="50" TOTAL_2="56" VAR="0.11690476190476193" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3319316693545489" CI_START="0.8085217261476271" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0377358490566038" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="53" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.12448194526712054" LOG_CI_START="-0.09230830548021093" LOG_EFFECT_SIZE="0.016086819893454795" METHOD="MH" MODIFIED="2009-03-31 21:15:40 -0400" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="0.0" P_Z="0.7711458251124601" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="96" TOTAL_2="96" WEIGHT="100.0" Z="0.29087643478674263">
<NAME>Lef/lef+MTX vs Plc/lef+MTX, at 48 weeks</NAME>
<GROUP_LABEL_1>Plc/lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef/lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef/Lef+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Plc/Lef+MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.331931669354549" CI_START="0.808521726147627" EFFECT_SIZE="1.0377358490566038" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="53" LOG_CI_END="0.12448194526712059" LOG_CI_START="-0.09230830548021099" LOG_EFFECT_SIZE="0.016086819893454795" MODIFIED="2008-11-24 10:18:25 -0500" MODIFIED_BY="[Empty name]" ORDER="34317" O_E="0.0" SE="0.12734366641803094" STUDY_ID="STD-Kremer-2004" TOTAL_1="96" TOTAL_2="96" VAR="0.016216409376786742" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3404215092468519" CI_START="0.9678911224714006" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1390268123138034" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.12724138818163785" LOG_CI_START="-0.014173493486338486" LOG_EFFECT_SIZE="0.05653394734764969" METHOD="MH" MODIFIED="2009-01-01 02:42:39 -0500" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="1.0" P_Q="0.0" P_Z="0.11709505360899469" Q="0.0" RANDOM="NO" SCALE="2.535106002937614" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="30" WEIGHT="100.0" Z="1.567084021120657">
<NAME>leflunomide vs. anti-TNF+MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>anti-TNF+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours anti-TNF+MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3404215092468519" CI_START="0.9678911224714006" EFFECT_SIZE="1.1390268123138034" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="26" LOG_CI_END="0.12724138818163785" LOG_CI_START="-0.014173493486338486" LOG_EFFECT_SIZE="0.05653394734764969" MODIFIED="2008-11-11 12:26:06 -0500" MODIFIED_BY="[Empty name]" ORDER="819" O_E="0.0" SE="0.08306780150672324" STUDY_ID="STD-Wislowska-2007" TOTAL_1="18" TOTAL_2="30" VAR="0.006900259647160373" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5583062881943164" CI_START="0.8674953425438741" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1626794258373205" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.19265282316915547" LOG_CI_START="-0.0617328481946391" LOG_EFFECT_SIZE="0.06545998748725818" METHOD="MH" MODIFIED="2009-03-31 21:15:49 -0400" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Q="0.0" P_Z="0.31311928267971534" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="27" WEIGHT="100.0" Z="1.008698463365801">
<NAME>Lef vs. CsA, at 12 months</NAME>
<GROUP_LABEL_1>CsA</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CsA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5583062881943164" CI_START="0.8674953425438741" EFFECT_SIZE="1.1626794258373205" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="19" LOG_CI_END="0.19265282316915547" LOG_CI_START="-0.0617328481946391" LOG_EFFECT_SIZE="0.06545998748725818" MODIFIED="2008-11-17 10:15:44 -0500" MODIFIED_BY="[Empty name]" ORDER="443" O_E="0.0" SE="0.14942740258847476" STUDY_ID="STD-Karanikolas-2006" TOTAL_1="33" TOTAL_2="27" VAR="0.022328548644338114" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.546038914875436" CI_START="0.8494866044540177" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1460101867572157" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="0.18922042121423702" LOG_CI_START="-0.07084346512639043" LOG_EFFECT_SIZE="0.05918847804392329" METHOD="MH" MODIFIED="2009-01-01 02:06:29 -0500" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="1.0" P_Q="0.0" P_Z="0.3723154856966142" Q="0.0" RANDOM="NO" SCALE="15.43314119213444" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="27" WEIGHT="100.0" Z="0.8921445180118933">
<NAME>Lef vs. Lef+CsA, at 12 months</NAME>
<GROUP_LABEL_1>Lef+CsA</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef+CsA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.546038914875436" CI_START="0.8494866044540177" EFFECT_SIZE="1.1460101867572157" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="19" LOG_CI_END="0.18922042121423702" LOG_CI_START="-0.07084346512639043" LOG_EFFECT_SIZE="0.05918847804392329" MODIFIED="2008-11-17 10:17:50 -0500" MODIFIED_BY="[Empty name]" ORDER="444" O_E="0.0" SE="0.15276281417348386" STUDY_ID="STD-Karanikolas-2006" TOTAL_1="31" TOTAL_2="27" VAR="0.02333647739420236" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.282565263882358E-30" CI_END="0.9918103452831515" CI_START="0.6919142832959375" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8284007147643513" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="74" I2="100.0" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="-0.003571366022773092" LOG_CI_START="-0.1599477040943204" LOG_EFFECT_SIZE="-0.08175953505854673" METHOD="MH" MODIFIED="2009-01-01 03:57:40 -0500" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.0" P_Q="0.0" P_Z="0.04041438267763415" Q="0.0" RANDOM="NO" SCALE="2.77" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="242" TOTAL_2="115" WEIGHT="100.0" Z="2.0494883827523047">
<NAME>Lef+ADA vs. ADA, at 12 weeks</NAME>
<GROUP_LABEL_1>ADA</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef+ADA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ADA+Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ADA</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9918103452831513" CI_START="0.6919142832959375" EFFECT_SIZE="0.8284007147643512" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="74" LOG_CI_END="-0.003571366022773189" LOG_CI_START="-0.1599477040943204" LOG_EFFECT_SIZE="-0.0817595350585468" MODIFIED="2008-11-21 08:05:09 -0500" MODIFIED_BY="[Empty name]" ORDER="467" O_E="0.0" SE="0.09185623505858444" STUDY_ID="STD-Mariette-2004" TOTAL_1="242" TOTAL_2="115" VAR="0.008437567919137917" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2302435221208396" CI_START="0.6328395141318175" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8823529411764706" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="0.08999108692328521" LOG_CI_START="-0.19870641156847066" LOG_EFFECT_SIZE="-0.0543576623225927" METHOD="MH" MODIFIED="2009-01-01 04:22:40 -0500" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="1.0" P_Q="0.0" P_Z="0.4604736905335419" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0" Z="0.7380670840077537">
<NAME>Weekly Lef vs. daily Lef, at 6 months</NAME>
<GROUP_LABEL_1>Daily Lef</GROUP_LABEL_1>
<GROUP_LABEL_2>Weekly Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours weekly Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours daily Lef</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2302435221208399" CI_START="0.6328395141318175" EFFECT_SIZE="0.8823529411764706" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.08999108692328528" LOG_CI_START="-0.19870641156847066" LOG_EFFECT_SIZE="-0.0543576623225927" MODIFIED="2008-11-21 10:32:05 -0500" MODIFIED_BY="[Empty name]" ORDER="477" O_E="0.0" SE="0.1695823396897228" STUDY_ID="STD-Jakez_x002d_Ocampo-2002" TOTAL_1="8" TOTAL_2="8" VAR="0.02875816993464053" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3131705384558523" CI_START="0.7615157138507636" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="0.1183211305836647" LOG_CI_START="-0.11832113058366475" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2009-01-01 04:26:18 -0500" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="6" TOTAL_2="7" WEIGHT="100.0" Z="0.0">
<NAME>Weekly Lef vs. daily Lef, at 12 months</NAME>
<GROUP_LABEL_1>Daily Lef</GROUP_LABEL_1>
<GROUP_LABEL_2>Weekly Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours weekly Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours daily Lef</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3131705384558523" CI_START="0.7615157138507637" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.1183211305836647" LOG_CI_START="-0.11832113058366467" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-21 10:34:05 -0500" MODIFIED_BY="[Empty name]" ORDER="478" O_E="0.0" SE="0.13900483560777413" STUDY_ID="STD-Jakez_x002d_Ocampo-2002" TOTAL_1="6" TOTAL_2="7" VAR="0.01932234432234431" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2009-07-22 12:17:28 -0400" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Treatment responder - ACR50</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.7557462440938899" CI_START="0.2468185041466534" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4318936877076412" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="43" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.12162400250059377" LOG_CI_START="-0.6076222840734193" LOG_EFFECT_SIZE="-0.36462314328700657" METHOD="MH" MODIFIED="2009-01-03 22:32:14 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.0032720775566547917" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="91" TOTAL_2="130" WEIGHT="99.99999999999999" Z="2.940949611836157">
<NAME>leflunomide vs. placebo, at 6 months</NAME>
<GROUP_LABEL_1>placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7557462440938899" CI_START="0.2468185041466534" EFFECT_SIZE="0.4318936877076412" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="43" LOG_CI_END="-0.12162400250059377" LOG_CI_START="-0.6076222840734193" LOG_EFFECT_SIZE="-0.36462314328700657" ORDER="34318" O_E="0.0" SE="0.2854777963261707" STUDY_ID="STD-Smolen-1999" TOTAL_1="91" TOTAL_2="130" VAR="0.08149757219524661" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.4330306173112913" CI_START="0.11576087401642422" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2238928376161837" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="62" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-0.36348139588853856" LOG_CI_START="-0.9364382028714207" LOG_EFFECT_SIZE="-0.6499597993799796" METHOD="MH" MODIFIED="2009-01-03 22:33:22 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="8.71792563447997E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="118" TOTAL_2="182" WEIGHT="100.00000000000001" Z="4.446749851500408">
<NAME>leflunomide vs. placebo, at 12 months</NAME>
<GROUP_LABEL_1>placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.4330306173112912" CI_START="0.11576087401642426" EFFECT_SIZE="0.2238928376161837" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="62" LOG_CI_END="-0.3634813958885386" LOG_CI_START="-0.9364382028714205" LOG_EFFECT_SIZE="-0.6499597993799796" ORDER="34319" O_E="0.0" SE="0.33655766460368075" STUDY_ID="STD-Strand-1999a" TOTAL_1="118" TOTAL_2="182" VAR="0.11327106160348367" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.15577404511947" CI_END="1.4396340319144385" CI_START="0.5161581408154546" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8620202000925579" ESTIMABLE="YES" EVENTS_1="301" EVENTS_2="288" I2="89.07793054883159" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.15825210451182325" LOG_CI_START="-0.28721721860266974" LOG_EFFECT_SIZE="-0.06448255704542323" METHOD="MH" MODIFIED="2009-01-03 22:36:53 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0024793534369171866" P_Q="0.0" P_Z="0.5704307346263608" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.123219959870798" TOTALS="YES" TOTAL_1="480" TOTAL_2="455" WEIGHT="100.0" Z="0.5674172513450335">
<NAME>leflunomide vs. methotrexate, at 12 months</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1257373270659237" CI_START="0.9791254726213775" EFFECT_SIZE="1.0498752746926412" ESTIMABLE="YES" EVENTS_1="259" EVENTS_2="226" LOG_CI_END="0.05143706661314671" LOG_CI_START="-0.009161650816443323" LOG_EFFECT_SIZE="0.021137707898351704" ORDER="34320" O_E="0.0" SE="0.03559598658663033" STUDY_ID="STD-Emery-1999" TOTAL_1="298" TOTAL_2="273" VAR="0.0012670742610755665" WEIGHT="55.00303931174602"/>
<DICH_DATA CI_END="0.9455529369516422" CI_START="0.4853213018295163" EFFECT_SIZE="0.6774193548387096" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="62" LOG_CI_END="-0.024314152083437502" LOG_CI_START="-0.3139706461172694" LOG_EFFECT_SIZE="-0.16914239910035345" ORDER="34321" O_E="0.0" SE="0.17014565841824272" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="182" VAR="0.028949545078577332" WEIGHT="44.996960688253985"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1027467928441348" CI_START="0.6029054678011556" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8153846153846154" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="65" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.04247580337892349" LOG_CI_START="-0.21975077746305657" LOG_EFFECT_SIZE="-0.08863748704206653" METHOD="MH" MODIFIED="2009-03-31 21:16:09 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.1851681853603379" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="190" TOTAL_2="190" WEIGHT="100.0" Z="1.325008942455571">
<NAME>leflunomide vs. methotrexate, at 2 years</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1027467928441348" CI_START="0.6029054678011556" EFFECT_SIZE="0.8153846153846154" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="65" LOG_CI_END="0.04247580337892349" LOG_CI_START="-0.21975077746305657" LOG_EFFECT_SIZE="-0.08863748704206653" ORDER="34322" O_E="0.0" SE="0.15403319162908877" STUDY_ID="STD-Cohen-2001" TOTAL_1="190" TOTAL_2="190" VAR="0.023726224123443586" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.307858292417658" CI_START="0.6417431228990629" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.916138125440451" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="43" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.11656069035289401" LOG_CI_START="-0.19263877665416845" LOG_EFFECT_SIZE="-0.03803904315063723" METHOD="MH" MODIFIED="2009-01-03 22:35:40 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.6296309678942539" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="132" TOTAL_2="130" WEIGHT="100.00000000000001" Z="0.4822463331084013">
<NAME>leflunomide vs. sulfasalazine, at 6 months</NAME>
<GROUP_LABEL_1>SSZ</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.307858292417658" CI_START="0.6417431228990629" EFFECT_SIZE="0.916138125440451" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="43" LOG_CI_END="0.11656069035289401" LOG_CI_START="-0.19263877665416845" LOG_EFFECT_SIZE="-0.03803904315063723" ORDER="34323" O_E="0.0" SE="0.1816252974819948" STUDY_ID="STD-Smolen-1999" TOTAL_1="132" TOTAL_2="130" VAR="0.032987748685423104" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3603795083017494" CI_START="0.630715930598889" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9262899262899262" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.13366008143585226" LOG_CI_START="-0.20016619947470674" LOG_EFFECT_SIZE="-0.033253059019427204" METHOD="MH" MODIFIED="2009-03-31 21:16:40 -0400" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.6961880430501226" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="74" TOTAL_2="78" WEIGHT="100.0" Z="0.3904713426162167">
<NAME>leflunomide vs. sulfasalazine, at 12 months</NAME>
<GROUP_LABEL_1>SSZ</GROUP_LABEL_1>
<GROUP_LABEL_2>Leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3603795083017496" CI_START="0.630715930598889" EFFECT_SIZE="0.9262899262899262" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="33" LOG_CI_END="0.13366008143585234" LOG_CI_START="-0.20016619947470674" LOG_EFFECT_SIZE="-0.033253059019427204" ORDER="34324" O_E="0.0" SE="0.19609120987360354" STUDY_ID="STD-Scott-2001" TOTAL_1="74" TOTAL_2="78" VAR="0.03845176258969363" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.7969024707712667" CI_START="0.2835830700006269" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.47538200339558573" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="-0.09859482665615901" LOG_CI_START="-0.5473197002336059" LOG_EFFECT_SIZE="-0.3229572634448824" METHOD="MH" MODIFIED="2008-12-31 11:42:05 -0500" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.0047835524443421325" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="57" TOTAL_2="60" WEIGHT="100.0" Z="2.821259271192752">
<NAME>leflunomide vs. sulfasalazine, at 24 months</NAME>
<GROUP_LABEL_1>SSZ</GROUP_LABEL_1>
<GROUP_LABEL_2>Leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7969024707712667" CI_START="0.2835830700006269" EFFECT_SIZE="0.47538200339558573" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="31" LOG_CI_END="-0.09859482665615901" LOG_CI_START="-0.5473197002336059" LOG_EFFECT_SIZE="-0.3229572634448824" ORDER="34325" O_E="0.0" SE="0.26358321196333995" STUDY_ID="STD-Scott-2001" TOTAL_1="57" TOTAL_2="60" VAR="0.06947610962891099" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.4778402312991523" CI_START="0.11069368633573407" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.22998673153471916" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="-0.32071728804015487" LOG_CI_START="-0.9558771493809662" LOG_EFFECT_SIZE="-0.6382972187105606" METHOD="MH" MODIFIED="2009-03-31 21:16:49 -0400" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="8.17229757121533E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="130" WEIGHT="100.0" Z="3.9392903621581565">
<NAME>leflunomide+MTX vs MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.4778402312991523" CI_START="0.11069368633573407" EFFECT_SIZE="0.22998673153471916" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="34" LOG_CI_END="-0.32071728804015487" LOG_CI_START="-0.9558771493809662" LOG_EFFECT_SIZE="-0.6382972187105606" ORDER="34326" O_E="0.0" SE="0.37309604664361357" STUDY_ID="STD-Kremer-2002" TOTAL_1="133" TOTAL_2="130" VAR="0.13920066002109346" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.669092199438444E-31" CI_END="1.1365094158927769" CI_START="0.5518138399588894" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7919227392449516" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="51" I2="100.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.05557303817215152" LOG_CI_START="-0.25820741124646884" LOG_EFFECT_SIZE="-0.1013171865371587" METHOD="MH" MODIFIED="2009-01-01 04:18:36 -0500" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.2056157869406834" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="201" TOTAL_2="198" WEIGHT="100.0" Z="1.2657132526624106">
<NAME>leflunomide10mg vs leflunomide 20 mg, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef10</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef20</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef10</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.136509415892777" CI_START="0.5518138399588894" EFFECT_SIZE="0.7919227392449517" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="51" LOG_CI_END="0.055573038172151604" LOG_CI_START="-0.25820741124646884" LOG_EFFECT_SIZE="-0.10131718653715863" ORDER="34327" O_E="0.0" SE="0.18431618922677256" STUDY_ID="STD-Poor-2004" TOTAL_1="201" TOTAL_2="198" VAR="0.03397245761107943" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7925422602867989" CI_START="0.005759099549186115" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.10160427807486631" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="0.25346940322017925" LOG_CI_START="-2.2396454143875193" LOG_EFFECT_SIZE="-0.9930880055836699" METHOD="MH" MODIFIED="2008-12-31 22:25:27 -0500" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="0.11842145995835247" Q="0.0" RANDOM="NO" SCALE="840.4349935842123" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="56" WEIGHT="100.0" Z="1.5614336818152768">
<NAME>leflunomide+SSZ vs. placebo+SSZ, at 24 weeks</NAME>
<GROUP_LABEL_1>Plc+SSZ</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef+SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7925422602867989" CI_START="0.005759099549186115" EFFECT_SIZE="0.10160427807486631" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.25346940322017925" LOG_CI_START="-2.2396454143875193" LOG_EFFECT_SIZE="-0.9930880055836699" ORDER="34328" O_E="0.0" SE="1.4644679849801443" STUDY_ID="STD-Dougados-2005" TOTAL_1="50" TOTAL_2="56" VAR="2.144666479031804" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2069313928673446" CI_START="0.5225009814949396" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7941176470588235" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="0.08168258364666757" LOG_CI_START="-0.28191288941320325" LOG_EFFECT_SIZE="-0.10011515288326783" METHOD="MH" MODIFIED="2009-03-31 21:17:03 -0400" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="0.2804349171074324" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="96" TOTAL_2="96" WEIGHT="100.0" Z="1.0793428878891225">
<NAME>Lef/lef+MTX vs Plc/lef+MTX, at 48 weeks</NAME>
<GROUP_LABEL_1>Plc/lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef/lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef/Lef+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Plc/Lef+MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2069313928673449" CI_START="0.5225009814949396" EFFECT_SIZE="0.7941176470588235" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="34" LOG_CI_END="0.08168258364666765" LOG_CI_START="-0.28191288941320325" LOG_EFFECT_SIZE="-0.10011515288326783" ORDER="34329" O_E="0.0" SE="0.21357778070198705" STUDY_ID="STD-Kremer-2004" TOTAL_1="96" TOTAL_2="96" VAR="0.045615468409586066" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3226620160484561" CI_START="0.5250354482236854" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="0.1214488817402681" LOG_CI_START="-0.2798113738355177" LOG_EFFECT_SIZE="-0.07918124604762482" METHOD="MH" MODIFIED="2009-03-31 21:17:13 -0400" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="0.0" P_Z="0.43921183149899656" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.7735248549929613">
<NAME>leflunomide vs. methotrexate, at 24 weeks</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3226620160484561" CI_START="0.5250354482236854" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="18" LOG_CI_END="0.1214488817402681" LOG_CI_START="-0.2798113738355177" LOG_EFFECT_SIZE="-0.07918124604762482" MODIFIED="2008-11-11 12:28:26 -0500" MODIFIED_BY="[Empty name]" ORDER="820" O_E="0.0" SE="0.2357022603955158" STUDY_ID="STD-Wislowska-2007" TOTAL_1="30" TOTAL_2="30" VAR="0.055555555555555546" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9864376237727512" CI_START="0.9710913257952325" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3888888888888888" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-002.13" LOG_CI_END="0.2980749323027265" LOG_CI_START="-0.012739925165263491" LOG_EFFECT_SIZE="0.14266750356873154" METHOD="MH" MODIFIED="2009-01-01 02:43:25 -0500" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="0.0" P_Z="0.07197268043495367" Q="0.0" RANDOM="NO" SCALE="4.554282434308712" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="30" WEIGHT="100.0" Z="1.7992908771277196">
<NAME>leflunomide vs. anti-TNF+MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>anti-TNF+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours anti-TNF+MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9864376237727512" CI_START="0.9710913257952325" EFFECT_SIZE="1.3888888888888888" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="18" LOG_CI_END="0.2980749323027265" LOG_CI_START="-0.012739925165263491" LOG_EFFECT_SIZE="0.14266750356873154" MODIFIED="2008-11-11 12:30:11 -0500" MODIFIED_BY="[Empty name]" ORDER="821" O_E="0.0" SE="0.18257418583505536" STUDY_ID="STD-Wislowska-2007" TOTAL_1="18" TOTAL_2="30" VAR="0.03333333333333333" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3272070037888835" CI_START="0.4349022124072609" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7597402597402597" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-002.14" LOG_CI_END="0.12293866483278922" LOG_CI_START="-0.3616083830133921" LOG_EFFECT_SIZE="-0.11933485909030142" METHOD="MH" MODIFIED="2009-03-31 21:17:22 -0400" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="0.0" P_Z="0.3343421041787791" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="27" WEIGHT="100.0" Z="0.9654048124193783">
<NAME>Lef vs. CsA, at 12 months</NAME>
<GROUP_LABEL_1>CsA</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CsA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3272070037888835" CI_START="0.4349022124072609" EFFECT_SIZE="0.7597402597402597" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.12293866483278922" LOG_CI_START="-0.3616083830133921" LOG_EFFECT_SIZE="-0.11933485909030142" MODIFIED="2008-12-30 11:56:13 -0500" MODIFIED_BY="[Empty name]" ORDER="1109" O_E="0.0" SE="0.284625334451417" STUDY_ID="STD-Karanikolas-2006" TOTAL_1="33" TOTAL_2="27" VAR="0.08101158101158101" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.3256020897113547" CI_START="1.0401421065304526" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.555299539170507" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-002.15" LOG_CI_END="0.3665354090056214" LOG_CI_START="0.017092677631406986" LOG_EFFECT_SIZE="0.1918140433185142" METHOD="MH" MODIFIED="2009-01-01 02:10:10 -0500" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="1.0" P_Q="0.0" P_Z="0.031420695114990536" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="27" WEIGHT="100.0" Z="2.151703743585351">
<NAME>Lef vs. Lef+CsA, at 12 months</NAME>
<GROUP_LABEL_1>Lef+CsA</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef+CsA</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3256020897113547" CI_START="1.0401421065304526" EFFECT_SIZE="1.555299539170507" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="14" LOG_CI_END="0.3665354090056214" LOG_CI_START="0.017092677631406986" LOG_EFFECT_SIZE="0.1918140433185142" MODIFIED="2008-11-17 10:22:31 -0500" MODIFIED_BY="[Empty name]" ORDER="446" O_E="0.0" SE="0.20526439017863124" STUDY_ID="STD-Karanikolas-2006" TOTAL_1="31" TOTAL_2="27" VAR="0.042133469875405366" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2033599689298338" CI_START="0.5796922523224404" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8352116203355873" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-002.16" LOG_CI_END="0.08039556012053263" LOG_CI_START="-0.23680250400407216" LOG_EFFECT_SIZE="-0.0782034719417698" METHOD="MH" MODIFIED="2009-07-22 12:17:28 -0400" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Q="0.0" P_Z="0.33382551978988184" Q="0.0" RANDOM="NO" SCALE="2.77" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="242" TOTAL_2="115" WEIGHT="100.0" Z="0.9664370991346661">
<NAME>Lef+ADA vs. ADA, at 12 weeks</NAME>
<GROUP_LABEL_1>ADA</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef+ADA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ADA+Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ADA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2033599689298338" CI_START="0.5796922523224403" EFFECT_SIZE="0.8352116203355873" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="33" LOG_CI_END="0.08039556012053263" LOG_CI_START="-0.23680250400407227" LOG_EFFECT_SIZE="-0.0782034719417698" MODIFIED="2008-11-21 08:07:10 -0500" MODIFIED_BY="[Empty name]" ORDER="468" O_E="0.0" SE="0.18632371302253348" STUDY_ID="STD-Mariette-2004" TOTAL_1="242" TOTAL_2="115" VAR="0.03471652603450341" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1986320720361552" CI_START="0.2724193852832669" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-002.17" LOG_CI_END="0.07868589401954948" LOG_CI_START="-0.5647619913921385" LOG_EFFECT_SIZE="-0.24303804868629447" METHOD="MH" MODIFIED="2009-07-22 12:17:28 -0400" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="1.0" P_Q="0.0" P_Z="0.13871207429144086" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0" Z="1.480604204622589">
<NAME>Weekly Lef vs. daily Lef, at 6 months</NAME>
<GROUP_LABEL_1>Daily Lef</GROUP_LABEL_1>
<GROUP_LABEL_2>Weekly Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours weekly Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours daily Lef</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1986320720361552" CI_START="0.2724193852832669" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.07868589401954948" LOG_CI_START="-0.5647619913921385" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2008-11-21 10:36:43 -0500" MODIFIED_BY="[Empty name]" ORDER="479" O_E="0.0" SE="0.3779644730092272" STUDY_ID="STD-Jakez_x002d_Ocampo-2002" TOTAL_1="8" TOTAL_2="8" VAR="0.14285714285714285" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6899782825025156" CI_START="0.7728634518577888" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-002.18" LOG_CI_END="0.22788112363738905" LOG_CI_START="-0.11189722968201563" LOG_EFFECT_SIZE="0.05799194697768673" METHOD="MH" MODIFIED="2009-07-22 12:17:28 -0400" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="1.0" P_Q="0.0" P_Z="0.5034719463821816" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="6" TOTAL_2="7" WEIGHT="100.00000000000001" Z="0.6690368963132602">
<NAME>Weekly Lef vs. daily Lef, at 12 months</NAME>
<GROUP_LABEL_1>Daily Lef</GROUP_LABEL_1>
<GROUP_LABEL_2>Weekly Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours weekly Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours daily Lef</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.689978282502516" CI_START="0.7728634518577887" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.22788112363738916" LOG_CI_START="-0.1118972296820157" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2008-11-21 10:38:53 -0500" MODIFIED_BY="[Empty name]" ORDER="480" O_E="0.0" SE="0.19958748666979315" STUDY_ID="STD-Jakez_x002d_Ocampo-2002" TOTAL_1="6" TOTAL_2="7" VAR="0.03983516483516486" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2010-06-16 23:23:49 -0400" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Treatment responder - ACR70</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.5302098807937486" CI_START="0.08654977668955108" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.21421845574387946" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-0.275552183177393" LOG_CI_START="-1.0627340483272452" LOG_EFFECT_SIZE="-0.6691431157523191" METHOD="MH" MODIFIED="2009-01-03 22:37:49 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="8.618378786382169E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="118" TOTAL_2="182" WEIGHT="100.0" Z="3.332130643349612">
<NAME>leflunomide vs. placebo, at 12 months</NAME>
<GROUP_LABEL_1>placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5302098807937486" CI_START="0.08654977668955108" EFFECT_SIZE="0.21421845574387946" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="36" LOG_CI_END="-0.275552183177393" LOG_CI_START="-1.0627340483272452" LOG_EFFECT_SIZE="-0.6691431157523191" ORDER="34330" O_E="0.0" SE="0.46239452420209937" STUDY_ID="STD-Strand-1999a" TOTAL_1="118" TOTAL_2="182" VAR="0.21380869601208585" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.7717933546722152" CI_START="0.25593750322121295" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-0.11249896512923999" LOG_CI_START="-0.5918660710934851" LOG_EFFECT_SIZE="-0.35218251811136253" METHOD="MH" MODIFIED="2009-01-03 22:42:10 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.00397799285163394" Q="0.0" RANDOM="NO" SCALE="6.849237792442749" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="182" TOTAL_2="182" WEIGHT="100.0" Z="2.879901615670647">
<NAME>leflunomide vs. methotrexate, at 12 months</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7717933546722152" CI_START="0.25593750322121295" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="36" LOG_CI_END="-0.11249896512923999" LOG_CI_START="-0.5918660710934851" LOG_EFFECT_SIZE="-0.35218251811136253" ORDER="34331" O_E="0.0" SE="0.2815826109488418" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="182" VAR="0.0792887667887668" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1810170822430315" CI_START="0.43742090632495434" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.71875" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.07225617929872614" LOG_CI_START="-0.3591004639033524" LOG_EFFECT_SIZE="-0.1434221423023131" METHOD="MH" MODIFIED="2008-12-31 09:43:09 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.19245863191151172" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="190" TOTAL_2="190" WEIGHT="100.0" Z="1.3033402310042728">
<NAME>leflunomide vs. methotrexate, at 2 years</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1810170822430315" CI_START="0.43742090632495434" EFFECT_SIZE="0.71875" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="32" LOG_CI_END="0.07225617929872614" LOG_CI_START="-0.3591004639033524" LOG_EFFECT_SIZE="-0.1434221423023131" ORDER="34332" O_E="0.0" SE="0.2533810274667216" STUDY_ID="STD-Cohen-2001" TOTAL_1="190" TOTAL_2="190" VAR="0.06420194508009153" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5534212824530211" CI_START="0.27750261068959475" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6565656565656566" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.1912892508562348" LOG_CI_START="-0.5567329267656235" LOG_EFFECT_SIZE="-0.18272183795469432" METHOD="MH" MODIFIED="2009-01-03 22:40:36 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.33829795722017986" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="132" TOTAL_2="130" WEIGHT="99.99999999999999" Z="0.9575336996524361">
<NAME>leflunomide vs. sulfasalazine, at 6 months</NAME>
<GROUP_LABEL_1>SSZ</GROUP_LABEL_1>
<GROUP_LABEL_2>Leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5534212824530211" CI_START="0.27750261068959475" EFFECT_SIZE="0.6565656565656566" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.1912892508562348" LOG_CI_START="-0.5567329267656235" LOG_EFFECT_SIZE="-0.18272183795469432" ORDER="34333" O_E="0.0" SE="0.43939192990457626" STUDY_ID="STD-Scott-2001" TOTAL_1="132" TOTAL_2="130" VAR="0.19306526806526805" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.2510283009271532" CI_START="0.5724191803752717" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.135135135135135" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.3523809551778774" LOG_CI_START="-0.24228582251606642" LOG_EFFECT_SIZE="0.05504756633090544" METHOD="MH" MODIFIED="2009-03-31 21:17:41 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.7167073236136552" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="74" TOTAL_2="78" WEIGHT="100.0" Z="0.3628628720896279">
<NAME>leflunomide vs. sulfasalazine, at 12 months</NAME>
<GROUP_LABEL_1>SSZ</GROUP_LABEL_1>
<GROUP_LABEL_2>Leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2510283009271532" CI_START="0.5724191803752717" EFFECT_SIZE="1.135135135135135" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.3523809551778774" LOG_CI_START="-0.24228582251606642" LOG_EFFECT_SIZE="0.05504756633090544" ORDER="34334" O_E="0.0" SE="0.3493102088654467" STUDY_ID="STD-Scott-2001" TOTAL_1="74" TOTAL_2="78" VAR="0.12201762201762202" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4321083887068957" CI_START="0.34387007443315865" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7017543859649122" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.15597588866731288" LOG_CI_START="-0.46360561735637085" LOG_EFFECT_SIZE="-0.15381486434452904" METHOD="MH" MODIFIED="2009-03-31 21:17:49 -0400" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.33048081752955605" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="57" TOTAL_2="60" WEIGHT="100.0" Z="0.9731458782136959">
<NAME>leflunomide vs. sulfasalazine, at 24 months</NAME>
<GROUP_LABEL_1>SSZ</GROUP_LABEL_1>
<GROUP_LABEL_2>Leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4321083887068957" CI_START="0.34387007443315865" EFFECT_SIZE="0.7017543859649122" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" LOG_CI_END="0.15597588866731288" LOG_CI_START="-0.46360561735637085" LOG_EFFECT_SIZE="-0.15381486434452904" ORDER="34335" O_E="0.0" SE="0.3639452436162303" STUDY_ID="STD-Scott-2001" TOTAL_1="57" TOTAL_2="60" VAR="0.13245614035087722" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.7731649669816486" CI_START="0.06580623743385101" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.22556390977443605" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="-0.11172783259388039" LOG_CI_START="-1.1817329399009662" LOG_EFFECT_SIZE="-0.6467303862474234" METHOD="MH" MODIFIED="2009-03-31 21:17:57 -0400" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.01782298776638937" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="130" WEIGHT="100.0" Z="2.369275167186361">
<NAME>leflunomide+MTX vs MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7731649669816486" CI_START="0.06580623743385101" EFFECT_SIZE="0.22556390977443608" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" LOG_CI_END="-0.11172783259388039" LOG_CI_START="-1.1817329399009662" LOG_EFFECT_SIZE="-0.6467303862474234" ORDER="34336" O_E="0.0" SE="0.6285262966428862" STUDY_ID="STD-Kremer-2002" TOTAL_1="133" TOTAL_2="130" VAR="0.3950453055716213" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4069731109646244" CI_START="0.37445646883128647" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7258444619010213" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="0.1482857975973079" LOG_CI_START="-0.42659866246440525" LOG_EFFECT_SIZE="-0.13915643243354867" METHOD="MH" MODIFIED="2009-01-01 04:18:15 -0500" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.3426933165461884" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="201" TOTAL_2="198" WEIGHT="100.0" Z="0.9488570825433632">
<NAME>leflunomide10mg vs leflunomide 20 mg, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef10</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef20</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef10</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4069731109646244" CI_START="0.37445646883128647" EFFECT_SIZE="0.7258444619010213" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="19" LOG_CI_END="0.1482857975973079" LOG_CI_START="-0.42659866246440525" LOG_EFFECT_SIZE="-0.13915643243354867" ORDER="34337" O_E="0.0" SE="0.33768997756422287" STUDY_ID="STD-Poor-2004" TOTAL_1="201" TOTAL_2="198" VAR="0.11403452094732533" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-12-31 22:28:12 -0500" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="56" WEIGHT="0.0" Z="0.0">
<NAME>leflunomide+SSZ vs. placebo+SSZ, at 24 weeks</NAME>
<GROUP_LABEL_1>Plc+SSZ</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef+SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="34338" O_E="0.0" SE="0.0" STUDY_ID="STD-Dougados-2005" TOTAL_1="50" TOTAL_2="56" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.403470554591932" CI_START="0.33677674850643935" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6875" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-003.10" LOG_CI_END="0.14720330538343335" LOG_CI_START="-0.4726579003788328" LOG_EFFECT_SIZE="-0.16272729749769974" METHOD="MH" MODIFIED="2009-03-31 21:18:06 -0400" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="0.30344777176050175" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="96" TOTAL_2="96" WEIGHT="100.0" Z="1.0290679249875447">
<NAME>Lef/lef+MTX vs Plc/lef+MTX, at 48 weeks</NAME>
<GROUP_LABEL_1>Plc/lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef/lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef/Lef+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Plc/Lef+MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.403470554591932" CI_START="0.33677674850643935" EFFECT_SIZE="0.6875" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.14720330538343335" LOG_CI_START="-0.4726579003788328" LOG_EFFECT_SIZE="-0.16272729749769974" ORDER="34339" O_E="0.0" SE="0.36410954062720957" STUDY_ID="STD-Kremer-2004" TOTAL_1="96" TOTAL_2="96" VAR="0.1325757575757576" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.5270106054871775" CI_START="0.09893112417381524" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-003.11" LOG_CI_END="0.402607064593003" LOG_CI_START="-1.0046670559209654" LOG_EFFECT_SIZE="-0.3010299956639812" METHOD="MH" MODIFIED="2009-03-31 21:18:13 -0400" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="0.4017433540090516" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.8385117599578504">
<NAME>leflunomide vs. methotrexate, at 24 weeks</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5270106054871775" CI_START="0.09893112417381524" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.402607064593003" LOG_CI_START="-1.0046670559209654" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2008-11-11 12:32:14 -0500" MODIFIED_BY="[Empty name]" ORDER="822" O_E="0.0" SE="0.8266397845091497" STUDY_ID="STD-Wislowska-2007" TOTAL_1="30" TOTAL_2="30" VAR="0.6833333333333333" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.426654609755907" CI_START="1.3487068025483597" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.75" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-003.12" LOG_CI_END="1.0181449874699857" LOG_CI_START="0.12991754798545224" LOG_EFFECT_SIZE="0.5740312677277188" METHOD="MH" MODIFIED="2009-01-01 02:44:12 -0500" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="0.0" P_Z="0.011298888400203794" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="30" WEIGHT="100.0" Z="2.5333164924495435">
<NAME>leflunomide vs. anti-TNF+MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>anti-TNF+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours anti-TNF)+MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.426654609755907" CI_START="1.3487068025483597" EFFECT_SIZE="3.75" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="1.0181449874699857" LOG_CI_START="0.12991754798545224" LOG_EFFECT_SIZE="0.5740312677277188" MODIFIED="2008-11-11 12:33:35 -0500" MODIFIED_BY="[Empty name]" ORDER="823" O_E="0.0" SE="0.521749194749951" STUDY_ID="STD-Wislowska-2007" TOTAL_1="18" TOTAL_2="30" VAR="0.27222222222222225" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.199317954276932" CI_START="0.572476963035864" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.122077922077922" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-003.13" LOG_CI_END="0.34228801963181904" LOG_CI_START="-0.24224198501899624" LOG_EFFECT_SIZE="0.05002301730641139" METHOD="MH" MODIFIED="2010-06-16 23:23:05 -0400" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="0.0" P_Z="0.7372778700569602" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="36" WEIGHT="100.00000000000001" Z="0.3354603238106108">
<NAME>Lef vs. CsA, at 12 months</NAME>
<GROUP_LABEL_1>CsA</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CsA</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1993179542769323" CI_START="0.572476963035864" EFFECT_SIZE="1.122077922077922" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.3422880196318191" LOG_CI_START="-0.24224198501899624" LOG_EFFECT_SIZE="0.05002301730641139" MODIFIED="2010-06-16 23:23:05 -0400" MODIFIED_BY="[Empty name]" ORDER="448" O_E="0.0" SE="0.3433558182020772" STUDY_ID="STD-Karanikolas-2006" TOTAL_1="35" TOTAL_2="36" VAR="0.1178932178932179" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.4440852191005438" CI_START="1.119562241727003" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9636363636363636" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-003.14" LOG_CI_END="0.5370738889277358" LOG_CI_START="0.04904824305767597" LOG_EFFECT_SIZE="0.2930610659927058" METHOD="MH" MODIFIED="2010-06-16 23:23:49 -0400" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="0.0" P_Z="0.01857610265403418" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="36" WEIGHT="100.00000000000001" Z="2.353930124276931">
<NAME>Lef vs. Lef+CsA, at 12 months</NAME>
<GROUP_LABEL_1>Lef+CsA</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef+CsA</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.4440852191005438" CI_START="1.119562241727003" EFFECT_SIZE="1.9636363636363636" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="11" LOG_CI_END="0.5370738889277358" LOG_CI_START="0.04904824305767597" LOG_EFFECT_SIZE="0.2930610659927058" MODIFIED="2010-06-16 23:23:49 -0400" MODIFIED_BY="[Empty name]" ORDER="447" O_E="0.0" SE="0.28666868014998115" STUDY_ID="STD-Karanikolas-2006" TOTAL_1="35" TOTAL_2="36" VAR="0.08217893217893218" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.702042481097104" CI_START="0.33571855241831916" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.15" LOG_CI_END="0.8262071762965649" LOG_CI_START="-0.47402465818520245" LOG_EFFECT_SIZE="0.17609125905568124" METHOD="MH" MODIFIED="2009-07-22 12:18:54 -0400" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="1.0" P_Q="0.0" P_Z="0.5955030193640014" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0" Z="0.5308784427340332">
<NAME>Weekly Lef vs. daily Lef, at 6 months</NAME>
<GROUP_LABEL_1>Daily Lef</GROUP_LABEL_1>
<GROUP_LABEL_2>Weekly Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours weekly Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours daily Lef</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.702042481097103" CI_START="0.33571855241831927" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8262071762965648" LOG_CI_START="-0.47402465818520234" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2008-11-21 10:39:47 -0500" MODIFIED_BY="[Empty name]" ORDER="481" O_E="0.0" SE="0.7637626158259733" STUDY_ID="STD-Jakez_x002d_Ocampo-2002" TOTAL_1="8" TOTAL_2="8" VAR="0.5833333333333333" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.22923756456156" CI_START="0.4236269693242174" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.16" LOG_CI_END="0.8590924966079385" LOG_CI_START="-0.3730163992353497" LOG_EFFECT_SIZE="0.24303804868629442" METHOD="MH" MODIFIED="2009-07-22 12:18:54 -0400" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Q="0.0" P_Z="0.4393920041742867" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="6" TOTAL_2="7" WEIGHT="100.0" Z="0.7732203280165517">
<NAME>Weekly Lef vs. daily Lef, at 12 months</NAME>
<GROUP_LABEL_1>Daily Lef</GROUP_LABEL_1>
<GROUP_LABEL_2>Weekly Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours weekly Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours daily Lef</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.22923756456156" CI_START="0.4236269693242174" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8590924966079385" LOG_CI_START="-0.3730163992353497" LOG_EFFECT_SIZE="0.24303804868629442" MODIFIED="2008-11-21 10:40:16 -0500" MODIFIED_BY="[Empty name]" ORDER="482" O_E="0.0" SE="0.7237468644557459" STUDY_ID="STD-Jakez_x002d_Ocampo-2002" TOTAL_1="6" TOTAL_2="7" VAR="0.5238095238095237" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2009-04-10 04:28:31 -0400" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Changes of tender joint count</NAME>
<CONT_OUTCOME CHI2="1.2393596474730528" CI_END="-0.4191058296788792" CI_START="-0.7206933614655873" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.5698995955722332" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.01" MODIFIED="2009-04-10 04:28:31 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5381170137017997" P_Q="1.0" P_Z="1.2884499534171574E-13" Q="0.0" RANDOM="NO" SCALE="1.28" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="413" TOTAL_2="311" UNITS="" WEIGHT="99.99999999999999" Z="7.407353185379586">
<NAME>leflunomide vs. placebo, at 6 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.2272065896606747" CI_START="-0.7863986534908365" EFFECT_SIZE="-0.5068026215757556" ESTIMABLE="YES" MEAN_1="-16.5" MEAN_2="-9.7" ORDER="34340" SD_1="14.1" SD_2="12.6" SE="0.14265365798580928" STUDY_ID="STD-Mladenovic-1995" TOTAL_1="101" TOTAL_2="102" WEIGHT="29.087390917228824"/>
<CONT_DATA CI_END="-0.42500367014063234" CI_START="-0.9767659996948204" EFFECT_SIZE="-0.7008848349177264" ESTIMABLE="YES" MEAN_1="-9.7" MEAN_2="-4.3" ORDER="34341" SD_1="7.8" SD_2="7.5" SE="0.1407582827813212" STUDY_ID="STD-Smolen-1999" TOTAL_1="130" TOTAL_2="91" WEIGHT="29.87601527497544"/>
<CONT_DATA CI_END="-0.2838668206336088" CI_START="-0.7546573634824849" EFFECT_SIZE="-0.5192620920580469" ESTIMABLE="YES" MEAN_1="-7.55" MEAN_2="-3.39" ORDER="34342" SD_1="7.86" SD_2="8.19" SE="0.12010183517717973" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="118" WEIGHT="41.036593807795725"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-2.807592284520351" CI_START="-6.592407715479649" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.7" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="1.1285696529951906E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="182" TOTAL_2="118" UNITS="" WEIGHT="100.0" Z="4.867783328078128">
<NAME>leflunomide vs. placebo, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.807592284520351" CI_START="-6.592407715479649" EFFECT_SIZE="-4.7" ESTIMABLE="YES" MEAN_1="-7.7" MEAN_2="-3.0" ORDER="34343" SD_1="7.8" SD_2="8.4" SE="0.9655318824257588" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="118" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.1472791296713245" CI_END="0.26077289226880607" CI_START="-1.289234531286489" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5142308195088415" ESTIMABLE="YES" I2="6.8588721250165525" I2_Q="0.0" ID="CMP-004.03" NO="3" P_CHI2="0.34176259694354494" P_Q="1.0" P_Z="0.19343780651625303" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="371" TOTAL_2="293" UNITS="" WEIGHT="100.0" Z="1.3004762050314032">
<NAME>leflunomide vs. methotrexate, at 3 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.12632215888856124" CI_START="-1.6663221588885622" EFFECT_SIZE="-0.7700000000000005" ESTIMABLE="YES" MEAN_1="-6.73" MEAN_2="-5.96" ORDER="34344" SD_1="5.22" SD_2="4.96" SE="0.457315627204702" STUDY_ID="STD-Bao-2000" TOTAL_1="291" TOTAL_2="213" WEIGHT="74.7617224529056"/>
<CONT_DATA CI_END="3.191306351441454" CI_START="-1.1913063514414541" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="-6.0" MEAN_2="-7.0" ORDER="34345" SD_1="5.0" SD_2="5.0" SE="1.118033988749895" STUDY_ID="STD-Lao-2001" TOTAL_1="40" TOTAL_2="40" WEIGHT="12.508388740933604"/>
<CONT_DATA CI_END="1.672158326761095" CI_START="-2.672158326761095" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="-6.8" MEAN_2="-6.3" ORDER="34346" SD_1="5.2" SD_2="4.7" SE="1.1082644088844502" STUDY_ID="STD-Shuai-2002" TOTAL_1="40" TOTAL_2="40" WEIGHT="12.729888806160801"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.9778749140152376" CI_START="-8.977874914015239" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.1152702194092115" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="21" UNITS="" WEIGHT="100.0" Z="1.5749403256572507">
<NAME>leflunomide vs. methotrexate, at 4 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9778749140152376" CI_START="-8.977874914015239" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="-9.9" MEAN_2="-5.9" ORDER="34347" SD_1="9.0" SD_2="6.4" SE="2.5397787680182287" STUDY_ID="STD-Reece-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.588067245391808" CI_END="0.15015053206577422" CI_START="-1.4382285696365056" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6440390187853656" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.05" MODIFIED="2008-11-12 10:13:57 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9643804416818462" P_Q="1.0" P_Z="0.11196772559551567" Q="0.0" RANDOM="NO" SCALE="3.202945862459739" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="390" TOTAL_2="373" UNITS="" WEIGHT="100.0" Z="1.5894105885742533">
<NAME>leflunomide vs. methotrexate, at 6 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8990406401200322" CI_START="-2.23904064012003" EFFECT_SIZE="-0.669999999999999" ESTIMABLE="YES" MEAN_1="-8.37" MEAN_2="-7.7" ORDER="34348" SD_1="5.9" SD_2="5.22" SE="0.800545649050913" STUDY_ID="STD-Bao-2000" TOTAL_1="104" TOTAL_2="89" WEIGHT="25.620048792050966"/>
<CONT_DATA CI_END="1.6295676217297448" CI_START="-3.629567621729745" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-9.0" MEAN_2="-8.0" ORDER="34349" SD_1="6.0" SD_2="6.0" SE="1.3416407864998738" STUDY_ID="STD-Lao-2001" TOTAL_1="40" TOTAL_2="40" WEIGHT="9.12178119074226"/>
<CONT_DATA CI_END="1.8412930138188708" CI_START="-3.2412930138188694" EFFECT_SIZE="-0.6999999999999993" ESTIMABLE="YES" MEAN_1="-9.1" MEAN_2="-8.4" ORDER="34350" SD_1="6.0" SD_2="4.6" SE="1.296601893638998" STUDY_ID="STD-Shuai-2002" TOTAL_1="34" TOTAL_2="34" WEIGHT="9.766497705973167"/>
<CONT_DATA CI_END="1.4831924702292212" CI_START="-1.743192470229221" EFFECT_SIZE="-0.1299999999999999" ESTIMABLE="YES" MEAN_1="-7.55" MEAN_2="-7.42" ORDER="34351" SD_1="7.86" SD_2="7.8" SE="0.8230725069204727" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="180" WEIGHT="24.236838282040594"/>
<CONT_DATA CI_END="0.5205795884560576" CI_START="-2.3205795884560567" EFFECT_SIZE="-0.8999999999999995" ESTIMABLE="YES" MEAN_1="-7.1" MEAN_2="-6.2" MODIFIED="2008-11-12 10:06:19 -0500" MODIFIED_BY="[Empty name]" ORDER="415" SD_1="3.0" SD_2="2.6" SE="0.7247988226627671" STUDY_ID="STD-Wislowska-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="31.25483402919302"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.876570984081081" CI_END="2.675188599766884" CI_START="-2.2146022064737445" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.23029319664656997" ESTIMABLE="YES" I2="85.45786843013836" I2_Q="0.0" ID="CMP-004.06" NO="6" P_CHI2="0.008733359574940591" P_Q="1.0" P_Z="0.8535303762352624" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="2.670558388441823" TOTALS="YES" TOTAL_1="677" TOTAL_2="669" UNITS="" WEIGHT="100.0" Z="0.1846158206751169">
<NAME>leflunomide vs. methotrexate, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.387223994826585" CI_START="0.41277600517341173" EFFECT_SIZE="1.3999999999999986" ESTIMABLE="YES" MEAN_1="-8.3" MEAN_2="-9.7" ORDER="34352" SD_1="7.9" SD_2="7.9" SE="0.5036949671594395" STUDY_ID="STD-Emery-1999" TOTAL_1="495" TOTAL_2="489" WEIGHT="53.21172786586284"/>
<CONT_DATA CI_END="0.4864508370762237" CI_START="-2.686450837076225" EFFECT_SIZE="-1.1000000000000005" ESTIMABLE="YES" MEAN_1="-7.7" MEAN_2="-6.6" ORDER="34353" SD_1="7.8" SD_2="7.6" SE="0.8094285658256712" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="180" WEIGHT="46.78827213413716"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.6743832397598797" CI_END="1.3853992563005781" CI_START="-1.8182968043668648" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.21644877403314325" ESTIMABLE="YES" I2="40.27651637605927" I2_Q="0.0" ID="CMP-004.07" NO="7" P_CHI2="0.19567253943862528" P_Q="1.0" P_Z="0.7911335057945283" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.5819956616340561" TOTALS="YES" TOTAL_1="371" TOTAL_2="399" UNITS="" WEIGHT="100.0" Z="0.2648389819566259">
<NAME>leflunomide vs. methotrexate, at 2 years</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9000902792702559" CI_START="-3.5000902792702537" EFFECT_SIZE="-1.299999999999999" ESTIMABLE="YES" MEAN_1="-10.1" MEAN_2="-8.8" ORDER="34354" SD_1="6.7" SD_2="9.0" SE="1.122515666932804" STUDY_ID="STD-Cohen-2001" TOTAL_1="98" TOTAL_2="101" WEIGHT="36.261692590184936"/>
<CONT_DATA CI_END="1.7379065807771596" CI_START="-0.9379065807771589" EFFECT_SIZE="0.40000000000000036" ESTIMABLE="YES" MEAN_1="-10.5" MEAN_2="-10.9" ORDER="34355" SD_1="8.1" SD_2="8.2" SE="0.6826179416205581" STUDY_ID="STD-Emery-1999" TOTAL_1="273" TOTAL_2="298" WEIGHT="63.73830740981507"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.24158249868358017" CI_START="-3.4415824986835792" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.08" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.08859577536707472" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="132" UNITS="" WEIGHT="100.0" Z="1.7028519642784152">
<NAME>leflunomide vs. sulfasalazine, at 6 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.24158249868357995" CI_START="-3.4415824986835792" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" MEAN_1="-9.7" MEAN_2="-8.1" ORDER="34356" SD_1="7.8" SD_2="7.4" SE="0.9396001728652911" STUDY_ID="STD-Smolen-1999" TOTAL_1="130" TOTAL_2="132" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.262796392391052" CI_START="-3.0627963923910526" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.09" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.41473137796178583" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="78" TOTAL_2="74" UNITS="" WEIGHT="100.0" Z="0.8155957686501951">
<NAME>leflunomide vs. sulfasalazine, at 12 months</NAME>
<GROUP_LABEL_1>Leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.262796392391052" CI_START="-3.0627963923910526" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" MEAN_1="-10.85" MEAN_2="-9.95" ORDER="34357" SD_1="6.8" SD_2="6.8" SE="1.103487823986009" STUDY_ID="STD-Scott-2001" TOTAL_1="78" TOTAL_2="74" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.8293019782461442" CI_START="-5.8306980217538555" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.33" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.10" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.009055722852733079" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="57" UNITS="" WEIGHT="100.0" Z="2.60994330852508">
<NAME>leflunomide vs. sulfasalazine, at 24 months</NAME>
<GROUP_LABEL_1>Leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.8293019782461442" CI_START="-5.8306980217538555" EFFECT_SIZE="-3.33" ESTIMABLE="YES" MEAN_1="-13.06" MEAN_2="-9.73" ORDER="34358" SD_1="7.0" SD_2="6.8" SE="1.2758897824036781" STUDY_ID="STD-Scott-2001" TOTAL_1="60" TOTAL_2="57" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.3855018700653373E-31" CI_END="-4.608170922159635" CI_START="-10.591829077840362" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-7.599999999999999" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-004.11" NO="11" P_CHI2="0.0" P_Q="1.0" P_Z="6.397886637752288E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="133" UNITS="" WEIGHT="100.0" Z="4.978802563566504">
<NAME>leflunomide+MTX vs MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-4.608170922159636" CI_START="-10.591829077840362" EFFECT_SIZE="-7.6" ESTIMABLE="YES" MEAN_1="-13.0" MEAN_2="-5.4" ORDER="34359" SD_1="11.98" SD_2="12.77" SE="1.5264714563326314" STUDY_ID="STD-Kremer-2002" TOTAL_1="130" TOTAL_2="133" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.8861388938415815" CI_START="-0.24613889384158094" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.3200000000000003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.12" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.0985487386786102" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="200" TOTAL_2="197" UNITS="" WEIGHT="100.0" Z="1.6519304065342808">
<NAME>Leflunomide 10 mg vs leflunomide 20 mg, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef10</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef20</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.8861388938415815" CI_START="-0.24613889384158094" EFFECT_SIZE="1.3200000000000003" ESTIMABLE="YES" MEAN_1="-7.57" MEAN_2="-8.89" ORDER="34360" SD_1="7.92" SD_2="8.0" SE="0.7990651390510667" STUDY_ID="STD-Poor-2004" TOTAL_1="200" TOTAL_2="197" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.2642457738195754" CI_START="-3.824245773819576" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.2800000000000002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.13" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.32410852209411234" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="50" UNITS="" WEIGHT="100.0" Z="0.986050139505578">
<NAME>leflunomide+SSZ vs. placebo+SSZ, at 24 months</NAME>
<GROUP_LABEL_1>Lef+SSZ</GROUP_LABEL_1>
<GROUP_LABEL_2>Plc+SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.2642457738195754" CI_START="-3.824245773819576" EFFECT_SIZE="-1.2800000000000002" ESTIMABLE="YES" MEAN_1="-2.68" MEAN_2="-1.4" ORDER="34361" SD_1="6.37" SD_2="6.93" SE="1.2981084315264269" STUDY_ID="STD-Dougados-2005" TOTAL_1="56" TOTAL_2="50" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.439104753351684" CI_START="-1.8391047533516818" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.8000000000000007" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.14" MODIFIED="2008-11-24 11:12:59 -0500" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.3323200332982206" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="90" TOTAL_2="87" UNITS="" WEIGHT="100.0" Z="0.9694513929347062">
<NAME>Lef/lef+MTX vs Plc/lef+MTX, at 48 weeks</NAME>
<GROUP_LABEL_1>Plc/lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef/lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Plc/Lef+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef/Lef+MTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.439104753351684" CI_START="-1.8391047533516818" EFFECT_SIZE="1.8000000000000007" ESTIMABLE="YES" MEAN_1="-14.1" MEAN_2="-15.9" ORDER="34362" SD_1="12.4" SD_2="12.3" SE="1.856720216318502" STUDY_ID="STD-Kremer-2004" TOTAL_1="90" TOTAL_2="87" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.716366888174828" CI_START="1.8836331118251735" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.3000000000000007" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.15" MODIFIED="2008-12-27 09:30:20 -0500" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="4.958653304015603E-6" Q="0.0" RANDOM="NO" SCALE="12.76" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="4.566529479742982">
<NAME>leflunomide vs. anti-TNF+MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef</GROUP_LABEL_1>
<GROUP_LABEL_2>Anti-TNF+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours anti-TNF+MTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.716366888174828" CI_START="1.8836331118251735" EFFECT_SIZE="3.3000000000000007" ESTIMABLE="YES" MEAN_1="-7.1" MEAN_2="-10.4" MODIFIED="2008-11-12 10:13:02 -0500" MODIFIED_BY="[Empty name]" ORDER="416" SD_1="3.0" SD_2="2.0" SE="0.7226494462892933" STUDY_ID="STD-Wislowska-2007" TOTAL_1="30" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.4861820502422693" CI_START="-10.086182050242272" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.8000000000000007" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.16" MODIFIED="2008-12-18 11:23:27 -0500" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.23609689040678428" Q="0.0" RANDOM="NO" SCALE="22.52072159793104" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="24" UNITS="" WEIGHT="100.0" Z="1.184799148628724">
<NAME>weekly Lef100 vs. weekly Lef200, at 6 months</NAME>
<GROUP_LABEL_1>weekly Lef200</GROUP_LABEL_1>
<GROUP_LABEL_2>weekly Lef100</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours weekly Lef200</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours weekly Lef100</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.4861820502422693" CI_START="-10.086182050242272" EFFECT_SIZE="-3.8000000000000007" ESTIMABLE="YES" MEAN_1="-16.0" MEAN_2="-12.2" MODIFIED="2008-12-18 11:23:18 -0500" MODIFIED_BY="[Empty name]" ORDER="551" SD_1="11.7" SD_2="10.2" SE="3.207294674711817" STUDY_ID="STD-Rozman-1994a" TOTAL_1="23" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2009-04-10 04:28:48 -0400" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Changes of swollen joint count</NAME>
<CONT_OUTCOME CHI2="1.1668132147827976" CI_END="-0.33795032982616807" CI_START="-0.6379976898917661" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.48797400985896705" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.01" MODIFIED="2009-04-10 04:28:48 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5579944562785573" P_Q="1.0" P_Z="1.8287922086844662E-10" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="413" TOTAL_2="311" UNITS="" WEIGHT="100.0" Z="6.37507015229911">
<NAME>leflunomide vs. placebo, at 6 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.25283373632895234" CI_START="-0.8129613175912311" EFFECT_SIZE="-0.5328975269600917" ESTIMABLE="YES" MEAN_1="-11.7" MEAN_2="-6.5" ORDER="34363" SD_1="9.1" SD_2="10.3" SE="0.14289231477733613" STUDY_ID="STD-Mladenovic-1995" TOTAL_1="101" TOTAL_2="102" WEIGHT="28.694965269417075"/>
<CONT_DATA CI_END="-0.3040251867485145" CI_START="-0.850699694800974" EFFECT_SIZE="-0.5773624407747442" ESTIMABLE="YES" MEAN_1="-7.2" MEAN_2="-3.4" ORDER="34364" SD_1="6.6" SD_2="6.5" SE="0.13946034528301493" STUDY_ID="STD-Smolen-1999" TOTAL_1="130" TOTAL_2="91" WEIGHT="30.12464754708322"/>
<CONT_DATA CI_END="-0.15749665790608697" CI_START="-0.6250644603542088" EFFECT_SIZE="-0.39128055913014786" ESTIMABLE="YES" MEAN_1="-5.58" MEAN_2="-3.1" ORDER="34365" SD_1="6.48" SD_2="6.07" SE="0.11927969241685994" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="118" WEIGHT="41.18038718349971"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-7.14978313891268" CI_START="-10.05021686108732" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.6" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="3.1534016998481683E-31" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="182" TOTAL_2="118" UNITS="" WEIGHT="100.0" Z="11.622875667303086">
<NAME>leflunomide vs. placebo, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-7.14978313891268" CI_START="-10.05021686108732" EFFECT_SIZE="-8.6" ESTIMABLE="YES" MEAN_1="-5.7" MEAN_2="2.9" ORDER="34366" SD_1="6.5" SD_2="6.1" SE="0.7399201579857819" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="118" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.5759272948023244" CI_END="0.5311231965554539" CI_START="-0.8163351720192484" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.1426059877318973" ESTIMABLE="YES" I2="22.358057075773207" I2_Q="0.0" ID="CMP-005.03" NO="3" P_CHI2="0.27583202769305437" P_Q="1.0" P_Z="0.6782451436361041" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="371" TOTAL_2="293" UNITS="" WEIGHT="100.0" Z="0.4148589766523597">
<NAME>leflunomide vs. methotrexate, at 3 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.37925102086839135" CI_START="-1.1992510208683917" EFFECT_SIZE="-0.41000000000000014" ESTIMABLE="YES" MEAN_1="-5.26" MEAN_2="-4.85" ORDER="34367" SD_1="4.67" SD_2="4.31" SE="0.4026864917385742" STUDY_ID="STD-Bao-2000" TOTAL_1="291" TOTAL_2="213" WEIGHT="72.86859838655057"/>
<CONT_DATA CI_END="2.5494875807614044" CI_START="-0.5494875807614041" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="-4.0" MEAN_2="-5.0" ORDER="34368" SD_1="3.0" SD_2="4.0" SE="0.7905694150420949" STUDY_ID="STD-Lao-2001" TOTAL_1="40" TOTAL_2="40" WEIGHT="18.905776579054134"/>
<CONT_DATA CI_END="1.9490967617207913" CI_START="-2.749096761720792" EFFECT_SIZE="-0.40000000000000036" ESTIMABLE="YES" MEAN_1="-5.4" MEAN_2="-5.0" ORDER="34369" SD_1="6.1" SD_2="4.5" SE="1.1985407794480751" STUDY_ID="STD-Shuai-2002" TOTAL_1="40" TOTAL_2="40" WEIGHT="8.225625034395291"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.440903371689795" CI_START="-4.440903371689795" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="21" UNITS="" WEIGHT="100.00000000000001" Z="0.0">
<NAME>leflunomide vs. methotrexate, at 4 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.440903371689795" CI_START="-4.440903371689795" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-4.6" MEAN_2="-4.6" ORDER="34370" SD_1="7.1" SD_2="7.0" SE="2.2658086611382013" STUDY_ID="STD-Reece-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.5201389377459607" CI_END="0.7542591035019501" CI_START="-0.4740650404360572" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="0.14009703153294645" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.05" MODIFIED="2008-11-12 10:16:07 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.8230683381926169" P_Q="1.0" P_Z="0.6548107675753077" Q="0.0" RANDOM="NO" SCALE="3.202945862459739" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="390" TOTAL_2="373" UNITS="" WEIGHT="99.99999999999999" Z="0.4470890481159597">
<NAME>leflunomide vs. methotrexate, at 6 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.334676028782541" CI_START="-1.1746760287825408" EFFECT_SIZE="0.08000000000000007" ESTIMABLE="YES" MEAN_1="-6.53" MEAN_2="-6.61" ORDER="34371" SD_1="4.67" SD_2="4.22" SE="0.6401525939656367" STUDY_ID="STD-Bao-2000" TOTAL_1="104" TOTAL_2="89" WEIGHT="23.960881107012714"/>
<CONT_DATA CI_END="2.7530450811531635" CI_START="-0.7530450811531633" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="-6.0" MEAN_2="-7.0" ORDER="34372" SD_1="4.0" SD_2="4.0" SE="0.8944271909999159" STUDY_ID="STD-Lao-2001" TOTAL_1="40" TOTAL_2="40" WEIGHT="12.273821881588692"/>
<CONT_DATA CI_END="2.1100854144729895" CI_START="-2.710085414472989" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="-6.8" MEAN_2="-6.5" ORDER="34373" SD_1="5.5" SD_2="4.6" SE="1.2296580108019513" STUDY_ID="STD-Shuai-2002" TOTAL_1="34" TOTAL_2="34" WEIGHT="6.493833012628136"/>
<CONT_DATA CI_END="1.5379937614036852" CI_START="-0.8979937614036846" EFFECT_SIZE="0.3200000000000003" ESTIMABLE="YES" MEAN_1="-5.58" MEAN_2="-5.9" ORDER="34374" SD_1="6.48" SD_2="5.29" SE="0.6214368075184361" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="180" WEIGHT="25.42587208978358"/>
<CONT_DATA CI_END="0.888324309683173" CI_START="-1.2883243096831734" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="-5.3" MEAN_2="-5.1" MODIFIED="2008-11-12 10:15:55 -0500" MODIFIED_BY="[Empty name]" ORDER="417" SD_1="2.2" SD_2="2.1" SE="0.5552777082985894" STUDY_ID="STD-Wislowska-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="31.845591908986872"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="10.132410609873112" CI_END="3.4356109380935047" CI_START="-1.462185201321755" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.9867128683858748" ESTIMABLE="YES" I2="90.13068026452076" I2_Q="0.0" ID="CMP-005.06" NO="6" P_CHI2="0.001456858264677452" P_Q="1.0" P_Z="0.42969658666517097" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="2.816583758266274" TOTALS="YES" TOTAL_1="677" TOTAL_2="669" UNITS="" WEIGHT="100.0" Z="0.789710976149127">
<NAME>leflunomide vs. methotrexate, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.1122449572448208" CI_START="1.2877550427551796" EFFECT_SIZE="2.2" ESTIMABLE="YES" MEAN_1="-6.8" MEAN_2="-9.0" ORDER="34375" SD_1="7.3" SD_2="7.3" SE="0.46543965319796304" STUDY_ID="STD-Emery-1999" TOTAL_1="495" TOTAL_2="489" WEIGHT="51.46851473543498"/>
<CONT_DATA CI_END="0.9398974645058784" CI_START="-1.539897464505878" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="-5.7" MEAN_2="-5.4" ORDER="34376" SD_1="6.5" SD_2="5.5" SE="0.6326123715976575" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="180" WEIGHT="48.53148526456501"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.3685528688583153" CI_END="2.123510846848804" CI_START="-1.1716612394603418" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.4759248036942312" ESTIMABLE="YES" I2="57.78012755602885" I2_Q="0.0" ID="CMP-005.07" NO="7" P_CHI2="0.12380193771222181" P_Q="1.0" P_Z="0.5712857804478471" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.8349228431846172" TOTALS="YES" TOTAL_1="371" TOTAL_2="399" UNITS="" WEIGHT="100.0" Z="0.5661588834559432">
<NAME>leflunomide vs. methotrexate, at 2 years</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.279307642532508" CI_START="-2.2793076425325065" EFFECT_SIZE="-0.4999999999999991" ESTIMABLE="YES" MEAN_1="-8.2" MEAN_2="-7.7" ORDER="34377" SD_1="6.1" SD_2="6.7" SE="0.9078267032289669" STUDY_ID="STD-Cohen-2001" TOTAL_1="98" TOTAL_2="101" WEIGHT="42.592658606221754"/>
<CONT_DATA CI_END="2.433384313152356" CI_START="-0.033384313152353906" EFFECT_SIZE="1.200000000000001" ESTIMABLE="YES" MEAN_1="-9.1" MEAN_2="-10.3" ORDER="34378" SD_1="7.7" SD_2="7.3" SE="0.6292892741301029" STUDY_ID="STD-Emery-1999" TOTAL_1="273" TOTAL_2="298" WEIGHT="57.407341393778246"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.4942245169148374" CI_START="-2.494224516914837" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.08" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.18962370675830137" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="132" UNITS="" WEIGHT="100.0" Z="1.3116930972239973">
<NAME>leflunomide vs. sulfasalazine, at 6 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.4942245169148374" CI_START="-2.494224516914837" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-7.2" MEAN_2="-6.2" ORDER="34379" SD_1="6.6" SD_2="5.7" SE="0.7623734561966902" STUDY_ID="STD-Smolen-1999" TOTAL_1="130" TOTAL_2="132" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.615328679084695" CI_START="-1.855328679084697" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.120000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.09" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.8921898477503111" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="78" TOTAL_2="74" UNITS="" WEIGHT="100.0" Z="0.1355337930961085">
<NAME>leflunomide vs. sulfasalazine, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.6153286790846948" CI_START="-1.8553286790846968" EFFECT_SIZE="-0.120000000000001" ESTIMABLE="YES" MEAN_1="-8.97" MEAN_2="-8.85" ORDER="34380" SD_1="5.3" SD_2="5.6" SE="0.885388044256296" STUDY_ID="STD-Scott-2001" TOTAL_1="78" TOTAL_2="74" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.5721654747193017" CI_START="-4.667834525280696" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.619999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.10" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.01215616082650553" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="57" UNITS="" WEIGHT="100.0" Z="2.507578408363376">
<NAME>leflunomide vs. sulfasalazine, at 24 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.5721654747193017" CI_START="-4.667834525280696" EFFECT_SIZE="-2.619999999999999" ESTIMABLE="YES" MEAN_1="-10.52" MEAN_2="-7.9" ORDER="34381" SD_1="5.7" SD_2="5.6" SE="1.0448327323531221" STUDY_ID="STD-Scott-2001" TOTAL_1="60" TOTAL_2="57" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-1.727130370724688" CI_START="-5.472869629275311" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.5999999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.11" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="1.6494906978071062E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="133" UNITS="" WEIGHT="100.0" Z="3.7674113745303206">
<NAME>leflunomide+MTX vs MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.727130370724688" CI_START="-5.472869629275311" EFFECT_SIZE="-3.5999999999999996" ESTIMABLE="YES" MEAN_1="-7.8" MEAN_2="-4.2" ORDER="34382" SD_1="7.43" SD_2="8.06" SE="0.9555632879217518" STUDY_ID="STD-Kremer-2002" TOTAL_1="130" TOTAL_2="133" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.8277407398784833" CI_START="-0.6677407398784831" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5800000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.12" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.3622585214313503" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="200" TOTAL_2="197" UNITS="" WEIGHT="100.00000000000001" Z="0.9110699640567493">
<NAME>Leflunomide 10 mg vs leflunomide 20 mg, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef10</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef20</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.8277407398784833" CI_START="-0.6677407398784831" EFFECT_SIZE="0.5800000000000001" ESTIMABLE="YES" MEAN_1="-6.38" MEAN_2="-6.96" ORDER="34383" SD_1="6.22" SD_2="6.46" SE="0.6366141162391263" STUDY_ID="STD-Poor-2004" TOTAL_1="200" TOTAL_2="197" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.289942075099553" CI_START="-2.7699420750995527" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.74" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.13" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.474924232018621" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="50" UNITS="" WEIGHT="100.0" Z="0.7144900174003785">
<NAME>leflunomide+SSZ vs. placebo+SSZ, at 24 months</NAME>
<GROUP_LABEL_1>Lef+SSZ</GROUP_LABEL_1>
<GROUP_LABEL_2>Plc+SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.289942075099553" CI_START="-2.7699420750995527" EFFECT_SIZE="-0.74" ESTIMABLE="YES" MEAN_1="-1.5" MEAN_2="-0.76" ORDER="34384" SD_1="4.84" SD_2="5.72" SE="1.0357037634933484" STUDY_ID="STD-Dougados-2005" TOTAL_1="56" TOTAL_2="50" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.2389630051063714" CI_START="-3.0389630051063685" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8999999999999986" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.14" MODIFIED="2008-11-24 11:14:11 -0500" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.4095512860007071" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="90" TOTAL_2="87" UNITS="" WEIGHT="100.0" Z="0.8246835414520526">
<NAME>Lef/lef+MTX vs Plc/lef+MTX, at 48 weeks</NAME>
<GROUP_LABEL_1>Plc/lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef/lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Plc/lef+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef/lef+MTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.2389630051063714" CI_START="-3.0389630051063685" EFFECT_SIZE="-0.8999999999999986" ESTIMABLE="YES" MEAN_1="-9.7" MEAN_2="-8.8" ORDER="34385" SD_1="7.0" SD_2="7.5" SE="1.0913277090692672" STUDY_ID="STD-Kremer-2004" TOTAL_1="90" TOTAL_2="87" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.5790594829496176" CI_START="0.2209405170503831" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.4000000000000004" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.15" MODIFIED="2008-12-27 09:31:03 -0500" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.019952712312718793" Q="0.0" RANDOM="NO" SCALE="3.61" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="18" UNITS="" WEIGHT="99.99999999999999" Z="2.327235918150305">
<NAME>leflunomide vs. anti-TNF+MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef</GROUP_LABEL_1>
<GROUP_LABEL_2>Anti-TNF+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours anti-TNF+MTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.5790594829496176" CI_START="0.2209405170503831" EFFECT_SIZE="1.4000000000000004" ESTIMABLE="YES" MEAN_1="-5.3" MEAN_2="-6.7" MODIFIED="2008-11-12 10:18:26 -0500" MODIFIED_BY="[Empty name]" ORDER="418" SD_1="2.2" SD_2="1.9" SE="0.6015720147155192" STUDY_ID="STD-Wislowska-2007" TOTAL_1="30" TOTAL_2="18" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.8854379308901796" CI_START="-6.085437930890179" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.16" MODIFIED="2008-12-18 11:25:21 -0500" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.4844654811200001" Q="0.0" RANDOM="NO" SCALE="22.52072159793104" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="24" UNITS="" WEIGHT="100.0" Z="0.6991385063357075">
<NAME>weekly Lef100 vs. weekly Lef200, at 6 months</NAME>
<GROUP_LABEL_1>weekly Lef200</GROUP_LABEL_1>
<GROUP_LABEL_2>weekly Lef100</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours weekly Lef200</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours weekly Lef100</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.8854379308901796" CI_START="-6.085437930890179" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" MEAN_1="-10.0" MEAN_2="-8.4" MODIFIED="2008-12-18 11:25:21 -0500" MODIFIED_BY="[Empty name]" ORDER="552" SD_1="8.8" SD_2="6.7" SE="2.288530792540445" STUDY_ID="STD-Rozman-1994a" TOTAL_1="23" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2009-07-22 12:18:58 -0400" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Changes of patient global assessment</NAME>
<CONT_OUTCOME CHI2="3.0214171647835864" CI_END="-0.4852871358720115" CI_START="-0.7884516202941947" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.6368693780831031" ESTIMABLE="YES" I2="33.80589667288618" I2_Q="0.0" ID="CMP-006.01" MODIFIED="2008-12-31 08:37:32 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.22075357408297147" P_Q="1.0" P_Z="1.7994116969436716E-16" Q="0.0" RANDOM="NO" SCALE="1.385458013417937" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="413" TOTAL_2="311" UNITS="" WEIGHT="100.0" Z="8.234744556430428">
<NAME>leflunomide vs. placebo, at 6 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.17211646232048683" CI_START="-0.7294542586208496" EFFECT_SIZE="-0.4507853604706682" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="-0.5" ORDER="34386" SD_1="1.0" SD_2="1.2" SE="0.1421806218625883" STUDY_ID="STD-Mladenovic-1995" TOTAL_1="101" TOTAL_2="102" WEIGHT="29.588275439958824"/>
<CONT_DATA CI_END="-0.3597325487631667" CI_START="-0.9086310876004697" EFFECT_SIZE="-0.6341818181818182" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-0.4" ORDER="34387" SD_1="1.1" SD_2="1.1" SE="0.1400277105005359" STUDY_ID="STD-Smolen-1999" TOTAL_1="130" TOTAL_2="91" WEIGHT="30.505102998463467"/>
<CONT_DATA CI_END="-0.5369406824123817" CI_START="-1.0168463084094062" EFFECT_SIZE="-0.7768934954108939" ESTIMABLE="YES" MEAN_1="-2.23" MEAN_2="-0.23" ORDER="34388" SD_1="2.56" SD_2="2.58" SE="0.12242715421876592" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="118" WEIGHT="39.90662156157771"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-1.5603918774597088" CI_START="-2.839608122540292" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.2" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="1.5675533611235098E-11" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="182" TOTAL_2="118" UNITS="" WEIGHT="100.0" Z="6.741504077313363">
<NAME>leflunomide vs. placebo, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.5603918774597088" CI_START="-2.839608122540292" EFFECT_SIZE="-2.2" ESTIMABLE="YES" MEAN_1="-2.1" MEAN_2="0.1" ORDER="34389" SD_1="2.7" SD_2="2.8" SE="0.32633667127836974" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="118" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.293700747530583" CI_END="0.05480858834408753" CI_START="-0.5244942361655729" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.23484282391074268" ESTIMABLE="YES" I2="62.21924707525327" I2_Q="0.0" ID="CMP-006.03" NO="3" P_CHI2="0.07087423084956102" P_Q="1.0" P_Z="0.11203905093992961" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="371" TOTAL_2="293" UNITS="" WEIGHT="99.99999999999999" Z="1.5890945371527767">
<NAME>leflunomide vs. methotrexate, at 3 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.06250860517745194" CI_START="-0.7774913948225479" EFFECT_SIZE="-0.41999999999999993" ESTIMABLE="YES" MEAN_1="-3.63" MEAN_2="-3.21" ORDER="34390" SD_1="2.04" SD_2="2.01" SE="0.18239692037322852" STUDY_ID="STD-Bao-2000" TOTAL_1="291" TOTAL_2="213" WEIGHT="65.64779084392687"/>
<CONT_DATA CI_END="1.0135657784036072" CI_START="-0.21356577840360724" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" MEAN_1="-2.5" MEAN_2="-2.9" ORDER="34391" SD_1="1.4" SD_2="1.4" SE="0.31304951684997057" STUDY_ID="STD-Lao-2001" TOTAL_1="40" TOTAL_2="40" WEIGHT="22.28584178225532"/>
<CONT_DATA CI_END="0.4338489350869482" CI_START="-1.233848935086947" EFFECT_SIZE="-0.39999999999999947" ESTIMABLE="YES" MEAN_1="-4.1" MEAN_2="-3.7" ORDER="34392" SD_1="2.0" SD_2="1.8" SE="0.42544094772365293" STUDY_ID="STD-Shuai-2002" TOTAL_1="40" TOTAL_2="40" WEIGHT="12.066367373817796"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.7278589376981275" CI_START="-0.5278589376981275" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.7549141461179878" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="21" UNITS="" WEIGHT="100.0" Z="0.3121662951435754">
<NAME>leflunomide vs. methotrexate, at 4 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7278589376981275" CI_START="-0.5278589376981275" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-1.0" ORDER="34393" SD_1="0.9" SD_2="1.1" SE="0.3203420790640025" STUDY_ID="STD-Reece-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.9130936089953521" CI_END="-0.2562197758311996" CI_START="-0.9537105569142138" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6049651663727067" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.05" NO="5" P_CHI2="0.8222670584266496" P_Q="1.0" P_Z="6.740309047705146E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="360" TOTAL_2="343" UNITS="" WEIGHT="99.99999999999999" Z="3.3999300640237875">
<NAME>leflunomide vs. methotrexate, at 6 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.08445078378104731" CI_START="-1.1244507837810482" EFFECT_SIZE="-0.5200000000000005" ESTIMABLE="YES" MEAN_1="-4.07" MEAN_2="-3.55" ORDER="34394" SD_1="2.02" SD_2="2.23" SE="0.3083989239337449" STUDY_ID="STD-Bao-2000" TOTAL_1="104" TOTAL_2="89" WEIGHT="33.28856408890301"/>
<CONT_DATA CI_END="0.5776175098237116" CI_START="-1.1776175098237114" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="-4.0" MEAN_2="-3.7" ORDER="34395" SD_1="1.9" SD_2="2.1" SE="0.44777226354476224" STUDY_ID="STD-Lao-2001" TOTAL_1="40" TOTAL_2="40" WEIGHT="15.790882184149298"/>
<CONT_DATA CI_END="0.17478004580879092" CI_START="-1.7747800458087906" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="YES" MEAN_1="-4.8" MEAN_2="-4.0" ORDER="34396" SD_1="2.1" SD_2="2.0" SE="0.49734589691327563" STUDY_ID="STD-Shuai-2002" TOTAL_1="34" TOTAL_2="34" WEIGHT="12.79981496425039"/>
<CONT_DATA CI_END="-0.1751569077778331" CI_START="-1.3048430922221668" EFFECT_SIZE="-0.74" ESTIMABLE="YES" MEAN_1="-2.23" MEAN_2="-1.49" ORDER="34397" SD_1="2.56" SD_2="2.91" SE="0.28819054670268285" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="180" WEIGHT="38.120738762697286"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.875097644888395" CI_END="0.7731361457346181" CI_START="-0.981705331226094" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.10428459274573797" ESTIMABLE="YES" I2="88.73251833374533" I2_Q="0.0" ID="CMP-006.06" NO="6" P_CHI2="0.0028908925489845583" P_Q="1.0" P_Z="0.8158012189479585" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.35936669925166853" TOTALS="YES" TOTAL_1="677" TOTAL_2="669" UNITS="" WEIGHT="100.0" Z="0.23294872911036107">
<NAME>leflunomide vs. methotrexate, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.4313239379641324" CI_START="0.1686760620358675" EFFECT_SIZE="0.29999999999999993" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-1.2" ORDER="34398" SD_1="1.1" SD_2="1.0" SE="0.0670032403656388" STUDY_ID="STD-Emery-1999" TOTAL_1="495" TOTAL_2="489" WEIGHT="55.07948969491801"/>
<CONT_DATA CI_END="-0.022634505125458837" CI_START="-1.1773654948745413" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="-2.1" MEAN_2="-1.5" ORDER="34399" SD_1="2.7" SD_2="2.9" SE="0.29457964504895323" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="180" WEIGHT="44.92051030508199"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.477049180338946" CI_END="0.6399017810529755" CI_START="-1.301086365970224" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3305922924586243" ESTIMABLE="YES" I2="84.56087066568068" I2_Q="0.0" ID="CMP-006.07" NO="7" P_CHI2="0.01092765216829572" P_Q="1.0" P_Z="0.5043579464415894" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.4228043533284039" TOTALS="YES" TOTAL_1="371" TOTAL_2="399" UNITS="" WEIGHT="100.0" Z="0.667648576606884">
<NAME>leflunomide vs. methotrexate, at 2 years</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.14955296776869853" CI_START="-1.6504470322313014" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" MEAN_1="-3.3" MEAN_2="-2.4" ORDER="34400" SD_1="2.6" SD_2="2.8" SE="0.38288817455357943" STUDY_ID="STD-Cohen-2001" TOTAL_1="98" TOTAL_2="101" WEIGHT="43.05922924586244"/>
<CONT_DATA CI_END="0.2729654516567296" CI_START="-0.07296545165672944" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="-1.2" MEAN_2="-1.3" ORDER="34401" SD_1="1.1" SD_2="1.0" SE="0.08824930101831407" STUDY_ID="STD-Emery-1999" TOTAL_1="273" TOTAL_2="298" WEIGHT="56.94077075413755"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.25467052730641165" CI_START="-0.25467052730641165" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.08" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="132" UNITS="" WEIGHT="100.0" Z="0.0">
<NAME>leflunomide vs. sulfasalazine, at 6 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.25467052730641165" CI_START="-0.25467052730641165" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-1.1" ORDER="34402" SD_1="1.1" SD_2="1.0" SE="0.12993633011382877" STUDY_ID="STD-Smolen-1999" TOTAL_1="130" TOTAL_2="132" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.37114399107525E-34" CI_END="0.6107200357591342" CI_START="-0.5507200357591342" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.030000000000000023" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-006.09" NO="9" P_CHI2="0.0" P_Q="1.0" P_Z="0.9193506176777657" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="78" TOTAL_2="74" UNITS="" WEIGHT="99.99999999999999" Z="0.10125174940681701">
<NAME>leflunomide vs. sulfasalazine, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6107200357591342" CI_START="-0.5507200357591342" EFFECT_SIZE="0.030000000000000027" ESTIMABLE="YES" MEAN_1="-1.41" MEAN_2="-1.44" ORDER="34403" SD_1="1.8" SD_2="1.85" SE="0.2962911769500765" STUDY_ID="STD-Scott-2001" TOTAL_1="78" TOTAL_2="74" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.0075756325958536985" CI_START="-1.3524243674041463" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6799999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.10" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.04747417872338646" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="57" UNITS="" WEIGHT="100.0" Z="1.9820452293130546">
<NAME>leflunomide vs. sulfasalazine, at 24 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.0075756325958536985" CI_START="-1.3524243674041463" EFFECT_SIZE="-0.6799999999999999" ESTIMABLE="YES" MEAN_1="-1.7" MEAN_2="-1.02" ORDER="34404" SD_1="1.86" SD_2="1.85" SE="0.343079961013643" STUDY_ID="STD-Scott-2001" TOTAL_1="60" TOTAL_2="57" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-9.135186000837201" CI_START="-21.8648139991628" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-15.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.11" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="1.8147565294637964E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="133" UNITS="" WEIGHT="100.0" Z="4.773028994149213">
<NAME>leflunomide+MTX vs MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-9.135186000837201" CI_START="-21.8648139991628" EFFECT_SIZE="-15.5" ESTIMABLE="YES" MEAN_1="-19.3" MEAN_2="-3.8" ORDER="34405" SD_1="28.49" SD_2="23.92" SE="3.247413753195283" STUDY_ID="STD-Kremer-2002" TOTAL_1="130" TOTAL_2="133" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="9.002529004792976" CI_START="-6.802529004792974" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.1000000000000014" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.12" MODIFIED="2008-11-24 11:15:02 -0500" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.7849923224656743" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="89" TOTAL_2="86" UNITS="" WEIGHT="100.0" Z="0.27281904080155195">
<NAME>Lef/lef+MTX vs Plc/lef+MTX, at 48 weeks</NAME>
<GROUP_LABEL_1>Plc/lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef/lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Plc/lef+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef/lef+MTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.002529004792976" CI_START="-6.802529004792974" EFFECT_SIZE="1.1000000000000014" ESTIMABLE="YES" MEAN_1="-20.9" MEAN_2="-22.0" ORDER="34406" SD_1="26.1" SD_2="27.2" SE="4.0319766419827685" STUDY_ID="STD-Kremer-2004" TOTAL_1="89" TOTAL_2="86" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.887570569613364" CI_START="-0.08757056961336418" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.13" MODIFIED="2009-07-22 12:18:58 -0400" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.10784770379994965" Q="0.0" RANDOM="NO" SCALE="1.49" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="24" UNITS="" WEIGHT="100.0" Z="1.6079428141811554">
<NAME>weekly Lef100 vs. weekly Lef200, at 6 months</NAME>
<GROUP_LABEL_1>weekly Lef200</GROUP_LABEL_1>
<GROUP_LABEL_2>weekly Lef100</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours weekly Lef100</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours weekly Lef200</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.887570569613364" CI_START="-0.08757056961336418" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="1.0" MODIFIED="2008-12-18 11:27:42 -0500" MODIFIED_BY="[Empty name]" ORDER="553" SD_1="0.9" SD_2="0.8" SE="0.2487650658171571" STUDY_ID="STD-Rozman-1994a" TOTAL_1="23" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2009-07-22 12:18:50 -0400" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Changes of physician global assessment</NAME>
<CONT_OUTCOME CHI2="2.3091937899180555" CI_END="-0.5165649235472971" CI_START="-0.8204102650220575" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.6684875942846773" ESTIMABLE="YES" I2="13.389685667266045" I2_Q="0.0" ID="CMP-007.01" MODIFIED="2008-12-31 08:38:40 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3151846062194167" P_Q="1.0" P_Z="6.454182238577725E-18" Q="0.0" RANDOM="NO" SCALE="2.76" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="413" TOTAL_2="311" UNITS="" WEIGHT="100.0" Z="8.624200736799036">
<NAME>leflunomide vs. placebo, at 6 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.21868636543446673" CI_START="-0.7775776445281736" EFFECT_SIZE="-0.49813200498132015" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-0.6" ORDER="34407" SD_1="1.0" SD_2="1.0" SE="0.14257692577572087" STUDY_ID="STD-Mladenovic-1995" TOTAL_1="101" TOTAL_2="102" WEIGHT="29.556329425722645"/>
<CONT_DATA CI_END="-0.5190701420432523" CI_START="-1.0754441436710334" EFFECT_SIZE="-0.7972571428571429" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-0.3" ORDER="34408" SD_1="1.0" SD_2="1.0" SE="0.14193475135675662" STUDY_ID="STD-Smolen-1999" TOTAL_1="130" TOTAL_2="91" WEIGHT="29.82438578392508"/>
<CONT_DATA CI_END="-0.45952493152819673" CI_START="-0.9362702598689664" EFFECT_SIZE="-0.6978975956985816" ESTIMABLE="YES" MEAN_1="-3.0" MEAN_2="-1.25" ORDER="34409" SD_1="2.54" SD_2="2.44" SE="0.12162094102271162" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="118" WEIGHT="40.619284790352275"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.133512474585252E-31" CI_END="-1.1925913034241908" CI_START="-2.4074086965758084" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.7999999999999996" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-007.02" NO="2" P_CHI2="0.0" P_Q="1.0" P_Z="6.3158001827961794E-9" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="182" TOTAL_2="118" UNITS="" WEIGHT="100.0" Z="5.808173626851895">
<NAME>leflunomide vs. placebo, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.1925913034241913" CI_START="-2.4074086965758084" EFFECT_SIZE="-1.7999999999999998" ESTIMABLE="YES" MEAN_1="-2.8" MEAN_2="-1.0" ORDER="34410" SD_1="2.8" SD_2="2.5" SE="0.30990809084604154" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="118" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.20232645894102" CI_END="0.023437808213195466" CI_START="-0.5612831407434955" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.26892266626515" ESTIMABLE="YES" I2="52.40731486377673" I2_Q="0.0" ID="CMP-007.03" NO="3" P_CHI2="0.12231411939696546" P_Q="1.0" P_Z="0.07141357041256616" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="371" TOTAL_2="293" UNITS="" WEIGHT="100.00000000000001" Z="1.8028385726443958">
<NAME>leflunomide vs. methotrexate, at 3 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.10326084995777318" CI_START="-0.8167391500422267" EFFECT_SIZE="-0.45999999999999996" ESTIMABLE="YES" MEAN_1="-3.61" MEAN_2="-3.15" ORDER="34411" SD_1="2.03" SD_2="2.01" SE="0.18201311496340733" STUDY_ID="STD-Bao-2000" TOTAL_1="291" TOTAL_2="213" WEIGHT="67.16387885281141"/>
<CONT_DATA CI_END="0.9358565411144695" CI_START="-0.33585654111446894" EFFECT_SIZE="0.30000000000000027" ESTIMABLE="YES" MEAN_1="-2.4" MEAN_2="-2.7" ORDER="34412" SD_1="1.5" SD_2="1.4" SE="0.32442256395016666" STUDY_ID="STD-Lao-2001" TOTAL_1="40" TOTAL_2="40" WEIGHT="21.14068375043192"/>
<CONT_DATA CI_END="0.6548903676127471" CI_START="-1.0548903676127466" EFFECT_SIZE="-0.19999999999999973" ESTIMABLE="YES" MEAN_1="-3.8" MEAN_2="-3.6" ORDER="34413" SD_1="1.9" SD_2="2.0" SE="0.43617656975128777" STUDY_ID="STD-Shuai-2002" TOTAL_1="40" TOTAL_2="40" WEIGHT="11.695437396756686"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.315526459854883E-33" CI_END="0.4652537598484534" CI_START="-0.6652537598484534" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.09999999999999999" ESTIMABLE="YES" I2="100.00000000000001" I2_Q="0.0" ID="CMP-007.04" NO="4" P_CHI2="0.0" P_Q="1.0" P_Z="0.7287862455694462" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="21" UNITS="" WEIGHT="100.00000000000001" Z="0.34674054800900883">
<NAME>leflunomide vs. methotrexate, at 4 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.4652537598484534" CI_START="-0.6652537598484534" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-0.8" ORDER="34414" SD_1="0.8" SD_2="1.0" SE="0.2884000748519375" STUDY_ID="STD-Reece-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.605436615177559" CI_END="-0.1470028844788447" CI_START="-0.818391101051045" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.4826969927649448" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.05" NO="5" P_CHI2="0.8951866714723005" P_Q="1.0" P_Z="0.004828673455382633" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="360" TOTAL_2="343" UNITS="" WEIGHT="99.99999999999999" Z="2.8182464270680088">
<NAME>leflunomide vs. methotrexate, at 6 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.005277130911383043" CI_START="-1.1852771309113828" EFFECT_SIZE="-0.5899999999999999" ESTIMABLE="YES" MEAN_1="-4.05" MEAN_2="-3.46" ORDER="34415" SD_1="2.01" SD_2="2.18" SE="0.3037184027904864" STUDY_ID="STD-Bao-2000" TOTAL_1="104" TOTAL_2="89" WEIGHT="31.801605180632357"/>
<CONT_DATA CI_END="0.6548903676127467" CI_START="-1.054890367612747" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="-3.7" MEAN_2="-3.5" ORDER="34416" SD_1="1.9" SD_2="2.0" SE="0.43617656975128777" STUDY_ID="STD-Lao-2001" TOTAL_1="40" TOTAL_2="40" WEIGHT="15.419368610945966"/>
<CONT_DATA CI_END="0.3519098409786334" CI_START="-1.5519098409786336" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="-4.5" MEAN_2="-3.9" ORDER="34417" SD_1="2.1" SD_2="1.9" SE="0.4856772106463062" STUDY_ID="STD-Shuai-2002" TOTAL_1="34" TOTAL_2="34" WEIGHT="12.436432152107729"/>
<CONT_DATA CI_END="0.05852046568411251" CI_START="-0.9985204656841129" EFFECT_SIZE="-0.4700000000000002" ESTIMABLE="YES" MEAN_1="-3.0" MEAN_2="-2.53" ORDER="34418" SD_1="2.54" SD_2="2.59" SE="0.26965825385211906" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="180" WEIGHT="40.342594056313935"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.590919396624011" CI_END="0.6836898130028991" CI_START="-0.6701016254576565" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.006794093772621319" ESTIMABLE="YES" I2="82.11385410771913" I2_Q="0.0" ID="CMP-007.06" NO="6" P_CHI2="0.01805393534908828" P_Q="1.0" P_Z="0.9843046895586651" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.2011789425639122" TOTALS="YES" TOTAL_1="677" TOTAL_2="669" UNITS="" WEIGHT="100.0" Z="0.019672423275283745">
<NAME>leflunomide vs. methotrexate, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.42496506263627676" CI_START="0.1750349373637231" EFFECT_SIZE="0.29999999999999993" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-1.2" ORDER="34419" SD_1="1.0" SD_2="1.0" SE="0.0637588566024607" STUDY_ID="STD-Emery-1999" TOTAL_1="495" TOTAL_2="489" WEIGHT="58.11344196751733"/>
<CONT_DATA CI_END="0.16661919166254924" CI_START="-0.9666191916625491" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="-2.8" MEAN_2="-2.4" ORDER="34420" SD_1="2.8" SD_2="2.7" SE="0.2890967365380022" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="180" WEIGHT="41.88655803248267"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.207640073079098" CI_END="0.8341034102070833" CI_START="-1.1109376213114404" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.13841710555217848" ESTIMABLE="YES" I2="86.1258332843915" I2_Q="0.0" ID="CMP-007.07" NO="7" P_CHI2="0.007259412380938857" P_Q="1.0" P_Z="0.7802769280474415" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.4306291664219571" TOTALS="YES" TOTAL_1="371" TOTAL_2="399" UNITS="" WEIGHT="100.00000000000001" Z="0.27895816831663106">
<NAME>leflunomide vs. methotrexate, at 2 years</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.00926254210111388" CI_START="-1.4092625421011133" EFFECT_SIZE="-0.6999999999999997" ESTIMABLE="YES" MEAN_1="-4.1" MEAN_2="-3.4" ORDER="34421" SD_1="2.4" SD_2="2.7" SE="0.3618752934725771" STUDY_ID="STD-Cohen-2001" TOTAL_1="98" TOTAL_2="101" WEIGHT="43.84171055521786"/>
<CONT_DATA CI_END="0.4729654516567293" CI_START="0.1270345483432703" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-1.4" ORDER="34422" SD_1="1.1" SD_2="1.0" SE="0.08824930101831407" STUDY_ID="STD-Emery-1999" TOTAL_1="273" TOTAL_2="298" WEIGHT="56.158289444782156"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.11948789972188115" CI_START="-0.3194878997218813" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.08" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.3718725440567937" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="132" UNITS="" WEIGHT="100.0" Z="0.8929713150581772">
<NAME>leflunomide vs. sulfasalazine, at 6 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.11948789972188117" CI_START="-0.31948789972188135" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-1.0" ORDER="34423" SD_1="1.0" SD_2="0.8" SE="0.11198568007023282" STUDY_ID="STD-Smolen-1999" TOTAL_1="130" TOTAL_2="132" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.136878174426805E-33" CI_END="0.4784078420475659" CI_START="-0.6984078420475657" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.10999999999999989" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-007.09" NO="9" P_CHI2="0.0" P_Q="1.0" P_Z="0.7140623030773681" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="78" TOTAL_2="74" UNITS="" WEIGHT="100.0" Z="0.366405786756964">
<NAME>leflunomide vs. sulfasalazine, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.4784078420475659" CI_START="-0.6984078420475657" EFFECT_SIZE="-0.10999999999999988" ESTIMABLE="YES" MEAN_1="-1.41" MEAN_2="-1.3" ORDER="34424" SD_1="1.85" SD_2="1.85" SE="0.30021359917266427" STUDY_ID="STD-Scott-2001" TOTAL_1="78" TOTAL_2="74" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.031107833304443" CI_START="-1.368892166695557" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.10" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.04025574413331844" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="57" UNITS="" WEIGHT="100.0" Z="2.051115048866293">
<NAME>leflunomide vs. sulfasalazine, at 24 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.031107833304443" CI_START="-1.368892166695557" EFFECT_SIZE="-0.7" ESTIMABLE="YES" MEAN_1="-1.8" MEAN_2="-1.1" ORDER="34425" SD_1="1.84" SD_2="1.85" SE="0.341277784679562" STUDY_ID="STD-Scott-2001" TOTAL_1="60" TOTAL_2="57" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-11.487312261479786" CI_START="-22.71268773852021" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-17.099999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.11" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="2.352826095815282E-9" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="133" UNITS="" WEIGHT="100.0" Z="5.9713609053318315">
<NAME>leflunomide+MTX vs MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-11.487312261479786" CI_START="-22.71268773852021" EFFECT_SIZE="-17.099999999999998" ESTIMABLE="YES" MEAN_1="-27.9" MEAN_2="-10.8" ORDER="34426" SD_1="23.1" SD_2="23.34" SE="2.8636688137090154" STUDY_ID="STD-Kremer-2002" TOTAL_1="130" TOTAL_2="133" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="10.906417480698055" CI_START="-2.1064174806980507" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="4.400000000000002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.12" MODIFIED="2008-11-24 11:15:58 -0500" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.1850265032961895" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="89" TOTAL_2="86" UNITS="" WEIGHT="100.00000000000001" Z="1.325436241612184">
<NAME>Lef/lef+MTX vs Plc/lef+MTX, at 48 weeks</NAME>
<GROUP_LABEL_1>Plc/lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef/lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Plc/lef+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef/lef+MTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="10.906417480698055" CI_START="-2.1064174806980507" EFFECT_SIZE="4.400000000000002" ESTIMABLE="YES" MEAN_1="-29.3" MEAN_2="-33.7" ORDER="34427" SD_1="22.9" SD_2="21.0" SE="3.319661755021951" STUDY_ID="STD-Kremer-2004" TOTAL_1="89" TOTAL_2="86" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.9147187520057437" CI_START="-0.11471875200574388" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.13" MODIFIED="2009-07-22 12:18:50 -0400" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.12772520246370642" Q="0.0" RANDOM="NO" SCALE="1.49" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="24" UNITS="" WEIGHT="100.0" Z="1.5231339265589319">
<NAME>weekly Lef100 vs. weekly Lef200, at 6 months</NAME>
<GROUP_LABEL_1>weekly Lef200</GROUP_LABEL_1>
<GROUP_LABEL_2>weekly Lef100</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours weekly Lef100</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours weekly Lef200</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9147187520057437" CI_START="-0.11471875200574388" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.1" MODIFIED="2008-12-18 11:31:50 -0500" MODIFIED_BY="[Empty name]" ORDER="554" SD_1="0.9" SD_2="0.9" SE="0.26261643380479416" STUDY_ID="STD-Rozman-1994a" TOTAL_1="23" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2008-12-27 09:32:33 -0500" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Changes of ESR (mm/hr)</NAME>
<CONT_OUTCOME CHI2="1.340653435941972" CI_END="-4.920963217972887" CI_START="-10.960480819410737" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-7.940722018691812" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.01" NO="1" P_CHI2="0.5115414619760592" P_Q="1.0" P_Z="2.551266035938352E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="413" TOTAL_2="311" UNITS="" WEIGHT="100.00000000000001" Z="5.153898107416686">
<NAME>leflunomide vs. placebo, at 6 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-3.0091575010988985" CI_START="-13.990842498901102" EFFECT_SIZE="-8.5" ESTIMABLE="YES" MEAN_1="-5.4" MEAN_2="3.1" ORDER="34428" SD_1="19.3" SD_2="20.6" SE="2.801501732793136" STUDY_ID="STD-Mladenovic-1995" TOTAL_1="101" TOTAL_2="102" WEIGHT="30.24590184161097"/>
<CONT_DATA CI_END="-4.329449986831715" CI_START="-17.270550013168286" EFFECT_SIZE="-10.8" ESTIMABLE="YES" MEAN_1="-7.4" MEAN_2="3.4" ORDER="34429" SD_1="23.2" SD_2="24.8" SE="3.3013616904224556" STUDY_ID="STD-Smolen-1999" TOTAL_1="130" TOTAL_2="91" WEIGHT="21.780212594062288"/>
<CONT_DATA CI_END="-1.9301674623739133" CI_START="-10.649832537626086" EFFECT_SIZE="-6.29" ESTIMABLE="YES" MEAN_1="-5.33" MEAN_2="0.96" ORDER="34430" SD_1="20.09" SD_2="17.95" SE="2.224445230634792" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="118" WEIGHT="47.97388556432675"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-4.122873484487675" CI_START="-13.677126515512326" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.9" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="2.607126758727275E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="182" TOTAL_2="118" UNITS="" WEIGHT="100.0" Z="3.6515004167805105">
<NAME>leflunomide vs. placebo, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-4.122873484487675" CI_START="-13.677126515512326" EFFECT_SIZE="-8.9" ESTIMABLE="YES" MEAN_1="-6.3" MEAN_2="2.6" ORDER="34431" SD_1="22.9" SD_2="19.0" SE="2.4373542336459697" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="118" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.4449522648202655" CI_END="2.7132723341884604" CI_START="-3.2405186902699907" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2636231780407651" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.03" NO="3" P_CHI2="0.8005342525671111" P_Q="1.0" P_Z="0.862205475230976" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="371" TOTAL_2="293" UNITS="" WEIGHT="100.0" Z="0.17356737323406066">
<NAME>leflunomide vs. methotrexate, at 3 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.6157699420961187" CI_START="-4.415769942096116" EFFECT_SIZE="-0.8999999999999986" ESTIMABLE="YES" MEAN_1="-20.09" MEAN_2="-19.19" ORDER="34432" SD_1="19.91" SD_2="19.88" SE="1.7937931359086503" STUDY_ID="STD-Bao-2000" TOTAL_1="291" TOTAL_2="213" WEIGHT="71.69457341818233"/>
<CONT_DATA CI_END="9.078118986433147" CI_START="-6.478118986433145" EFFECT_SIZE="1.3000000000000007" ESTIMABLE="YES" MEAN_1="-19.7" MEAN_2="-21.0" ORDER="34433" SD_1="16.4" SD_2="19.0" SE="3.9685009764393406" STUDY_ID="STD-Lao-2001" TOTAL_1="40" TOTAL_2="40" WEIGHT="14.647989422572678"/>
<CONT_DATA CI_END="9.455249301235165" CI_START="-6.655249301235168" EFFECT_SIZE="1.3999999999999986" ESTIMABLE="YES" MEAN_1="-20.3" MEAN_2="-21.7" ORDER="34434" SD_1="19.4" SD_2="17.3" SE="4.109896592373097" STUDY_ID="STD-Shuai-2002" TOTAL_1="40" TOTAL_2="40" WEIGHT="13.657437159245"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="20.981227353763288" CI_START="-4.381227353763284" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="8.3" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.19955600222007852" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="21" UNITS="" WEIGHT="99.99999999999999" Z="1.2828175552624914">
<NAME>leflunomide vs. methotrexate, at 4 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="20.981227353763288" CI_START="-4.381227353763284" EFFECT_SIZE="8.3" ESTIMABLE="YES" MEAN_1="-3.3" MEAN_2="-11.6" ORDER="34435" SD_1="18.3" SD_2="22.1" SE="6.470132846211047" STUDY_ID="STD-Reece-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.0337159204516686" CI_END="4.479760650728291" CI_START="-1.4061349211323177" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="1.5368128647979868" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.05" MODIFIED="2008-11-12 10:21:37 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.7295576063501799" P_Q="1.0" P_Z="0.3060729903508397" Q="0.0" RANDOM="NO" SCALE="17.599991030804258" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="390" TOTAL_2="373" UNITS="" WEIGHT="100.00000000000001" Z="1.0234968762891978">
<NAME>leflunomide vs. methotrexate, at 6 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.275505568632244" CI_START="-2.475505568632241" EFFECT_SIZE="3.400000000000002" ESTIMABLE="YES" MEAN_1="-18.61" MEAN_2="-22.01" ORDER="34436" SD_1="20.38" SD_2="21.08" SE="2.997762007351911" STUDY_ID="STD-Bao-2000" TOTAL_1="104" TOTAL_2="89" WEIGHT="25.088496127991203"/>
<CONT_DATA CI_END="14.90199157560257" CI_START="-2.9019915756025707" EFFECT_SIZE="6.0" ESTIMABLE="YES" MEAN_1="-24.0" MEAN_2="-30.0" ORDER="34437" SD_1="19.6" SD_2="21.0" SE="4.541915895302334" STUDY_ID="STD-Lao-2001" TOTAL_1="40" TOTAL_2="40" WEIGHT="10.929259954002832"/>
<CONT_DATA CI_END="11.013794266624265" CI_START="-9.413794266624263" EFFECT_SIZE="0.8000000000000007" ESTIMABLE="YES" MEAN_1="-25.9" MEAN_2="-26.7" ORDER="34438" SD_1="22.7" SD_2="20.2" SE="5.211215281091576" STUDY_ID="STD-Shuai-2002" TOTAL_1="34" TOTAL_2="34" WEIGHT="8.30215624110365"/>
<CONT_DATA CI_END="4.208245744365467" CI_START="-4.128245744365467" EFFECT_SIZE="0.040000000000000036" ESTIMABLE="YES" MEAN_1="-5.33" MEAN_2="-5.37" ORDER="34439" SD_1="20.09" SD_2="20.37" SE="2.126695070544182" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="180" WEIGHT="49.84923327368359"/>
<CONT_DATA CI_END="11.187551342804928" CI_START="-13.187551342804928" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-41.0" MEAN_2="-40.0" MODIFIED="2008-11-12 10:21:29 -0500" MODIFIED_BY="[Empty name]" ORDER="419" SD_1="26.0" SD_2="22.0" SE="6.21825270205921" STUDY_ID="STD-Wislowska-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="5.830854403218735"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="19.996335174099617" CI_END="20.372614337609875" CI_START="-6.2823082024788794" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="7.045153067565498" ESTIMABLE="YES" I2="94.99908362560728" I2_Q="0.0" ID="CMP-008.06" NO="6" P_CHI2="7.75915920325776E-6" P_Q="1.0" P_Z="0.3001672796162077" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="87.8551525369616" TOTALS="YES" TOTAL_1="448" TOTAL_2="462" UNITS="" WEIGHT="100.0" Z="1.0360747630935927">
<NAME>leflunomide vs. methotrexate, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="17.725199542137144" CI_START="9.874800457862854" EFFECT_SIZE="13.799999999999999" ESTIMABLE="YES" MEAN_1="-14.4" MEAN_2="-28.2" ORDER="34440" SD_1="24.1" SD_2="22.7" SE="2.0026896275128614" STUDY_ID="STD-Emery-1999" TOTAL_1="266" TOTAL_2="282" WEIGHT="50.33200784974631"/>
<CONT_DATA CI_END="4.686104180345539" CI_START="-4.286104180345538" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="-6.3" MEAN_2="-6.5" ORDER="34441" SD_1="22.9" SD_2="20.6" SE="2.2888707219782383" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="180" WEIGHT="49.66799215025368"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.4669067595681495" CI_END="18.759319904480524" CI_START="-3.7355864243759305" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="7.511866740052297" ESTIMABLE="YES" I2="86.60757349462557" I2_Q="0.0" ID="CMP-008.07" NO="7" P_CHI2="0.006284384302562063" P_Q="1.0" P_Z="0.1905321800840605" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="57.269257973321146" TOTALS="YES" TOTAL_1="364" TOTAL_2="383" UNITS="" WEIGHT="99.99999999999999" Z="1.30900640811117">
<NAME>leflunomide vs. methotrexate, at 2 years</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.471426616872225" CI_START="-5.671426616872224" EFFECT_SIZE="1.4000000000000004" ESTIMABLE="YES" MEAN_1="-6.5" MEAN_2="-7.9" ORDER="34442" SD_1="27.2" SD_2="23.5" SE="3.6079370195833875" STUDY_ID="STD-Cohen-2001" TOTAL_1="98" TOTAL_2="101" WEIGHT="46.853332695197416"/>
<CONT_DATA CI_END="17.146511773979356" CI_START="8.653488226020645" EFFECT_SIZE="12.9" ESTIMABLE="YES" MEAN_1="-14.1" MEAN_2="-27.0" ORDER="34443" SD_1="26.3" SD_2="24.3" SE="2.166627452073251" STUDY_ID="STD-Emery-1999" TOTAL_1="266" TOTAL_2="282" WEIGHT="53.14666730480257"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="14.926329024283966" CI_START="3.4736709757160362" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="9.200000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.08" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.001638832107700992" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="129" TOTAL_2="132" UNITS="" WEIGHT="100.0" Z="3.148905447329448">
<NAME>leflunomide vs. sulfasalazine, at 6 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="14.926329024283966" CI_START="3.4736709757160362" EFFECT_SIZE="9.200000000000001" ESTIMABLE="YES" MEAN_1="-7.4" MEAN_2="-16.6" ORDER="34444" SD_1="23.2" SD_2="24.0" SE="2.921650126967902" STUDY_ID="STD-Smolen-1999" TOTAL_1="129" TOTAL_2="132" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="16.334681054932712" CI_START="-0.1346810549327131" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="8.1" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.09" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.05386655854397816" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="76" TOTAL_2="74" UNITS="" WEIGHT="100.0" Z="1.9279080961204467">
<NAME>leflunomide vs. sulfasalazine, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="16.334681054932712" CI_START="-0.1346810549327131" EFFECT_SIZE="8.1" ESTIMABLE="YES" MEAN_1="-12.4" MEAN_2="-20.5" ORDER="34445" SD_1="28.0" SD_2="23.3" SE="4.201445087709176" STUDY_ID="STD-Scott-2001" TOTAL_1="76" TOTAL_2="74" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="8.83134113803332" CI_START="-11.031341138033323" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1000000000000014" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.10" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.8281409115486891" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="56" UNITS="" WEIGHT="100.0" Z="0.2170865297072055">
<NAME>leflunomide vs. sulfasalazine, at 24 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.831341138033322" CI_START="-11.031341138033325" EFFECT_SIZE="-1.1000000000000014" ESTIMABLE="YES" MEAN_1="-16.1" MEAN_2="-15.0" ORDER="34446" SD_1="27.3" SD_2="26.8" SE="5.067103893934008" STUDY_ID="STD-Scott-2001" TOTAL_1="58" TOTAL_2="56" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.906189614506594" CI_START="-4.306189614506595" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.8000000000000003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.11" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.7587880735502034" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="133" UNITS="" WEIGHT="100.0" Z="0.307072652213593">
<NAME>leflunomide+MTX vs MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.906189614506594" CI_START="-4.306189614506595" EFFECT_SIZE="0.8000000000000003" ESTIMABLE="YES" MEAN_1="-1.9" MEAN_2="-2.7" ORDER="34447" SD_1="20.88" SD_2="21.37" SE="2.6052466549301756" STUDY_ID="STD-Kremer-2002" TOTAL_1="130" TOTAL_2="133" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="9.520318014182752" CI_START="-8.440318014182754" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.54" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.12" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.906182093135438" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="50" UNITS="" WEIGHT="100.0" Z="0.11785557593618766">
<NAME>leflunomide+SSZ vs. placebo+SSZ, at 24 months</NAME>
<GROUP_LABEL_1>Lef+SSZ</GROUP_LABEL_1>
<GROUP_LABEL_2>Plc+SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.520318014182752" CI_START="-8.440318014182754" EFFECT_SIZE="0.54" ESTIMABLE="YES" MEAN_1="-4.88" MEAN_2="-5.42" ORDER="34448" SD_1="25.65" SD_2="21.5" SE="4.581879098298925" STUDY_ID="STD-Dougados-2005" TOTAL_1="56" TOTAL_2="50" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.489878754214773" CI_START="-9.289878754214774" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.4" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.13" MODIFIED="2008-11-24 11:17:14 -0500" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.49477869927822227" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="86" TOTAL_2="92" UNITS="" WEIGHT="100.0" Z="0.6827280610734385">
<NAME>Lef/lef+MTX vs Plc/lef+MTX, at 48 weeks</NAME>
<GROUP_LABEL_1>Plc/lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef/lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Plc/lef+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef/lef+MTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.489878754214773" CI_START="-9.289878754214774" EFFECT_SIZE="-2.4" ESTIMABLE="YES" MEAN_1="-4.5" MEAN_2="-2.1" ORDER="34449" SD_1="22.7" SD_2="24.2" SE="3.5153088569796473" STUDY_ID="STD-Kremer-2004" TOTAL_1="86" TOTAL_2="92" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="28.19305736999408" CI_START="-2.193057369994081" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="13.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.14" MODIFIED="2008-12-27 09:32:33 -0500" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.09353251268711164" Q="0.0" RANDOM="NO" SCALE="44.17" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="1.6770509831248424">
<NAME>leflunomide vs. anti-TNF+MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef</GROUP_LABEL_1>
<GROUP_LABEL_2>Anti-TNF+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours anti-TNF+MTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="28.19305736999408" CI_START="-2.193057369994081" EFFECT_SIZE="13.0" ESTIMABLE="YES" MEAN_1="-41.0" MEAN_2="-54.0" MODIFIED="2008-11-12 10:23:31 -0500" MODIFIED_BY="[Empty name]" ORDER="420" SD_1="26.0" SD_2="26.0" SE="7.751702321999271" STUDY_ID="STD-Wislowska-2007" TOTAL_1="30" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2008-11-24 11:18:20 -0500" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Changes of CRP (mg/dl)</NAME>
<CONT_OUTCOME CHI2="3.809637295033685" CI_END="-0.7931165916559116" CI_START="-1.6849142070979353" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.2390153993769235" ESTIMABLE="YES" I2="73.75078196279685" I2_Q="0.0" ID="CMP-009.01" NO="1" P_CHI2="0.05095852861113015" P_Q="1.0" P_Z="5.147577779228506E-8" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="312" TOTAL_2="208" UNITS="" WEIGHT="100.00000000000001" Z="5.446136022388042">
<NAME>leflunomide vs. placebo, at 6 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.1272142120971884" CI_START="-3.072785787902811" EFFECT_SIZE="-2.0999999999999996" ESTIMABLE="YES" MEAN_1="-2.3" MEAN_2="-0.2" ORDER="34450" SD_1="3.5" SD_2="3.7" SE="0.49632839969306647" STUDY_ID="STD-Smolen-1999" TOTAL_1="130" TOTAL_2="90" WEIGHT="21.010587098800325"/>
<CONT_DATA CI_END="-0.5082910272790815" CI_START="-1.5117089727209185" EFFECT_SIZE="-1.01" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="0.31" ORDER="34451" SD_1="2.36" SD_2="2.03" SE="0.2559786693420567" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="118" WEIGHT="78.98941290119969"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.5648505595540728" CI_START="-1.615149440445927" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0899999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="4.739792287964787E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="182" TOTAL_2="118" UNITS="" WEIGHT="100.0" Z="4.0681005797789345">
<NAME>leflunomide vs. placebo, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.5648505595540728" CI_START="-1.615149440445927" EFFECT_SIZE="-1.0899999999999999" ESTIMABLE="YES" MEAN_1="-0.62" MEAN_2="0.47" ORDER="34452" SD_1="2.45" SD_2="2.14" SE="0.2679383114119641" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="118" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.9277145866307532" CI_END="-0.09269355251941747" CI_START="-5.939803944390958" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.0162487484551876" ESTIMABLE="YES" I2="31.687330140277695" I2_Q="0.0" ID="CMP-009.03" NO="3" P_CHI2="0.23134224940715697" P_Q="1.0" P_Z="0.04316538774148877" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="371" TOTAL_2="293" UNITS="" WEIGHT="100.0" Z="2.0221061410451515">
<NAME>leflunomide vs. methotrexate, at 3 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.861102631391145" CI_START="-7.938897368608856" EFFECT_SIZE="-4.4" ESTIMABLE="YES" MEAN_1="-18.5" MEAN_2="-14.1" ORDER="34453" SD_1="23.73" SD_2="16.8" SE="1.8055930601394852" STUDY_ID="STD-Bao-2000" TOTAL_1="291" TOTAL_2="213" WEIGHT="68.2474862175324"/>
<CONT_DATA CI_END="10.263320500961006" CI_START="-4.663320500961005" EFFECT_SIZE="2.8000000000000007" ESTIMABLE="YES" MEAN_1="-13.2" MEAN_2="-16.0" ORDER="34454" SD_1="18.0" SD_2="16.0" SE="3.8078865529319543" STUDY_ID="STD-Lao-2001" TOTAL_1="40" TOTAL_2="40" WEIGHT="15.344700313506602"/>
<CONT_DATA CI_END="4.517485873766757" CI_START="-9.917485873766756" EFFECT_SIZE="-2.6999999999999993" ESTIMABLE="YES" MEAN_1="-14.2" MEAN_2="-11.5" ORDER="34455" SD_1="17.9" SD_2="14.9" SE="3.6824584179593933" STUDY_ID="STD-Shuai-2002" TOTAL_1="40" TOTAL_2="40" WEIGHT="16.40781346896101"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="16.420778102926683" CI_START="-22.42077810292669" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.0000000000000018" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.7620705255534448" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="21" UNITS="" WEIGHT="100.0" Z="0.30276294402097487">
<NAME>leflunomide vs. methotrexate, at 4 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="16.420778102926683" CI_START="-22.420778102926683" EFFECT_SIZE="-3.0000000000000018" ESTIMABLE="YES" MEAN_1="-17.1" MEAN_2="-14.1" ORDER="34456" SD_1="33.8" SD_2="27.0" SE="9.908742332060845" STUDY_ID="STD-Reece-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.897859751725156" CI_END="0.24708921543373266" CI_START="-0.6026384227238247" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.17777460364504602" ESTIMABLE="YES" I2="48.68979061868968" I2_Q="0.0" ID="CMP-009.05" NO="5" P_CHI2="0.1424265592495516" P_Q="1.0" P_Z="0.4121577649759308" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="360" TOTAL_2="343" UNITS="" WEIGHT="100.0" Z="0.8201023595411561">
<NAME>leflunomide vs. methotrexate, at 6 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="-14.65" MEAN_2="0.0" ORDER="34457" SD_1="20.98" SD_2="0.0" SE="0.0" STUDY_ID="STD-Bao-2000" TOTAL_1="104" TOTAL_2="89" WEIGHT="0.0"/>
<CONT_DATA CI_END="14.558338627660968" CI_START="-0.9583386276609662" EFFECT_SIZE="6.800000000000001" ESTIMABLE="YES" MEAN_1="-13.2" MEAN_2="-20.0" ORDER="34458" SD_1="17.4" SD_2="18.0" SE="3.9584087712109772" STUDY_ID="STD-Lao-2001" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.2998900348517866"/>
<CONT_DATA CI_END="4.92634956818484" CI_START="-13.72634956818484" EFFECT_SIZE="-4.4" ESTIMABLE="YES" MEAN_1="-19.8" MEAN_2="-15.4" ORDER="34459" SD_1="21.2" SD_2="17.9" SE="4.758429053671341" STUDY_ID="STD-Shuai-2002" TOTAL_1="34" TOTAL_2="34" WEIGHT="0.20752772164337194"/>
<CONT_DATA CI_END="0.2359458558890744" CI_START="-0.6159458558890742" EFFECT_SIZE="-0.18999999999999995" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="-0.51" ORDER="34460" SD_1="2.36" SD_2="1.73" SE="0.21732330759589508" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="180" WEIGHT="99.49258224350484"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.6597282965410471" CI_END="1.5419346002272012" CI_START="-0.3024572395514321" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.6197386803378846" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.06" NO="6" P_CHI2="0.4166561785089895" P_Q="1.0" P_Z="0.18779011703298157" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="442" TOTAL_2="465" UNITS="" WEIGHT="100.0" Z="1.3171447271577836">
<NAME>leflunomide vs. methotrexate, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.6423136531207008" CI_START="-0.2423136531207014" EFFECT_SIZE="0.6999999999999997" ESTIMABLE="YES" MEAN_1="-2.2" MEAN_2="-2.9" ORDER="34461" SD_1="6.9" SD_2="3.7" SE="0.48078110646601213" STUDY_ID="STD-Emery-1999" TOTAL_1="260" TOTAL_2="285" WEIGHT="95.77572001778341"/>
<CONT_DATA CI_END="3.2869047353599603" CI_START="-5.686904735359961" EFFECT_SIZE="-1.2000000000000002" ESTIMABLE="YES" MEAN_1="-6.2" MEAN_2="-5.0" ORDER="34462" SD_1="24.5" SD_2="18.7" SE="2.2892791759196047" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="180" WEIGHT="4.224279982216587"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.3946046209959713" CI_END="2.7166946489876915" CI_START="-3.6697960637977953" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.4765507074050517" ESTIMABLE="YES" I2="28.295089163992607" I2_Q="0.0" ID="CMP-009.07" NO="7" P_CHI2="0.23762923606883435" P_Q="1.0" P_Z="0.7699048494633529" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="2.993620433550414" TOTALS="YES" TOTAL_1="358" TOTAL_2="386" UNITS="" WEIGHT="100.00000000000001" Z="0.29249936007927274">
<NAME>leflunomide vs. methotrexate, at 2 years</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.2046214426241173" CI_START="-12.004621442624117" EFFECT_SIZE="-4.4" ESTIMABLE="YES" MEAN_1="-9.8" MEAN_2="-5.4" ORDER="34463" SD_1="27.9" SD_2="26.8" SE="3.8799801948445998" STUDY_ID="STD-Cohen-2001" TOTAL_1="98" TOTAL_2="101" WEIGHT="14.707624074022856"/>
<CONT_DATA CI_END="0.874731146253316" CI_START="-0.4747311462533166" EFFECT_SIZE="0.19999999999999973" ESTIMABLE="YES" MEAN_1="-2.6" MEAN_2="-2.8" ORDER="34464" SD_1="4.2" SD_2="3.8" SE="0.34425691062463876" STUDY_ID="STD-Emery-1999" TOTAL_1="260" TOTAL_2="285" WEIGHT="85.29237592597715"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.4186572738816816" CI_START="-1.9813427261183179" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1999999999999997" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.08" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.0026112092813282456" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="130" UNITS="" WEIGHT="100.0" Z="3.0101474075691463">
<NAME>leflunomide vs. sulfasalazine, at 6 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.4186572738816816" CI_START="-1.9813427261183179" EFFECT_SIZE="-1.1999999999999997" ESTIMABLE="YES" MEAN_1="-2.3" MEAN_2="-1.1" ORDER="34465" SD_1="3.5" SD_2="2.9" SE="0.3986515733357601" STUDY_ID="STD-Smolen-1999" TOTAL_1="130" TOTAL_2="130" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.03321409100483774" CI_START="-2.1667859089951627" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.09" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.043281117720568564" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="78" TOTAL_2="72" UNITS="" WEIGHT="100.0" Z="2.0209869335683517">
<NAME>leflunomide vs. sulfasalazine, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.03321409100483774" CI_START="-2.1667859089951627" EFFECT_SIZE="-1.1" ESTIMABLE="YES" MEAN_1="-2.7" MEAN_2="-1.6" ORDER="34466" SD_1="3.9" SD_2="2.7" SE="0.544288526426931" STUDY_ID="STD-Scott-2001" TOTAL_1="78" TOTAL_2="72" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.026552344279546336" CI_START="-2.773447655720454" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.4000000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.10" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.04573235785905269" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="57" TOTAL_2="54" UNITS="" WEIGHT="100.0" Z="1.9978552272650782">
<NAME>leflunomide vs. sulfasalazine, at 24 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.026552344279546336" CI_START="-2.773447655720454" EFFECT_SIZE="-1.4000000000000001" ESTIMABLE="YES" MEAN_1="-2.7" MEAN_2="-1.3" ORDER="34467" SD_1="4.3" SD_2="3.0" SE="0.7007514763301946" STUDY_ID="STD-Scott-2001" TOTAL_1="57" TOTAL_2="54" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-4.364937697914309" CI_START="-19.83506230208569" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-12.1" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.11" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.0021695614789985504" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="133" UNITS="" WEIGHT="100.0" Z="3.0659823136188527">
<NAME>leflunomide+MTX vs MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-4.364937697914308" CI_START="-19.835062302085692" EFFECT_SIZE="-12.1" ESTIMABLE="YES" MEAN_1="-10.9" MEAN_2="1.2" ORDER="34468" SD_1="32.9" SD_2="31.05" SE="3.9465328766747123" STUDY_ID="STD-Kremer-2002" TOTAL_1="130" TOTAL_2="133" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.343428624351173" CI_START="-18.643428624351174" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.15" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.12" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.1279444282090277" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="50" UNITS="" WEIGHT="100.0" Z="1.5222580765387466">
<NAME>leflunomide+SSZ vs. placebo+SSZ, at 24 months</NAME>
<GROUP_LABEL_1>Lef+SSZ</GROUP_LABEL_1>
<GROUP_LABEL_2>Plc+SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.343428624351173" CI_START="-18.643428624351174" EFFECT_SIZE="-8.15" ESTIMABLE="YES" MEAN_1="-4.87" MEAN_2="3.28" ORDER="34469" SD_1="26.6" SD_2="28.31" SE="5.353888493422327" STUDY_ID="STD-Dougados-2005" TOTAL_1="56" TOTAL_2="50" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="13.521990006472622" CI_START="-3.521990006472622" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="5.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.13" MODIFIED="2008-11-24 11:18:20 -0500" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.25016653846159886" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="90" TOTAL_2="89" UNITS="" WEIGHT="100.0" Z="1.149945014633567">
<NAME>Lef/lef+MTX vs Plc/lef+MTX, at 48 weeks</NAME>
<GROUP_LABEL_1>Plc/lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef/lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Plc/lef+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef/lef+MTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="13.521990006472622" CI_START="-3.521990006472622" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="-8.7" MEAN_2="-13.7" ORDER="34470" SD_1="24.5" SD_2="33.0" SE="4.34803398107975" STUDY_ID="STD-Kremer-2004" TOTAL_1="90" TOTAL_2="89" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2008-12-27 09:38:18 -0500" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Changes of pain (VAS, mm)</NAME>
<CONT_OUTCOME CHI2="2.453235896597352" CI_END="-11.713893549792678" CI_START="-15.914221831741555" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-13.814057690767116" ESTIMABLE="YES" I2="18.475023018617662" I2_Q="0.0" ID="CMP-010.01" NO="1" P_CHI2="0.2932828771671282" P_Q="1.0" P_Z="5.001227299498817E-38" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="413" TOTAL_2="311" UNITS="" WEIGHT="100.0" Z="12.89187593770635">
<NAME>leflunomide vs. placebo, at 6 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-10.645005922813354" CI_START="-15.354994077186646" EFFECT_SIZE="-13.0" ESTIMABLE="YES" MEAN_1="-10.0" MEAN_2="3.0" ORDER="34471" SD_1="8.1" SD_2="9.0" SE="1.2015496691584844" STUDY_ID="STD-Mladenovic-1995" TOTAL_1="101" TOTAL_2="102" WEIGHT="79.52924130062073"/>
<CONT_DATA CI_END="-10.512192472279942" CI_START="-26.487807527720058" EFFECT_SIZE="-18.5" ESTIMABLE="YES" MEAN_1="-27.3" MEAN_2="-8.8" ORDER="34472" SD_1="29.7" SD_2="29.9" SE="4.075486891966825" STUDY_ID="STD-Smolen-1999" TOTAL_1="130" TOTAL_2="91" WEIGHT="6.912757060303429"/>
<CONT_DATA CI_END="-10.496316768693386" CI_START="-21.90368323130662" EFFECT_SIZE="-16.200000000000003" ESTIMABLE="YES" MEAN_1="-23.01" MEAN_2="-6.81" ORDER="34473" SD_1="25.98" SD_2="23.7" SE="2.9100959386481295" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="118" WEIGHT="13.558001639075846"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-11.958274695008658" CI_START="-24.041725304991342" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-18.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="5.242554221818951E-9" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="182" TOTAL_2="118" UNITS="" WEIGHT="100.0" Z="5.839284300558172">
<NAME>leflunomide vs. placebo, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-11.958274695008658" CI_START="-24.041725304991342" EFFECT_SIZE="-18.0" ESTIMABLE="YES" MEAN_1="-22.0" MEAN_2="-4.0" ORDER="34474" SD_1="29.0" SD_2="24.0" SE="3.0825695536487916" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="118" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.332549504315547" CI_END="0.17099451334273785" CI_START="-0.4414086562274887" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.13520707144237543" ESTIMABLE="YES" I2="53.837803861032654" I2_Q="0.0" ID="CMP-010.03" NO="3" P_CHI2="0.11460382693840665" P_Q="1.0" P_Z="0.3867939551953533" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="371" TOTAL_2="293" UNITS="" WEIGHT="100.00000000000001" Z="0.865446175493059">
<NAME>leflunomide vs. methotrexate, at 3 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.016179980591731757" CI_START="-0.7361799805917324" EFFECT_SIZE="-0.3600000000000003" ESTIMABLE="YES" MEAN_1="-3.72" MEAN_2="-3.36" ORDER="34475" SD_1="2.14" SD_2="2.12" SE="0.19193208832355682" STUDY_ID="STD-Bao-2000" TOTAL_1="291" TOTAL_2="213" WEIGHT="66.25573998633118"/>
<CONT_DATA CI_END="1.0358565411144691" CI_START="-0.2358565411144693" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" MEAN_1="-2.4" MEAN_2="-2.8" ORDER="34476" SD_1="1.5" SD_2="1.4" SE="0.32442256395016666" STUDY_ID="STD-Lao-2001" TOTAL_1="40" TOTAL_2="40" WEIGHT="23.189777498249384"/>
<CONT_DATA CI_END="1.042516499741791" CI_START="-0.8425164997417901" EFFECT_SIZE="0.10000000000000053" ESTIMABLE="YES" MEAN_1="-4.1" MEAN_2="-4.2" ORDER="34477" SD_1="2.2" SD_2="2.1" SE="0.48088460154178364" STUDY_ID="STD-Shuai-2002" TOTAL_1="40" TOTAL_2="40" WEIGHT="10.554482515419448"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="8.01971051387775" CI_START="-20.21971051387775" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.1" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.3971378306237313" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="21" UNITS="" WEIGHT="100.0" Z="0.8467440103636281">
<NAME>leflunomide vs. methotrexate, at 4 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.01971051387775" CI_START="-20.21971051387775" EFFECT_SIZE="-6.1" ESTIMABLE="YES" MEAN_1="-16.2" MEAN_2="-10.1" ORDER="34478" SD_1="25.8" SD_2="17.7" SE="7.204066312060948" STUDY_ID="STD-Reece-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.971168490404084" CI_END="0.1459763421290176" CI_START="-0.7770010708151818" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.31551236434308205" ESTIMABLE="YES" I2="19.536020400007445" I2_Q="0.0" ID="CMP-010.05" MODIFIED="2008-11-12 10:25:37 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.29026866670260143" P_Q="1.0" P_Z="0.18024675100188395" Q="0.0" RANDOM="NO" SCALE="12.762713697726328" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="390" TOTAL_2="373" UNITS="" WEIGHT="100.0" Z="1.339995675120398">
<NAME>leflunomide vs. methotrexate, at 6 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.3011305795361878" CI_START="-0.9811305795361875" EFFECT_SIZE="-0.33999999999999986" ESTIMABLE="YES" MEAN_1="-4.17" MEAN_2="-3.83" ORDER="34479" SD_1="2.07" SD_2="2.42" SE="0.3271134493252651" STUDY_ID="STD-Bao-2000" TOTAL_1="104" TOTAL_2="89" WEIGHT="51.81185861091267"/>
<CONT_DATA CI_END="0.7338489350869476" CI_START="-0.9338489350869478" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="-3.7" MEAN_2="-3.6" ORDER="34480" SD_1="1.8" SD_2="2.0" SE="0.42544094772365293" STUDY_ID="STD-Lao-2001" TOTAL_1="40" TOTAL_2="40" WEIGHT="30.630028296162543"/>
<CONT_DATA CI_END="0.8408666160938971" CI_START="-1.4408666160938968" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="-4.8" MEAN_2="-4.5" ORDER="34481" SD_1="2.4" SD_2="2.4" SE="0.5820855000871992" STUDY_ID="STD-Shuai-2002" TOTAL_1="34" TOTAL_2="34" WEIGHT="16.362603657515997"/>
<CONT_DATA CI_END="0.5110739492662635" CI_START="-10.471073949266264" EFFECT_SIZE="-4.98" ESTIMABLE="YES" MEAN_1="-23.01" MEAN_2="-18.03" ORDER="34482" SD_1="25.98" SD_2="27.3" SE="2.801619821884052" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="180" WEIGHT="0.7063298658553716"/>
<CONT_DATA CI_END="1.5982219802913642" CI_START="-11.598221980291363" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="-48.0" MEAN_2="-43.0" MODIFIED="2008-11-12 10:25:29 -0500" MODIFIED_BY="[Empty name]" ORDER="421" SD_1="14.0" SD_2="12.0" SE="3.3665016461206925" STUDY_ID="STD-Wislowska-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.48917956955341946"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="30.945041781421537" CI_END="17.067695148978608" CI_START="-6.440518680385464" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="5.313588234296571" ESTIMABLE="YES" I2="96.76846453443676" I2_Q="0.0" ID="CMP-010.06" NO="6" P_CHI2="2.654437603055726E-8" P_Q="1.0" P_Z="0.37560365324069944" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="69.67329446479495" TOTALS="YES" TOTAL_1="455" TOTAL_2="477" UNITS="" WEIGHT="100.0" Z="0.8860257647383144">
<NAME>leflunomide vs. methotrexate, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="15.68701098172486" CI_START="7.312989018275147" EFFECT_SIZE="11.500000000000004" ESTIMABLE="YES" MEAN_1="-23.7" MEAN_2="-35.2" ORDER="34483" SD_1="26.6" SD_2="24.2" SE="2.136269347167328" STUDY_ID="STD-Emery-1999" TOTAL_1="273" TOTAL_2="297" WEIGHT="48.44656861913807"/>
<CONT_DATA CI_END="0.08721890438042423" CI_START="-1.0872189043804248" EFFECT_SIZE="-0.5000000000000002" ESTIMABLE="YES" MEAN_1="-2.2" MEAN_2="-1.7" ORDER="34484" SD_1="2.9" SD_2="2.8" SE="0.29960698717544415" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="180" WEIGHT="51.55343138086193"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="9.513145780219721" CI_END="11.60825371453921" CI_START="-15.208171246503326" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.7999587659820577" ESTIMABLE="YES" I2="89.48823004395393" I2_Q="0.0" ID="CMP-010.07" NO="7" P_CHI2="0.002040067995469297" P_Q="1.0" P_Z="0.7924646719241684" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="83.98022948474856" TOTALS="YES" TOTAL_1="371" TOTAL_2="398" UNITS="" WEIGHT="100.0" Z="0.2631114594959672">
<NAME>leflunomide vs. methotrexate, at 2 years</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.495529677686986" CI_START="-16.504470322313015" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="-33.0" MEAN_2="-24.0" ORDER="34485" SD_1="26.0" SD_2="28.0" SE="3.8288817455357944" STUDY_ID="STD-Cohen-2001" TOTAL_1="98" TOTAL_2="101" WEIGHT="47.444954496219395"/>
<CONT_DATA CI_END="9.112838610395244" CI_START="0.2871613896047549" EFFECT_SIZE="4.699999999999999" ESTIMABLE="YES" MEAN_1="-27.1" MEAN_2="-31.8" ORDER="34486" SD_1="27.7" SD_2="25.9" SE="2.2514896422603434" STUDY_ID="STD-Emery-1999" TOTAL_1="273" TOTAL_2="297" WEIGHT="52.5550455037806"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.7926137675118126" CI_START="-14.207386232488187" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-7.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.08" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.02841031756380869" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="132" UNITS="" WEIGHT="100.0" Z="2.1915734944336673">
<NAME>leflunomide vs. sulfasalazine, at 6 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.7926137675118126" CI_START="-14.207386232488187" EFFECT_SIZE="-7.5" ESTIMABLE="YES" MEAN_1="-27.3" MEAN_2="-19.8" ORDER="34487" SD_1="29.7" SD_2="25.5" SE="3.4221987166066286" STUDY_ID="STD-Smolen-1999" TOTAL_1="130" TOTAL_2="132" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-2.448406987336611" CI_START="-20.351593012663386" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-11.399999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.09" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.012558625552644755" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="77" TOTAL_2="74" UNITS="" WEIGHT="100.0" Z="2.4960461665480342">
<NAME>leflunomide vs. sulfasalazine, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.448406987336611" CI_START="-20.351593012663386" EFFECT_SIZE="-11.399999999999999" ESTIMABLE="YES" MEAN_1="-35.5" MEAN_2="-24.1" ORDER="34488" SD_1="26.7" SD_2="29.3" SE="4.567223215973564" STUDY_ID="STD-Scott-2001" TOTAL_1="77" TOTAL_2="74" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-5.0374310185067905" CI_START="-25.162568981493212" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-15.100000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.10" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.0032700334138272163" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="57" UNITS="" WEIGHT="100.0" Z="2.941143183314911">
<NAME>leflunomide vs. sulfasalazine, at 24 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-5.0374310185067905" CI_START="-25.162568981493212" EFFECT_SIZE="-15.100000000000001" ESTIMABLE="YES" MEAN_1="-41.7" MEAN_2="-26.6" ORDER="34489" SD_1="27.5" SD_2="28.0" SE="5.134058105590444" STUDY_ID="STD-Scott-2001" TOTAL_1="60" TOTAL_2="57" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-10.10464880951766" CI_START="-23.695351190482338" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-16.9" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.11" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="1.0912895563723439E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="133" UNITS="" WEIGHT="99.99999999999999" Z="4.87441935085268">
<NAME>leflunomide+MTX vs MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-10.10464880951766" CI_START="-23.695351190482338" EFFECT_SIZE="-16.9" ESTIMABLE="YES" MEAN_1="-25.2" MEAN_2="-8.3" ORDER="34490" SD_1="29.47" SD_2="26.65" SE="3.467079621913057" STUDY_ID="STD-Kremer-2002" TOTAL_1="130" TOTAL_2="133" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.002980254526969E-34" CI_END="7.99126570827149" CI_START="-9.77126570827149" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8900000000000005" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-010.12" NO="12" P_CHI2="0.0" P_Q="1.0" P_Z="0.8442893978528941" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="50" UNITS="" WEIGHT="100.0" Z="0.19640983656372846">
<NAME>leflunomide+SSZ vs. placebo+SSZ, at 24 months</NAME>
<GROUP_LABEL_1>Lef+SSZ</GROUP_LABEL_1>
<GROUP_LABEL_2>Plc+SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.99126570827149" CI_START="-9.77126570827149" EFFECT_SIZE="-0.8900000000000006" ESTIMABLE="YES" MEAN_1="-9.21" MEAN_2="-8.32" ORDER="34491" SD_1="24.91" SD_2="21.74" SE="4.531341278883581" STUDY_ID="STD-Dougados-2005" TOTAL_1="56" TOTAL_2="50" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="8.227450064481731" CI_START="-7.62745006448173" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.3000000000000007" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.13" MODIFIED="2008-11-24 11:19:28 -0500" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.940874090404556" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="89" TOTAL_2="86" UNITS="" WEIGHT="100.0" Z="0.07417128970593628">
<NAME>Lef/lef+MTX vs Plc/lef+MTX, at 48 weeks</NAME>
<GROUP_LABEL_1>Plc/lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef/lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Plc/lef+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef/lef+MTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.227450064481731" CI_START="-7.62745006448173" EFFECT_SIZE="0.3000000000000007" ESTIMABLE="YES" MEAN_1="-26.9" MEAN_2="-27.2" ORDER="34492" SD_1="26.8" SD_2="26.7" SE="4.044691701996794" STUDY_ID="STD-Kremer-2004" TOTAL_1="89" TOTAL_2="86" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="20.707924069252012" CI_START="1.2920759307479877" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="11.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.14" MODIFIED="2008-12-27 09:38:18 -0500" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.026362793171126796" Q="0.0" RANDOM="NO" SCALE="22.52072159793104" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="18" UNITS="" WEIGHT="100.00000000000001" Z="2.2208253459899328">
<NAME>leflunomide vs. anti-TNF+MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef</GROUP_LABEL_1>
<GROUP_LABEL_2>anti-TNF+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours anti-TNF+MTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="20.707924069252012" CI_START="1.2920759307479877" EFFECT_SIZE="11.0" ESTIMABLE="YES" MEAN_1="-48.0" MEAN_2="-59.0" MODIFIED="2008-12-27 09:38:12 -0500" MODIFIED_BY="[Empty name]" ORDER="422" SD_1="14.0" SD_2="18.0" SE="4.953113498935123" STUDY_ID="STD-Wislowska-2007" TOTAL_1="30" TOTAL_2="18" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2009-07-22 12:17:39 -0400" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Changes in hand joint radiographs</NAME>
<CONT_OUTCOME CHI2="18.59685370271208" CI_END="-0.12700621124053169" CI_START="-1.3317784523042213" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7293923317723765" ESTIMABLE="YES" I2="67.73647792301024" I2_Q="70.433685343514" ID="CMP-011.01" NO="1" P_CHI2="0.004901550365124074" P_Q="0.004671461654517262" P_Z="0.017634715373478393" Q="16.911137076406455" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="1.1668849121147002" TOTALS="SUB" TOTAL_1="869" TOTAL_2="808" UNITS="" WEIGHT="600.0" Z="2.373199932978825">
<NAME>Total Sharp score</NAME>
<GROUP_LABEL_1>Leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.0898148764110744" CI_START="-7.210185123588927" DF="0" EFFECT_SIZE="-4.65" ESTIMABLE="YES" I2="0.0" ID="CMP-011.01.01" NO="1" P_CHI2="1.0" P_Z="3.710901314830946E-4" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="62" WEIGHT="100.0" Z="3.559833405849681">
<NAME>leflunomide vs. placebo, at 6 months</NAME>
<CONT_DATA CI_END="-2.0898148764110744" CI_START="-7.210185123588927" EFFECT_SIZE="-4.65" ESTIMABLE="YES" MEAN_1="1.23" MEAN_2="5.88" ORDER="34493" SD_1="2.85" SD_2="10.0" SE="1.306240902273378" STUDY_ID="STD-Sharp-2000" TOTAL_1="87" TOTAL_2="62" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.4793992753481531" CI_START="-2.780600724651847" DF="0" EFFECT_SIZE="-1.6300000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-011.01.02" NO="2" P_CHI2="1.0" P_Z="0.005493318380491859" STUDIES="1" TAU2="0.0" TOTAL_1="131" TOTAL_2="83" WEIGHT="100.0" Z="2.7765855055992295">
<NAME>leflunomide vs. placebo, at 12 months</NAME>
<CONT_DATA CI_END="-0.4793992753481531" CI_START="-2.780600724651847" EFFECT_SIZE="-1.6300000000000001" ESTIMABLE="YES" MEAN_1="0.53" MEAN_2="2.16" ORDER="34494" SD_1="4.53" SD_2="3.95" SE="0.5870519732646308" STUDY_ID="STD-Sharp-2000" TOTAL_1="131" TOTAL_2="83" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.6857166263056262" CI_END="1.2297502924260262" CI_START="-1.0677857137074387" DF="1" EFFECT_SIZE="0.08098228935929372" ESTIMABLE="YES" I2="40.678048469417156" ID="CMP-011.01.03" NO="3" P_CHI2="0.19416665719930892" P_Z="0.8901080623633789" STUDIES="2" TAU2="0.30272603670940246" TOTAL_1="433" TOTAL_2="460" WEIGHT="100.0" Z="0.13816747167930712">
<NAME>leflunomide vs. methotrexate, at 12 months</NAME>
<CONT_DATA CI_END="2.4373455652996485" CI_START="-0.7173455652996488" EFFECT_SIZE="0.8599999999999999" ESTIMABLE="YES" MEAN_1="2.48" MEAN_2="1.62" ORDER="34495" SD_1="5.36" SD_2="13.38" SE="0.8047829336363062" STUDY_ID="STD-Emery-1999" TOTAL_1="302" TOTAL_2="324" WEIGHT="36.14608929174539"/>
<CONT_DATA CI_END="0.5906782149646918" CI_START="-1.3106782149646916" EFFECT_SIZE="-0.36" ESTIMABLE="YES" MEAN_1="0.53" MEAN_2="0.89" ORDER="34496" SD_1="4.53" SD_2="3.27" SE="0.4850488184800946" STUDY_ID="STD-Strand-1999a" TOTAL_1="131" TOTAL_2="136" WEIGHT="63.85391070825461"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.7397304863608953" CI_START="-0.9397304863608951" DF="0" EFFECT_SIZE="0.40000000000000013" ESTIMABLE="YES" I2="0.0" ID="CMP-011.01.04" NO="4" P_CHI2="1.0" P_Z="0.5584256365413653" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="66" WEIGHT="100.0" Z="0.5851815733070008">
<NAME>leflunomide vs. methotrexate, at 24 months</NAME>
<CONT_DATA CI_END="1.7397304863608953" CI_START="-0.9397304863608951" EFFECT_SIZE="0.40000000000000013" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="1.2" ORDER="34497" SD_1="4.2" SD_2="3.8" SE="0.6835485227935402" STUDY_ID="STD-Cohen-2001" TOTAL_1="71" TOTAL_2="66" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.1534292489075333" CI_START="-3.333429248907533" DF="0" EFFECT_SIZE="-1.0899999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-011.01.05" NO="5" P_CHI2="1.0" P_Z="0.3409577358353938" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="84" WEIGHT="100.00000000000001" Z="0.9522746234092239">
<NAME>leflunomide vs. sulfasalazine, at 6 months</NAME>
<CONT_DATA CI_END="1.1534292489075333" CI_START="-3.333429248907533" EFFECT_SIZE="-1.0899999999999999" ESTIMABLE="YES" MEAN_1="1.23" MEAN_2="2.32" ORDER="34498" SD_1="2.85" SD_2="10.11" SE="1.1446277924509922" STUDY_ID="STD-Sharp-2000" TOTAL_1="87" TOTAL_2="84" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.3195499813738754" CI_START="-2.139549981373875" DF="0" EFFECT_SIZE="-0.4099999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-011.01.06" NO="6" P_CHI2="1.0" P_Z="0.6422028958986452" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="53" WEIGHT="100.0" Z="0.4646209952389411">
<NAME>leflunomide vs. sulfasalazine, at 12 months</NAME>
<CONT_DATA CI_END="1.3195499813738756" CI_START="-2.139549981373875" EFFECT_SIZE="-0.4099999999999999" ESTIMABLE="YES" MEAN_1="0.97" MEAN_2="1.38" ORDER="34499" SD_1="6.11" SD_2="2.88" SE="0.8824396749207358" STUDY_ID="STD-Sharp-2000" TOTAL_1="60" TOTAL_2="53" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="10.182070884854715" CI_END="0.003373546963982019" CI_START="-0.011342379687794312" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.003984416361906147" ESTIMABLE="YES" I2="70.53644554309341" I2_Q="70.53644554309341" ID="CMP-011.02" MODIFIED="2008-12-01 10:05:17 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.017080263393427386" P_Q="0.017080263393427386" P_Z="0.2885347025348044" Q="10.182070884854715" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="271" TOTAL_2="216" UNITS="" WEIGHT="400.0" Z="1.061341599960409">
<NAME>Total Larsen score</NAME>
<GROUP_LABEL_1>lelfunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.016407853199238015" CI_START="-0.06359214680076199" DF="0" EFFECT_SIZE="-0.04" ESTIMABLE="YES" I2="0.0" ID="CMP-011.02.01" NO="1" P_CHI2="1.0" P_Z="8.902980830548274E-4" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="60" WEIGHT="100.0" Z="3.323078651709222">
<NAME>leflunomide vs. placebo, at 6 months</NAME>
<CONT_DATA CI_END="-0.016407853199238015" CI_START="-0.06359214680076199" EFFECT_SIZE="-0.04" ESTIMABLE="YES" MEAN_1="0.01" MEAN_2="0.05" ORDER="34500" SD_1="0.03" SD_2="0.09" SE="0.012037030775490686" STUDY_ID="STD-Scott-2001" TOTAL_1="91" TOTAL_2="60" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.00910453831388962" CI_START="-0.00910453831388962" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-011.02.02" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="77" WEIGHT="100.0" Z="0.0">
<NAME>leflunomide vs. sulfasalazine, at 6 months</NAME>
<CONT_DATA CI_END="0.00910453831388962" CI_START="-0.00910453831388962" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.01" MEAN_2="0.01" ORDER="34501" SD_1="0.03" SD_2="0.03" SE="0.004645257966832583" STUDY_ID="STD-Scott-2001" TOTAL_1="91" TOTAL_2="77" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.014797239896994255" CI_START="-0.014797239896994255" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-011.02.03" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="52" WEIGHT="100.0" Z="0.0">
<NAME>leflunomide vs. sulfasalazine, at 12 months</NAME>
<CONT_DATA CI_END="0.014797239896994257" CI_START="-0.014797239896994257" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.02" MEAN_2="0.02" ORDER="34502" SD_1="0.04" SD_2="0.04" SE="0.00754975092078885" STUDY_ID="STD-Scott-2001" TOTAL_1="61" TOTAL_2="52" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.1121040534113297" CI_START="-0.19210405341132972" DF="0" EFFECT_SIZE="-0.04000000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-011.02.04" NO="4" P_CHI2="1.0" P_Z="0.6062545634985925" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0" Z="0.5154271541310715">
<NAME>leflunomide vs. sulfasalazine, at 24 months</NAME>
<CONT_DATA CI_END="0.1121040534113297" CI_START="-0.19210405341132972" EFFECT_SIZE="-0.04000000000000001" ESTIMABLE="YES" MEAN_1="-0.07" MEAN_2="-0.03" ORDER="34503" SD_1="0.33" SD_2="0.24" SE="0.07760553490324673" STUDY_ID="STD-Scott-2001" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="16.488132250823362" CI_END="-7.424801659518592E-4" CI_START="-0.01584775515021465" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.008295117658083256" ESTIMABLE="YES" I2="57.54522165692573" I2_Q="57.54522165692573" ID="CMP-011.03" MODIFIED="2009-07-22 12:17:39 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.021012322036742526" P_Q="0.021012322036742526" P_Z="0.03134675024238326" Q="16.488132250823362" RANDOM="NO" SCALE="0.2304456443545034" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="542" TOTAL_2="432" UNITS="" WEIGHT="800.0" Z="2.152642950797482">
<NAME>Larsen erosion score, hands and feet</NAME>
<GROUP_LABEL_1>lelfunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.016407853199238015" CI_START="-0.06359214680076199" DF="0" EFFECT_SIZE="-0.04" ESTIMABLE="YES" I2="0.0" ID="CMP-011.03.01" NO="1" P_CHI2="1.0" P_Z="8.902980830548274E-4" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="60" WEIGHT="100.0" Z="3.323078651709222">
<NAME>leflunomide vs. placebo, hands, at 6 months</NAME>
<CONT_DATA CI_END="-0.016407853199238015" CI_START="-0.06359214680076199" EFFECT_SIZE="-0.04" ESTIMABLE="YES" MEAN_1="0.01" MEAN_2="0.05" ORDER="34504" SD_1="0.03" SD_2="0.09" SE="0.012037030775490686" STUDY_ID="STD-Larsen-2001" TOTAL_1="91" TOTAL_2="60" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.010854260491829243" CI_START="-0.010854260491829243" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-011.03.02" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="77" WEIGHT="100.0" Z="0.0">
<NAME>leflunomide vs. sulfasalazine, hands, at 6 months</NAME>
<CONT_DATA CI_END="0.010854260491829243" CI_START="-0.010854260491829243" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.01" MEAN_2="0.01" ORDER="34505" SD_1="0.03" SD_2="0.04" SE="0.005537989767896892" STUDY_ID="STD-Larsen-2001" TOTAL_1="91" TOTAL_2="77" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.016602276044510537" CI_START="-0.016602276044510537" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-011.03.03" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="52" WEIGHT="100.0" Z="0.0">
<NAME>leflunomide vs. sulfasalazine, hands, at 12 months</NAME>
<CONT_DATA CI_END="0.016602276044510537" CI_START="-0.016602276044510537" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.02" MEAN_2="0.02" ORDER="34506" SD_1="0.05" SD_2="0.04" SE="0.00847070465348709" STUDY_ID="STD-Larsen-2001" TOTAL_1="61" TOTAL_2="52" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="8.964873518931792E-33" CI_END="0.08363697650004526" CI_START="-0.20363697650004525" DF="0" EFFECT_SIZE="-0.05999999999999999" ESTIMABLE="YES" I2="100.0" ID="CMP-011.03.04" NO="4" P_CHI2="0.0" P_Z="0.4129486792369328" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="99.99999999999999" Z="0.8187156395092052">
<NAME>leflunomide vs. sulfasalazine, hands, at 24 months</NAME>
<CONT_DATA CI_END="0.08363697650004526" CI_START="-0.20363697650004525" EFFECT_SIZE="-0.06" ESTIMABLE="YES" MEAN_1="-0.06" MEAN_2="0.0" ORDER="34507" SD_1="0.33" SD_2="0.2" SE="0.07328551832229337" STUDY_ID="STD-Larsen-2001" TOTAL_1="28" TOTAL_2="27" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.016094940874947804" CI_START="-0.0839050591250522" DF="0" EFFECT_SIZE="-0.049999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-011.03.05" NO="5" P_CHI2="1.0" P_Z="0.003847874339372966" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="60" WEIGHT="100.0" Z="2.8903709875731374">
<NAME>leflunomide vs. placebo, feet, at 6 months</NAME>
<CONT_DATA CI_END="-0.016094940874947804" CI_START="-0.0839050591250522" EFFECT_SIZE="-0.049999999999999996" ESTIMABLE="YES" MEAN_1="0.01" MEAN_2="0.06" ORDER="34508" SD_1="0.04" SD_2="0.13" SE="0.01729881742342766" STUDY_ID="STD-Larsen-2001" TOTAL_1="91" TOTAL_2="60" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.02017726811094861" CI_START="-0.040177268110948613" DF="0" EFFECT_SIZE="-0.01" ESTIMABLE="YES" I2="0.0" ID="CMP-011.03.06" NO="6" P_CHI2="1.0" P_Z="0.5160258663754885" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="77" WEIGHT="100.0" Z="0.6494835706579284">
<NAME>leflunomide vs. sulfasalazine, feet, at 6 months</NAME>
<CONT_DATA CI_END="0.02017726811094861" CI_START="-0.040177268110948613" EFFECT_SIZE="-0.01" ESTIMABLE="YES" MEAN_1="0.01" MEAN_2="0.02" ORDER="34509" SD_1="0.04" SD_2="0.13" SE="0.015396848283429212" STUDY_ID="STD-Larsen-2001" TOTAL_1="91" TOTAL_2="77" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.01510441731431806" CI_START="-0.03510441731431806" DF="0" EFFECT_SIZE="-0.009999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-011.03.07" NO="7" P_CHI2="1.0" P_Z="0.43496440937720615" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="52" WEIGHT="100.0" Z="0.7807247465657001">
<NAME>leflunomide vs. sulfasalazine, feet, at 12 months</NAME>
<CONT_DATA CI_END="0.01510441731431806" CI_START="-0.03510441731431806" EFFECT_SIZE="-0.009999999999999998" ESTIMABLE="YES" MEAN_1="0.02" MEAN_2="0.03" ORDER="34510" SD_1="0.05" SD_2="0.08" SE="0.012808611542017352" STUDY_ID="STD-Larsen-2001" TOTAL_1="61" TOTAL_2="52" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.23706564565483676" CI_START="-0.2770656456548367" DF="0" EFFECT_SIZE="-0.01999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-011.03.08" NO="8" P_CHI2="1.0" P_Z="0.878802503820774" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0" Z="0.15248743016962338">
<NAME>leflunomide vs. sulfasalazine, feet, at 24 months</NAME>
<CONT_DATA CI_END="0.23706564565483676" CI_START="-0.2770656456548367" EFFECT_SIZE="-0.01999999999999999" ESTIMABLE="YES" MEAN_1="-0.12" MEAN_2="-0.1" ORDER="34511" SD_1="0.53" SD_2="0.44" SE="0.1311583517261224" STUDY_ID="STD-Larsen-2001" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2008-12-28 03:08:57 -0500" MODIFIED_BY="[Empty name]" NO="12">
<NAME>Changes in function and health-related quality of life</NAME>
<CONT_OUTCOME CHI2="8.360610828287259" CI_END="-0.3346230491330161" CI_START="-0.5168125366052703" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.4257177928691432" ESTIMABLE="YES" I2="76.07830287670839" I2_Q="0.0" ID="CMP-012.01" NO="1" P_CHI2="0.015293856686492635" P_Q="1.0" P_Z="5.208936490285469E-20" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="387" TOTAL_2="292" UNITS="" WEIGHT="100.0" Z="9.159601392791378">
<NAME>Changes of HAQ scores in leflunomide vs. placebo, at 6 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.9371291291990689" CI_START="-9.062870870800932" EFFECT_SIZE="-5.5" ESTIMABLE="YES" MEAN_1="-13.6" MEAN_2="-8.1" ORDER="34512" SD_1="12.9" SD_2="13.0" SE="1.817824663567495" STUDY_ID="STD-Mladenovic-1995" TOTAL_1="101" TOTAL_2="102" WEIGHT="0.06537120220377278"/>
<CONT_DATA CI_END="-0.32605643312335825" CI_START="-0.5939435668766417" EFFECT_SIZE="-0.46" ESTIMABLE="YES" MEAN_1="-0.5" MEAN_2="-0.04" ORDER="34513" SD_1="0.5" SD_2="0.5" SE="0.06833981028894996" STUDY_ID="STD-Smolen-1999" TOTAL_1="130" TOTAL_2="91" WEIGHT="46.25332062361488"/>
<CONT_DATA CI_END="-0.2656683282750535" CI_START="-0.5143316717249465" EFFECT_SIZE="-0.39" ESTIMABLE="YES" MEAN_1="-0.46" MEAN_2="-0.07" ORDER="34514" SD_1="0.58" SD_2="0.43" SE="0.06343569203600623" STUDY_ID="STD-Strand-1999b" TOTAL_1="156" TOTAL_2="99" WEIGHT="53.681308174181346"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.3587021761954122" CI_START="-0.6012978238045877" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.48" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="8.766829986796188E-15" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="164" TOTAL_2="100" UNITS="" WEIGHT="100.0" Z="7.755973545698876">
<NAME>Changes of HAQ scores in leflunomide vs. placebo, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.3587021761954122" CI_START="-0.6012978238045877" EFFECT_SIZE="-0.48" ESTIMABLE="YES" MEAN_1="-0.45" MEAN_2="0.03" ORDER="34515" SD_1="0.57" SD_2="0.43" SE="0.061887782000776284" STUDY_ID="STD-Strand-1999b" TOTAL_1="164" TOTAL_2="100" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="17.21552523513048" CI_END="0.1437030986463997" CI_START="-0.12454824369872454" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.009577427473837588" ESTIMABLE="YES" I2="94.19128962757772" I2_Q="0.0" ID="CMP-012.03" NO="3" P_CHI2="3.337020678151337E-5" P_Q="1.0" P_Z="0.8886964016892838" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="80" TOTAL_2="80" UNITS="" WEIGHT="100.0" Z="0.13995391597418635">
<NAME>Changes of HAQ scores in leflunomide vs. MTX, at 3 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.4519971941581384" CI_START="0.08800280584186165" EFFECT_SIZE="0.27" ESTIMABLE="YES" MEAN_1="-0.73" MEAN_2="-1.0" ORDER="34516" SD_1="0.43" SD_2="0.4" SE="0.0928574175820112" STUDY_ID="STD-Lao-2001" TOTAL_1="40" TOTAL_2="40" WEIGHT="54.31182938137502"/>
<CONT_DATA CI_END="-0.10156877032050932" CI_START="-0.4984312296794908" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="-0.7" ORDER="34517" SD_1="0.5" SD_2="0.4" SE="0.10124228365658294" STUDY_ID="STD-Shuai-2002" TOTAL_1="40" TOTAL_2="40" WEIGHT="45.68817061862498"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.267464255599828" CI_END="0.08543877691386215" CI_START="-0.10709959906305347" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.010830411074595654" ESTIMABLE="YES" I2="53.133760936003824" I2_Q="0.0" ID="CMP-012.04" MODIFIED="2008-11-12 10:30:14 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.11839466857692271" P_Q="1.0" P_Z="0.8254829074841987" Q="0.0" RANDOM="NO" SCALE="0.4868620718506314" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="104" TOTAL_2="104" UNITS="" WEIGHT="99.99999999999997" Z="0.22049854255046034">
<NAME>Changes of HAQ scores in leflunomide vs. MTX, at 6 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.2984312296794906" CI_START="-0.09843122967949086" EFFECT_SIZE="0.09999999999999987" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-1.2" ORDER="34518" SD_1="0.4" SD_2="0.5" SE="0.10124228365658294" STUDY_ID="STD-Lao-2001" TOTAL_1="40" TOTAL_2="40" WEIGHT="23.537187654910305"/>
<CONT_DATA CI_END="0.015228887499454224" CI_START="-0.41522888749945414" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" MEAN_1="-1.2" MEAN_2="-1.0" ORDER="34519" SD_1="0.4" SD_2="0.5" SE="0.10981267472114395" STUDY_ID="STD-Shuai-2002" TOTAL_1="34" TOTAL_2="34" WEIGHT="20.00660950667376"/>
<CONT_DATA CI_END="0.13812429132330672" CI_START="-0.11812429132330671" EFFECT_SIZE="0.010000000000000009" ESTIMABLE="YES" MEAN_1="-0.45" MEAN_2="-0.46" MODIFIED="2008-11-12 10:29:54 -0500" MODIFIED_BY="[Empty name]" ORDER="423" SD_1="0.29" SD_2="0.21" SE="0.06537073759208575" STUDY_ID="STD-Wislowska-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="56.45620283841592"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="10.679750743490349" CI_END="0.05272618790254953" CI_START="-0.08537552276155451" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.016324667429502487" ESTIMABLE="YES" I2="90.63648558830334" I2_Q="0.0" ID="CMP-012.05" NO="5" P_CHI2="0.0010831526178998185" P_Q="1.0" P_Z="0.643102652835041" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="416" TOTAL_2="445" UNITS="" WEIGHT="100.00000000000001" Z="0.46336515409631934">
<NAME>Changes of HAQ scores in leflunomide vs. MTX, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.1428457048556901" CI_START="-0.02284570485569" EFFECT_SIZE="0.06000000000000005" ESTIMABLE="YES" MEAN_1="-0.48" MEAN_2="-0.54" ORDER="34520" SD_1="0.5" SD_2="0.47" SE="0.04226899346578121" STUDY_ID="STD-Emery-1999" TOTAL_1="252" TOTAL_2="278" WEIGHT="69.470133028199"/>
<CONT_DATA CI_END="-0.06502975922081751" CI_START="-0.3149702407791825" EFFECT_SIZE="-0.19" ESTIMABLE="YES" MEAN_1="-0.45" MEAN_2="-0.26" ORDER="34521" SD_1="0.57" SD_2="0.59" SE="0.06376149856065305" STUDY_ID="STD-Strand-1999b" TOTAL_1="164" TOTAL_2="167" WEIGHT="30.52986697180101"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.14465984755950756" CI_START="-0.04465984755950757" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.04999999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.06" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.30054433609975895" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="252" TOTAL_2="278" UNITS="" WEIGHT="100.0" Z="1.0352668185462321">
<NAME>Changes of HAQ scores in leflunomide vs. MTX, at 2 years</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.14465984755950756" CI_START="-0.04465984755950757" EFFECT_SIZE="0.04999999999999999" ESTIMABLE="YES" MEAN_1="-0.45" MEAN_2="-0.5" ORDER="34522" SD_1="0.56" SD_2="0.55" SE="0.04829672805529711" STUDY_ID="STD-Emery-1999" TOTAL_1="252" TOTAL_2="278" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.07642144216204647" CI_START="-0.4235785578379536" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.25000000000000006" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.07" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.004759476119142199" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="116" TOTAL_2="113" UNITS="" WEIGHT="100.0" Z="2.82287744660519">
<NAME>Changes of HAQ scores in leflunomide vs. SSZ, at 6 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.07642144216204647" CI_START="-0.4235785578379536" EFFECT_SIZE="-0.25000000000000006" ESTIMABLE="YES" MEAN_1="-0.66" MEAN_2="-0.41" ORDER="34523" SD_1="0.69" SD_2="0.65" SE="0.08856211604249828" STUDY_ID="STD-Scott-2001" TOTAL_1="116" TOTAL_2="113" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.048875447111117465" CI_START="-0.3288754471111175" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.14" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.08" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.14628413231866988" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="66" TOTAL_2="62" UNITS="" WEIGHT="100.0" Z="1.4527825719675362">
<NAME>Changes of HAQ scores in leflunomide vs. SSZ, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.048875447111117465" CI_START="-0.3288754471111175" EFFECT_SIZE="-0.14" ESTIMABLE="YES" MEAN_1="-0.67" MEAN_2="-0.53" ORDER="34524" SD_1="0.55" SD_2="0.54" SE="0.09636679479875289" STUDY_ID="STD-Scott-2001" TOTAL_1="66" TOTAL_2="62" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.010597108982920433" CI_START="-0.5694028910170796" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.29000000000000004" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.09" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.0419212654757287" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="51" TOTAL_2="45" UNITS="" WEIGHT="100.00000000000001" Z="2.0343009102288447">
<NAME>Changes of HAQ scores in leflunomide vs. SSZ, at 24 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.010597108982920433" CI_START="-0.5694028910170796" EFFECT_SIZE="-0.29000000000000004" ESTIMABLE="YES" MEAN_1="-0.89" MEAN_2="-0.6" ORDER="34525" SD_1="0.67" SD_2="0.72" SE="0.14255511490056652" STUDY_ID="STD-Scott-2001" TOTAL_1="51" TOTAL_2="45" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.23541376762569866" CI_START="-0.4645862323743013" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.35" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.10" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="2.1421018184890526E-9" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="182" TOTAL_2="118" UNITS="" WEIGHT="100.0" Z="5.986647613547576">
<NAME>Changes of MHAQ scores in leflunomide vs. placebo, at 6 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.23541376762569866" CI_START="-0.4645862323743013" EFFECT_SIZE="-0.35" ESTIMABLE="YES" MEAN_1="-0.32" MEAN_2="0.03" ORDER="34526" SD_1="0.47" SD_2="0.51" SE="0.05846343773566396" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="118" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.23986769620663462" CI_START="-0.48013230379336536" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.36" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.11" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="4.269045517383139E-9" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="178" TOTAL_2="118" UNITS="" WEIGHT="100.0" Z="5.873416326453465">
<NAME>Changes of MHAQ scores in leflunomide vs. placebo, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.23986769620663462" CI_START="-0.48013230379336536" EFFECT_SIZE="-0.36" ESTIMABLE="YES" MEAN_1="-0.29" MEAN_2="0.07" ORDER="34527" SD_1="0.54" SD_2="0.5" SE="0.06129311800673565" STUDY_ID="STD-Strand-1999a" TOTAL_1="178" TOTAL_2="118" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.72306988671566E-32" CI_END="-0.022124644742333208" CI_START="-0.21787535525766683" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.12000000000000001" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-012.12" NO="12" P_CHI2="0.0" P_Q="1.0" P_Z="0.01626064248961929" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="182" TOTAL_2="180" UNITS="" WEIGHT="100.0" Z="2.4030122549811446">
<NAME>Changes of MHAQ scores in leflunomide vs. MTX, at 6 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.022124644742333194" CI_START="-0.2178753552576668" EFFECT_SIZE="-0.12" ESTIMABLE="YES" MEAN_1="-0.32" MEAN_2="-0.2" ORDER="34528" SD_1="0.47" SD_2="0.48" SE="0.04993732335374278" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="180" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.03202661243045593" CI_START="-0.24797338756954404" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.13999999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.13" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.011043470998480671" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="178" TOTAL_2="179" UNITS="" WEIGHT="100.0" Z="2.5413202643000696">
<NAME>Changes of MHAQ scores in leflunomide vs. MTX, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.03202661243045593" CI_START="-0.24797338756954404" EFFECT_SIZE="-0.13999999999999999" ESTIMABLE="YES" MEAN_1="-0.29" MEAN_2="-0.15" ORDER="34529" SD_1="0.54" SD_2="0.5" SE="0.05508947532772253" STUDY_ID="STD-Strand-1999a" TOTAL_1="178" TOTAL_2="179" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.01104604616610863" CI_START="-0.28895395383389133" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.14999999999999997" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.14" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.034364379413980316" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="98" TOTAL_2="101" UNITS="" WEIGHT="100.0" Z="2.115769933631797">
<NAME>Changes of MHAQ scores in leflunomide vs. MTX, at 24 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.01104604616610863" CI_START="-0.28895395383389133" EFFECT_SIZE="-0.14999999999999997" ESTIMABLE="YES" MEAN_1="-0.43" MEAN_2="-0.28" ORDER="34530" SD_1="0.5" SD_2="0.5" SE="0.07089617713893846" STUDY_ID="STD-Cohen-2001" TOTAL_1="98" TOTAL_2="101" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.15947629285263E-31" CI_END="-4.0219240453908345" CI_START="-8.458075954609168" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.240000000000001" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-012.15" NO="15" P_CHI2="0.0" P_Q="1.0" P_Z="3.510344050603426E-8" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="165" TOTAL_2="101" UNITS="" WEIGHT="100.0" Z="5.513866753803272">
<NAME>Changes of PET top 5 scores in leflunomide vs. placebo, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-4.021924045390834" CI_START="-8.458075954609168" EFFECT_SIZE="-6.24" ESTIMABLE="YES" MEAN_1="-6.9" MEAN_2="-0.66" ORDER="34531" SD_1="9.87" SD_2="8.35" SE="1.1316922005225947" STUDY_ID="STD-Strand-1999b" TOTAL_1="165" TOTAL_2="101" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-1.3765363487568392" CI_START="-5.623463651243162" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.5000000000000004" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.16" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.0012356889245302614" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="165" TOTAL_2="168" UNITS="" WEIGHT="100.0" Z="3.230511594523478">
<NAME>Changes of PET top 5 scores in leflunomide vs. MTX, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.3765363487568392" CI_START="-5.623463651243162" EFFECT_SIZE="-3.5000000000000004" ESTIMABLE="YES" MEAN_1="-6.9" MEAN_2="-3.4" ORDER="34532" SD_1="9.87" SD_2="9.9" SE="1.083419730154621" STUDY_ID="STD-Strand-1999b" TOTAL_1="165" TOTAL_2="168" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.658209794509869E-31" CI_END="-4.285757927326689" CI_START="-8.914242072673309" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.599999999999999" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-012.17" NO="17" P_CHI2="0.0" P_Q="1.0" P_Z="2.2755090752754994E-8" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="95" TOTAL_2="156" UNITS="" WEIGHT="100.0" Z="5.58963232529151">
<NAME>Changes of SF-36 physical component scores in leflunomide vs. placebo, at 12 months</NAME>
<GROUP_LABEL_1>placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-4.28575792732669" CI_START="-8.914242072673309" EFFECT_SIZE="-6.6" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="7.6" ORDER="34533" SD_1="7.92" SD_2="10.7" SE="1.1807574480591254" STUDY_ID="STD-Strand-1999b" TOTAL_1="95" TOTAL_2="156" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.5930390340217722" CI_START="-5.406960965978228" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.18" NO="18" P_CHI2="1.0" P_Q="1.0" P_Z="0.014570998021312747" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="160" TOTAL_2="156" UNITS="" WEIGHT="100.00000000000001" Z="2.442869675383572">
<NAME>Changes of SF-36 physical component scores in leflunomide vs. MTX, at 12 months</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.5930390340217722" CI_START="-5.406960965978228" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="4.6" MEAN_2="7.6" ORDER="34534" SD_1="11.13" SD_2="10.7" SE="1.228063875134456" STUDY_ID="STD-Strand-1999b" TOTAL_1="160" TOTAL_2="156" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.1312423309030226" CI_START="-3.531242330903022" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.19" NO="19" P_CHI2="1.0" P_Q="1.0" P_Z="0.6279714533692651" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="95" TOTAL_2="156" UNITS="" WEIGHT="100.0" Z="0.48458401960260594">
<NAME>Changes of SF-36 mental component scores in leflunomide vs. placebo, at 12 months</NAME>
<GROUP_LABEL_1>placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.1312423309030226" CI_START="-3.531242330903022" EFFECT_SIZE="-0.7" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="1.5" ORDER="34535" SD_1="10.81" SD_2="11.56" SE="1.444537937041446" STUDY_ID="STD-Strand-1999b" TOTAL_1="95" TOTAL_2="156" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.8100270906113924" CI_START="-3.0100270906113926" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.20" NO="20" P_CHI2="1.0" P_Q="1.0" P_Z="0.6255835920738622" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="160" TOTAL_2="156" UNITS="" WEIGHT="99.99999999999999" Z="0.4879523534425093">
<NAME>Changes of SF-36 mental component scores in leflunomide vs. MTX, at 12 months</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.8100270906113924" CI_START="-3.0100270906113926" EFFECT_SIZE="-0.6" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="1.5" ORDER="34536" SD_1="10.24" SD_2="11.56" SE="1.2296282531829046" STUDY_ID="STD-Strand-1999b" TOTAL_1="160" TOTAL_2="156" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-4.74968439873775" CI_START="-14.250315601262251" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-9.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.21" NO="21" P_CHI2="1.0" P_Q="1.0" P_Z="8.867120344668793E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="77" TOTAL_2="121" UNITS="" WEIGHT="100.0" Z="3.919667537075413">
<NAME>Changes of work productivity scores in leflunomide vs. placebo, at 12 months</NAME>
<GROUP_LABEL_1>placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-4.74968439873775" CI_START="-14.250315601262251" EFFECT_SIZE="-9.5" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="9.8" ORDER="34537" SD_1="16.68" SD_2="16.54" SE="2.4236749444031287" STUDY_ID="STD-Strand-1999b" TOTAL_1="77" TOTAL_2="121" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.7673609256365737" CI_START="-6.367360925636575" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.3000000000000007" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.22" NO="22" P_CHI2="1.0" P_Q="1.0" P_Z="0.26772581301913456" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="131" TOTAL_2="121" UNITS="" WEIGHT="100.0" Z="1.108315009870092">
<NAME>Changes of work productivity scores in leflunomide vs. MTX, at 12 months</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.7673609256365737" CI_START="-6.367360925636575" EFFECT_SIZE="-2.3000000000000007" ESTIMABLE="YES" MEAN_1="7.5" MEAN_2="9.8" ORDER="34538" SD_1="16.37" SD_2="16.54" SE="2.0752222784292966" STUDY_ID="STD-Strand-1999b" TOTAL_1="131" TOTAL_2="121" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.18320530715713756" CI_START="-0.4167946928428625" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.23" NO="23" P_CHI2="1.0" P_Q="1.0" P_Z="4.793908063597706E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="133" UNITS="" WEIGHT="100.0" Z="5.034382822112533">
<NAME>Changes of HAQ scores in leflunomide+MTX vs. MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.18320530715713756" CI_START="-0.4167946928428625" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.1" ORDER="34539" SD_1="0.53" SD_2="0.43" SE="0.059590223985809994" STUDY_ID="STD-Kremer-2002" TOTAL_1="130" TOTAL_2="133" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.141148361532494E-32" CI_END="0.273470217702692" CI_START="-0.03347021770269197" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.12000000000000001" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-012.24" NO="24" P_CHI2="0.0" P_Q="1.0" P_Z="0.1253949692180737" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="147" TOTAL_2="144" UNITS="" WEIGHT="100.0" Z="1.5325167427626647">
<NAME>Changes of HAQ scores in leflunomide10mg vs. leflunomide20mg, at 24 months</NAME>
<GROUP_LABEL_1>Lef10</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef20</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.273470217702692" CI_START="-0.033470217702691984" EFFECT_SIZE="0.12" ESTIMABLE="YES" MEAN_1="-0.37" MEAN_2="-0.49" ORDER="34540" SD_1="0.61" SD_2="0.72" SE="0.07830257030906969" STUDY_ID="STD-Poor-2004" TOTAL_1="147" TOTAL_2="144" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.06693942184324499" CI_START="-0.226939421843245" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.08" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.25" NO="25" P_CHI2="1.0" P_Q="1.0" P_Z="0.285932653845305" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="50" UNITS="" WEIGHT="100.00000000000001" Z="1.0670868089468566">
<NAME>Changes of HAQ-DI in leflunomide+SSZ vs. placebo+SSZ, at 24 months</NAME>
<GROUP_LABEL_1>Lef+SSZ</GROUP_LABEL_1>
<GROUP_LABEL_2>Plc+SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.06693942184324499" CI_START="-0.226939421843245" EFFECT_SIZE="-0.08" ESTIMABLE="YES" MEAN_1="-0.11" MEAN_2="-0.03" ORDER="34541" SD_1="0.38" SD_2="0.39" SE="0.07497047037715203" STUDY_ID="STD-Dougados-2005" TOTAL_1="56" TOTAL_2="50" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0603128662365852" CI_START="-0.20031286623658517" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.06999999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.26" NO="26" P_CHI2="1.0" P_Q="1.0" P_Z="0.2924182811151832" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="50" UNITS="" WEIGHT="100.0" Z="1.052831411663676">
<NAME>Changes of mean HAQ scores in leflunomide+SSZ vs. placebo+SSZ, at 24 months</NAME>
<GROUP_LABEL_1>Lef+SSZ</GROUP_LABEL_1>
<GROUP_LABEL_2>Plc+SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0603128662365852" CI_START="-0.20031286623658517" EFFECT_SIZE="-0.06999999999999999" ESTIMABLE="YES" MEAN_1="-0.09" MEAN_2="-0.02" ORDER="34542" SD_1="0.32" SD_2="0.36" SE="0.06648737796432815" STUDY_ID="STD-Dougados-2005" TOTAL_1="56" TOTAL_2="50" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.9565071314346145" CI_START="-7.636507131434616" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.3400000000000007" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.27" NO="27" P_CHI2="1.0" P_Q="1.0" P_Z="0.38653774331002677" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="21" UNITS="" WEIGHT="100.0" Z="0.8659132537751301">
<NAME>Changes of MHAQ scores in leflunomide vs. MTX, at 4 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.9565071314346145" CI_START="-7.636507131434616" EFFECT_SIZE="-2.3400000000000007" ESTIMABLE="YES" MEAN_1="-6.44" MEAN_2="-4.1" ORDER="34543" SD_1="8.89" SD_2="7.82" SE="2.7023492131553373" STUDY_ID="STD-Reece-2002" TOTAL_1="18" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.20887509520673106" CI_END="-0.00564925908711951" CI_START="-0.15430935699567894" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.07997930804139922" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.28" MODIFIED="2008-12-28 03:08:57 -0500" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="0.6476505378057196" P_Q="0.6476505378057196" P_Z="0.03495098066355463" Q="0.20887509520673106" RANDOM="NO" SCALE="0.09658120993482423" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="395" TOTAL_2="302" UNITS="" WEIGHT="200.0" Z="2.1089258715004737">
<NAME>Changes of Chinese disability scores in leflunomide vs. MTX</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.0041414376503259714" CI_START="-0.17585856234967395" DF="0" EFFECT_SIZE="-0.08999999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-012.28.01" NO="1" P_CHI2="1.0" P_Z="0.039926937956619286" STUDIES="1" TAU2="0.0" TOTAL_1="291" TOTAL_2="213" WEIGHT="100.0" Z="2.054503986337416">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="-0.0041414376503259714" CI_START="-0.17585856234967395" EFFECT_SIZE="-0.08999999999999997" ESTIMABLE="YES" MEAN_1="-0.86" MEAN_2="-0.77" ORDER="34544" SD_1="0.48" SD_2="0.49" SE="0.043806193903008106" STUDY_ID="STD-Bao-2000" TOTAL_1="291" TOTAL_2="213" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="8.386592844718558E-33" CI_END="0.09850653275521717" CI_START="-0.19850653275521726" DF="0" EFFECT_SIZE="-0.05000000000000005" ESTIMABLE="YES" I2="100.0" ID="CMP-012.28.02" NO="2" P_CHI2="0.0" P_Z="0.5093234609926458" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="89" WEIGHT="100.0" Z="0.6598915038204609">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="0.09850653275521717" CI_START="-0.19850653275521726" EFFECT_SIZE="-0.050000000000000044" ESTIMABLE="YES" MEAN_1="-1.07" MEAN_2="-1.02" ORDER="34545" SD_1="0.42" SD_2="0.6" SE="0.07577003145293372" STUDY_ID="STD-Bao-2000" TOTAL_1="104" TOTAL_2="89" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.3699160409377131" CI_START="0.050083959062286965" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.21000000000000002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.29" MODIFIED="2008-11-24 11:21:06 -0500" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="1.0" P_Q="1.0" P_Z="0.010058743568801692" Q="0.0" RANDOM="NO" SCALE="0.67" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="91" TOTAL_2="91" UNITS="" WEIGHT="100.00000000000001" Z="2.5738033179155915">
<NAME>Change of HAQ-DI in Lef/lef+MTX vs Plc/lef+MTX, at 48 weeks</NAME>
<GROUP_LABEL_1>Plc/lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef/lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Plc/lef+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef/lef+MTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.3699160409377131" CI_START="0.050083959062286965" EFFECT_SIZE="0.21000000000000002" ESTIMABLE="YES" MEAN_1="-0.33" MEAN_2="-0.54" ORDER="34546" SD_1="0.53" SD_2="0.57" SE="0.08159131606453505" STUDY_ID="STD-Kremer-2004" TOTAL_1="91" TOTAL_2="91" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.3442704939064014" CI_START="-5.144270493906403" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.9000000000000004" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.30" MODIFIED="2008-11-24 11:22:23 -0500" MODIFIED_BY="[Empty name]" NO="30" P_CHI2="1.0" P_Q="1.0" P_Z="0.25103106085873006" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="80" TOTAL_2="81" UNITS="" WEIGHT="100.0" Z="1.1478486697150045">
<NAME>Change of SF-36 physical component scores in Lef/lef+MTX vs Plc/lef+MTX, at 48 weeks</NAME>
<GROUP_LABEL_1>Plc/lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef/lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef/lef+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Plc/lef+MTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.3442704939064014" CI_START="-5.144270493906403" EFFECT_SIZE="-1.9000000000000004" ESTIMABLE="YES" MEAN_1="6.6" MEAN_2="8.5" ORDER="34547" SD_1="10.06" SD_2="10.93" SE="1.6552704638946396" STUDY_ID="STD-Kremer-2004" TOTAL_1="80" TOTAL_2="81" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.22963899588559356" CI_START="-5.629638995885594" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.7" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.31" MODIFIED="2008-11-24 11:23:28 -0500" MODIFIED_BY="[Empty name]" NO="31" P_CHI2="1.0" P_Q="1.0" P_Z="0.07086638481362371" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="80" TOTAL_2="81" UNITS="" WEIGHT="100.0" Z="1.806332713924867">
<NAME>Change of SF-36 mental component scores in Lef/lef+MTX vs Plc/lef+MTX, at 48 weeks</NAME>
<GROUP_LABEL_1>Plc/lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef/lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef/lef+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Plc/lef+MTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.22963899588559356" CI_START="-5.629638995885594" EFFECT_SIZE="-2.7" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="4.2" ORDER="34548" SD_1="10.33" SD_2="8.54" SE="1.4947412396320607" STUDY_ID="STD-Kremer-2004" TOTAL_1="80" TOTAL_2="81" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.132961539732778E-31" CI_END="0.6418603232806397" CI_START="0.3381396767193603" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.49" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-012.32" MODIFIED="2008-12-27 09:41:31 -0500" MODIFIED_BY="[Empty name]" NO="32" P_CHI2="0.0" P_Q="1.0" P_Z="2.546857865230449E-10" Q="0.0" RANDOM="NO" SCALE="1.12" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="6.324116343739296">
<NAME>Changes of HAQ score, leflunomide vs. anti-TNF, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef</GROUP_LABEL_1>
<GROUP_LABEL_2>Anti-TNF+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours anti-TNF+MTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6418603232806397" CI_START="0.33813967671936024" EFFECT_SIZE="0.48999999999999994" ESTIMABLE="YES" MEAN_1="-0.45" MEAN_2="-0.94" MODIFIED="2008-11-12 10:33:12 -0500" MODIFIED_BY="[Empty name]" ORDER="424" SD_1="0.29" SD_2="0.24" SE="0.07748118051071068" STUDY_ID="STD-Wislowska-2007" TOTAL_1="30" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2009-08-04 00:40:15 -0400" MODIFIED_BY="[Empty name]" NO="13">
<NAME>Response rate in Chinese and Indian leflunomide studies</NAME>
<DICH_OUTCOME CHI2="9.277102728466335" CI_END="1.3686764733946377" CI_START="0.8754313891228338" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0946151590233022" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="102" I2="56.88309036692893" I2_Q="0.0" ID="CMP-013.01" LOG_CI_END="0.13630080209712092" LOG_CI_START="-0.057777885551963955" LOG_EFFECT_SIZE="0.03926145827257852" METHOD="MH" MODIFIED="2008-11-21 05:40:17 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.05453447549801471" P_Q="0.0" P_Z="0.4277847672005243" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.03395889500011981" TOTALS="YES" TOTAL_1="196" TOTAL_2="165" WEIGHT="100.0" Z="0.7929880928905679">
<NAME>Response rate, Lef vs. MTX, at 3 months</NAME>
<GROUP_LABEL_1>Leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5346505919231386" CI_START="0.8510878344906068" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="21" LOG_CI_END="0.18600951123137516" LOG_CI_START="-0.07002561727600165" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="34549" O_E="0.0" SE="0.15039630187955955" STUDY_ID="STD-Bao-2000" TOTAL_1="30" TOTAL_2="30" VAR="0.022619047619047608" WEIGHT="22.971203375980735"/>
<DICH_DATA CI_END="2.6616533007746925" CI_START="1.040243046821474" EFFECT_SIZE="1.6639610389610389" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="11" LOG_CI_END="0.4251514848853197" LOG_CI_START="0.017134821569375496" LOG_EFFECT_SIZE="0.22114315322734762" ORDER="34553" O_E="0.0" SE="0.23967100774684258" STUDY_ID="STD-Hu-2001" TOTAL_1="56" TOTAL_2="25" VAR="0.05744219195438708" WEIGHT="14.219343224510503"/>
<DICH_DATA CI_END="1.4865878292617878" CI_START="0.8686485175186952" EFFECT_SIZE="1.1363636363636365" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="22" LOG_CI_END="0.17219057289980882" LOG_CI_START="-0.061155917200145966" LOG_EFFECT_SIZE="0.05551732784983142" ORDER="34550" O_E="0.0" SE="0.13706888336846837" STUDY_ID="STD-Jiang-2001" TOTAL_1="30" TOTAL_2="30" VAR="0.018787878787878784" WEIGHT="24.639676195611674"/>
<DICH_DATA CI_END="1.0479287514533984" CI_START="0.7075980544007315" EFFECT_SIZE="0.8611111111111112" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="36" LOG_CI_END="0.020331756023176186" LOG_CI_START="-0.15021336988920528" LOG_EFFECT_SIZE="-0.06494080693301456" ORDER="34551" O_E="0.0" SE="0.1001790511729214" STUDY_ID="STD-Lao-2001" TOTAL_1="40" TOTAL_2="40" VAR="0.010035842293906805" WEIGHT="29.541338497228047"/>
<DICH_DATA CI_END="1.9531728413643763" CI_START="0.5119874589805664" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.2907406768410486" LOG_CI_START="-0.29074067684104865" LOG_EFFECT_SIZE="0.0" ORDER="34552" O_E="0.0" SE="0.3415650255319866" STUDY_ID="STD-Shuai-2002" TOTAL_1="40" TOTAL_2="40" VAR="0.11666666666666667" WEIGHT="8.628438706669026"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4908729962112257" CI_END="1.184138183740286" CI_START="0.9455478175252471" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.058139534883721" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="86" I2="0.0" I2_Q="0.0" ID="CMP-013.02" LOG_CI_END="0.07340238560832371" LOG_CI_START="-0.02431650345327188" LOG_EFFECT_SIZE="0.02454294107752592" METHOD="MH" MODIFIED="2008-12-31 10:14:54 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.47452722490292765" P_Q="0.0" P_Z="0.3248581025151158" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="104" TOTAL_2="104" WEIGHT="100.00000000000001" Z="0.9845236893006082">
<NAME>Response rate, Lef vs. MTX, at 6 months</NAME>
<GROUP_LABEL_1>Leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5809990301656551" CI_START="0.8964164639254756" EFFECT_SIZE="1.1904761904761905" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="21" LOG_CI_END="0.19893160352244715" LOG_CI_START="-0.04749017564621051" LOG_EFFECT_SIZE="0.07572071393811834" ORDER="34554" O_E="0.0" SE="0.1447493728911492" STUDY_ID="STD-Bao-2000" TOTAL_1="30" TOTAL_2="30" VAR="0.02095238095238096" WEIGHT="24.41860465116279"/>
<DICH_DATA CI_END="1.1329147728625442" CI_START="0.8826789304488392" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="37" LOG_CI_END="0.0541972399007259" LOG_CI_START="-0.054197239900725884" LOG_EFFECT_SIZE="0.0" ORDER="34555" O_E="0.0" SE="0.06367145399670134" STUDY_ID="STD-Lao-2001" TOTAL_1="40" TOTAL_2="40" VAR="0.004054054054054054" WEIGHT="43.02325581395349"/>
<DICH_DATA CI_END="1.276491089044688" CI_START="0.8403537563552074" EFFECT_SIZE="1.0357142857142858" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="28" LOG_CI_END="0.10601778741897791" LOG_CI_START="-0.07553785430550415" LOG_EFFECT_SIZE="0.015239966556736905" ORDER="34556" O_E="0.0" SE="0.1066466826638816" STUDY_ID="STD-Shuai-2002" TOTAL_1="34" TOTAL_2="34" VAR="0.011373514923210662" WEIGHT="32.55813953488372"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0403624508176834" CI_START="0.8980636569783099" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9665980070144186" ESTIMABLE="YES" EVENTS_1="179" EVENTS_2="253" I2="0.0" I2_Q="0.0" ID="CMP-013.03" LOG_CI_END="0.017184669074620188" LOG_CI_START="-0.04669287837213056" LOG_EFFECT_SIZE="-0.01475410464875517" METHOD="MH" MODIFIED="2009-03-31 21:22:53 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.3652510718324977" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="213" TOTAL_2="291" WEIGHT="100.0" Z="0.9054046340711869">
<NAME>Overall effective rate, Lef vs. MTX, at 12 weeks</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0403624508176834" CI_START="0.8980636569783099" EFFECT_SIZE="0.9665980070144186" ESTIMABLE="YES" EVENTS_1="179" EVENTS_2="253" LOG_CI_END="0.017184669074620188" LOG_CI_START="-0.04669287837213056" LOG_EFFECT_SIZE="-0.01475410464875517" MODIFIED="2008-11-21 05:39:41 -0500" MODIFIED_BY="[Empty name]" ORDER="455" O_E="0.0" SE="0.03752198756918084" STUDY_ID="STD-Bao-2003" TOTAL_1="213" TOTAL_2="291" VAR="0.0014078995511417614" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0042334775355644" CI_START="0.8079285284276837" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.900749063670412" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="96" I2="0.0" I2_Q="0.0" ID="CMP-013.04" LOG_CI_END="0.001834695097101063" LOG_CI_START="-0.09262705640655039" LOG_EFFECT_SIZE="-0.04539618065472466" METHOD="MH" MODIFIED="2009-03-31 21:23:01 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.05958815053283175" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="89" TOTAL_2="104" WEIGHT="100.0" Z="1.883828696856101">
<NAME>Overall effective rate, Lef vs. MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0042334775355644" CI_START="0.8079285284276838" EFFECT_SIZE="0.900749063670412" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="96" LOG_CI_END="0.001834695097101063" LOG_CI_START="-0.09262705640655032" LOG_EFFECT_SIZE="-0.04539618065472466" MODIFIED="2008-11-21 05:44:20 -0500" MODIFIED_BY="[Empty name]" ORDER="456" O_E="0.0" SE="0.055487300426456033" STUDY_ID="STD-Bao-2003" TOTAL_1="89" TOTAL_2="104" VAR="0.0030788405086157877" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.5506207483366175E-30" CI_END="1.0104789570473185" CI_START="0.7570884653090311" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8746553394440719" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="189" I2="100.0" I2_Q="0.0" ID="CMP-013.05" LOG_CI_END="0.0045272738796367056" LOG_CI_START="-0.1208533704988856" LOG_EFFECT_SIZE="-0.05816304830962445" METHOD="MH" MODIFIED="2009-03-31 21:23:10 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.06899961242258726" Q="0.0" RANDOM="NO" SCALE="2.58" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="213" TOTAL_2="291" WEIGHT="100.0" Z="1.818422300873978">
<NAME>Remarkable improvement rate, Lef vs. MTX, at 12 weeks</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0104789570473183" CI_START="0.7570884653090311" EFFECT_SIZE="0.8746553394440718" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="189" LOG_CI_END="0.00452727387963661" LOG_CI_START="-0.1208533704988856" LOG_EFFECT_SIZE="-0.058163048309624515" MODIFIED="2008-11-21 05:46:24 -0500" MODIFIED_BY="[Empty name]" ORDER="457" O_E="0.0" SE="0.07364921115214328" STUDY_ID="STD-Bao-2003" TOTAL_1="213" TOTAL_2="291" VAR="0.005424206303332985" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.272840518579007E-30" CI_END="1.0996184425958415" CI_START="0.8091668286849125" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9432787329091649" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="83" I2="100.0" I2_Q="0.0" ID="CMP-013.06" LOG_CI_END="0.04124201513872669" LOG_CI_START="-0.09196192918148637" LOG_EFFECT_SIZE="-0.025359957021379845" METHOD="MH" MODIFIED="2009-03-31 21:23:19 -0400" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.45549029263042096" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="89" TOTAL_2="104" WEIGHT="100.0" Z="0.7462932522764006">
<NAME>Remarkable improvement rate, Lef vs. MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0996184425958413" CI_START="0.8091668286849125" EFFECT_SIZE="0.9432787329091648" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="83" LOG_CI_END="0.0412420151387266" LOG_CI_START="-0.09196192918148637" LOG_EFFECT_SIZE="-0.025359957021379897" MODIFIED="2008-11-21 05:47:26 -0500" MODIFIED_BY="[Empty name]" ORDER="458" O_E="0.0" SE="0.07824465626385167" STUDY_ID="STD-Bao-2003" TOTAL_1="89" TOTAL_2="104" VAR="0.006122226233848303" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.862064186810539" CI_START="0.6245624096826253" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7337662337662337" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="154" I2="0.0" I2_Q="0.0" ID="CMP-013.07" LOG_CI_END="-0.06446039665809476" LOG_CI_START="-0.20442415804799202" LOG_EFFECT_SIZE="-0.13444227735304337" METHOD="MH" MODIFIED="2008-12-31 12:47:52 -0500" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="1.6635640314680488E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="233" TOTAL_2="233" WEIGHT="100.0" Z="3.7652892290808335">
<NAME>Significant improvement rate, Lef+MTX vs. MTX, at 3 years</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.862064186810539" CI_START="0.6245624096826253" EFFECT_SIZE="0.7337662337662337" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="154" LOG_CI_END="-0.06446039665809476" LOG_CI_START="-0.20442415804799202" LOG_EFFECT_SIZE="-0.13444227735304337" MODIFIED="2008-11-21 09:44:46 -0500" MODIFIED_BY="[Empty name]" ORDER="472" O_E="0.0" SE="0.08221540627221838" STUDY_ID="STD-Amit-2006" TOTAL_1="233" TOTAL_2="233" VAR="0.006759373028505924" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9141141817075217" CI_START="0.5222054109358083" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6909090909090909" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="55" I2="0.0" I2_Q="0.0" ID="CMP-013.08" LOG_CI_END="-0.03899955329424174" LOG_CI_START="-0.28215863246062556" LOG_EFFECT_SIZE="-0.1605790928774337" METHOD="MH" MODIFIED="2008-12-31 12:48:45 -0500" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.00963475333550986" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="83" TOTAL_2="83" WEIGHT="100.0" Z="2.588669440506689">
<NAME>Significant improvement rate, Lef+MTX vs MTX, at 2 years</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9141141817075217" CI_START="0.5222054109358083" EFFECT_SIZE="0.6909090909090909" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="55" LOG_CI_END="-0.03899955329424174" LOG_CI_START="-0.28215863246062556" LOG_EFFECT_SIZE="-0.1605790928774337" MODIFIED="2008-12-02 11:22:58 -0500" MODIFIED_BY="[Empty name]" ORDER="475" O_E="0.0" SE="0.1428328467591881" STUDY_ID="STD-Amit-2004" TOTAL_1="83" TOTAL_2="83" VAR="0.02040122211333371" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.6830252461503579" CI_START="0.2689116843381249" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-013.09" LOG_CI_END="-0.16556324352028987" LOG_CI_START="-0.570390327068899" LOG_EFFECT_SIZE="-0.36797678529459443" METHOD="MH" MODIFIED="2008-12-31 12:57:54 -0500" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="3.664902488849272E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="3.563107685395923">
<NAME>Remarkable improvement rate, Lef+MTX vs. MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6830252461503579" CI_START="0.2689116843381249" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="28" LOG_CI_END="-0.16556324352028987" LOG_CI_START="-0.570390327068899" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2008-12-04 11:42:59 -0500" MODIFIED_BY="[Empty name]" ORDER="479" O_E="0.0" SE="0.23779743280283544" STUDY_ID="STD-Lao-2002" TOTAL_1="32" TOTAL_2="32" VAR="0.05654761904761904" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9147094686753614" CI_START="0.157939533171769" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.38009049773755654" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-013.10" LOG_CI_END="-0.0387168252637308" LOG_CI_START="-0.8015091499827274" LOG_EFFECT_SIZE="-0.420112987623229" METHOD="MH" MODIFIED="2009-03-31 21:23:26 -0400" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="0.030855860794039566" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="78" TOTAL_2="84" WEIGHT="99.99999999999999" Z="2.1589266134327807">
<NAME>Remission rate, Lef+MTX vs. MTX+CQ+SSZ, at 12 weeks</NAME>
<GROUP_LABEL_1>MTX+CQ+SSZ</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MTX+CQ+SSZ</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9147094686753613" CI_START="0.157939533171769" EFFECT_SIZE="0.38009049773755654" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" LOG_CI_END="-0.038716825263730846" LOG_CI_START="-0.8015091499827274" LOG_EFFECT_SIZE="-0.420112987623229" MODIFIED="2008-12-04 12:18:45 -0500" MODIFIED_BY="[Empty name]" ORDER="490" O_E="0.0" SE="0.44806798742284254" STUDY_ID="STD-Gao-2004" TOTAL_1="78" TOTAL_2="84" VAR="0.2007649213531566" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" MODIFIED="2009-03-31 21:20:30 -0400" MODIFIED_BY="[Empty name]" NO="14">
<NAME>DAS28 score</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2356636679055368" CI_START="0.46941135769020775" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7616" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-014.01" LOG_CI_END="0.09190027734686519" LOG_CI_START="-0.3284464065940293" LOG_EFFECT_SIZE="-0.11827306462358204" METHOD="MH" MODIFIED="2009-03-31 21:18:52 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.2700483603865548" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="56" WEIGHT="100.00000000000001" Z="1.1029512345861372">
<NAME>DAS28 response rate, Lef+SSZ vs. SSZ, at 24 weeks</NAME>
<GROUP_LABEL_1>Plc+SSZ</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef+SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2356636679055368" CI_START="0.4694113576902078" EFFECT_SIZE="0.7616" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="25" LOG_CI_END="0.09190027734686519" LOG_CI_START="-0.32844640659402924" LOG_EFFECT_SIZE="-0.11827306462358204" ORDER="34557" O_E="0.0" SE="0.2469137228965248" STUDY_ID="STD-Dougados-2005" TOTAL_1="50" TOTAL_2="56" VAR="0.06096638655462184" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.6140937335386961" CI_START="-0.41409373353869616" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.02" MODIFIED="2008-11-17 08:00:02 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.7030204037480522" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="56" UNITS="" WEIGHT="100.0" Z="0.3812464258315116">
<NAME>Mean DAS28 score change, Lef+SSZ vs. SSZ, at 24 weeks</NAME>
<GROUP_LABEL_1>Plc+SSZ</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef+SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6140937335386961" CI_START="-0.41409373353869616" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="-0.6" MEAN_2="-0.7" ORDER="34558" SD_1="1.3" SD_2="1.4" SE="0.26229754097208" STUDY_ID="STD-Dougados-2005" TOTAL_1="50" TOTAL_2="56" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0449197811816213" CI_START="0.36056703432821796" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6138107416879796" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-014.03" LOG_CI_END="0.0190829508036114" LOG_CI_START="-0.44301398217213284" LOG_EFFECT_SIZE="-0.21196551568426075" METHOD="MH" MODIFIED="2009-03-31 21:19:01 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.07216354243570276" Q="0.0" RANDOM="NO" SCALE="22.4" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="24" WEIGHT="100.0" Z="1.7980849776703367">
<NAME>DAS28 responders for 24-week completers, Lef+SSZ vs. SSZ</NAME>
<GROUP_LABEL_1>Plc+SSZ</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef+SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0449197811816213" CI_START="0.36056703432821796" EFFECT_SIZE="0.6138107416879796" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="17" LOG_CI_END="0.0190829508036114" LOG_CI_START="-0.44301398217213284" LOG_EFFECT_SIZE="-0.21196551568426075" MODIFIED="2008-11-17 08:18:16 -0500" MODIFIED_BY="[Empty name]" ORDER="34559" O_E="0.0" SE="0.2714380258466614" STUDY_ID="STD-Dougados-2005" TOTAL_1="23" TOTAL_2="24" VAR="0.07367860187553282" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.3512440481752355" CI_START="0.14875595182476448" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.25" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.04" MODIFIED="2008-11-17 10:39:02 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="1.3003413275023578E-6" Q="0.0" RANDOM="NO" SCALE="0.649833603361485" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="33" UNITS="" WEIGHT="100.0" Z="4.839701740164774">
<NAME>Mean DAS28 score change, Lef vs. CsA, at 12 months</NAME>
<GROUP_LABEL_1>Lef</GROUP_LABEL_1>
<GROUP_LABEL_2>CsA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.3512440481752355" CI_START="0.14875595182476448" EFFECT_SIZE="0.25" ESTIMABLE="YES" MEAN_1="-2.28" MEAN_2="-2.53" ORDER="451" SD_1="0.22" SD_2="0.17" SE="0.05165607581253311" STUDY_ID="STD-Karanikolas-2006" TOTAL_1="27" TOTAL_2="33" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.9029958861670315" CI_START="0.23700411383296816" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5699999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.05" MODIFIED="2008-12-31 10:57:45 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="7.938370563479191E-4" Q="0.0" RANDOM="NO" SCALE="1.494348361683669" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="21" UNITS="" WEIGHT="100.0" Z="3.354934753240315">
<NAME>Mean DAS28 score change, Lef vs. MTX, at 16 weeks</NAME>
<GROUP_LABEL_1>Lef</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9029958861670315" CI_START="0.23700411383296816" EFFECT_SIZE="0.5699999999999998" ESTIMABLE="YES" MEAN_1="-2.21" MEAN_2="-2.78" MODIFIED="2008-12-31 10:57:45 -0500" MODIFIED_BY="[Empty name]" ORDER="407" SD_1="0.459" SD_2="0.611" SE="0.16989898222296979" STUDY_ID="STD-Fiehn-2007" TOTAL_1="19" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.4228063517501517" CI_START="0.6387858762794135" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.244047619047619" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-014.06" LOG_CI_END="0.3843187035608635" LOG_CI_START="-0.19464469479048124" LOG_EFFECT_SIZE="0.09483700438519115" METHOD="MH" MODIFIED="2008-12-31 11:05:59 -0500" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.5208062099527586" Q="0.0" RANDOM="NO" SCALE="166.81" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="21" TOTAL_2="19" WEIGHT="100.0" Z="0.64210315721493">
<NAME>EULAR remission (DAS28 &lt;3.2), Lef vs MTX, at 16 weeks</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.4228063517501517" CI_START="0.6387858762794135" EFFECT_SIZE="1.244047619047619" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.3843187035608635" LOG_CI_START="-0.19464469479048124" LOG_EFFECT_SIZE="0.09483700438519115" MODIFIED="2008-11-10 09:06:08 -0500" MODIFIED_BY="[Empty name]" ORDER="408" O_E="0.0" SE="0.3400859661066226" STUDY_ID="STD-Fiehn-2007" TOTAL_1="21" TOTAL_2="19" VAR="0.11565846434267488" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="7.807824098867174E-33" CI_END="0.2078245998028561" CI_START="-0.40782459980285585" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.09999999999999985" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-014.07" MODIFIED="2008-11-12 10:36:56 -0500" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="1.0" P_Z="0.5243108046551334" Q="0.0" RANDOM="NO" SCALE="1.283540321247617" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.6367145399670124">
<NAME>Mean DAS28 score change, Lef vs. MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.2078245998028561" CI_START="-0.40782459980285585" EFFECT_SIZE="-0.09999999999999987" ESTIMABLE="YES" MEAN_1="-1.9" MEAN_2="-1.8" MODIFIED="2008-11-12 10:36:48 -0500" MODIFIED_BY="[Empty name]" ORDER="425" SD_1="0.7" SD_2="0.5" SE="0.15705625319186328" STUDY_ID="STD-Wislowska-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.1735947052870976" CI_START="0.4264052947129028" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.8000000000000003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.08" MODIFIED="2009-01-01 03:12:58 -0500" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="2.704924371076175E-5" Q="0.0" RANDOM="NO" SCALE="3.61" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="4.196984500696016">
<NAME>Mean DAS28 score change, Lef vs. anti-TNF+MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef</GROUP_LABEL_1>
<GROUP_LABEL_2>Anti-TNF</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.1735947052870976" CI_START="0.4264052947129028" EFFECT_SIZE="0.8000000000000003" ESTIMABLE="YES" MEAN_1="-1.9" MEAN_2="-2.7" MODIFIED="2008-11-12 10:39:14 -0500" MODIFIED_BY="[Empty name]" ORDER="426" SD_1="0.7" SD_2="0.6" SE="0.19061304607327728" STUDY_ID="STD-Wislowska-2007" TOTAL_1="30" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.5639184979939795" CI_START="0.21910996010107084" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-014.09" LOG_CI_END="0.659337880227438" LOG_CI_START="-0.659337880227438" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2009-03-31 21:19:19 -0400" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.0">
<NAME>DAS28 remission, Lef vs. MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.5639184979939795" CI_START="0.21910996010107084" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.659337880227438" LOG_CI_START="-0.659337880227438" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-17 07:37:18 -0500" MODIFIED_BY="[Empty name]" ORDER="435" O_E="0.0" SE="0.7745966692414834" STUDY_ID="STD-Wislowska-2007" TOTAL_1="30" TOTAL_2="30" VAR="0.6" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.633535878489302" CI_START="0.27521401561494013" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-014.10" LOG_CI_END="0.5603294528884348" LOG_CI_START="-0.5603294528884348" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2009-03-31 21:19:28 -0400" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.0">
<NAME>DAS28 low disease activity, Lef vs. MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.633535878489302" CI_START="0.27521401561494013" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5603294528884348" LOG_CI_START="-0.5603294528884348" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-17 07:39:30 -0500" MODIFIED_BY="[Empty name]" ORDER="436" O_E="0.0" SE="0.6582805886043833" STUDY_ID="STD-Wislowska-2007" TOTAL_1="30" TOTAL_2="30" VAR="0.43333333333333335" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4405402866425228" CI_START="0.761870861308714" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0476190476190477" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-014.11" LOG_CI_END="0.15852540841433976" LOG_CI_START="-0.11811863623776578" LOG_EFFECT_SIZE="0.02020338608828699" METHOD="MH" MODIFIED="2009-03-31 21:19:36 -0400" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="0.77466876618359" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.2862733528104429">
<NAME>DAS28 moderate disease activity, Lef vs. MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4405402866425228" CI_START="0.761870861308714" EFFECT_SIZE="1.0476190476190477" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="21" LOG_CI_END="0.15852540841433976" LOG_CI_START="-0.11811863623776578" LOG_EFFECT_SIZE="0.02020338608828699" MODIFIED="2008-11-17 07:40:37 -0500" MODIFIED_BY="[Empty name]" ORDER="437" O_E="0.0" SE="0.1625020812387534" STUDY_ID="STD-Wislowska-2007" TOTAL_1="30" TOTAL_2="30" VAR="0.026406926406926406" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.224499169520389" CI_START="0.04785147664650698" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-014.12" LOG_CI_END="0.7180446644790355" LOG_CI_START="-1.320104655806998" LOG_EFFECT_SIZE="-0.3010299956639812" METHOD="MH" MODIFIED="2009-03-31 21:19:44 -0400" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="0.0" P_Z="0.5626131970048236" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.5789644005914643">
<NAME>DAS28 high disease activity, Lef vs. MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.224499169520386" CI_START="0.047851476646507" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7180446644790353" LOG_CI_START="-1.3201046558069978" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2008-11-17 07:45:19 -0500" MODIFIED_BY="[Empty name]" ORDER="438" O_E="0.0" SE="1.1972189997378646" STUDY_ID="STD-Wislowska-2007" TOTAL_1="30" TOTAL_2="30" VAR="1.4333333333333331" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.393693964381482" CI_START="0.3756955306994712" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-014.13" LOG_CI_END="0.8688614705363834" LOG_CI_START="-0.4251639713036707" LOG_EFFECT_SIZE="0.22184874961635637" METHOD="MH" MODIFIED="2009-01-01 03:18:56 -0500" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="0.0" P_Z="0.5015610598098114" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="30" WEIGHT="100.0" Z="0.6720355646872164">
<NAME>DAS28 remission, Lef vs. anti-TNF+MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>anti-TNF+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours anti-TNF+MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.393693964381482" CI_START="0.3756955306994712" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.8688614705363834" LOG_CI_START="-0.4251639713036707" LOG_EFFECT_SIZE="0.22184874961635637" MODIFIED="2008-11-17 07:48:35 -0500" MODIFIED_BY="[Empty name]" ORDER="439" O_E="0.0" SE="0.7601169500660919" STUDY_ID="STD-Wislowska-2007" TOTAL_1="18" TOTAL_2="30" VAR="0.5777777777777777" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.510009735160013" CI_START="1.1683595937900644" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.3333333333333335" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-014.14" LOG_CI_END="0.9781809615140816" LOG_CI_START="0.06757652904659345" LOG_EFFECT_SIZE="0.5228787452803376" METHOD="MH" MODIFIED="2009-01-01 03:22:27 -0500" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="0.0" P_Z="0.024394132799700537" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="30" WEIGHT="100.0" Z="2.2508643105414365">
<NAME>DAS28 low disease activity, Lef vs. anti-TNF+MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>Anti-TNF+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours anti-TNF+MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.510009735160013" CI_START="1.1683595937900644" EFFECT_SIZE="3.3333333333333335" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.9781809615140816" LOG_CI_START="0.06757652904659345" LOG_EFFECT_SIZE="0.5228787452803376" MODIFIED="2008-11-17 07:50:51 -0500" MODIFIED_BY="[Empty name]" ORDER="440" O_E="0.0" SE="0.5348935511960404" STUDY_ID="STD-Wislowska-2007" TOTAL_1="18" TOTAL_2="30" VAR="0.2861111111111111" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0375975669357183" CI_START="0.29745826816088045" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-014.15" LOG_CI_END="0.01602894469935581" LOG_CI_START="-0.526573954905968" LOG_EFFECT_SIZE="-0.255272505103306" METHOD="MH" MODIFIED="2009-01-01 03:26:43 -0500" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="1.0" P_Q="0.0" P_Z="0.06515894809286303" Q="0.0" RANDOM="NO" SCALE="15.43314119213444" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="30" WEIGHT="100.0" Z="1.8441660249501848">
<NAME>DAS28 moderate disease activity, Lef vs. anti-TNF+MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>Anti-TNF+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours anti-TNF+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0375975669357183" CI_START="0.29745826816088045" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="21" LOG_CI_END="0.01602894469935581" LOG_CI_START="-0.526573954905968" LOG_EFFECT_SIZE="-0.255272505103306" MODIFIED="2008-11-17 07:52:40 -0500" MODIFIED_BY="[Empty name]" ORDER="441" O_E="0.0" SE="0.3187276291558383" STUDY_ID="STD-Wislowska-2007" TOTAL_1="18" TOTAL_2="30" VAR="0.10158730158730159" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.438469828951918" CI_START="0.0165384007829027" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3263157894736842" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-014.16" LOG_CI_END="0.8087826649057157" LOG_CI_START="-1.7815064878148659" LOG_EFFECT_SIZE="-0.4863619114545751" METHOD="MH" MODIFIED="2009-01-01 03:27:16 -0500" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Q="0.0" P_Z="0.46171875822559294" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="30" WEIGHT="100.0" Z="0.73601962846644">
<NAME>DAS28 high disease activity, Lef vs. anti-TNF+MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>Anti-TNF+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours anti-TNF+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.438469828951918" CI_START="0.0165384007829027" EFFECT_SIZE="0.3263157894736842" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.8087826649057157" LOG_CI_START="-1.7815064878148659" LOG_EFFECT_SIZE="-0.4863619114545751" MODIFIED="2008-11-17 07:54:22 -0500" MODIFIED_BY="[Empty name]" ORDER="442" O_E="0.0" SE="1.5215486704461683" STUDY_ID="STD-Wislowska-2007" TOTAL_1="18" TOTAL_2="30" VAR="2.3151103565365023" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="9.187821963249453E-31" CI_END="0.5735068416795555" CI_START="0.34649315832044547" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.46000000000000046" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-014.17" MODIFIED="2008-11-17 10:41:58 -0500" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.0" P_Q="1.0" P_Z="1.973687259280478E-15" Q="0.0" RANDOM="NO" SCALE="1.201416250163911" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="31" UNITS="" WEIGHT="100.0" Z="7.9429875727995025">
<NAME>Mean DAS28 score change, Lef vs. Lef+CsA, at 12 months</NAME>
<GROUP_LABEL_1>Lef</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef+CsA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef+CsA</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5735068416795555" CI_START="0.3464931583204454" EFFECT_SIZE="0.4600000000000004" ESTIMABLE="YES" MEAN_1="-2.28" MEAN_2="-2.74" MODIFIED="2008-11-17 10:41:43 -0500" MODIFIED_BY="[Empty name]" ORDER="452" SD_1="0.22" SD_2="0.22" SE="0.05791271807792514" STUDY_ID="STD-Karanikolas-2006" TOTAL_1="27" TOTAL_2="31" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="4.117893856345621E-32" CI_END="2.868995091553966" CI_START="0.33599462926464485" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9818181818181819" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="100.0" I2_Q="0.0" ID="CMP-014.18" LOG_CI_END="0.45772980523001694" LOG_CI_START="-0.4736676645725675" LOG_EFFECT_SIZE="-0.007968929671275292" METHOD="MH" MODIFIED="2009-03-31 21:19:57 -0400" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.0" P_Q="0.0" P_Z="0.9732452019752916" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="27" WEIGHT="100.00000000000001" Z="0.0335384530394799">
<NAME>DAS28 &lt;3.2, Lef vs. CsA, at 12 months</NAME>
<GROUP_LABEL_1>CsA</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.868995091553966" CI_START="0.33599462926464485" EFFECT_SIZE="0.9818181818181818" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.45772980523001694" LOG_CI_START="-0.4736676645725675" LOG_EFFECT_SIZE="-0.00796892967127534" MODIFIED="2008-11-17 10:44:26 -0500" MODIFIED_BY="[Empty name]" ORDER="453" O_E="0.0" SE="0.5471074842538707" STUDY_ID="STD-Karanikolas-2006" TOTAL_1="33" TOTAL_2="27" VAR="0.2993265993265994" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.342735124854243E-32" CI_END="4.465592205791685" CI_START="0.6794931310640889" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.741935483870968" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" I2="100.0" I2_Q="0.0" ID="CMP-014.19" LOG_CI_END="0.649879061131161" LOG_CI_START="-0.16781492915376917" LOG_EFFECT_SIZE="0.24103206598869586" METHOD="MH" MODIFIED="2009-01-01 02:15:50 -0500" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.0" P_Q="0.0" P_Z="0.2478942957233229" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="27" WEIGHT="99.99999999999999" Z="1.1554791256139971">
<NAME>DAS28 &lt;3.2, Lef vs. Lef+CsA, at 12 months</NAME>
<GROUP_LABEL_1>Lef+CsA</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.465592205791685" CI_START="0.6794931310640887" EFFECT_SIZE="1.7419354838709677" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.649879061131161" LOG_CI_START="-0.16781492915376933" LOG_EFFECT_SIZE="0.2410320659886958" MODIFIED="2008-11-17 10:45:33 -0500" MODIFIED_BY="[Empty name]" ORDER="454" O_E="0.0" SE="0.48031749754389963" STUDY_ID="STD-Karanikolas-2006" TOTAL_1="31" TOTAL_2="27" VAR="0.230704898446834" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3366244773179845" CI_START="0.1047324587809437" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3741496598639456" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-014.20" LOG_CI_END="0.1260094100023955" LOG_CI_START="-0.9799187005102598" LOG_EFFECT_SIZE="-0.42695464525393223" METHOD="MH" MODIFIED="2009-03-31 21:20:05 -0400" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="1.0" P_Q="0.0" P_Z="0.13019648317415244" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="49" TOTAL_2="11" WEIGHT="100.0" Z="1.5133275296562896">
<NAME>EULAR good response, Lef vs. Lef+MTX, at 3 months</NAME>
<GROUP_LABEL_1>Lef</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3366244773179845" CI_START="0.1047324587809437" EFFECT_SIZE="0.3741496598639456" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.1260094100023955" LOG_CI_START="-0.9799187005102598" LOG_EFFECT_SIZE="-0.42695464525393223" MODIFIED="2008-11-20 09:58:33 -0500" MODIFIED_BY="[Empty name]" ORDER="448" O_E="0.0" SE="0.6496276465475713" STUDY_ID="STD-Antony-2006" TOTAL_1="49" TOTAL_2="11" VAR="0.42201607915893624" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3542815245404607" CI_START="0.47464421696727377" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8017492711370262" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-014.21" LOG_CI_END="0.13170895374760566" LOG_CI_START="-0.3236318061726214" LOG_EFFECT_SIZE="-0.09596142621250786" METHOD="MH" MODIFIED="2009-03-31 21:20:14 -0400" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="1.0" P_Q="0.0" P_Z="0.4087413005921563" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="49" TOTAL_2="11" WEIGHT="100.0" Z="0.8261107102055347">
<NAME>EULAR moderate response, Lef vs. Lef+MTX, at 3 months</NAME>
<GROUP_LABEL_1>Lef</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3542815245404607" CI_START="0.47464421696727377" EFFECT_SIZE="0.8017492711370262" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="7" LOG_CI_END="0.13170895374760566" LOG_CI_START="-0.3236318061726214" LOG_EFFECT_SIZE="-0.09596142621250786" MODIFIED="2008-11-20 09:59:01 -0500" MODIFIED_BY="[Empty name]" ORDER="449" O_E="0.0" SE="0.26746941635025456" STUDY_ID="STD-Antony-2006" TOTAL_1="49" TOTAL_2="11" VAR="0.07153988868274583" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="28.562582620093817" CI_START="0.6369464750502662" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.26530612244898" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-014.22" LOG_CI_END="1.455797473655464" LOG_CI_START="-0.19589706149038313" LOG_EFFECT_SIZE="0.6299502060825404" METHOD="MH" MODIFIED="2009-03-31 21:20:23 -0400" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="1.0" P_Q="0.0" P_Z="0.13490241779444087" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="49" TOTAL_2="11" WEIGHT="100.0" Z="1.4950460750496342">
<NAME>EULAR response-no improvement, Lef vs. Lef+MTX, at 3 months</NAME>
<GROUP_LABEL_1>Lef</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef</GRAPH_LABEL_2>
<DICH_DATA CI_END="28.562582620093817" CI_START="0.6369464750502662" EFFECT_SIZE="4.26530612244898" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="1" LOG_CI_END="1.455797473655464" LOG_CI_START="-0.19589706149038313" LOG_EFFECT_SIZE="0.6299502060825404" MODIFIED="2008-11-20 10:00:56 -0500" MODIFIED_BY="[Empty name]" ORDER="450" O_E="0.0" SE="0.9702135459644806" STUDY_ID="STD-Antony-2006" TOTAL_1="49" TOTAL_2="11" VAR="0.9413143247729713" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.087624523308518" CI_START="0.17984849265363967" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.346938775510204" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-014.23" LOG_CI_END="1.003788908766258" LOG_CI_START="-0.745093197739548" LOG_EFFECT_SIZE="0.12934785551335498" METHOD="MH" MODIFIED="2009-03-31 21:20:30 -0400" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="1.0" P_Q="0.0" P_Z="0.7718781513231163" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="49" TOTAL_2="11" WEIGHT="100.0" Z="0.28991907154929186">
<NAME>DAS28 remission, Lef vs. Lef+MTX, at 3 months</NAME>
<GROUP_LABEL_1>Lef</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.087624523308518" CI_START="0.17984849265363967" EFFECT_SIZE="1.346938775510204" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.003788908766258" LOG_CI_START="-0.745093197739548" LOG_EFFECT_SIZE="0.12934785551335498" MODIFIED="2008-11-20 10:03:50 -0500" MODIFIED_BY="[Empty name]" ORDER="451" O_E="0.0" SE="1.0273020064675575" STUDY_ID="STD-Antony-2006" TOTAL_1="49" TOTAL_2="11" VAR="1.0553494124922698" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0495165611222472" CI_START="0.4737704052502655" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7051452945881098" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-014.24" LOG_CI_END="0.020989296036340713" LOG_CI_START="-0.32443207159537724" LOG_EFFECT_SIZE="-0.1517213877795182" METHOD="MH" MODIFIED="2009-01-01 04:05:32 -0500" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="1.0" P_Q="0.0" P_Z="0.08511079063539108" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="242" TOTAL_2="115" WEIGHT="100.0" Z="1.721772209815">
<NAME>EULAR good response, Lef+ADA vs. ADA, at 12 weeks</NAME>
<GROUP_LABEL_1>ADA</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef+ADA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef+ADA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ADA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0495165611222472" CI_START="0.4737704052502655" EFFECT_SIZE="0.7051452945881098" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="31" LOG_CI_END="0.020989296036340713" LOG_CI_START="-0.32443207159537724" LOG_EFFECT_SIZE="-0.1517213877795182" MODIFIED="2008-11-21 08:43:55 -0500" MODIFIED_BY="[Empty name]" ORDER="470" O_E="0.0" SE="0.20290222121021723" STUDY_ID="STD-Mariette-2004" TOTAL_1="242" TOTAL_2="115" VAR="0.04116931137203992" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9307452489081612" CI_START="0.7319051425046808" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8253588516746412" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="95" I2="0.0" I2_Q="0.0" ID="CMP-014.25" LOG_CI_END="-0.031169172008022918" LOG_CI_START="-0.13554520139549922" LOG_EFFECT_SIZE="-0.08335718670176105" METHOD="MH" MODIFIED="2009-01-01 04:03:24 -0500" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="1.0" P_Q="0.0" P_Z="0.0017448049670539386" Q="0.0" RANDOM="NO" SCALE="2.91509546315063" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="242" TOTAL_2="115" WEIGHT="100.0" Z="3.130547976327519">
<NAME>EULAR moderate response, Lef+ADA vs. ADA, at 12 weeks</NAME>
<GROUP_LABEL_1>ADA</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef+ADA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef+ADA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ADA</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9307452489081612" CI_START="0.7319051425046808" EFFECT_SIZE="0.8253588516746412" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="95" LOG_CI_END="-0.031169172008022918" LOG_CI_START="-0.13554520139549922" LOG_EFFECT_SIZE="-0.08335718670176105" MODIFIED="2008-11-21 08:46:05 -0500" MODIFIED_BY="[Empty name]" ORDER="471" O_E="0.0" SE="0.06131099633188179" STUDY_ID="STD-Mariette-2004" TOTAL_1="242" TOTAL_2="115" VAR="0.0037590382712080223" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2269369755943775" CI_START="0.8940322432816925" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0473400673400672" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="99" I2="0.0" I2_Q="0.0" ID="CMP-014.26" LOG_CI_END="0.08882225477707292" LOG_CI_START="-0.04864681808685204" LOG_EFFECT_SIZE="0.02008771834511044" METHOD="MH" MODIFIED="2008-12-31 11:02:03 -0500" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="1.0" P_Q="0.0" P_Z="0.5667795108454481" Q="0.0" RANDOM="NO" SCALE="4.036926701668557" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="150" TOTAL_2="151" WEIGHT="100.0" Z="0.5728009023087388">
<NAME>EULAR response rate, Lef vs. MTX, at 16 weeks</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2269369755943775" CI_START="0.8940322432816925" EFFECT_SIZE="1.0473400673400672" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="99" LOG_CI_END="0.08882225477707292" LOG_CI_START="-0.04864681808685204" LOG_EFFECT_SIZE="0.02008771834511044" MODIFIED="2008-12-04 11:50:44 -0500" MODIFIED_BY="[Empty name]" ORDER="481" O_E="0.0" SE="0.0807500138831549" STUDY_ID="STD-Lau-2002" TOTAL_1="150" TOTAL_2="151" VAR="0.0065205647421297105" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" MODIFIED="2009-01-03 11:25:47 -0500" MODIFIED_BY="[Empty name]" NO="15">
<NAME>Dynamic enhanced MRI assessment of knee joint, at 4 months</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.5542285776754667" CI_START="-6.834228577675467" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.14" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-015.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.09572947682077992" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="17" UNITS="" WEIGHT="100.0" Z="1.665919360985577">
<NAME>Maximal signal intensity enhancement (ME) (/100), at 4 months</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5542285776754663" CI_START="-6.834228577675466" EFFECT_SIZE="-3.14" ESTIMABLE="YES" MEAN_1="0.59" MEAN_2="3.73" ORDER="34560" SD_1="5.15" SD_2="5.82" SE="1.884845133285647" STUDY_ID="STD-Reece-2002" TOTAL_1="17" TOTAL_2="17" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.031564506025816896" CI_START="-0.2884354939741831" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.16" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-015.02" MODIFIED="2009-01-03 11:25:47 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.014620403501320023" Q="0.0" RANDOM="NO" SCALE="1.0041221991425402" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="17" UNITS="" WEIGHT="100.0" Z="2.4416477705878132">
<NAME>Initial rate of enhancement (IRE) (/100), at 4 months</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.031564506025816896" CI_START="-0.2884354939741831" EFFECT_SIZE="-0.16" ESTIMABLE="YES" MEAN_1="-0.03" MEAN_2="0.13" ORDER="34561" SD_1="0.21" SD_2="0.17" SE="0.06552951737239351" STUDY_ID="STD-Dougados-2005" TOTAL_1="17" TOTAL_2="17" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-016" MODIFIED="2009-03-31 21:22:11 -0400" MODIFIED_BY="[Empty name]" NO="16">
<NAME>Adverse events</NAME>
<DICH_OUTCOME CHI2="1.5849415910729885" CI_END="0.8315674080927852" CI_START="0.5887759524539293" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6997191527530706" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="134" I2="0.0" I2_Q="0.0" ID="CMP-016.01" LOG_CI_END="-0.08010254045989898" LOG_CI_START="-0.23004993632313356" LOG_EFFECT_SIZE="-0.15507623839151627" METHOD="MH" MODIFIED="2009-01-01 04:43:49 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4527249886847573" P_Q="0.0" P_Z="5.0347864133127946E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="416" TOTAL_2="311" WEIGHT="99.99999999999999" Z="4.054006278075593">
<NAME>Total withdrawals in leflunomide vs. placebo</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2170227576034183" CI_START="0.5091992159883543" EFFECT_SIZE="1.0625" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.34577015114374343" LOG_CI_START="-0.29311227369904524" LOG_EFFECT_SIZE="0.026328938722349145" ORDER="34562" O_E="0.0" SE="0.37528269887166155" STUDY_ID="STD-Mladenovic-1995" TOTAL_1="104" TOTAL_2="102" VAR="0.1408371040723982" WEIGHT="7.638131152068941"/>
<DICH_DATA CI_END="0.9005845217155592" CI_START="0.443105699489049" EFFECT_SIZE="0.6317073170731707" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="41" LOG_CI_END="-0.04547552149843356" LOG_CI_START="-0.3534926637785337" LOG_EFFECT_SIZE="-0.19948409263848366" ORDER="34563" O_E="0.0" SE="0.18093079408477533" STUDY_ID="STD-Smolen-1999" TOTAL_1="130" TOTAL_2="91" VAR="0.03273595224814737" WEIGHT="30.407077540711857"/>
<DICH_DATA CI_END="0.8374586522351066" CI_START="0.5658283840812547" EFFECT_SIZE="0.6883733550400217" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="81" LOG_CI_END="-0.07703662614117346" LOG_CI_START="-0.2473152704868894" LOG_EFFECT_SIZE="-0.16217594831403143" ORDER="34564" O_E="0.0" SE="0.10002251858155706" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="118" VAR="0.010004504223397928" WEIGHT="61.954791307219196"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0526681773283" CI_END="4.4669497489174725" CI_START="1.6741828135487558" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.734682888128633" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-016.02" LOG_CI_END="0.6500110668907765" LOG_CI_START="0.22380287933256535" LOG_EFFECT_SIZE="0.4369069731116709" METHOD="MH" MODIFIED="2009-01-01 09:36:43 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5907667948708644" P_Q="0.0" P_Z="5.8612821475878024E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="416" TOTAL_2="311" WEIGHT="100.00000000000001" Z="4.018326990850354">
<NAME>Withdrawals due to adverse events in leflunomide vs. placebo</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="23.73623705036325" CI_START="1.2258777804576517" EFFECT_SIZE="5.394230769230769" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.3754118705665634" LOG_CI_START="0.08844717334819868" LOG_EFFECT_SIZE="0.731929521957381" ORDER="34565" O_E="0.0" SE="0.755969433724062" STUDY_ID="STD-Mladenovic-1995" TOTAL_1="104" TOTAL_2="102" VAR="0.5714897847250789" WEIGHT="9.520356403085861"/>
<DICH_DATA CI_END="5.332808068558648" CI_START="0.9213928286826873" EFFECT_SIZE="2.216666666666667" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="6" LOG_CI_END="0.7269559534061351" LOG_CI_START="-0.03555517223925076" LOG_EFFECT_SIZE="0.3457003905834422" ORDER="34566" O_E="0.0" SE="0.4479028096950458" STUDY_ID="STD-Smolen-1999" TOTAL_1="130" TOTAL_2="91" VAR="0.2006169269327164" WEIGHT="33.278168875039945"/>
<DICH_DATA CI_END="4.983128075255149" CI_START="1.3497059792869996" EFFECT_SIZE="2.5934065934065935" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="10" LOG_CI_END="0.6975020494551781" LOG_CI_START="0.1302391718428478" LOG_EFFECT_SIZE="0.413870610649013" ORDER="34567" O_E="0.0" SE="0.3332130223060138" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="118" VAR="0.11103091823430807" WEIGHT="57.20147472187421"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0655045341866916" CI_START="0.5298699556146274" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7513846153846154" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="50" I2="0.0" I2_Q="0.0" ID="CMP-016.03" LOG_CI_END="0.027555302166663957" LOG_CI_START="-0.2758307049066853" LOG_EFFECT_SIZE="-0.12413770137001068" METHOD="MH" MODIFIED="2009-01-01 09:26:27 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.10872880793960918" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="132" WEIGHT="100.0" Z="1.6039330630696211">
<NAME>Total withdrawals in leflunomide vs.SSZ, at 6 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0655045341866916" CI_START="0.5298699556146274" EFFECT_SIZE="0.7513846153846154" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="50" LOG_CI_END="0.027555302166663957" LOG_CI_START="-0.2758307049066853" LOG_EFFECT_SIZE="-0.12413770137001068" ORDER="34568" O_E="0.0" SE="0.1782104423398409" STUDY_ID="STD-Smolen-1999" TOTAL_1="130" TOTAL_2="132" VAR="0.031758961758961764" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3310669476958843" CI_START="0.44739223581678056" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7716923076923077" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-016.04" LOG_CI_END="0.12419989941434761" LOG_CI_START="-0.34931155705473865" LOG_EFFECT_SIZE="-0.11255582882019555" METHOD="MH" MODIFIED="2009-01-01 09:38:06 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.3514478021516" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="132" WEIGHT="100.0" Z="0.9317847233630395">
<NAME>Withdrawals due to adverse events in leflunomide vs. SSZ, at 6 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3310669476958843" CI_START="0.44739223581678045" EFFECT_SIZE="0.7716923076923077" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="25" LOG_CI_END="0.12419989941434761" LOG_CI_START="-0.34931155705473876" LOG_EFFECT_SIZE="-0.11255582882019555" ORDER="34569" O_E="0.0" SE="0.2781429734494531" STUDY_ID="STD-Smolen-1999" TOTAL_1="130" TOTAL_2="132" VAR="0.07736351367930316" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5864412413969373" CI_END="1.4751468657989601" CI_START="1.0784420528237302" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2612931515586383" ESTIMABLE="YES" EVENTS_1="238" EVENTS_2="188" I2="36.965834352651335" I2_Q="0.0" ID="CMP-016.05" LOG_CI_END="0.16883526087746414" LOG_CI_START="0.032796814422336625" LOG_EFFECT_SIZE="0.10081603764990037" METHOD="MH" MODIFIED="2009-01-01 09:34:00 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.20783536666325464" P_Q="0.0" P_Z="0.003672538008910801" Q="0.0" RANDOM="NO" SCALE="2.1672526666150587" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="683" TOTAL_2="680" WEIGHT="100.0" Z="2.9049994028418435">
<NAME>Total withdrawals in leflunomide vs. MTX, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6808380054192573" CI_START="1.1022969170490422" EFFECT_SIZE="1.3611695527863192" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="111" LOG_CI_END="0.22552585933915095" LOG_CI_START="0.042298592762022955" LOG_EFFECT_SIZE="0.13391222605058692" ORDER="34570" O_E="0.0" SE="0.1076286033770023" STUDY_ID="STD-Emery-1999" TOTAL_1="501" TOTAL_2="498" VAR="0.01158391626488407" WEIGHT="59.115044247787615"/>
<DICH_DATA CI_END="1.404004632735411" CI_START="0.8884784762769566" EFFECT_SIZE="1.1168831168831168" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="77" LOG_CI_END="0.14736854081950276" LOG_CI_START="-0.0513530886773311" LOG_EFFECT_SIZE="0.048007726071085825" ORDER="34571" O_E="0.0" SE="0.11673006885437094" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="182" VAR="0.013625908974746182" WEIGHT="40.88495575221239"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.01625274446452" CI_END="1.828005843191186" CI_START="1.1255412823220534" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.43439744870019" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="93" I2="66.84627964830807" I2_Q="0.0" ID="CMP-016.06" LOG_CI_END="0.26197757961533613" LOG_CI_START="0.05136142857320873" LOG_EFFECT_SIZE="0.15666950409427247" METHOD="MH" MODIFIED="2009-01-01 09:38:31 -0500" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.08243394612372468" P_Q="0.0" P_Z="0.0035467745347199245" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="683" TOTAL_2="680" WEIGHT="99.99999999999999" Z="2.915888301834034">
<NAME>Withdrawals due to adverse events in leflunomide vs. MTX, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6676684767773293" CI_START="0.9560173675128808" EFFECT_SIZE="1.2626638614662566" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="74" LOG_CI_END="0.22210971955330044" LOG_CI_START="-0.0195342180309119" LOG_EFFECT_SIZE="0.10128775076119427" ORDER="34572" O_E="0.0" SE="0.14194284509374872" STUDY_ID="STD-Emery-1999" TOTAL_1="501" TOTAL_2="498" VAR="0.020147771273307948" WEIGHT="79.61859356376638"/>
<DICH_DATA CI_END="3.491772636012711" CI_START="1.269307433788133" EFFECT_SIZE="2.1052631578947367" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="19" LOG_CI_END="0.5430459572157267" LOG_CI_START="0.10356682353454011" LOG_EFFECT_SIZE="0.3233063903751334" ORDER="34573" O_E="0.0" SE="0.25815221858112597" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="182" VAR="0.06664256795835743" WEIGHT="20.381406436233608"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8463852203012783" CI_END="18.44464817552757" CI_START="2.363103394973095" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="6.602015656045772" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-016.07" LOG_CI_END="1.2658703756439162" LOG_CI_START="0.3734827241223808" LOG_EFFECT_SIZE="0.8196765498831484" METHOD="MH" MODIFIED="2009-01-01 10:16:58 -0500" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.654952487999103" P_Q="0.0" P_Z="3.175629924316534E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="416" TOTAL_2="312" WEIGHT="100.0" Z="3.6005350679244597">
<NAME>alopecia, leflunomide vs. placebo</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="56.42488364189793" CI_START="0.8856925748843969" EFFECT_SIZE="7.069306930693069" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.7514706721585944" LOG_CI_START="-0.052716996171530715" LOG_EFFECT_SIZE="0.8493768379935318" ORDER="34574" O_E="0.0" SE="1.059788767250109" STUDY_ID="STD-Mladenovic-1995" TOTAL_1="101" TOTAL_2="102" VAR="1.1231522311895055" WEIGHT="21.760467287482346"/>
<DICH_DATA CI_END="16.763371540671994" CI_START="0.8634483839243499" EFFECT_SIZE="3.8045112781954886" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.22436137075317" LOG_CI_START="-0.06376361900774327" LOG_EFFECT_SIZE="0.5802988758727132" ORDER="34575" O_E="0.0" SE="0.7566509953070957" STUDY_ID="STD-Smolen-1999" TOTAL_1="133" TOTAL_2="92" VAR="0.5725207286992184" WEIGHT="51.70612596653341"/>
<DICH_DATA CI_END="86.25884135894533" CI_START="1.5789290983799305" EFFECT_SIZE="11.67032967032967" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="1" LOG_CI_END="1.9358036203437143" LOG_CI_START="0.1983626285049988" LOG_EFFECT_SIZE="1.0670831244243566" ORDER="34576" O_E="0.0" SE="1.0205814390776777" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="118" VAR="1.0415864737898637" WEIGHT="26.533406745984248"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.929961313250864" CI_START="0.6283491256710014" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-016.08" LOG_CI_END="0.5943882751783862" LOG_CI_START="-0.20179898489044967" LOG_EFFECT_SIZE="0.1962946451439682" METHOD="MH" MODIFIED="2009-01-01 10:17:44 -0500" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.3338280554704707" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="133" WEIGHT="100.0" Z="0.9664320295880781">
<NAME>alopecia, leflunomide vs. SSZ</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.929961313250864" CI_START="0.6283491256710014" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.5943882751783862" LOG_CI_START="-0.20179898489044967" LOG_EFFECT_SIZE="0.1962946451439682" ORDER="34577" O_E="0.0" SE="0.4676843377549342" STUDY_ID="STD-Smolen-1999" TOTAL_1="133" TOTAL_2="133" VAR="0.21872863978127136" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.05595873492522" CI_END="2.237462116745508" CI_START="1.3206454912385164" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7189805863641807" ESTIMABLE="YES" EVENTS_1="135" EVENTS_2="76" I2="29.13790757801263" I2_Q="0.0" ID="CMP-016.09" LOG_CI_END="0.3497556908582678" LOG_CI_START="0.12078625299574425" LOG_EFFECT_SIZE="0.23527097192700602" METHOD="MH" MODIFIED="2009-01-01 10:19:20 -0500" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.21651183612119862" P_Q="0.0" P_Z="5.6298944506264116E-5" Q="0.0" RANDOM="NO" SCALE="470.58" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1221" TOTAL_2="1108" WEIGHT="100.0" Z="4.027809439454801">
<NAME>alopecia, leflunomide vs. MTX</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.04903241503103" CI_START="0.2947559422868078" EFFECT_SIZE="1.2199312714776633" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7032081588959057" LOG_CI_START="-0.530537430757532" LOG_EFFECT_SIZE="0.08633536406918683" MODIFIED="2008-11-21 06:13:11 -0500" MODIFIED_BY="[Empty name]" ORDER="462" O_E="0.0" SE="0.7247082665015928" STUDY_ID="STD-Bao-2003" TOTAL_1="291" TOTAL_2="213" VAR="0.5252020715357437" WEIGHT="4.43731041939837"/>
<DICH_DATA CI_END="2.3434339903749635" CI_START="1.209746943797288" EFFECT_SIZE="1.6837345716729806" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="49" LOG_CI_END="0.36985272486299003" LOG_CI_START="0.0826945336170741" LOG_EFFECT_SIZE="0.22627362924003205" ORDER="34579" O_E="0.0" SE="0.1686781429938226" STUDY_ID="STD-Emery-1999" TOTAL_1="501" TOTAL_2="498" VAR="0.028452315923844465" WEIGHT="62.95125925105923"/>
<DICH_DATA CI_END="1.833696227641365" CI_START="0.004538680214573949" EFFECT_SIZE="0.0912280701754386" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.26332739153788864" LOG_CI_START="-2.343070415613273" LOG_EFFECT_SIZE="-1.0398715120376922" ORDER="34582" O_E="0.0" SE="1.5310109737978166" STUDY_ID="STD-Hu-2001" TOTAL_1="56" TOTAL_2="25" VAR="2.3439946018893387" WEIGHT="4.398178753794435"/>
<DICH_DATA CI_END="4.660501214038062" CI_START="0.2145691963319019" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6684326254422859" LOG_CI_START="-0.6684326254422859" LOG_EFFECT_SIZE="0.0" ORDER="34580" O_E="0.0" SE="0.7852812659593164" STUDY_ID="STD-Lao-2001" TOTAL_1="40" TOTAL_2="40" VAR="0.6166666666666666" WEIGHT="3.842619332262506"/>
<DICH_DATA CI_END="6.90010912337214" CI_START="1.5105648908753067" EFFECT_SIZE="3.228476821192053" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="8" LOG_CI_END="0.8388559590421281" LOG_CI_START="0.17913938644064437" LOG_EFFECT_SIZE="0.5089976727413862" MODIFIED="2008-12-04 11:55:00 -0500" MODIFIED_BY="[Empty name]" ORDER="482" O_E="0.0" SE="0.3875207803958136" STUDY_ID="STD-Lau-2002" TOTAL_1="151" TOTAL_2="150" VAR="0.1501723552385804" WEIGHT="10.281028025189606"/>
<DICH_DATA CI_END="3.3665238830137048" CI_START="0.7953859956033237" EFFECT_SIZE="1.6363636363636365" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" LOG_CI_END="0.5271816998151839" LOG_CI_START="-0.09942205992502198" LOG_EFFECT_SIZE="0.21387981994508104" ORDER="34581" O_E="0.0" SE="0.3680701502100319" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="182" VAR="0.13547563547563546" WEIGHT="14.089604218295856"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5634492073637691" CI_END="7.53993283066231" CI_START="1.857664884682031" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="3.7425483901190324" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-016.10" LOG_CI_END="0.8773674769834814" LOG_CI_START="0.26896737173517477" LOG_EFFECT_SIZE="0.5731674243593281" METHOD="MH" MODIFIED="2009-01-01 10:21:16 -0500" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.45761627296536733" P_Q="0.0" P_Z="2.2169076818522702E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="416" TOTAL_2="312" WEIGHT="100.00000000000003" Z="3.6929234533823108">
<NAME>Elevated liver function tests, leflunomide vs. placebo</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.888995510202671" CI_START="0.9429093523064109" EFFECT_SIZE="2.3564356435643563" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.7700412232116794" LOG_CI_START="-0.02553005666394074" LOG_EFFECT_SIZE="0.3722555832738694" ORDER="34583" O_E="0.0" SE="0.4673225079402882" STUDY_ID="STD-Mladenovic-1995" TOTAL_1="101" TOTAL_2="102" VAR="0.21839032642760073" WEIGHT="58.52944482675903"/>
<DICH_DATA CI_END="92.94668865706635" CI_START="0.2539325993602586" EFFECT_SIZE="4.858208955223881" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.968233922095217" LOG_CI_START="-0.5952815416884483" LOG_EFFECT_SIZE="0.6864761902033844" ORDER="34584" O_E="0.0" SE="1.505821673032726" STUDY_ID="STD-Smolen-1999" TOTAL_1="133" TOTAL_2="92" VAR="2.2674989109750783" WEIGHT="5.7869104773756534"/>
<DICH_DATA CI_END="18.80247208525252" CI_START="1.8108868078176943" EFFECT_SIZE="5.835164835164835" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="3" LOG_CI_END="1.2742149525830082" LOG_CI_START="0.2578913049377425" LOG_EFFECT_SIZE="0.7660531287603755" ORDER="34585" O_E="0.0" SE="0.596993541510022" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="118" VAR="0.35640128860467846" WEIGHT="35.68364469586533"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.4601111460462968" CI_START="0.14633485181292097" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-016.11" LOG_CI_END="0.39095472865792025" LOG_CI_START="-0.834652227890633" LOG_EFFECT_SIZE="-0.22184874961635637" METHOD="MH" MODIFIED="2009-01-01 10:21:51 -0500" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="0.47798237844560243" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="133" WEIGHT="100.0" Z="0.7095513891138349">
<NAME>Elevated liver function tests, leflunomide vs. SSZ</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.4601111460462968" CI_START="0.14633485181292097" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.39095472865792025" LOG_CI_START="-0.834652227890633" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="34586" O_E="0.0" SE="0.7199275931289" STUDY_ID="STD-Smolen-1999" TOTAL_1="133" TOTAL_2="133" VAR="0.5182957393483709" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.246035829104134" CI_END="1.3901732339328647" CI_START="0.3120665682267026" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6586551376509912" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="121" I2="75.37860902144413" I2_Q="0.0" ID="CMP-016.12" LOG_CI_END="0.14306892245072705" LOG_CI_START="-0.505752754924415" LOG_EFFECT_SIZE="-0.18134191623684395" METHOD="MH" MODIFIED="2009-01-01 10:23:04 -0500" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.002706190978766454" P_Q="0.0" P_Z="0.27325508018796363" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.45493263970396425" TOTALS="YES" TOTAL_1="1070" TOTAL_2="958" WEIGHT="99.99999999999999" Z="1.0955972560891833">
<NAME>Elevated liver function tests, leflunomide vs. MTX</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3007210405504148" CI_START="0.2178630940438657" EFFECT_SIZE="0.5323336457357076" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.11418416547781082" LOG_CI_START="-0.6618163329047129" LOG_EFFECT_SIZE="-0.273816083713451" MODIFIED="2008-11-21 06:15:05 -0500" MODIFIED_BY="[Empty name]" ORDER="463" O_E="0.0" SE="0.45582653401431256" STUDY_ID="STD-Bao-2003" TOTAL_1="291" TOTAL_2="213" VAR="0.20777782911150125" WEIGHT="21.91805819114629"/>
<DICH_DATA CI_END="0.5137470088774614" CI_START="0.2292299454766008" EFFECT_SIZE="0.3431708012546336" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="84" LOG_CI_END="-0.28925069364491535" LOG_CI_START="-0.6397286488959921" LOG_EFFECT_SIZE="-0.4644896712704537" ORDER="34588" O_E="0.0" SE="0.20587248580834103" STUDY_ID="STD-Emery-1999" TOTAL_1="501" TOTAL_2="498" VAR="0.04238348041290557" WEIGHT="29.207431715597203"/>
<DICH_DATA CI_END="15.177452632757605" CI_START="0.2100995198180836" EFFECT_SIZE="1.7857142857142858" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.1811988861594425" LOG_CI_START="-0.6775749401718433" LOG_EFFECT_SIZE="0.2518119729937996" ORDER="34591" O_E="0.0" SE="1.0918529466658307" STUDY_ID="STD-Hu-2001" TOTAL_1="56" TOTAL_2="25" VAR="1.1921428571428572" WEIGHT="8.818859030558494"/>
<DICH_DATA CI_END="2.577129902321556" CI_START="0.0970071395216797" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.41113631006800627" LOG_CI_START="-1.0131963013959686" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="34589" O_E="0.0" SE="0.8366600265340756" STUDY_ID="STD-Lao-2001" TOTAL_1="40" TOTAL_2="40" VAR="0.7" WEIGHT="12.576773848128829"/>
<DICH_DATA CI_END="2.1886426576723803" CI_START="0.7552905992647634" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="21" LOG_CI_END="0.34017485957180443" LOG_CI_START="-0.12188592072166818" LOG_EFFECT_SIZE="0.10914446942506809" ORDER="34590" O_E="0.0" SE="0.27141678958213633" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="182" VAR="0.07366707366707367" WEIGHT="27.478877214569174"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.7459151314521812" CI_END="1.988231306234097" CI_START="1.283872736066496" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5976970823869692" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="70" I2="27.164536984713834" I2_Q="0.0" ID="CMP-016.13" LOG_CI_END="0.2984669078165858" LOG_CI_START="0.10852197640939432" LOG_EFFECT_SIZE="0.20349444211299006" METHOD="MH" MODIFIED="2009-01-01 10:00:19 -0500" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.2533567656887362" P_Q="0.0" P_Z="2.6744398908694942E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="416" TOTAL_2="312" WEIGHT="100.0" Z="4.199551676801742">
<NAME>GI symptoms, leflunomide vs. placebo</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="13.887928723292623" CI_START="1.1750060417201305" EFFECT_SIZE="4.03960396039604" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="1.1426374789182363" LOG_CI_START="0.07004009969623849" LOG_EFFECT_SIZE="0.6063387893072374" ORDER="34592" O_E="0.0" SE="0.6300490099976582" STUDY_ID="STD-Mladenovic-1995" TOTAL_1="101" TOTAL_2="102" VAR="0.39696175499902925" WEIGHT="3.5657826088662063"/>
<DICH_DATA CI_END="2.675264763548468" CI_START="1.0206985652484613" EFFECT_SIZE="1.6524644945697577" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="18" LOG_CI_END="0.42736676940697815" LOG_CI_START="0.008897504302521739" LOG_EFFECT_SIZE="0.21813213685474994" ORDER="34593" O_E="0.0" SE="0.245810917778628" STUDY_ID="STD-Smolen-1999" TOTAL_1="133" TOTAL_2="92" VAR="0.06042300729917142" WEIGHT="25.418498919281507"/>
<DICH_DATA CI_END="1.858161405725957" CI_START="1.1400686761643652" EFFECT_SIZE="1.4554832922179861" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="49" LOG_CI_END="0.26908343547656444" LOG_CI_START="0.0569310134249596" LOG_EFFECT_SIZE="0.163007224450762" ORDER="34594" O_E="0.0" SE="0.12461938288453878" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="118" VAR="0.015529990590523275" WEIGHT="71.01571847185228"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2226157887986042" CI_START="0.6298755508270822" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8775510204081632" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="49" I2="0.0" I2_Q="0.0" ID="CMP-016.14" LOG_CI_END="0.08728999994700051" LOG_CI_START="-0.20074524884485484" LOG_EFFECT_SIZE="-0.05672762444892715" METHOD="MH" MODIFIED="2009-01-01 10:03:01 -0500" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="0.0" P_Z="0.44010417411127056" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="133" WEIGHT="100.0" Z="0.7720173229822761">
<NAME>GI symptoms, leflunomide vs. SSZ</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2226157887986042" CI_START="0.6298755508270822" EFFECT_SIZE="0.8775510204081632" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="49" LOG_CI_END="0.08728999994700051" LOG_CI_START="-0.20074524884485484" LOG_EFFECT_SIZE="-0.05672762444892715" ORDER="34595" O_E="0.0" SE="0.16919333093781233" STUDY_ID="STD-Smolen-1999" TOTAL_1="133" TOTAL_2="133" VAR="0.028626383233832084" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="56.26723971457586" CI_END="0.9173366873326482" CI_START="0.27791143876655877" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5049142091583134" ESTIMABLE="YES" EVENTS_1="349" EVENTS_2="335" I2="91.11383457698786" I2_Q="0.0" ID="CMP-016.15" LOG_CI_END="-0.037471237270216506" LOG_CI_START="-0.55609357740054" LOG_EFFECT_SIZE="-0.2967824073353783" METHOD="MH" MODIFIED="2009-01-01 10:03:45 -0500" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="7.159373094367538E-11" P_Q="0.0" P_Z="0.024884911384558506" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.3315624902446033" TOTALS="YES" TOTAL_1="1100" TOTAL_2="988" WEIGHT="100.0" Z="2.2431846243887894">
<NAME>GI symptoms, leflunomide vs. MTX</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.4258521535582309" CI_START="0.13978863741268907" EFFECT_SIZE="0.24398625429553264" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="45" LOG_CI_END="-0.3707411521613493" LOG_CI_START="-0.8545281283723147" LOG_EFFECT_SIZE="-0.612634640266832" MODIFIED="2008-11-21 06:09:13 -0500" MODIFIED_BY="[Empty name]" ORDER="461" O_E="0.0" SE="0.284178864610476" STUDY_ID="STD-Bao-2003" TOTAL_1="291" TOTAL_2="213" VAR="0.08075762709129923" WEIGHT="22.508322036483346"/>
<DICH_DATA CI_END="1.5147278904941972" CI_START="1.105402809628041" EFFECT_SIZE="1.293980087162952" ESTIMABLE="YES" EVENTS_1="220" EVENTS_2="169" LOG_CI_END="0.18033462209846027" LOG_CI_START="0.04352056410354873" LOG_EFFECT_SIZE="0.11192759310100447" ORDER="34597" O_E="0.0" SE="0.0803652549067205" STUDY_ID="STD-Emery-1999" TOTAL_1="501" TOTAL_2="498" VAR="0.0064585741962221626" WEIGHT="27.455785924080416"/>
<DICH_DATA CI_END="0.3780286021101068" CI_START="0.021088189441253586" EFFECT_SIZE="0.08928571428571429" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.42247533966368395" LOG_CI_START="-1.6759607056766792" LOG_EFFECT_SIZE="-1.0492180226701815" ORDER="34601" O_E="0.0" SE="0.7363035088486657" STUDY_ID="STD-Hu-2001" TOTAL_1="56" TOTAL_2="25" VAR="0.542142857142857" WEIGHT="10.622155410708997"/>
<DICH_DATA CI_END="5.224499169520386" CI_START="0.047851476646507" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7180446644790353" LOG_CI_START="-1.3201046558069978" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="34598" O_E="0.0" SE="1.1972189997378646" STUDY_ID="STD-Jiang-2001" TOTAL_1="30" TOTAL_2="30" VAR="1.4333333333333331" WEIGHT="5.258459938050429"/>
<DICH_DATA CI_END="0.481032388019739" CI_START="0.009239387108092335" EFFECT_SIZE="0.06666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="15" LOG_CI_END="-0.3178256814957932" LOG_CI_START="-2.034356836615569" LOG_EFFECT_SIZE="-1.1760912590556813" ORDER="34599" O_E="0.0" SE="1.0082988974836116" STUDY_ID="STD-Lao-2001" TOTAL_1="40" TOTAL_2="40" VAR="1.0166666666666668" WEIGHT="6.883573119260077"/>
<DICH_DATA CI_END="1.4055387572210325" CI_START="0.9742868423758657" EFFECT_SIZE="1.1702127659574468" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="94" LOG_CI_END="0.14784282562126624" LOG_CI_START="-0.011313162504213464" LOG_EFFECT_SIZE="0.06826483155852639" ORDER="34600" O_E="0.0" SE="0.09348901525975403" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="182" VAR="0.008740195974238522" WEIGHT="27.271703571416726"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.15837249065523173" CI_END="2.3716535041632727" CI_START="1.0656623811196586" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5897741727797112" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-016.16" LOG_CI_END="0.37505123940473567" LOG_CI_START="0.027619635046088796" LOG_EFFECT_SIZE="0.2013354372254122" METHOD="MH" MODIFIED="2009-03-31 21:21:07 -0400" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.9238678666423538" P_Q="0.0" P_Z="0.023111589362523027" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="416" TOTAL_2="312" WEIGHT="100.00000000000001" Z="2.271584972828692">
<NAME>Allergy or rash, leflunomide vs. placebo</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.772188064246964" CI_START="0.547116750208707" EFFECT_SIZE="1.615841584158416" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6787175501817354" LOG_CI_START="-0.26191998891133583" LOG_EFFECT_SIZE="0.2083987806351998" ORDER="34602" O_E="0.0" SE="0.5525351466941832" STUDY_ID="STD-Mladenovic-1995" TOTAL_1="101" TOTAL_2="102" VAR="0.30529508833236263" WEIGHT="14.191089182487106"/>
<DICH_DATA CI_END="3.0974718689764655" CI_START="0.6179096720999517" EFFECT_SIZE="1.3834586466165413" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="8" LOG_CI_END="0.4910073708338093" LOG_CI_START="-0.2090750067489079" LOG_EFFECT_SIZE="0.14096618204245065" ORDER="34603" O_E="0.0" SE="0.41123185405574736" STUDY_ID="STD-Smolen-1999" TOTAL_1="133" TOTAL_2="92" VAR="0.1691116377901275" WEIGHT="26.976120877480792"/>
<DICH_DATA CI_END="2.793166670948939" CI_START="1.008165653356138" EFFECT_SIZE="1.6780866192630899" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="17" LOG_CI_END="0.44609685124477705" LOG_CI_START="0.0035318976131511327" LOG_EFFECT_SIZE="0.22481437442896407" ORDER="34604" O_E="0.0" SE="0.2599648444950692" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="118" VAR="0.06758172037334549" WEIGHT="58.832789940032114"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9154171338071209" CI_START="0.5220794898145138" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-016.17" LOG_CI_END="0.28226336795638735" LOG_CI_START="-0.2822633679563874" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2009-01-01 10:15:04 -0500" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="133" WEIGHT="100.0" Z="0.0">
<NAME>Allergy or rash, leflunomide vs. SSZ</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9154171338071209" CI_START="0.5220794898145138" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" LOG_CI_END="0.28226336795638735" LOG_CI_START="-0.2822633679563874" LOG_EFFECT_SIZE="0.0" ORDER="34605" O_E="0.0" SE="0.331605799127575" STUDY_ID="STD-Smolen-1999" TOTAL_1="133" TOTAL_2="133" VAR="0.1099624060150376" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.640057042052628" CI_END="1.915278351582971" CI_START="1.1857275002867587" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5069831492673764" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="93" I2="0.0" I2_Q="0.0" ID="CMP-016.18" LOG_CI_END="0.28223189985646097" LOG_CI_START="0.07398489246874244" LOG_EFFECT_SIZE="0.1781083961626017" METHOD="MH" MODIFIED="2009-01-01 10:15:36 -0500" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.4505103195880632" P_Q="0.0" P_Z="8.005191728240643E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1030" TOTAL_2="918" WEIGHT="100.0" Z="3.352615206354018">
<NAME>Allergy or rash, leflunomide vs. MTX</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="237.93592853254177" CI_START="0.8149088228999065" EFFECT_SIZE="13.924657534246576" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.3764600258342004" LOG_CI_START="-0.08889098012699742" LOG_EFFECT_SIZE="1.1437845228536014" MODIFIED="2008-11-21 06:18:34 -0500" MODIFIED_BY="[Empty name]" ORDER="464" O_E="0.0" SE="1.4481593845859055" STUDY_ID="STD-Bao-2003" TOTAL_1="291" TOTAL_2="213" VAR="2.0971656031642287" WEIGHT="0.6109846990659152"/>
<DICH_DATA CI_END="1.9252628591755552" CI_START="1.0575230333164438" EFFECT_SIZE="1.4268881591655398" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="62" LOG_CI_END="0.28449003280348095" LOG_CI_START="0.024289835274780357" LOG_EFFECT_SIZE="0.15438993403913068" ORDER="34607" O_E="0.0" SE="0.1528428840401093" STUDY_ID="STD-Emery-1999" TOTAL_1="501" TOTAL_2="498" VAR="0.023360947201698297" WEIGHT="65.84031841106204"/>
<DICH_DATA CI_END="45.842405691034116" CI_START="0.11346700536434874" EFFECT_SIZE="2.280701754385965" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.6612674002099261" LOG_CI_START="-0.9451304069412354" LOG_EFFECT_SIZE="0.35806849663434537" ORDER="34609" O_E="0.0" SE="1.5310109737978166" STUDY_ID="STD-Hu-2001" TOTAL_1="56" TOTAL_2="25" VAR="2.3439946018893387" WEIGHT="0.7271010352557818"/>
<DICH_DATA CI_END="2.141080867057906" CI_START="0.9409117559099136" EFFECT_SIZE="1.4193548387096775" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="31" LOG_CI_END="0.33063307058905644" LOG_CI_START="-0.026451105285226907" LOG_EFFECT_SIZE="0.15209098265191476" ORDER="34608" O_E="0.0" SE="0.20975301250373204" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="182" VAR="0.04399632625439077" WEIGHT="32.821595854616255"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3157128185245467" CI_END="19.32052700688628" CI_START="0.5826598825589594" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.355189412955632" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-016.19" LOG_CI_END="1.2860189685112071" LOG_CI_START="-0.23458488303059324" LOG_EFFECT_SIZE="0.5257170427403068" METHOD="MH" MODIFIED="2009-01-01 10:31:04 -0500" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.5741956656613154" P_Q="0.0" P_Z="0.17534324583949962" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="315" TOTAL_2="210" WEIGHT="100.0" Z="1.355233276287123">
<NAME>hypertension, leflunomide vs. placebo</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="19.63989621329649" CI_START="0.21926822136693197" EFFECT_SIZE="2.075187969924812" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.293139188435059" LOG_CI_START="-0.6590243062387949" LOG_EFFECT_SIZE="0.31705744109813194" ORDER="34610" O_E="0.0" SE="1.1467105001365692" STUDY_ID="STD-Smolen-1999" TOTAL_1="133" TOTAL_2="92" VAR="1.3149449711234606" WEIGHT="66.11306344490441"/>
<DICH_DATA CI_END="107.71327597174826" CI_START="0.3179856543175656" EFFECT_SIZE="5.852459016393443" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.032269234643749" LOG_CI_START="-0.4975924724408969" LOG_EFFECT_SIZE="0.7673383811014262" ORDER="34611" O_E="0.0" SE="1.4860532897589398" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="118" VAR="2.208354380003368" WEIGHT="33.88693655509559"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.86541692186525" CI_START="0.20553223209011884" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-016.20" LOG_CI_END="0.6871200612759742" LOG_CI_START="-0.6871200612759742" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2009-01-01 10:31:38 -0500" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="133" WEIGHT="100.0" Z="0.0">
<NAME>hypertension, leflunomide vs. SSZ</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.86541692186525" CI_START="0.20553223209011884" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6871200612759742" LOG_CI_START="-0.6871200612759742" LOG_EFFECT_SIZE="0.0" ORDER="34612" O_E="0.0" SE="0.8072354505853322" STUDY_ID="STD-Smolen-1999" TOTAL_1="133" TOTAL_2="133" VAR="0.6516290726817042" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5681839512867571" CI_END="3.689898466656343" CI_START="1.4236445976376833" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.2919650996223466" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-016.21" LOG_CI_END="0.5670144160296429" LOG_CI_START="0.15340158442072085" LOG_EFFECT_SIZE="0.36020800022518185" METHOD="MH" MODIFIED="2009-01-01 10:32:12 -0500" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.4509815866325173" P_Q="0.0" P_Z="6.406476140858826E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="683" TOTAL_2="680" WEIGHT="100.0" Z="3.41379499585778">
<NAME>hypertension, leflunomide vs. MTX</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.035559970609015" CI_START="1.4696421423236194" EFFECT_SIZE="2.4353293413173653" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="20" LOG_CI_END="0.6059038055443798" LOG_CI_START="0.1672115969696289" LOG_EFFECT_SIZE="0.3865577012570043" ORDER="34613" O_E="0.0" SE="0.2576899748782636" STUDY_ID="STD-Emery-1999" TOTAL_1="501" TOTAL_2="498" VAR="0.06640412315276013" WEIGHT="86.99049355384815"/>
<DICH_DATA CI_END="5.873567970142226" CI_START="0.3026742495898501" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7689019988630552" LOG_CI_START="-0.5190245256464554" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="34614" O_E="0.0" SE="0.756534415836003" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="182" VAR="0.5723443223443223" WEIGHT="13.009506446151843"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7350252211954469" CI_END="2.8687014887620332" CI_START="0.44490975979075364" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1297403640998642" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-016.22" LOG_CI_END="0.4576853587972946" LOG_CI_START="-0.3517280672194132" LOG_EFFECT_SIZE="0.05297864578894074" METHOD="MH" MODIFIED="2009-01-01 10:28:16 -0500" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.3912591807338086" P_Q="0.0" P_Z="0.7975095227496504" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="234" TOTAL_2="194" WEIGHT="100.00000000000001" Z="0.25657157234721994">
<NAME>Weight loss, leflunomide vs. placebo</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.78257997173051" CI_START="0.3783510115304159" EFFECT_SIZE="2.01980198019802" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0327226878847615" LOG_CI_START="-0.42210510059824924" LOG_EFFECT_SIZE="0.3053087936432562" ORDER="34615" O_E="0.0" SE="0.854573044468618" STUDY_ID="STD-Mladenovic-1995" TOTAL_1="101" TOTAL_2="102" VAR="0.7302950883323627" WEIGHT="25.18773033334257"/>
<DICH_DATA CI_END="2.639094536864432" CI_START="0.2610837952406025" EFFECT_SIZE="0.8300751879699249" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.4214549476672598" LOG_CI_START="-0.5832200828150712" LOG_EFFECT_SIZE="-0.08088256757390568" ORDER="34616" O_E="0.0" SE="0.5901510861269292" STUDY_ID="STD-Smolen-1999" TOTAL_1="133" TOTAL_2="92" VAR="0.3482783044567942" WEIGHT="74.81226966665744"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="14.596250765595746" CI_START="0.6165966962703564" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-016.23" LOG_CI_END="1.1642413159956366" LOG_CI_START="-0.20999880655631192" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="MH" MODIFIED="2009-01-01 10:28:39 -0500" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="1.0" P_Q="0.0" P_Z="0.1735274542630676" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="133" WEIGHT="100.0" Z="1.360956444456816">
<NAME>Weight loss, leflunomide vs. SSZ</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.596250765595746" CI_START="0.6165966962703564" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1642413159956366" LOG_CI_START="-0.20999880655631192" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="34617" O_E="0.0" SE="0.8072354505853322" STUDY_ID="STD-Smolen-1999" TOTAL_1="133" TOTAL_2="133" VAR="0.6516290726817042" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6613128119857157" CI_START="0.39262555086963713" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8076347305389222" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-016.24" LOG_CI_END="0.22045141434693477" LOG_CI_START="-0.40602144126016704" LOG_EFFECT_SIZE="-0.09278501345661616" METHOD="MH" MODIFIED="2009-01-01 10:29:00 -0500" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="1.0" P_Q="0.0" P_Z="0.5615311345829237" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="501" TOTAL_2="498" WEIGHT="100.0" Z="0.5805687606490143">
<NAME>Weight loss, leflunomide vs. MTX</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6613128119857157" CI_START="0.39262555086963713" EFFECT_SIZE="0.8076347305389222" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.22045141434693477" LOG_CI_START="-0.40602144126016704" LOG_EFFECT_SIZE="-0.09278501345661616" ORDER="34618" O_E="0.0" SE="0.3679932564742606" STUDY_ID="STD-Emery-1999" TOTAL_1="501" TOTAL_2="498" VAR="0.13541903681053094" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.6561196051210234" CI_END="1.3395428310990263" CI_START="0.8717385010255959" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0806160556098767" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="78" I2="24.702185995540965" I2_Q="0.0" ID="CMP-016.25" LOG_CI_END="0.12695660447843804" LOG_CI_START="-0.059613772628863713" LOG_EFFECT_SIZE="0.03367141592478717" METHOD="MH" MODIFIED="2009-01-01 10:25:30 -0500" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="0.26499106653015136" P_Q="0.0" P_Z="0.47928584125385876" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="416" TOTAL_2="312" WEIGHT="100.0" Z="0.7074516709916483">
<NAME>Infections, leflunomide vs. placebo</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6598574545114642" CI_START="0.485491642150064" EFFECT_SIZE="0.8976897689768977" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="18" LOG_CI_END="0.22007079323449338" LOG_CI_START="-0.313818242170706" LOG_EFFECT_SIZE="-0.04687372446810631" ORDER="34619" O_E="0.0" SE="0.3136090621903618" STUDY_ID="STD-Mladenovic-1995" TOTAL_1="101" TOTAL_2="102" VAR="0.0983506438879182" WEIGHT="19.76575371160555"/>
<DICH_DATA CI_END="2.182210690366276" CI_START="0.02436313570743688" EFFECT_SIZE="0.23057644110275688" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.3388966789957339" LOG_CI_START="-1.6132668156781198" LOG_EFFECT_SIZE="-0.637185068341193" ORDER="34620" O_E="0.0" SE="1.1467105001365692" STUDY_ID="STD-Smolen-1999" TOTAL_1="133" TOTAL_2="92" VAR="1.3149449711234606" WEIGHT="3.913865672604608"/>
<DICH_DATA CI_END="1.468511954750003" CI_START="0.9346919241784555" EFFECT_SIZE="1.1715828031617506" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="57" LOG_CI_END="0.16687748634457045" LOG_CI_START="-0.02933150963710763" LOG_EFFECT_SIZE="0.0687729883537314" ORDER="34621" O_E="0.0" SE="0.11525413548983195" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="118" VAR="0.013283515747508539" WEIGHT="76.32038061578984"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.2073469483261077" CI_START="0.028314533901159265" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-016.26" LOG_CI_END="0.3438706004481227" LOG_CI_START="-1.5479905831040472" LOG_EFFECT_SIZE="-0.6020599913279624" METHOD="MH" MODIFIED="2009-01-01 10:26:24 -0500" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="1.0" P_Q="0.0" P_Z="0.21222684001301773" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="133" WEIGHT="100.0" Z="1.247465627810703">
<NAME>Infections, leflunomide vs. SSZ</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2073469483261077" CI_START="0.028314533901159265" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3438706004481227" LOG_CI_START="-1.5479905831040472" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="34622" O_E="0.0" SE="1.1112886240824378" STUDY_ID="STD-Smolen-1999" TOTAL_1="133" TOTAL_2="133" VAR="1.2349624060150375" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.34606042630074757" CI_END="1.1508465509547923" CI_START="0.8097641589401842" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9653570787035848" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="117" I2="0.0" I2_Q="0.0" ID="CMP-016.27" LOG_CI_END="0.06101742048793543" LOG_CI_START="-0.09164144949767862" LOG_EFFECT_SIZE="-0.015312014504871591" METHOD="MH" MODIFIED="2009-01-01 10:26:54 -0500" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="0.5563519377965482" P_Q="0.0" P_Z="0.6941885759725355" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="683" TOTAL_2="680" WEIGHT="100.0" Z="0.39317724496626166">
<NAME>Infections, leflunomide vs. MTX</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.1221462349928126" CI_START="0.4944814671137463" EFFECT_SIZE="1.2425149700598803" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.49445324067486085" LOG_CI_START="-0.3058499808738044" LOG_EFFECT_SIZE="0.09430162990052825" ORDER="34623" O_E="0.0" SE="0.4701020739025239" STUDY_ID="STD-Emery-1999" TOTAL_1="501" TOTAL_2="498" VAR="0.22099595988745402" WEIGHT="6.856732274371937"/>
<DICH_DATA CI_END="1.124704997599086" CI_START="0.7939311257286612" EFFECT_SIZE="0.944954128440367" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="109" LOG_CI_END="0.05103862492238469" LOG_CI_START="-0.10021717139328758" LOG_EFFECT_SIZE="-0.02458927323545143" ORDER="34624" O_E="0.0" SE="0.08884840348409297" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="182" VAR="0.007894038801672183" WEIGHT="93.14326772562806"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6051500240470533" CI_START="0.8305133032056496" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1545988258317026" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="56" I2="0.0" I2_Q="0.0" ID="CMP-016.28" LOG_CI_END="0.20551562961994477" LOG_CI_START="-0.08065340660508184" LOG_EFFECT_SIZE="0.06243111150743147" METHOD="MH" MODIFIED="2009-01-01 09:49:48 -0500" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="1.0" P_Q="0.0" P_Z="0.3924526298465364" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="292" TOTAL_2="320" WEIGHT="100.0" Z="0.8551779862944424">
<NAME>Total withdrawals in leflunomide vs. MTX, at 2 years</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6051500240470535" CI_START="0.8305133032056495" EFFECT_SIZE="1.1545988258317026" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="56" LOG_CI_END="0.20551562961994482" LOG_CI_START="-0.08065340660508191" LOG_EFFECT_SIZE="0.06243111150743147" ORDER="34625" O_E="0.0" SE="0.16809710843815598" STUDY_ID="STD-Emery-1999" TOTAL_1="292" TOTAL_2="320" VAR="0.028256637865269166" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.4738364992315516" CI_START="0.7746018723248527" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.384282624369142" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-016.29" LOG_CI_END="0.39337099285656785" LOG_CI_START="-0.11092145759603844" LOG_EFFECT_SIZE="0.1412247676302647" METHOD="MH" MODIFIED="2009-03-31 21:21:25 -0400" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="1.0" P_Q="0.0" P_Z="0.27231032749326545" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="292" TOTAL_2="320" WEIGHT="100.0" Z="1.0977576921166712">
<NAME>Withdrawals due to adverse events in leflunomide vs. MTX, at 2 years</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.4738364992315516" CI_START="0.7746018723248527" EFFECT_SIZE="1.384282624369142" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="19" LOG_CI_END="0.39337099285656785" LOG_CI_START="-0.11092145759603844" LOG_EFFECT_SIZE="0.1412247676302647" ORDER="34626" O_E="0.0" SE="0.2962238816837503" STUDY_ID="STD-Emery-1999" TOTAL_1="292" TOTAL_2="320" VAR="0.0877485880797885" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.6264332634917427" CI_START="0.4348964728620036" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.06875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-016.30" LOG_CI_END="0.4193663700485121" LOG_CI_START="-0.3616141145760539" LOG_EFFECT_SIZE="0.02887612773622909" METHOD="MH" MODIFIED="2009-03-31 21:21:35 -0400" MODIFIED_BY="[Empty name]" NO="30" P_CHI2="1.0" P_Q="0.0" P_Z="0.8847612477571498" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="80" TOTAL_2="76" WEIGHT="100.0" Z="0.14493619620519488">
<NAME>Total withdrawals in leflunomide vs.SSZ, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6264332634917427" CI_START="0.4348964728620036" EFFECT_SIZE="1.06875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.4193663700485121" LOG_CI_START="-0.3616141145760539" LOG_EFFECT_SIZE="0.02887612773622909" ORDER="34627" O_E="0.0" SE="0.45875180258421766" STUDY_ID="STD-Scott-2001" TOTAL_1="80" TOTAL_2="76" VAR="0.210453216374269" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9000985960898424" CI_START="0.0759960563610523" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.38" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-016.31" LOG_CI_END="0.27877613707218624" LOG_CI_START="-1.119208943838566" LOG_EFFECT_SIZE="-0.42021640338318983" METHOD="MH" MODIFIED="2009-03-31 21:21:43 -0400" MODIFIED_BY="[Empty name]" NO="31" P_CHI2="1.0" P_Q="0.0" P_Z="0.23868497028504332" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="80" TOTAL_2="76" WEIGHT="100.00000000000001" Z="1.1782801227141093">
<NAME>Withdrawals due to adverse events in leflunomide vs. SSZ, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9000985960898424" CI_START="0.0759960563610523" EFFECT_SIZE="0.38" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.27877613707218624" LOG_CI_START="-1.119208943838566" LOG_EFFECT_SIZE="-0.42021640338318983" ORDER="34628" O_E="0.0" SE="0.8211833566647329" STUDY_ID="STD-Scott-2001" TOTAL_1="80" TOTAL_2="76" VAR="0.6743421052631579" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5885181349808248" CI_START="0.3886307151180004" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-016.32" LOG_CI_END="0.2009921772224326" LOG_CI_START="-0.41046287826245853" LOG_EFFECT_SIZE="-0.104735350520013" METHOD="MH" MODIFIED="2009-03-31 21:21:55 -0400" MODIFIED_BY="[Empty name]" NO="32" P_CHI2="1.0" P_Q="0.0" P_Z="0.5019406418576737" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="60" WEIGHT="100.0" Z="0.6714394233427883">
<NAME>Total withdrawals in leflunomide vs.SSZ, at 24 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5885181349808248" CI_START="0.3886307151180004" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.2009921772224326" LOG_CI_START="-0.41046287826245853" LOG_EFFECT_SIZE="-0.104735350520013" ORDER="34629" O_E="0.0" SE="0.35917172634316447" STUDY_ID="STD-Scott-2001" TOTAL_1="60" TOTAL_2="60" VAR="0.129004329004329" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7569283366188426" CI_START="0.25296674609948216" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-016.33" LOG_CI_END="0.24475404741121923" LOG_CI_START="-0.5969365655225818" LOG_EFFECT_SIZE="-0.17609125905568127" METHOD="MH" MODIFIED="2009-03-31 21:22:02 -0400" MODIFIED_BY="[Empty name]" NO="33" P_CHI2="1.0" P_Q="0.0" P_Z="0.4121627807455758" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="60" WEIGHT="100.0" Z="0.8200935603605042">
<NAME>Withdrawals due to adverse events in leflunomide vs. SSZ, at 24 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7569283366188426" CI_START="0.25296674609948216" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.24475404741121923" LOG_CI_START="-0.5969365655225818" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="34630" O_E="0.0" SE="0.4944132324730442" STUDY_ID="STD-Scott-2001" TOTAL_1="60" TOTAL_2="60" VAR="0.24444444444444446" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7587303767852" CI_END="0.7291041360790489" CI_START="0.41575429992341695" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5505707762557078" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="95" I2="0.0" I2_Q="0.0" ID="CMP-016.34" LOG_CI_END="-0.13721043808174152" LOG_CI_START="-0.3811632504106545" LOG_EFFECT_SIZE="-0.25918684424619803" METHOD="MH" MODIFIED="2009-03-31 21:22:11 -0400" MODIFIED_BY="[Empty name]" NO="34" P_CHI2="0.6239566933688775" P_Q="0.0" P_Z="3.117427262129055E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="401" TOTAL_2="323" WEIGHT="100.0" Z="4.164714275187173">
<NAME>Reported adverse events in leflunomide vs. MTX, at 6 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8343432171525592" CI_START="0.42827048820648855" EFFECT_SIZE="0.597766323024055" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="60" LOG_CI_END="-0.0786552603299071" LOG_CI_START="-0.368281851474692" LOG_EFFECT_SIZE="-0.22346855590229955" MODIFIED="2008-11-21 06:01:59 -0500" MODIFIED_BY="[Empty name]" ORDER="459" O_E="0.0" SE="0.1701280933131948" STUDY_ID="STD-Bao-2003" TOTAL_1="291" TOTAL_2="213" VAR="0.028943568134383126" WEIGHT="66.43835616438356"/>
<DICH_DATA CI_END="0.9437547096576521" CI_START="0.05232579561621084" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.02514086807986647" LOG_CI_START="-1.2812841594708209" LOG_EFFECT_SIZE="-0.6532125137753437" ORDER="34632" O_E="0.0" SE="0.7378647873726218" STUDY_ID="STD-Jiang-2001" TOTAL_1="30" TOTAL_2="30" VAR="0.5444444444444445" WEIGHT="8.63013698630137"/>
<DICH_DATA CI_END="1.0437059042988464" CI_START="0.2685400316838146" EFFECT_SIZE="0.5294117647058824" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" LOG_CI_END="0.018578140300781656" LOG_CI_START="-0.5709909641786798" LOG_EFFECT_SIZE="-0.27620641193894907" ORDER="34633" O_E="0.0" SE="0.3463158103853704" STUDY_ID="STD-Lao-2001" TOTAL_1="40" TOTAL_2="40" VAR="0.11993464052287583" WEIGHT="16.301369863013697"/>
<DICH_DATA CI_END="1.5124577344609882" CI_START="0.20406651258829142" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.17968324716130685" LOG_CI_START="-0.690228257367919" LOG_EFFECT_SIZE="-0.255272505103306" ORDER="34634" O_E="0.0" SE="0.510990323891863" STUDY_ID="STD-Shuai-2002" TOTAL_1="40" TOTAL_2="40" VAR="0.26111111111111107" WEIGHT="8.63013698630137"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.639055582384503" CI_END="0.5749665946613316" CI_START="0.09805438299384726" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.23744050766790056" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="20" I2="64.5330681568794" I2_Q="0.0" ID="CMP-016.35" LOG_CI_END="-0.24035738692026365" LOG_CI_START="-1.0085329887631695" LOG_EFFECT_SIZE="-0.6244451878417165" METHOD="MH" MODIFIED="2009-01-01 09:54:52 -0500" MODIFIED_BY="[Empty name]" NO="35" P_CHI2="0.05963415019965279" P_Q="0.0" P_Z="0.0014401287470472712" Q="0.0" RANDOM="NO" SCALE="249.81" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="401" TOTAL_2="323" WEIGHT="100.00000000000001" Z="3.186485161863817">
<NAME>Withdrawals due to adverse events in leflunomide vs. MTX, at 6 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.42710607068105066" CI_START="0.007422509805069453" EFFECT_SIZE="0.056304520222045996" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="13" LOG_CI_END="-0.3694642556756229" LOG_CI_START="-2.12944922003239" LOG_EFFECT_SIZE="-1.2494567378540062" MODIFIED="2008-11-21 06:05:14 -0500" MODIFIED_BY="[Empty name]" ORDER="460" O_E="0.0" SE="1.0338238801292448" STUDY_ID="STD-Bao-2003" TOTAL_1="291" TOTAL_2="213" VAR="1.0687918151254872" WEIGHT="66.68429402432577"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="34636" O_E="0.0" SE="0.0" STUDY_ID="STD-Jiang-2001" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.7633577414555113" CI_START="0.23160229687195705" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4414371118737813" LOG_CI_START="-0.6352571378898941" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="34637" O_E="0.0" SE="0.6324555320336759" STUDY_ID="STD-Lao-2001" TOTAL_1="40" TOTAL_2="40" VAR="0.39999999999999997" WEIGHT="22.210470650449498"/>
<DICH_DATA CI_END="4.038645960707643" CI_START="0.009904309609993965" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6062357833382839" LOG_CI_START="-2.0041757920103214" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="34638" O_E="0.0" SE="1.5333686811054679" STUDY_ID="STD-Shuai-2002" TOTAL_1="40" TOTAL_2="40" VAR="2.351219512195122" WEIGHT="11.105235325224749"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="51.81078489953381" CI_END="1.9589302791767478" CI_START="0.9144212479633373" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3383898798772988" ESTIMABLE="YES" EVENTS_1="167" EVENTS_2="174" I2="80.69899921533523" I2_Q="0.0" ID="CMP-016.36" LOG_CI_END="0.29201897917613173" LOG_CI_START="-0.03885369100514513" LOG_EFFECT_SIZE="0.1265826440854933" METHOD="MH" MODIFIED="2008-11-21 06:21:20 -0500" MODIFIED_BY="[Empty name]" NO="36" P_CHI2="1.2369392965450032E-7" P_Q="0.0" P_Z="0.13370379847970185" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.6827683578701778" TOTALS="SUB" TOTAL_1="2238" TOTAL_2="2016" WEIGHT="700.0" Z="1.4996549780886563">
<NAME>**Elevated liver function tests, reported as adverse event</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.2321037049129615" CI_END="5.867281947001326" CI_START="1.0189717631655997" DF="1" EFFECT_SIZE="2.4451164860851997" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="6" I2="0.0" ID="CMP-016.36.01" LOG_CI_END="0.7684369583517932" LOG_CI_START="0.008162149392808182" LOG_EFFECT_SIZE="0.3882995538723007" NO="1" P_CHI2="0.629968353973168" P_Z="0.04527962297109988" STUDIES="2" TAU2="0.0" TOTAL_1="237" TOTAL_2="194" WEIGHT="99.99999999999999" Z="2.0020475013364196">
<NAME>Leflunomide vs. placebo, at 6 months</NAME>
<DICH_DATA CI_END="5.722545834651602" CI_START="0.9151619514003579" EFFECT_SIZE="2.2884615384615383" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.7575892798361485" LOG_CI_START="-0.03850204432068546" LOG_EFFECT_SIZE="0.3595436177577316" ORDER="34639" O_E="0.0" SE="0.467627984525334" STUDY_ID="STD-Mladenovic-1995" TOTAL_1="104" TOTAL_2="102" VAR="0.21867593191122603" WEIGHT="91.20432207183963"/>
<DICH_DATA CI_END="92.94668865706635" CI_START="0.2539325993602586" EFFECT_SIZE="4.858208955223881" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.968233922095217" LOG_CI_START="-0.5952815416884483" LOG_EFFECT_SIZE="0.6864761902033844" ORDER="34640" O_E="0.0" SE="1.505821673032726" STUDY_ID="STD-Smolen-1999" TOTAL_1="133" TOTAL_2="92" VAR="2.2674989109750783" WEIGHT="8.795677928160353"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="18.80247208525252" CI_START="1.8108868078176943" DF="0" EFFECT_SIZE="5.835164835164834" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="3" I2="0.0" ID="CMP-016.36.02" LOG_CI_END="1.2742149525830082" LOG_CI_START="0.2578913049377425" LOG_EFFECT_SIZE="0.7660531287603753" NO="2" P_CHI2="1.0" P_Z="0.0031303151083673765" STUDIES="1" TAU2="0.0" TOTAL_1="182" TOTAL_2="118" WEIGHT="100.0" Z="2.9546425414645414">
<NAME>Leflunomide vs. placebo, at 1 year</NAME>
<DICH_DATA CI_END="18.80247208525252" CI_START="1.8108868078176943" EFFECT_SIZE="5.835164835164835" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="3" LOG_CI_END="1.2742149525830082" LOG_CI_START="0.2578913049377425" LOG_EFFECT_SIZE="0.7660531287603755" ORDER="34641" O_E="0.0" SE="0.596993541510022" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="118" VAR="0.35640128860467846" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.254052195238975" CI_START="1.2668581838431727" DF="0" EFFECT_SIZE="3.2336842105263157" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="5" I2="0.0" ID="CMP-016.36.03" LOG_CI_END="0.9166672108501682" LOG_CI_START="0.10272800129108495" LOG_EFFECT_SIZE="0.5096976060706266" NO="3" P_CHI2="1.0" P_Z="0.014100156715423742" STUDIES="1" TAU2="0.0" TOTAL_1="190" TOTAL_2="128" WEIGHT="100.0" Z="2.4547016267857935">
<NAME>Leflunomide vs. placebo, at 2 years</NAME>
<DICH_DATA CI_END="8.254052195238975" CI_START="1.2668581838431727" EFFECT_SIZE="3.2336842105263157" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="5" LOG_CI_END="0.9166672108501682" LOG_CI_START="0.10272800129108495" LOG_EFFECT_SIZE="0.5096976060706266" ORDER="34642" O_E="0.0" SE="0.4781119207590727" STUDY_ID="STD-Cohen-2001" TOTAL_1="190" TOTAL_2="128" VAR="0.22859100877192984" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4601111460462968" CI_START="0.14633485181292097" DF="0" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-016.36.04" LOG_CI_END="0.39095472865792025" LOG_CI_START="-0.834652227890633" LOG_EFFECT_SIZE="-0.22184874961635637" NO="4" P_CHI2="1.0" P_Z="0.47798237844560243" STUDIES="1" TAU2="0.0" TOTAL_1="133" TOTAL_2="133" WEIGHT="100.0" Z="0.7095513891138349">
<NAME>Leflunomide vs. SSZ, at 6 months</NAME>
<DICH_DATA CI_END="2.4601111460462968" CI_START="0.14633485181292097" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.39095472865792025" LOG_CI_START="-0.834652227890633" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="34643" O_E="0.0" SE="0.7199275931289" STUDY_ID="STD-Smolen-1999" TOTAL_1="133" TOTAL_2="133" VAR="0.5182957393483709" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.004326076553585866" CI_END="1.1499263220573355" CI_START="0.23946389317065317" DF="1" EFFECT_SIZE="0.5247531171315325" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" I2="0.0" ID="CMP-016.36.05" LOG_CI_END="0.06067001518056917" LOG_CI_START="-0.620759961075683" LOG_EFFECT_SIZE="-0.28004497294755687" MODIFIED="2008-11-21 06:21:20 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9475586190214208" P_Z="0.10718854101023609" STUDIES="2" TAU2="0.0" TOTAL_1="331" TOTAL_2="253" WEIGHT="100.0" Z="1.6109595414167674">
<NAME>Leflunomide vs. MTX, at 6 months</NAME>
<DICH_DATA CI_END="1.3007210405504148" CI_START="0.2178630940438657" EFFECT_SIZE="0.5323336457357076" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.11418416547781082" LOG_CI_START="-0.6618163329047129" LOG_EFFECT_SIZE="-0.273816083713451" MODIFIED="2008-11-21 06:21:20 -0500" MODIFIED_BY="[Empty name]" ORDER="465" O_E="0.0" SE="0.45582653401431256" STUDY_ID="STD-Bao-2003" TOTAL_1="291" TOTAL_2="213" VAR="0.20777782911150125" WEIGHT="77.11137874838094"/>
<DICH_DATA CI_END="2.577129902321556" CI_START="0.0970071395216797" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.41113631006800627" LOG_CI_START="-1.0131963013959686" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="34645" O_E="0.0" SE="0.8366600265340756" STUDY_ID="STD-Lao-2001" TOTAL_1="40" TOTAL_2="40" VAR="0.7" WEIGHT="22.888621251619064"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="15.540826121069905" CI_END="2.4492219329737934" CI_START="0.17036584818417058" DF="1" EFFECT_SIZE="0.6459595745883439" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="102" I2="93.56533563782544" ID="CMP-016.36.06" LOG_CI_END="0.3890281399221307" LOG_CI_START="-0.7686174602247197" LOG_EFFECT_SIZE="-0.18979466015129445" NO="6" P_CHI2="8.074305266059234E-5" P_Z="0.5204397694071958" STUDIES="2" TAU2="0.865511772721444" TOTAL_1="683" TOTAL_2="680" WEIGHT="100.0" Z="0.6426676666975948">
<NAME>Leflunomide vs. MTX, at 1 year</NAME>
<DICH_DATA CI_END="0.5030320119710912" CI_START="0.21824540100230844" EFFECT_SIZE="0.3313373253493014" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="81" LOG_CI_END="-0.2984043764152008" LOG_CI_START="-0.6610548992391805" LOG_EFFECT_SIZE="-0.47972963782719064" ORDER="34646" O_E="0.0" SE="0.21302271225584546" STUDY_ID="STD-Emery-1999" TOTAL_1="501" TOTAL_2="498" VAR="0.045378675936836727" WEIGHT="50.764522653448"/>
<DICH_DATA CI_END="2.1886426576723803" CI_START="0.7552905992647634" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="21" LOG_CI_END="0.34017485957180443" LOG_CI_START="-0.12188592072166818" LOG_EFFECT_SIZE="0.10914446942506809" ORDER="34647" O_E="0.0" SE="0.27141678958213633" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="182" VAR="0.07366707366707367" WEIGHT="49.235477346551995"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.007650477356243" CI_END="2.138073879360958" CI_START="0.2971153298905974" DF="1" EFFECT_SIZE="0.7970285603394651" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="38" I2="75.04772420523864" ID="CMP-016.36.07" LOG_CI_END="0.33002270781590337" LOG_CI_START="-0.5270749398653447" LOG_EFFECT_SIZE="-0.09852611602472072" NO="7" P_CHI2="0.0452943088830412" P_Z="0.6522719152369234" STUDIES="2" TAU2="0.38325565366554754" TOTAL_1="482" TOTAL_2="510" WEIGHT="100.0" Z="0.4506082579213505">
<NAME>Leflunomide vs. MTX, at 2 years</NAME>
<DICH_DATA CI_END="2.2275329950353933" CI_START="0.7162937072501856" EFFECT_SIZE="1.263157894736842" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="19" LOG_CI_END="0.3478241456856458" LOG_CI_START="-0.14490886416809165" LOG_EFFECT_SIZE="0.10145764075877703" ORDER="34648" O_E="0.0" SE="0.2894338090558209" STUDY_ID="STD-Cohen-2001" TOTAL_1="190" TOTAL_2="190" VAR="0.08377192982456139" WEIGHT="54.274181024096535"/>
<DICH_DATA CI_END="1.037953563618874" CI_START="0.2051299629167806" EFFECT_SIZE="0.46142754145638065" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="19" LOG_CI_END="0.016177924307046974" LOG_CI_START="-0.6879708984858425" LOG_EFFECT_SIZE="-0.33589648708939773" ORDER="34649" O_E="0.0" SE="0.4136205041014309" STUDY_ID="STD-Emery-1999" TOTAL_1="292" TOTAL_2="320" VAR="0.17108192141312184" WEIGHT="45.72581897590346"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.973384128461353" CI_END="1.7492494181639908" CI_START="0.49376041977146184" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9293600631604726" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="43" I2="38.33528768758655" I2_Q="0.0" ID="CMP-016.37" LOG_CI_END="0.2428517381290059" LOG_CI_START="-0.30648372640041943" LOG_EFFECT_SIZE="-0.03181599413570673" METHOD="MH" MODIFIED="2008-11-21 06:23:46 -0500" MODIFIED_BY="[Empty name]" NO="37" P_CHI2="0.11276876816874326" P_Q="0.0" P_Z="0.820399318041943" Q="0.0" RANDOM="YES" SCALE="96.79311098422177" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.3624343631630248" TOTALS="SUB" TOTAL_1="2198" TOTAL_2="1976" WEIGHT="700.0" Z="0.2270314103668526">
<NAME>**Elevated liver function tests, withdrawals</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.033538608517548" CI_START="0.12731252945422186" DF="0" EFFECT_SIZE="1.3834586466165413" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-016.37.01" LOG_CI_END="1.1770612172650248" LOG_CI_START="-0.8951288531801236" LOG_EFFECT_SIZE="0.14096618204245065" NO="1" P_CHI2="1.0" P_Z="0.7897283254279887" STUDIES="2" TAU2="0.0" TOTAL_1="237" TOTAL_2="194" WEIGHT="99.99999999999999" Z="0.26666341450228825">
<NAME>Leflunomide vs. placebo, at 6 months</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="34650" O_E="0.0" SE="0.0" STUDY_ID="STD-Mladenovic-1995" TOTAL_1="104" TOTAL_2="102" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.033538608517548" CI_START="0.12731252945422186" EFFECT_SIZE="1.3834586466165413" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.1770612172650248" LOG_CI_START="-0.8951288531801236" LOG_EFFECT_SIZE="0.14096618204245065" ORDER="34651" O_E="0.0" SE="1.2172147048857598" STUDY_ID="STD-Smolen-1999" TOTAL_1="133" TOTAL_2="92" VAR="1.4816116377901274" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="18.33929806201332" CI_START="0.9684233290487735" DF="0" EFFECT_SIZE="4.214285714285714" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="2" I2="0.0" ID="CMP-016.37.02" LOG_CI_END="1.263382708998767" LOG_CI_START="-0.013934757070954533" LOG_EFFECT_SIZE="0.6247239759639062" NO="2" P_CHI2="1.0" P_Z="0.05521253400557213" STUDIES="1" TAU2="0.0" TOTAL_1="182" TOTAL_2="118" WEIGHT="100.0" Z="1.9171999533295159">
<NAME>Leflunomide vs. placebo, at 1 year</NAME>
<DICH_DATA CI_END="18.33929806201332" CI_START="0.9684233290487735" EFFECT_SIZE="4.214285714285714" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="2" LOG_CI_END="1.263382708998767" LOG_CI_START="-0.013934757070954533" LOG_EFFECT_SIZE="0.6247239759639062" ORDER="34652" O_E="0.0" SE="0.7503026023927846" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="118" VAR="0.562953995157385" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.704062214859153" CI_START="0.12346259390927435" DF="0" EFFECT_SIZE="1.3473684210526315" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-016.37.03" LOG_CI_END="1.1674373316041184" LOG_CI_START="-0.9084646028860776" LOG_EFFECT_SIZE="0.12948636435902058" NO="3" P_CHI2="1.0" P_Z="0.8068364405262862" STUDIES="1" TAU2="0.0" TOTAL_1="190" TOTAL_2="128" WEIGHT="100.0" Z="0.2445092481644969">
<NAME>Leflunomide vs. placebo, at 2 years</NAME>
<DICH_DATA CI_END="14.704062214859153" CI_START="0.12346259390927435" EFFECT_SIZE="1.3473684210526315" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.1674373316041184" LOG_CI_START="-0.9084646028860776" LOG_EFFECT_SIZE="0.12948636435902058" ORDER="34653" O_E="0.0" SE="1.219395072199844" STUDY_ID="STD-Cohen-2001" TOTAL_1="190" TOTAL_2="128" VAR="1.4869243421052631" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.994832009841666" CI_START="0.14296268996782324" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-016.37.04" LOG_CI_END="0.8447772887957016" LOG_CI_START="-0.8447772887957016" LOG_EFFECT_SIZE="0.0" NO="4" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="133" TOTAL_2="133" WEIGHT="100.0" Z="0.0">
<NAME>Leflunomide vs. SSZ, at 6 months</NAME>
<DICH_DATA CI_END="6.994832009841666" CI_START="0.14296268996782324" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8447772887957016" LOG_CI_START="-0.8447772887957016" LOG_EFFECT_SIZE="0.0" ORDER="34654" O_E="0.0" SE="0.9924527223072329" STUDY_ID="STD-Smolen-1999" TOTAL_1="133" TOTAL_2="133" VAR="0.9849624060150375" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.625543182492337" CI_START="0.020599407798606896" DF="0" EFFECT_SIZE="0.18298969072164945" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-016.37.05" LOG_CI_END="0.21099851100165393" LOG_CI_START="-1.686145264751918" LOG_EFFECT_SIZE="-0.737573376875132" MODIFIED="2008-11-21 06:23:35 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.12751037094022322" STUDIES="1" TAU2="0.0" TOTAL_1="291" TOTAL_2="213" WEIGHT="100.0" Z="1.5239933558083942">
<NAME>Leflunomide vs. MTX, at 6 months</NAME>
<DICH_DATA CI_END="1.625543182492337" CI_START="0.020599407798606896" EFFECT_SIZE="0.18298969072164947" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.21099851100165393" LOG_CI_START="-1.686145264751918" LOG_EFFECT_SIZE="-0.737573376875132" MODIFIED="2008-11-21 06:23:35 -0500" MODIFIED_BY="[Empty name]" ORDER="466" O_E="0.0" SE="1.1143916448907945" STUDY_ID="STD-Bao-2003" TOTAL_1="291" TOTAL_2="213" VAR="1.2418687382024103" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.751650927823629" CI_END="2.861976234668264" CI_START="0.2804301529513921" DF="1" EFFECT_SIZE="0.8958707681531252" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" I2="73.34506809832358" ID="CMP-016.37.06" LOG_CI_END="0.4566660231360965" LOG_CI_START="-0.5521752911463542" LOG_EFFECT_SIZE="-0.047754634005128846" NO="6" P_CHI2="0.0527556507241308" P_Z="0.8527943865157316" STUDIES="2" TAU2="0.5151503639784054" TOTAL_1="683" TOTAL_2="680" WEIGHT="100.0" Z="0.18555418264470358">
<NAME>Leflunomide vs. MTX, at 1 year</NAME>
<DICH_DATA CI_END="1.1507631885363492" CI_START="0.21465315765430598" EFFECT_SIZE="0.49700598802395207" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="0.060985960907518656" LOG_CI_START="-0.6682627184505374" LOG_EFFECT_SIZE="-0.3036383787715094" ORDER="34656" O_E="0.0" SE="0.4283642840941037" STUDY_ID="STD-Emery-1999" TOTAL_1="501" TOTAL_2="498" VAR="0.183495959887454" WEIGHT="50.26475201837098"/>
<DICH_DATA CI_END="3.826435660901863" CI_START="0.6901004574522556" EFFECT_SIZE="1.625" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.5827944153395326" LOG_CI_START="-0.1610876847097462" LOG_EFFECT_SIZE="0.21085336531489315" ORDER="34657" O_E="0.0" SE="0.43696002784472854" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="182" VAR="0.19093406593406592" WEIGHT="49.73524798162903"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9632426119332056" CI_END="1.4240868201654626" CI_START="0.07742058078412652" DF="1" EFFECT_SIZE="0.33204461854430056" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" I2="0.0" ID="CMP-016.37.07" LOG_CI_END="0.1535364670883285" LOG_CI_START="-1.1111435750682748" LOG_EFFECT_SIZE="-0.4788035539899731" NO="7" P_CHI2="0.32637144857077893" P_Z="0.13778998756630656" STUDIES="2" TAU2="0.0" TOTAL_1="482" TOTAL_2="510" WEIGHT="100.0" Z="1.4840713701622905">
<NAME>Leflunomide vs. MTX, at 2 years</NAME>
<DICH_DATA CI_END="2.6973718265972915" CI_START="0.09268280981319975" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.43094081709024257" LOG_CI_START="-1.033000808418205" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="34658" O_E="0.0" SE="0.8599265574515804" STUDY_ID="STD-Cohen-2001" TOTAL_1="190" TOTAL_2="190" VAR="0.7394736842105263" WEIGHT="74.63006344304017"/>
<DICH_DATA CI_END="1.7933717425153115" CI_START="0.005531197059561629" EFFECT_SIZE="0.0995966490847037" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.2536703224618697" LOG_CI_START="-2.2571808686767945" LOG_EFFECT_SIZE="-1.0017552731074624" ORDER="34659" O_E="0.0" SE="1.4748864185886985" STUDY_ID="STD-Emery-1999" TOTAL_1="292" TOTAL_2="320" VAR="2.1752899477373977" WEIGHT="25.36993655695982"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4316234427211478" CI_START="0.6042301690562465" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9300699300699301" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-016.38" LOG_CI_END="0.15582880131413737" LOG_CI_START="-0.21879759431008935" LOG_EFFECT_SIZE="-0.031484396497976" METHOD="MH" MODIFIED="2009-01-02 08:28:08 -0500" MODIFIED_BY="[Empty name]" NO="38" P_CHI2="1.0" P_Q="0.0" P_Z="0.7418238513249509" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="133" WEIGHT="100.0" Z="0.32943905678717406">
<NAME>Total withdrawals in leflunomide+MTX vs.MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4316234427211476" CI_START="0.6042301690562465" EFFECT_SIZE="0.9300699300699301" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="33" LOG_CI_END="0.15582880131413732" LOG_CI_START="-0.21879759431008935" LOG_EFFECT_SIZE="-0.031484396497976" ORDER="34660" O_E="0.0" SE="0.22005739922023693" STUDY_ID="STD-Kremer-2002" TOTAL_1="130" TOTAL_2="133" VAR="0.048425258951574734" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.9678907457593895" CI_START="0.8337038714552355" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8188034188034188" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-016.39" LOG_CI_END="0.5985597055267344" LOG_CI_START="-0.07898818177303658" LOG_EFFECT_SIZE="0.25978576187684893" METHOD="MH" MODIFIED="2009-01-02 08:28:36 -0500" MODIFIED_BY="[Empty name]" NO="39" P_CHI2="1.0" P_Q="0.0" P_Z="0.13284399204088898" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="133" WEIGHT="100.0" Z="1.502980812187663">
<NAME>Withdrawals due to adverse events in leflunomide+MTX vs. MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.9678907457593895" CI_START="0.8337038714552355" EFFECT_SIZE="1.8188034188034188" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="9" LOG_CI_END="0.5985597055267344" LOG_CI_START="-0.07898818177303658" LOG_EFFECT_SIZE="0.25978576187684893" ORDER="34661" O_E="0.0" SE="0.3979949829160189" STUDY_ID="STD-Kremer-2002" TOTAL_1="130" TOTAL_2="133" VAR="0.1584000064263222" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.095033980599733" CI_START="0.7267243184822261" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.892069404960298" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="101" I2="0.0" I2_Q="0.0" ID="CMP-016.40" LOG_CI_END="0.03942759621538646" LOG_CI_START="-0.1386303067037696" LOG_EFFECT_SIZE="-0.04960135524419157" METHOD="MH" MODIFIED="2009-01-02 09:13:58 -0500" MODIFIED_BY="[Empty name]" NO="40" P_CHI2="1.0" P_Q="0.0" P_Z="0.27484667128312756" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="202" TOTAL_2="200" WEIGHT="100.0" Z="1.0919691658632187">
<NAME>Reported adverse events in leflunomide10mg vs.leflunomide20mg, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef10</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef20</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef10</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef20</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.095033980599733" CI_START="0.7267243184822261" EFFECT_SIZE="0.892069404960298" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="101" LOG_CI_END="0.03942759621538646" LOG_CI_START="-0.1386303067037696" LOG_EFFECT_SIZE="-0.04960135524419157" ORDER="34662" O_E="0.0" SE="0.1045920935755468" STUDY_ID="STD-Poor-2004" TOTAL_1="202" TOTAL_2="200" VAR="0.010939506038515939" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.0995420659209487" CI_START="0.7789930377783005" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.278877887788779" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-016.41" LOG_CI_END="0.3221245804811394" LOG_CI_START="-0.10846642380109116" LOG_EFFECT_SIZE="0.10682907834002411" METHOD="MH" MODIFIED="2009-01-02 09:14:27 -0500" MODIFIED_BY="[Empty name]" NO="41" P_CHI2="1.0" P_Q="0.0" P_Z="0.33078739581538674" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="202" TOTAL_2="200" WEIGHT="100.0" Z="0.972529123765979">
<NAME>Withdrawals due to adverse events in leflunomide10mg vs. leflunomide20mg, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef10</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef20</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef10</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef20</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0995420659209487" CI_START="0.7789930377783005" EFFECT_SIZE="1.278877887788779" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="24" LOG_CI_END="0.3221245804811394" LOG_CI_START="-0.10846642380109116" LOG_EFFECT_SIZE="0.10682907834002411" ORDER="34663" O_E="0.0" SE="0.25293128737522913" STUDY_ID="STD-Poor-2004" TOTAL_1="202" TOTAL_2="200" VAR="0.06397423613329073" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.203007792692167" CI_START="0.7714291300506825" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9633458646616542" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="38" I2="0.0" I2_Q="0.0" ID="CMP-016.42" LOG_CI_END="0.08026844056698189" LOG_CI_START="-0.1127039657014944" LOG_EFFECT_SIZE="-0.016217762567256256" METHOD="MH" MODIFIED="2009-01-02 08:46:38 -0500" MODIFIED_BY="[Empty name]" NO="42" P_CHI2="1.0" P_Q="0.0" P_Z="0.7418245814195656" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="50" WEIGHT="100.0" Z="0.3294380907228876">
<NAME>Related adverse events in Lef+SSZ vs.Plc+SSZ, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef+SSZ</GROUP_LABEL_1>
<GROUP_LABEL_2>Plc+SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.203007792692167" CI_START="0.7714291300506825" EFFECT_SIZE="0.9633458646616542" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="38" LOG_CI_END="0.08026844056698189" LOG_CI_START="-0.1127039657014944" LOG_EFFECT_SIZE="-0.016217762567256256" ORDER="34664" O_E="0.0" SE="0.11335294667091976" STUDY_ID="STD-Dougados-2005" TOTAL_1="56" TOTAL_2="50" VAR="0.012848890518980378" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.768120129517999" CI_START="0.4711464112903054" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7857142857142858" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-016.43" LOG_CI_END="0.8304680585303426" LOG_CI_START="-0.3268441125427433" LOG_EFFECT_SIZE="0.2518119729937996" METHOD="MH" MODIFIED="2009-01-02 08:47:27 -0500" MODIFIED_BY="[Empty name]" NO="43" P_CHI2="1.0" P_Q="0.0" P_Z="0.3937084231150336" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="50" WEIGHT="100.0" Z="0.8529114447767301">
<NAME>Serious adverse events in Lef+SSZ vs. Plc+SSZ, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef+SSZ</GROUP_LABEL_1>
<GROUP_LABEL_2>Plc+SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.768120129517999" CI_START="0.4711464112903054" EFFECT_SIZE="1.7857142857142858" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8304680585303426" LOG_CI_START="-0.3268441125427433" LOG_EFFECT_SIZE="0.2518119729937996" ORDER="34665" O_E="0.0" SE="0.6798108980759702" STUDY_ID="STD-Dougados-2005" TOTAL_1="56" TOTAL_2="50" VAR="0.46214285714285713" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2217038372693612" CI_END="2.3989791868356143" CI_START="0.9047016095606386" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4732142857142856" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-016.44" LOG_CI_END="0.3800264801138689" LOG_CI_START="-0.043494637026419716" LOG_EFFECT_SIZE="0.16826592154372463" METHOD="MH" MODIFIED="2009-01-02 08:48:46 -0500" MODIFIED_BY="[Empty name]" NO="44" P_CHI2="0.747803753460933" P_Q="0.0" P_Z="0.11937638412464195" Q="0.0" RANDOM="NO" SCALE="44.58914411375222" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="224" TOTAL_2="200" WEIGHT="400.0" Z="1.5573964683413892">
<NAME>Withdrawals due to adverse events in Lef+SSZ vs. Plc+SSZ, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef+SSZ</GROUP_LABEL_1>
<GROUP_LABEL_2>Plc+SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3410684658882968" CI_START="0.7661827283676634" DF="0" EFFECT_SIZE="1.3392857142857142" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" I2="0.0" ID="CMP-016.44.01" LOG_CI_END="0.3694141150732508" LOG_CI_START="-0.11566764230225164" LOG_EFFECT_SIZE="0.1268732363854996" NO="1" P_CHI2="1.0" P_Z="0.3052414864253755" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="50" WEIGHT="100.0" Z="1.0252579905829051">
<NAME>Overall</NAME>
<DICH_DATA CI_END="2.3410684658882968" CI_START="0.7661827283676634" EFFECT_SIZE="1.3392857142857142" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" LOG_CI_END="0.3694141150732508" LOG_CI_START="-0.11566764230225164" LOG_EFFECT_SIZE="0.1268732363854996" ORDER="34666" O_E="0.0" SE="0.2849394254757951" STUDY_ID="STD-Dougados-2005" TOTAL_1="56" TOTAL_2="50" VAR="0.08119047619047619" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.927799989861494" CI_START="0.3171280199828591" DF="0" EFFECT_SIZE="1.1160714285714286" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-016.44.02" LOG_CI_END="0.5941493646772713" LOG_CI_START="-0.4987653840015217" LOG_EFFECT_SIZE="0.047691990337874815" NO="2" P_CHI2="1.0" P_Z="0.864180062666418" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="50" WEIGHT="100.0" Z="0.17105558054965733">
<NAME>Rash</NAME>
<DICH_DATA CI_END="3.927799989861494" CI_START="0.3171280199828591" EFFECT_SIZE="1.1160714285714286" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5941493646772713" LOG_CI_START="-0.4987653840015217" LOG_EFFECT_SIZE="0.047691990337874815" ORDER="34667" O_E="0.0" SE="0.6419835333891806" STUDY_ID="STD-Dougados-2005" TOTAL_1="56" TOTAL_2="50" VAR="0.41214285714285714" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="30.90241295983746" CI_START="0.41275424211674305" DF="0" EFFECT_SIZE="3.5714285714285716" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-016.44.03" LOG_CI_END="1.4899923918594082" LOG_CI_START="-0.3843084545438466" LOG_EFFECT_SIZE="0.5528419686577808" NO="3" P_CHI2="1.0" P_Z="0.24759194912690619" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="50" WEIGHT="100.0" Z="1.156218170408217">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="30.90241295983746" CI_START="0.41275424211674305" EFFECT_SIZE="3.5714285714285716" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.4899923918594082" LOG_CI_START="-0.3843084545438466" LOG_EFFECT_SIZE="0.5528419686577808" ORDER="34668" O_E="0.0" SE="1.1009735951160942" STUDY_ID="STD-Dougados-2005" TOTAL_1="56" TOTAL_2="50" VAR="1.2121428571428572" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="24.9305700924723" CI_START="0.2877890425829279" DF="0" EFFECT_SIZE="2.6785714285714284" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-016.44.04" LOG_CI_END="1.3967322097185368" LOG_CI_START="-0.5409257456195753" LOG_EFFECT_SIZE="0.4279032320494808" NO="4" P_CHI2="1.0" P_Z="0.38667753913158187" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="50" WEIGHT="100.0" Z="0.8656583803914174">
<NAME>Diarrhea</NAME>
<DICH_DATA CI_END="24.9305700924723" CI_START="0.2877890425829279" EFFECT_SIZE="2.6785714285714284" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3967322097185368" LOG_CI_START="-0.5409257456195753" LOG_EFFECT_SIZE="0.4279032320494808" ORDER="34669" O_E="0.0" SE="1.1381898745271768" STUDY_ID="STD-Dougados-2005" TOTAL_1="56" TOTAL_2="50" VAR="1.2954761904761904" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8098833862134374" CI_START="0.8526241818543502" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2422360248447204" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-016.45" LOG_CI_END="0.25765059345728136" LOG_CI_START="-0.06924235419301841" LOG_EFFECT_SIZE="0.09420411963213145" METHOD="MH" MODIFIED="2009-01-02 08:48:04 -0500" MODIFIED_BY="[Empty name]" NO="45" P_CHI2="1.0" P_Q="0.0" P_Z="0.2586253704550521" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="50" WEIGHT="100.0" Z="1.1296461609309423">
<NAME>Total withdrawals, Lef+SSZ vs. Plc+SSZ, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef+SSZ</GROUP_LABEL_1>
<GROUP_LABEL_2>Plc+SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8098833862134374" CI_START="0.8526241818543502" EFFECT_SIZE="1.2422360248447204" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="23" LOG_CI_END="0.25765059345728136" LOG_CI_START="-0.06924235419301841" LOG_EFFECT_SIZE="0.09420411963213145" ORDER="34670" O_E="0.0" SE="0.19201853559597407" STUDY_ID="STD-Dougados-2005" TOTAL_1="56" TOTAL_2="50" VAR="0.03687111801242236" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.875637998879146" CI_END="2.8335381644263924" CI_START="1.2268746238364767" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8645096056622852" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="31" I2="49.37035966114306" I2_Q="0.0" ID="CMP-016.46" LOG_CI_END="0.4523290664527809" LOG_CI_START="0.08880018378808142" LOG_EFFECT_SIZE="0.27056462512043117" METHOD="MH" MODIFIED="2009-01-02 08:38:13 -0500" MODIFIED_BY="[Empty name]" NO="46" P_CHI2="0.0788367978652631" P_Q="0.0" P_Z="0.0035285485795266518" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="576" TOTAL_2="575" WEIGHT="600.0" Z="2.917495395906384">
<NAME>Reported adverse events, Lef/Lef+MTX vs Plc/Lef+MTX, at 48 weeks</NAME>
<GROUP_LABEL_1>Plc/Lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef/Lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Plc/Lef+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef/Lef+MTX</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.798823550495161" CI_START="0.30657559456624145" DF="0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-016.46.01" LOG_CI_END="0.7633398940194418" LOG_CI_START="-0.513462420802842" LOG_EFFECT_SIZE="0.12493873660829992" MODIFIED="2008-11-24 11:05:26 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7012926602571291" STUDIES="1" TAU2="0.0" TOTAL_1="96" TOTAL_2="96" WEIGHT="100.0" Z="0.38357609660237446">
<NAME>nausea</NAME>
<DICH_DATA CI_END="5.798823550495161" CI_START="0.30657559456624145" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7633398940194418" LOG_CI_START="-0.513462420802842" LOG_EFFECT_SIZE="0.12493873660829992" MODIFIED="2008-11-24 11:05:26 -0500" MODIFIED_BY="[Empty name]" ORDER="475" O_E="0.0" SE="0.75" STUDY_ID="STD-Kremer-2004" TOTAL_1="96" TOTAL_2="96" VAR="0.5625" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="17.711326544011577" CI_START="1.606003049729884" DF="0" EFFECT_SIZE="5.333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="3" I2="0.0" ID="CMP-016.46.02" LOG_CI_END="1.2482510902227626" LOG_CI_START="0.205746365649762" LOG_EFFECT_SIZE="0.7269987279362623" MODIFIED="2008-11-24 11:05:50 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0062647605914239205" STUDIES="1" TAU2="0.0" TOTAL_1="96" TOTAL_2="96" WEIGHT="100.0" Z="2.7335920691297173">
<NAME>diarrhea</NAME>
<DICH_DATA CI_END="17.711326544011577" CI_START="1.606003049729884" EFFECT_SIZE="5.333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="3" LOG_CI_END="1.2482510902227626" LOG_CI_START="0.205746365649762" LOG_EFFECT_SIZE="0.7269987279362623" MODIFIED="2008-11-24 11:05:50 -0500" MODIFIED_BY="[Empty name]" ORDER="479" O_E="0.0" SE="0.6123724356957945" STUDY_ID="STD-Kremer-2004" TOTAL_1="96" TOTAL_2="96" VAR="0.37499999999999994" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4569886762488258" CI_START="0.29902208530838825" DF="0" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" ID="CMP-016.46.03" LOG_CI_END="0.3904031549115087" LOG_CI_START="-0.5242967341727351" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2008-11-24 11:06:17 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.7741895647844612" STUDIES="1" TAU2="0.0" TOTAL_1="96" TOTAL_2="96" WEIGHT="100.0" Z="0.2868991198587469">
<NAME>rash</NAME>
<DICH_DATA CI_END="2.4569886762488258" CI_START="0.29902208530838825" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.3904031549115087" LOG_CI_START="-0.5242967341727351" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2008-11-24 11:06:17 -0500" MODIFIED_BY="[Empty name]" ORDER="480" O_E="0.0" SE="0.5372992426855598" STUDY_ID="STD-Kremer-2004" TOTAL_1="96" TOTAL_2="96" VAR="0.28869047619047616" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="62.73745671132549" CI_START="1.0201242344662433" DF="0" EFFECT_SIZE="8.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" I2="0.0" ID="CMP-016.46.04" LOG_CI_END="1.7975269090282053" LOG_CI_START="0.0086530649556818" LOG_EFFECT_SIZE="0.9030899869919435" MODIFIED="2008-11-24 11:06:35 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.047824417906495685" STUDIES="1" TAU2="0.0" TOTAL_1="96" TOTAL_2="96" WEIGHT="100.0" Z="1.978925294444851">
<NAME>alopecia</NAME>
<DICH_DATA CI_END="62.737456711325436" CI_START="1.0201242344662438" EFFECT_SIZE="8.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.797526909028205" LOG_CI_START="0.008653064955681989" LOG_EFFECT_SIZE="0.9030899869919435" MODIFIED="2008-11-24 11:06:35 -0500" MODIFIED_BY="[Empty name]" ORDER="481" O_E="0.0" SE="1.0507933510765408" STUDY_ID="STD-Kremer-2004" TOTAL_1="96" TOTAL_2="96" VAR="1.1041666666666665" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.696624180479434" CI_START="0.8120443266349896" DF="0" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" I2="0.0" ID="CMP-016.46.05" LOG_CI_END="0.8863002808522217" LOG_CI_START="-0.09042026350814639" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2008-11-24 11:07:07 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.11024894296549063" STUDIES="1" TAU2="0.0" TOTAL_1="96" TOTAL_2="96" WEIGHT="100.0" Z="1.5970752115499338">
<NAME>infection</NAME>
<DICH_DATA CI_END="7.696624180479434" CI_START="0.8120443266349896" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.8863002808522217" LOG_CI_START="-0.09042026350814639" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2008-11-24 11:07:07 -0500" MODIFIED_BY="[Empty name]" ORDER="482" O_E="0.0" SE="0.5737304826019501" STUDY_ID="STD-Kremer-2004" TOTAL_1="96" TOTAL_2="96" VAR="0.3291666666666666" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.145200641077445" CI_START="0.5294271307472107" DF="0" EFFECT_SIZE="1.0657051282051282" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" I2="0.0" ID="CMP-016.46.06" LOG_CI_END="0.33146791807676385" LOG_CI_START="-0.2761938068354027" LOG_EFFECT_SIZE="0.027637055620680608" MODIFIED="2008-11-24 11:28:48 -0500" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.8585013596999531" STUDIES="1" TAU2="0.0" TOTAL_1="96" TOTAL_2="95" WEIGHT="100.0" Z="0.17828219693479577">
<NAME>elevated liver enzymes</NAME>
<DICH_DATA CI_END="2.145200641077445" CI_START="0.5294271307472107" EFFECT_SIZE="1.0657051282051282" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.33146791807676385" LOG_CI_START="-0.2761938068354027" LOG_EFFECT_SIZE="0.027637055620680608" MODIFIED="2008-11-24 11:28:48 -0500" MODIFIED_BY="[Empty name]" ORDER="483" O_E="0.0" SE="0.3569435051874568" STUDY_ID="STD-Kremer-2004" TOTAL_1="96" TOTAL_2="95" VAR="0.127408665895508" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7222027002408389" CI_START="0.4361339759867251" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8666666666666667" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-016.47" LOG_CI_END="0.23608426582570288" LOG_CI_START="-0.3603800793233918" LOG_EFFECT_SIZE="-0.062147906748844454" METHOD="MH" MODIFIED="2009-01-02 08:42:59 -0500" MODIFIED_BY="[Empty name]" NO="47" P_CHI2="1.0" P_Q="0.0" P_Z="0.6829563083496192" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="96" TOTAL_2="96" WEIGHT="100.0" Z="0.4084323226792085">
<NAME>Serious adverse events in Lef/Lef+MTX vs. Plc/Lef+MTX, at 48 weeks</NAME>
<GROUP_LABEL_1>Plc/Lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef/Lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Plc/Lef+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef/Lef+MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7222027002408389" CI_START="0.4361339759867251" EFFECT_SIZE="0.8666666666666667" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.23608426582570288" LOG_CI_START="-0.3603800793233918" LOG_EFFECT_SIZE="-0.062147906748844454" MODIFIED="2008-11-24 10:40:28 -0500" MODIFIED_BY="[Empty name]" ORDER="472" O_E="0.0" SE="0.3503661088867048" STUDY_ID="STD-Kremer-2004" TOTAL_1="96" TOTAL_2="96" VAR="0.12275641025641025" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.9953697060747126" CI_START="0.654343267218418" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-016.48" LOG_CI_END="0.47645043320247793" LOG_CI_START="-0.18419436184600194" LOG_EFFECT_SIZE="0.14612803567823798" METHOD="MH" MODIFIED="2009-01-02 08:32:46 -0500" MODIFIED_BY="[Empty name]" NO="48" P_CHI2="1.0" P_Q="0.0" P_Z="0.3859152003373584" Q="0.0" RANDOM="NO" SCALE="29.94" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="96" TOTAL_2="96" WEIGHT="100.0" Z="0.8670489473542687">
<NAME>Total withdrawals, Lef/Lef+MTX vs. Plc/Lef+MTX, at 48 weeks</NAME>
<GROUP_LABEL_1>Plc/Lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef/Lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Plc/Lef+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef/Lef+MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9953697060747126" CI_START="0.654343267218418" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" LOG_CI_END="0.47645043320247793" LOG_CI_START="-0.18419436184600194" LOG_EFFECT_SIZE="0.14612803567823798" MODIFIED="2008-12-18 12:00:33 -0500" MODIFIED_BY="[Empty name]" ORDER="559" O_E="0.0" SE="0.3880660228559544" STUDY_ID="STD-Kremer-2004" TOTAL_1="96" TOTAL_2="96" VAR="0.15059523809523812" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.831228006100619" CI_START="0.20698671201964655" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-016.49" LOG_CI_END="0.6840575341651937" LOG_CI_START="-0.6840575341651937" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2009-01-02 08:33:19 -0500" MODIFIED_BY="[Empty name]" NO="49" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="161.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="96" TOTAL_2="96" WEIGHT="100.0" Z="0.0">
<NAME>Withdrawals due to adverse events, Lef/Lef+MTX vs. Plc/Lef+MTX, at 48 weeks</NAME>
<GROUP_LABEL_1>Plc/Lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef/Lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Plc/Lef+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef/Lef+MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.831228006100619" CI_START="0.20698671201964655" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6840575341651937" LOG_CI_START="-0.6840575341651937" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-24 10:50:10 -0500" MODIFIED_BY="[Empty name]" ORDER="473" O_E="0.0" SE="0.8036375634160796" STUDY_ID="STD-Kremer-2004" TOTAL_1="96" TOTAL_2="96" VAR="0.6458333333333334" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="18.835315064607727" CI_START="1.0162094413788683" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.375" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-016.50" LOG_CI_END="1.2749728891889367" LOG_CI_START="0.006983225527727281" LOG_EFFECT_SIZE="0.640978057358332" METHOD="MH" MODIFIED="2009-01-01 11:06:40 -0500" MODIFIED_BY="[Empty name]" NO="50" P_CHI2="1.0" P_Q="0.0" P_Z="0.04752937210119931" Q="0.0" RANDOM="NO" SCALE="29.94" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="36" TOTAL_2="35" WEIGHT="100.0" Z="1.981552284385885">
<NAME>Total withdrawals, Lef vs. CsA, at 12 months</NAME>
<GROUP_LABEL_1>Lef</GROUP_LABEL_1>
<GROUP_LABEL_2>CsA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CsA</GRAPH_LABEL_2>
<DICH_DATA CI_END="18.835315064607727" CI_START="1.0162094413788683" EFFECT_SIZE="4.375" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.2749728891889367" LOG_CI_START="0.006983225527727281" LOG_EFFECT_SIZE="0.640978057358332" MODIFIED="2009-01-01 11:06:30 -0500" MODIFIED_BY="[Empty name]" ORDER="455" O_E="0.0" SE="0.7448234050846582" STUDY_ID="STD-Karanikolas-2006" TOTAL_1="36" TOTAL_2="35" VAR="0.5547619047619048" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="156.85381459475747" CI_START="0.4888678614231671" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="8.756756756756756" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-016.51" LOG_CI_END="2.195495084954766" LOG_CI_START="-0.31080851267553233" LOG_EFFECT_SIZE="0.9423432861396172" METHOD="MH" MODIFIED="2009-01-01 11:12:15 -0500" MODIFIED_BY="[Empty name]" NO="51" P_CHI2="1.0" P_Q="0.0" P_Z="0.14052174116414637" Q="0.0" RANDOM="NO" SCALE="431.01" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="36" TOTAL_2="35" WEIGHT="100.0" Z="1.4738508963184394">
<NAME>Withdrawals due to adverse events, Lef vs. CsA, at 12 months</NAME>
<GROUP_LABEL_1>Lef</GROUP_LABEL_1>
<GROUP_LABEL_2>CsA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CsA</GRAPH_LABEL_2>
<DICH_DATA CI_END="156.85381459475747" CI_START="0.4888678614231671" EFFECT_SIZE="8.756756756756756" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.195495084954766" LOG_CI_START="-0.31080851267553233" LOG_EFFECT_SIZE="0.9423432861396172" MODIFIED="2009-01-01 11:12:15 -0500" MODIFIED_BY="[Empty name]" ORDER="456" O_E="0.0" SE="1.4722151396509335" STUDY_ID="STD-Karanikolas-2006" TOTAL_1="36" TOTAL_2="35" VAR="2.1674174174174174" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3488381272180727" CI_START="0.15493304023644933" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.45714285714285713" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-016.52" LOG_CI_END="0.12995983353095683" LOG_CI_START="-0.8098559569196587" LOG_EFFECT_SIZE="-0.3399480616943509" METHOD="MH" MODIFIED="2009-01-02 09:06:37 -0500" MODIFIED_BY="[Empty name]" NO="52" P_CHI2="1.0" P_Q="0.0" P_Z="0.15621775468016794" Q="0.0" RANDOM="NO" SCALE="29.94" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="36" WEIGHT="100.0" Z="1.4179075608330918">
<NAME>Total withdrawals, Lef vs. Lef+CsA, at 12 months</NAME>
<GROUP_LABEL_1>Lef+CsA</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef+CsA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3488381272180727" CI_START="0.15493304023644933" EFFECT_SIZE="0.45714285714285713" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.12995983353095683" LOG_CI_START="-0.8098559569196587" LOG_EFFECT_SIZE="-0.3399480616943509" MODIFIED="2008-11-17 10:54:37 -0500" MODIFIED_BY="[Empty name]" ORDER="457" O_E="0.0" SE="0.5520524474738834" STUDY_ID="STD-Karanikolas-2006" TOTAL_1="35" TOTAL_2="36" VAR="0.30476190476190473" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.631077436208686" CI_START="0.10052527997788245" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5142857142857142" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-016.53" LOG_CI_END="0.42013363015458804" LOG_CI_START="-0.9977247086485272" LOG_EFFECT_SIZE="-0.2887955392469696" METHOD="MH" MODIFIED="2009-01-02 09:06:53 -0500" MODIFIED_BY="[Empty name]" NO="53" P_CHI2="1.0" P_Q="0.0" P_Z="0.42462220237766224" Q="0.0" RANDOM="NO" SCALE="431.01" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="36" WEIGHT="100.0" Z="0.7984279392787537">
<NAME>Withdrawals due to adverse events, Lef vs. Lef+CsA, at 12 months</NAME>
<GROUP_LABEL_1>Lef+CsA</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CsA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.631077436208686" CI_START="0.10052527997788245" EFFECT_SIZE="0.5142857142857142" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.42013363015458804" LOG_CI_START="-0.9977247086485272" LOG_EFFECT_SIZE="-0.2887955392469696" MODIFIED="2008-11-17 10:55:50 -0500" MODIFIED_BY="[Empty name]" ORDER="458" O_E="0.0" SE="0.8328570067249201" STUDY_ID="STD-Karanikolas-2006" TOTAL_1="35" TOTAL_2="36" VAR="0.6936507936507936" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.817176968888557E-33" CI_END="8.02767124757876" CI_START="0.02669948711964154" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.462962962962963" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="100.0" I2_Q="0.0" ID="CMP-016.54" LOG_CI_END="0.9045895787773421" LOG_CI_START="-1.5734970810792037" LOG_EFFECT_SIZE="-0.33445375115093084" METHOD="MH" MODIFIED="2009-01-02 09:07:15 -0500" MODIFIED_BY="[Empty name]" NO="54" P_CHI2="0.0" P_Q="0.0" P_Z="0.5967699651056404" Q="0.0" RANDOM="NO" SCALE="431.01" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="49" WEIGHT="100.0" Z="0.529051156579079">
<NAME>Withdrawals due to adverse events, Lef vs. Lef+MTX, at 3 months</NAME>
<GROUP_LABEL_1>Lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.02767124757876" CI_START="0.02669948711964154" EFFECT_SIZE="0.46296296296296297" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.9045895787773421" LOG_CI_START="-1.5734970810792037" LOG_EFFECT_SIZE="-0.3344537511509309" MODIFIED="2008-11-20 10:08:05 -0500" MODIFIED_BY="[Empty name]" ORDER="453" O_E="0.0" SE="1.4556403707265366" STUDY_ID="STD-Antony-2006" TOTAL_1="11" TOTAL_2="49" VAR="2.118888888888889" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4285718007246306" CI_START="0.3937498974253004" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-016.55" LOG_CI_END="0.15490207312258586" LOG_CI_START="-0.4047795463391858" LOG_EFFECT_SIZE="-0.12493873660829993" METHOD="MH" MODIFIED="2009-01-02 08:55:58 -0500" MODIFIED_BY="[Empty name]" NO="55" P_CHI2="1.0" P_Q="0.0" P_Z="0.38154530345586646" Q="0.0" RANDOM="NO" SCALE="29.94" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="233" TOTAL_2="233" WEIGHT="100.0" Z="0.8750525852955219">
<NAME>Total withdrawals, Lef+MTX vs. MTX, at 36 months</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef+MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4285718007246306" CI_START="0.3937498974253004" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="20" LOG_CI_END="0.15490207312258586" LOG_CI_START="-0.4047795463391858" LOG_EFFECT_SIZE="-0.12493873660829993" MODIFIED="2008-11-21 09:52:09 -0500" MODIFIED_BY="[Empty name]" ORDER="475" O_E="0.0" SE="0.32875975374054256" STUDY_ID="STD-Amit-2006" TOTAL_1="233" TOTAL_2="233" VAR="0.1080829756795422" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8134070754170961" CI_START="0.40514558893624897" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-016.56" LOG_CI_END="0.2584953058951849" LOG_CI_START="-0.39238888515641135" LOG_EFFECT_SIZE="-0.06694678963061322" METHOD="MH" MODIFIED="2009-01-02 08:56:42 -0500" MODIFIED_BY="[Empty name]" NO="56" P_CHI2="1.0" P_Q="0.0" P_Z="0.6868123035416808" Q="0.0" RANDOM="NO" SCALE="431.01" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="233" TOTAL_2="233" WEIGHT="100.0" Z="0.40318477038008155">
<NAME>Withdrawals due to adverse events, Lef+MTX vs. MTX, at 36 months</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef+MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8134070754170961" CI_START="0.40514558893624897" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.2584953058951849" LOG_CI_START="-0.39238888515641135" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2008-11-21 09:54:08 -0500" MODIFIED_BY="[Empty name]" ORDER="476" O_E="0.0" SE="0.3823325957524159" STUDY_ID="STD-Amit-2006" TOTAL_1="233" TOTAL_2="233" VAR="0.1461782137747803" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.63088666609965" CI_START="0.8465897796370725" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-016.57" LOG_CI_END="1.0265694882425271" LOG_CI_START="-0.0723269788032026" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="MH" MODIFIED="2009-01-02 10:03:01 -0500" MODIFIED_BY="[Empty name]" NO="57" P_CHI2="1.0" P_Q="0.0" P_Z="0.08876233462882928" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0" Z="1.7019628391801616">
<NAME>Reported adverse events, weekly Lef vs. daily Lef</NAME>
<GROUP_LABEL_1>daily Lef</GROUP_LABEL_1>
<GROUP_LABEL_2>weekly Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours daily Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours weekly Lef</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.63088666609965" CI_START="0.8465897796370725" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.0265694882425271" LOG_CI_START="-0.0723269788032026" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2008-11-21 10:52:51 -0500" MODIFIED_BY="[Empty name]" ORDER="483" O_E="0.0" SE="0.6454972243679028" STUDY_ID="STD-Jakez_x002d_Ocampo-2002" TOTAL_1="8" TOTAL_2="8" VAR="0.41666666666666663" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="90.1806363901012" CI_START="0.2772213747955338" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-016.58" LOG_CI_END="1.9551132957269735" LOG_CI_START="-0.5571732870549357" LOG_EFFECT_SIZE="0.6989700043360189" METHOD="MH" MODIFIED="2009-01-02 10:02:26 -0500" MODIFIED_BY="[Empty name]" NO="58" P_CHI2="1.0" P_Q="0.0" P_Z="0.27544678733539196" Q="0.0" RANDOM="NO" SCALE="431.01" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0" Z="1.0906049048396544">
<NAME>Withdrawals due to adverse events, weekly Lef vs. daily Lef</NAME>
<GROUP_LABEL_1>daily Lef</GROUP_LABEL_1>
<GROUP_LABEL_2>weekly Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours daily Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours weekly Lef</GRAPH_LABEL_2>
<DICH_DATA CI_END="90.1806363901012" CI_START="0.2772213747955338" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9551132957269735" LOG_CI_START="-0.5571732870549357" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2008-11-21 10:51:49 -0500" MODIFIED_BY="[Empty name]" ORDER="485" O_E="0.0" SE="1.4757295747452437" STUDY_ID="STD-Jakez_x002d_Ocampo-2002" TOTAL_1="8" TOTAL_2="8" VAR="2.1777777777777776" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.009108803879009" CI_START="0.5192567307588873" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-016.59" LOG_CI_END="0.47843789131933057" LOG_CI_START="-0.2846178653032177" LOG_EFFECT_SIZE="0.09691001300805642" METHOD="MH" MODIFIED="2009-01-02 08:54:01 -0500" MODIFIED_BY="[Empty name]" NO="59" P_CHI2="1.0" P_Q="0.0" P_Z="0.6185962744902083" Q="0.0" RANDOM="NO" SCALE="29.94" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="83" TOTAL_2="83" WEIGHT="100.0" Z="0.49784077661065124">
<NAME>Total withdrawals, Lef+MTX vs. MTX, at 24 months</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef+MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.009108803879009" CI_START="0.5192567307588873" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.47843789131933057" LOG_CI_START="-0.2846178653032177" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2008-12-02 11:29:28 -0500" MODIFIED_BY="[Empty name]" ORDER="479" O_E="0.0" SE="0.4482227286269978" STUDY_ID="STD-Amit-2004" TOTAL_1="83" TOTAL_2="83" VAR="0.2009036144578313" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.233573242366921" CI_START="0.46296588904747427" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-016.60" LOG_CI_END="0.6267070776261904" LOG_CI_START="-0.3344510062697144" LOG_EFFECT_SIZE="0.14612803567823798" METHOD="MH" MODIFIED="2009-01-02 08:54:37 -0500" MODIFIED_BY="[Empty name]" NO="60" P_CHI2="1.0" P_Q="0.0" P_Z="0.5512022282755797" Q="0.0" RANDOM="NO" SCALE="431.01" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="83" TOTAL_2="83" WEIGHT="100.0" Z="0.5959595863773619">
<NAME>Withdrawals due to adverse events, Lef+MTX vs. MTX, at 24 months</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef+MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.233573242366921" CI_START="0.46296588904747427" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6267070776261904" LOG_CI_START="-0.3344510062697144" LOG_EFFECT_SIZE="0.14612803567823798" MODIFIED="2008-12-02 11:30:19 -0500" MODIFIED_BY="[Empty name]" ORDER="480" O_E="0.0" SE="0.5645890162897027" STUDY_ID="STD-Amit-2004" TOTAL_1="83" TOTAL_2="83" VAR="0.3187607573149742" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.488600411843581" CI_START="1.2910228556689636" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-016.61" LOG_CI_END="0.9772021578182929" LOG_CI_START="0.11093393088225852" LOG_EFFECT_SIZE="0.5440680443502757" METHOD="MH" MODIFIED="2009-01-02 08:57:03 -0500" MODIFIED_BY="[Empty name]" NO="61" P_CHI2="1.0" P_Q="0.0" P_Z="0.013818460393870502" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="2.461948248609657">
<NAME>Reported adverse events in Lef+MTX vs. MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.488600411843576" CI_START="1.2910228556689638" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" LOG_CI_END="0.9772021578182927" LOG_CI_START="0.11093393088225859" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2008-12-04 12:10:15 -0500" MODIFIED_BY="[Empty name]" ORDER="487" O_E="0.0" SE="0.5088502445991073" STUDY_ID="STD-Lao-2002" TOTAL_1="32" TOTAL_2="32" VAR="0.2589285714285714" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.931409775025128" CI_START="0.046558835083477614" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4791666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-016.62" LOG_CI_END="0.6929710916891421" LOG_CI_START="-1.331997894405131" LOG_EFFECT_SIZE="-0.31951340135799433" METHOD="MH" MODIFIED="2009-01-02 09:17:23 -0500" MODIFIED_BY="[Empty name]" NO="62" P_CHI2="1.0" P_Q="0.0" P_Z="0.5362372749139819" Q="0.0" RANDOM="NO" SCALE="431.01" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="0.6185129387560958">
<NAME>Withdrawals due to adverse events, weekly Lef200 vs. weekly Lef100, at 6 months</NAME>
<GROUP_LABEL_1>weekly Lef100</GROUP_LABEL_1>
<GROUP_LABEL_2>weekly Lef200</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours weekly Lef100</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours weekly Lef200</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.931409775025128" CI_START="0.046558835083477614" EFFECT_SIZE="0.4791666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6929710916891421" LOG_CI_START="-1.331997894405131" LOG_EFFECT_SIZE="-0.31951340135799433" MODIFIED="2008-12-18 11:52:46 -0500" MODIFIED_BY="[Empty name]" ORDER="558" O_E="0.0" SE="1.1894768061899181" STUDY_ID="STD-Rozman-1994a" TOTAL_1="24" TOTAL_2="23" VAR="1.414855072463768" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-017" MODIFIED="2009-07-22 12:41:18 -0400" MODIFIED_BY="[Empty name]" NO="17">
<NAME>Subgroup analysis</NAME>
<DICH_OUTCOME CHI2="99.94369104333268" CI_END="1.0826200023920067" CI_START="0.8033225727646052" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="0.932573367434418" ESTIMABLE="YES" EVENTS_1="1026" EVENTS_2="1156" I2="85.99211230458758" I2_Q="0.0" ID="CMP-017.01" LOG_CI_END="0.03447604681584377" LOG_CI_START="-0.09511002951440396" LOG_EFFECT_SIZE="-0.03031699134928006" METHOD="MH" MODIFIED="2009-07-22 12:41:18 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="4.9960036108132044E-15" P_Q="0.0" P_Z="0.3591022536406784" Q="0.0" RANDOM="YES" SCALE="2.81" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.07444052560738074" TOTALS="SUB" TOTAL_1="2013" TOTAL_2="2081" WEIGHT="300.0" Z="0.9170770941898113">
<NAME>ACR20 Treatment responder</NAME>
<GROUP_LABEL_1>control</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="36.73737092060124" CI_END="1.1512396460016279" CI_START="0.731684742114357" DF="6" EFFECT_SIZE="0.9177932683870179" ESTIMABLE="YES" EVENTS_1="612" EVENTS_2="597" I2="83.66785687259026" ID="CMP-017.01.01" LOG_CI_END="0.061165737272588554" LOG_CI_START="-0.13567600125283136" LOG_EFFECT_SIZE="-0.03725513199012141" MODIFIED="2008-12-09 11:47:17 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.981118312843755E-6" P_Z="0.4581462445838539" STUDIES="7" TAU2="0.06663285915519787" TOTAL_1="1127" TOTAL_2="1136" WEIGHT="100.0" Z="0.7419027843070428">
<NAME>Quality of blinding = 1</NAME>
<DICH_DATA CI_END="1.1120095431232828" CI_START="0.7446878537338171" EFFECT_SIZE="0.91" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="100" LOG_CI_END="0.046108514321576345" LOG_CI_START="-0.12802572967938916" LOG_EFFECT_SIZE="-0.040958607678906384" ORDER="34677" O_E="0.0" SE="0.10228731690457672" STUDY_ID="STD-Cohen-2001" TOTAL_1="190" TOTAL_2="190" VAR="0.010462695199537308" WEIGHT="17.341244145970258"/>
<DICH_DATA CI_END="1.8763265886990554" CI_START="0.4911724886012451" EFFECT_SIZE="0.96" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.27330843283054834" LOG_CI_START="-0.30876596675141155" LOG_EFFECT_SIZE="-0.017728766960431602" ORDER="34678" O_E="0.0" SE="0.3419133836291904" STUDY_ID="STD-Dougados-2005" TOTAL_1="50" TOTAL_2="56" VAR="0.11690476190476193" WEIGHT="7.284244085290946"/>
<DICH_DATA CI_END="1.431288752059266" CI_START="1.1510758129384389" EFFECT_SIZE="1.283558282208589" ESTIMABLE="YES" EVENTS_1="317" EVENTS_2="250" LOG_CI_END="0.15572725834084816" LOG_CI_START="0.06110392837047647" LOG_EFFECT_SIZE="0.10841559335566235" ORDER="34679" O_E="0.0" SE="0.05558221241763383" STUDY_ID="STD-Emery-1999" TOTAL_1="489" TOTAL_2="495" VAR="0.0030893823372389684" WEIGHT="19.17512693247832"/>
<DICH_DATA CI_END="0.7152113269311353" CI_START="0.3659560295851551" EFFECT_SIZE="0.5116013071895424" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="60" LOG_CI_END="-0.14556561615741917" LOG_CI_START="-0.4365710928998727" LOG_EFFECT_SIZE="-0.291068354528646" ORDER="34680" O_E="0.0" SE="0.1709380575388592" STUDY_ID="STD-Mladenovic-1995" TOTAL_1="102" TOTAL_2="101" VAR="0.02921981951515834" WEIGHT="13.947787888455208"/>
<DICH_DATA CI_END="1.0581971181918692" CI_START="0.731030750685526" EFFECT_SIZE="0.8795309168443497" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="112" LOG_CI_END="0.024566574475311027" LOG_CI_START="-0.1360643541335897" LOG_EFFECT_SIZE="-0.055748889829139364" ORDER="34681" O_E="0.0" SE="0.0943554026007887" STUDY_ID="STD-Poor-2004" TOTAL_1="201" TOTAL_2="198" VAR="0.008902941999956924" WEIGHT="17.699326811775624"/>
<DICH_DATA CI_END="1.8132673198095044" CI_START="0.500218290237172" EFFECT_SIZE="0.9523809523809523" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.2584618344099575" LOG_CI_START="-0.3008404325498337" LOG_EFFECT_SIZE="-0.021189299069938095" ORDER="34682" O_E="0.0" SE="0.3285369202030541" STUDY_ID="STD-Reece-2002" TOTAL_1="21" TOTAL_2="18" VAR="0.10793650793650794" WEIGHT="7.658461807517798"/>
<DICH_DATA CI_END="1.2871062437819107" CI_START="0.8303191106230083" EFFECT_SIZE="1.0337837837837838" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="52" LOG_CI_END="0.10961439708606277" LOG_CI_START="-0.08075496624077991" LOG_EFFECT_SIZE="0.014429715422641409" MODIFIED="2008-12-09 11:44:37 -0500" MODIFIED_BY="[Empty name]" ORDER="548" O_E="0.0" SE="0.11182390636173375" STUDY_ID="STD-Scott-2001" TOTAL_1="74" TOTAL_2="78" VAR="0.0125045860339978" WEIGHT="16.89380832851184"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="34.06581999540338" CI_END="0.9403242762197991" CI_START="0.36008856029280345" DF="3" EFFECT_SIZE="0.5818934737839564" ESTIMABLE="YES" EVENTS_1="232" EVENTS_2="433" I2="91.1935188984008" ID="CMP-017.01.02" LOG_CI_END="-0.026722351627082225" LOG_CI_START="-0.4435906755757488" LOG_EFFECT_SIZE="-0.23515651360141548" MODIFIED="2008-12-09 11:48:39 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.9188160671479437E-7" P_Z="0.02701910854336441" STUDIES="4" TAU2="0.21391339365238496" TOTAL_1="585" TOTAL_2="765" WEIGHT="100.00000000000003" Z="2.2112416363183933">
<NAME>Quality of blinding &gt; 1</NAME>
<DICH_DATA CI_END="1.0885060370614963" CI_START="0.8409951695079767" EFFECT_SIZE="0.9567801832965548" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="207" LOG_CI_END="0.03683084206358449" LOG_CI_START="-0.07520649868729044" LOG_EFFECT_SIZE="-0.01918782831185299" MODIFIED="2008-12-09 11:48:39 -0500" MODIFIED_BY="[Empty name]" ORDER="550" O_E="0.0" SE="0.06581128855084503" STUDY_ID="STD-Bao-2003" TOTAL_1="243" TOTAL_2="323" VAR="0.004331125700722587" WEIGHT="27.47449066892894"/>
<DICH_DATA CI_END="0.6265815684325445" CI_START="0.2863188904240985" EFFECT_SIZE="0.42355889724310775" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="60" LOG_CI_END="-0.2030223845034222" LOG_CI_START="-0.5431499976427272" LOG_EFFECT_SIZE="-0.3730861910730747" ORDER="34684" O_E="0.0" SE="0.19979264361686652" STUDY_ID="STD-Kremer-2002" TOTAL_1="133" TOTAL_2="130" VAR="0.03991710044341623" WEIGHT="23.622681868352483"/>
<DICH_DATA CI_END="0.7503402220134416" CI_START="0.36473353095230193" EFFECT_SIZE="0.5231388329979879" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="71" LOG_CI_END="-0.12474177255518132" LOG_CI_START="-0.43802430896984695" LOG_EFFECT_SIZE="-0.28138304076251414" ORDER="34685" O_E="0.0" SE="0.18402371266354045" STUDY_ID="STD-Smolen-1999" TOTAL_1="91" TOTAL_2="130" VAR="0.0338647268224733" WEIGHT="24.19970334354141"/>
<DICH_DATA CI_END="0.7019715692279247" CI_START="0.3608572336380819" EFFECT_SIZE="0.503300624442462" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="95" LOG_CI_END="-0.15368047701188517" LOG_CI_START="-0.4426645845393663" LOG_EFFECT_SIZE="-0.2981725307756257" ORDER="34686" O_E="0.0" SE="0.16975069525604536" STUDY_ID="STD-Strand-1999a" TOTAL_1="118" TOTAL_2="182" VAR="0.02881529853991078" WEIGHT="24.703124119177183"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.948801445215317" CI_END="1.2963163790742285" CI_START="0.8388518639286762" DF="3" EFFECT_SIZE="1.0427930815016413" ESTIMABLE="YES" EVENTS_1="182" EVENTS_2="126" I2="72.59974057424326" ID="CMP-017.01.03" LOG_CI_END="0.11271100841546176" LOG_CI_START="-0.07631472613025841" LOG_EFFECT_SIZE="0.01819814114260164" MODIFIED="2009-07-22 12:41:18 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.012006013229230228" P_Z="0.7058878057034117" STUDIES="4" TAU2="0.03434476688789703" TOTAL_1="301" TOTAL_2="180" WEIGHT="99.99999999999999" Z="0.3773846065012783">
<NAME>Quality of blinding &lt; 1</NAME>
<DICH_DATA CI_END="1.5801794573018788" CI_START="0.8128471981515345" EFFECT_SIZE="1.1333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.1987064115684707" LOG_CI_START="-0.08999108692328527" LOG_EFFECT_SIZE="0.054357662322592676" MODIFIED="2008-12-09 11:57:52 -0500" MODIFIED_BY="[Empty name]" ORDER="551" O_E="0.0" SE="0.1695823396897228" STUDY_ID="STD-Jakez_x002d_Ocampo-2002" TOTAL_1="8" TOTAL_2="8" VAR="0.02875816993464053" WEIGHT="19.537432966063967"/>
<DICH_DATA CI_END="1.5583062881943164" CI_START="0.8674953425438741" EFFECT_SIZE="1.1626794258373205" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="19" LOG_CI_END="0.19265282316915547" LOG_CI_START="-0.0617328481946391" LOG_EFFECT_SIZE="0.06545998748725818" MODIFIED="2008-12-09 11:58:55 -0500" MODIFIED_BY="[Empty name]" ORDER="552" O_E="0.0" SE="0.14942740258847476" STUDY_ID="STD-Karanikolas-2006" TOTAL_1="33" TOTAL_2="27" VAR="0.022328548644338114" WEIGHT="21.75396633413577"/>
<DICH_DATA CI_END="0.9918103452831513" CI_START="0.6919142832959375" EFFECT_SIZE="0.8284007147643512" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="74" LOG_CI_END="-0.003571366022773189" LOG_CI_START="-0.1599477040943204" LOG_EFFECT_SIZE="-0.0817595350585468" MODIFIED="2008-12-09 11:59:38 -0500" MODIFIED_BY="[Empty name]" ORDER="553" O_E="0.0" SE="0.09185623505858444" STUDY_ID="STD-Mariette-2004" TOTAL_1="242" TOTAL_2="115" VAR="0.008437567919137917" WEIGHT="28.81725374953985"/>
<DICH_DATA CI_END="1.3404215092468519" CI_START="0.9678911224714006" EFFECT_SIZE="1.1390268123138034" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="26" LOG_CI_END="0.12724138818163785" LOG_CI_START="-0.014173493486338486" LOG_EFFECT_SIZE="0.05653394734764969" MODIFIED="2008-12-09 11:59:54 -0500" MODIFIED_BY="[Empty name]" ORDER="554" O_E="0.0" SE="0.08306780150672324" STUDY_ID="STD-Wislowska-2007" TOTAL_1="18" TOTAL_2="30" VAR="0.006900259647160373" WEIGHT="29.891346950260395"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="48.76307106751753" CI_END="1.2815845343267795" CI_START="1.0605899778097916" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1658626474945541" ESTIMABLE="YES" EVENTS_1="760" EVENTS_2="702" I2="85.64487460129865" I2_Q="0.0" ID="CMP-017.02" LOG_CI_END="0.1077472578716657" LOG_CI_START="0.025547518876764888" LOG_EFFECT_SIZE="0.06664738837421526" METHOD="MH" MODIFIED="2008-12-09 12:06:07 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="2.524840614359647E-8" P_Q="0.0" P_Z="0.001481567295365093" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.05833427867230073" TOTALS="SUB" TOTAL_1="1447" TOTAL_2="1336" WEIGHT="200.0" Z="3.178269967139888">
<NAME>ACR20 Treatment responder</NAME>
<GROUP_LABEL_1>control</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.431288752059266" CI_START="1.1510758129384389" DF="0" EFFECT_SIZE="1.283558282208589" ESTIMABLE="YES" EVENTS_1="317" EVENTS_2="250" I2="0.0" ID="CMP-017.02.01" LOG_CI_END="0.15572725834084816" LOG_CI_START="0.06110392837047647" LOG_EFFECT_SIZE="0.10841559335566235" NO="1" P_CHI2="1.0" P_Z="7.079132033366704E-6" STUDIES="1" TAU2="0.0" TOTAL_1="489" TOTAL_2="495" WEIGHT="100.0" Z="4.491295294853245">
<NAME>RA duration &lt; 5 years</NAME>
<DICH_DATA CI_END="1.431288752059266" CI_START="1.1510758129384389" EFFECT_SIZE="1.283558282208589" ESTIMABLE="YES" EVENTS_1="317" EVENTS_2="250" LOG_CI_END="0.15572725834084816" LOG_CI_START="0.06110392837047647" LOG_EFFECT_SIZE="0.10841559335566235" ORDER="34687" O_E="0.0" SE="0.05558221241763383" STUDY_ID="STD-Emery-1999" TOTAL_1="489" TOTAL_2="495" VAR="0.0030893823372389684" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="28.29151997246512" CI_END="1.049910803308494" CI_START="0.7164782735418845" DF="6" EFFECT_SIZE="0.8673167124686592" ESTIMABLE="YES" EVENTS_1="443" EVENTS_2="452" I2="78.79223171522939" ID="CMP-017.02.02" LOG_CI_END="0.02115240452100074" LOG_CI_START="-0.1447969745952243" LOG_EFFECT_SIZE="-0.06182228503711183" MODIFIED="2008-12-09 12:05:08 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="8.279738570238226E-5" P_Z="0.1442026330416077" STUDIES="7" TAU2="0.04747217660631171" TOTAL_1="958" TOTAL_2="841" WEIGHT="99.99999999999999" Z="1.4603182339097016">
<NAME>RA duration =&gt; 5 years</NAME>
<DICH_DATA CI_END="1.8763265886990554" CI_START="0.4911724886012451" EFFECT_SIZE="0.96" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.27330843283054834" LOG_CI_START="-0.30876596675141155" LOG_EFFECT_SIZE="-0.017728766960431602" ORDER="34688" O_E="0.0" SE="0.3419133836291904" STUDY_ID="STD-Dougados-2005" TOTAL_1="50" TOTAL_2="56" VAR="0.11690476190476193" WEIGHT="5.780768533710369"/>
<DICH_DATA CI_END="0.6265815684325445" CI_START="0.2863188904240985" EFFECT_SIZE="0.42355889724310775" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="60" LOG_CI_END="-0.2030223845034222" LOG_CI_START="-0.5431499976427272" LOG_EFFECT_SIZE="-0.3730861910730747" ORDER="34689" O_E="0.0" SE="0.19979264361686652" STUDY_ID="STD-Kremer-2002" TOTAL_1="133" TOTAL_2="130" VAR="0.03991710044341623" WEIGHT="10.873474022124514"/>
<DICH_DATA CI_END="0.9918103452831513" CI_START="0.6919142832959375" EFFECT_SIZE="0.8284007147643512" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="74" LOG_CI_END="-0.003571366022773189" LOG_CI_START="-0.1599477040943204" LOG_EFFECT_SIZE="-0.0817595350585468" MODIFIED="2008-12-09 12:04:27 -0500" MODIFIED_BY="[Empty name]" ORDER="555" O_E="0.0" SE="0.09185623505858444" STUDY_ID="STD-Mariette-2004" TOTAL_1="242" TOTAL_2="115" VAR="0.008437567919137917" WEIGHT="16.99569622214826"/>
<DICH_DATA CI_END="1.0581971181918692" CI_START="0.731030750685526" EFFECT_SIZE="0.8795309168443497" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="112" LOG_CI_END="0.024566574475311027" LOG_CI_START="-0.1360643541335897" LOG_EFFECT_SIZE="-0.055748889829139364" ORDER="34690" O_E="0.0" SE="0.0943554026007887" STUDY_ID="STD-Poor-2004" TOTAL_1="201" TOTAL_2="198" VAR="0.008902941999956924" WEIGHT="16.85539751053931"/>
<DICH_DATA CI_END="1.2760288510455133" CI_START="0.8257053343849237" EFFECT_SIZE="1.0264618011096884" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="71" LOG_CI_END="0.10586049390568614" LOG_CI_START="-0.08317490967991055" LOG_EFFECT_SIZE="0.011342792112887806" MODIFIED="2008-12-09 12:04:52 -0500" MODIFIED_BY="[Empty name]" ORDER="556" O_E="0.0" SE="0.1110403318065187" STUDY_ID="STD-Smolen-1999" TOTAL_1="132" TOTAL_2="130" VAR="0.012329955287701769" WEIGHT="15.889484266155092"/>
<DICH_DATA CI_END="1.0904522777924728" CI_START="0.716976130702748" EFFECT_SIZE="0.8842105263157894" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="95" LOG_CI_END="0.03760666400467908" LOG_CI_START="-0.1444953024586114" LOG_EFFECT_SIZE="-0.05344431922696612" ORDER="34691" O_E="0.0" SE="0.10696759651980872" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="182" VAR="0.011442066705224595" WEIGHT="16.12895253169432"/>
<DICH_DATA CI_END="1.3404215092468519" CI_START="0.9678911224714006" EFFECT_SIZE="1.1390268123138034" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="26" LOG_CI_END="0.12724138818163785" LOG_CI_START="-0.014173493486338486" LOG_EFFECT_SIZE="0.05653394734764969" MODIFIED="2008-12-09 12:05:08 -0500" MODIFIED_BY="[Empty name]" ORDER="557" O_E="0.0" SE="0.08306780150672324" STUDY_ID="STD-Wislowska-2007" TOTAL_1="18" TOTAL_2="30" VAR="0.006900259647160373" WEIGHT="17.476226913628132"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="22.893379246960922" CI_END="0.7052239483496684" CI_START="0.47138594377578463" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.576569732526859" ESTIMABLE="YES" EVENTS_1="267" EVENTS_2="398" I2="82.52769957265703" I2_Q="0.0" ID="CMP-017.03" LOG_CI_END="-0.15167294813177024" LOG_CI_START="-0.32662337181514783" LOG_EFFECT_SIZE="-0.23914815997345898" METHOD="MH" MODIFIED="2008-12-09 12:16:57 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.3299071373773508E-4" P_Q="0.0" P_Z="8.39908464646142E-8" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.09037025069221644" TOTALS="SUB" TOTAL_1="709" TOTAL_2="741" WEIGHT="200.0" Z="5.358338329780646">
<NAME>ACR20 Treatment responder</NAME>
<GROUP_LABEL_1>control</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.007916107513028785" CI_END="0.6607302395851424" CI_START="0.4044001357255574" DF="1" EFFECT_SIZE="0.5169133375781783" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="131" I2="0.0" ID="CMP-017.03.01" LOG_CI_END="-0.17997581641790883" LOG_CI_START="-0.3931887073222563" LOG_EFFECT_SIZE="-0.2865822618700825" NO="1" P_CHI2="0.9291037577328208" P_Z="1.3729832834765442E-7" STUDIES="2" TAU2="0.0" TOTAL_1="193" TOTAL_2="231" WEIGHT="100.0" Z="5.268826940913029">
<NAME>Concomitant steroid use &lt;50%</NAME>
<DICH_DATA CI_END="0.7152113269311353" CI_START="0.3659560295851551" EFFECT_SIZE="0.5116013071895424" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="60" LOG_CI_END="-0.14556561615741917" LOG_CI_START="-0.4365710928998727" LOG_EFFECT_SIZE="-0.291068354528646" ORDER="34692" O_E="0.0" SE="0.1709380575388592" STUDY_ID="STD-Mladenovic-1995" TOTAL_1="102" TOTAL_2="101" VAR="0.02921981951515834" WEIGHT="53.681493786493434"/>
<DICH_DATA CI_END="0.7503402220134416" CI_START="0.36473353095230193" EFFECT_SIZE="0.5231388329979879" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="71" LOG_CI_END="-0.12474177255518132" LOG_CI_START="-0.43802430896984695" LOG_EFFECT_SIZE="-0.28138304076251414" ORDER="34693" O_E="0.0" SE="0.18402371266354045" STUDY_ID="STD-Smolen-1999" TOTAL_1="91" TOTAL_2="130" VAR="0.0338647268224733" WEIGHT="46.318506213506566"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.37951621895608" CI_END="1.0271774216556144" CI_START="0.5076514405120367" DF="2" EFFECT_SIZE="0.7221136321694199" ESTIMABLE="YES" EVENTS_1="210" EVENTS_2="267" I2="83.84427981977592" ID="CMP-017.03.02" LOG_CI_END="0.011645464620664764" LOG_CI_START="-0.2944343771238093" LOG_EFFECT_SIZE="-0.14139445625157232" NO="2" P_CHI2="0.002050333352457301" P_Z="0.07016842355912817" STUDIES="3" TAU2="0.07871189025774009" TOTAL_1="516" TOTAL_2="510" WEIGHT="100.0" Z="1.8108219103044492">
<NAME>Concomitant steroid use =&gt; 50%</NAME>
<DICH_DATA CI_END="0.6265815684325445" CI_START="0.2863188904240985" EFFECT_SIZE="0.42355889724310775" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="60" LOG_CI_END="-0.2030223845034222" LOG_CI_START="-0.5431499976427272" LOG_EFFECT_SIZE="-0.3730861910730747" ORDER="34694" O_E="0.0" SE="0.19979264361686652" STUDY_ID="STD-Kremer-2002" TOTAL_1="133" TOTAL_2="130" VAR="0.03991710044341623" WEIGHT="27.249204290317973"/>
<DICH_DATA CI_END="1.0581971181918692" CI_START="0.731030750685526" EFFECT_SIZE="0.8795309168443497" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="112" LOG_CI_END="0.024566574475311027" LOG_CI_START="-0.1360643541335897" LOG_EFFECT_SIZE="-0.055748889829139364" ORDER="34695" O_E="0.0" SE="0.0943554026007887" STUDY_ID="STD-Poor-2004" TOTAL_1="201" TOTAL_2="198" VAR="0.008902941999956924" WEIGHT="36.89495852554188"/>
<DICH_DATA CI_END="1.0904522777924728" CI_START="0.716976130702748" EFFECT_SIZE="0.8842105263157894" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="95" LOG_CI_END="0.03760666400467908" LOG_CI_START="-0.1444953024586114" LOG_EFFECT_SIZE="-0.05344431922696612" ORDER="34696" O_E="0.0" SE="0.10696759651980872" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="182" VAR="0.011442066705224595" WEIGHT="35.85583718414015"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="77.45659389926477" CI_END="1.0483085135196057" CI_START="0.6737464669050804" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8404130872436192" ESTIMABLE="YES" EVENTS_1="768" EVENTS_2="897" I2="88.38058898935726" I2_Q="0.0" ID="CMP-017.04" LOG_CI_END="0.020489112801772052" LOG_CI_START="-0.17150349921915778" LOG_EFFECT_SIZE="-0.07550719320869288" METHOD="MH" MODIFIED="2008-12-09 12:16:11 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="5.161426841482353E-13" P_Q="0.0" P_Z="0.12316202651163609" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.08302995787062893" TOTALS="SUB" TOTAL_1="1517" TOTAL_2="1653" WEIGHT="200.0" Z="1.54163618802803">
<NAME>ACR20 Treatment responder</NAME>
<GROUP_LABEL_1>control</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="62.37237267899976" CI_END="1.1079847468646158" CI_START="0.6683968338446329" DF="6" EFFECT_SIZE="0.8605658003618644" ESTIMABLE="YES" EVENTS_1="584" EVENTS_2="610" I2="90.38035633039154" ID="CMP-017.04.01" LOG_CI_END="0.04453378169374114" LOG_CI_START="-0.17496561600046184" LOG_EFFECT_SIZE="-0.06521591715336036" MODIFIED="2008-12-09 12:15:53 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.4816925464344877E-11" P_Z="0.2441575351641334" STUDIES="7" TAU2="0.09944223863379605" TOTAL_1="1133" TOTAL_2="1144" WEIGHT="99.99999999999999" Z="1.1646578549377948">
<NAME>Withdrawals &lt; 50% patients randomized</NAME>
<DICH_DATA CI_END="1.431288752059266" CI_START="1.1510758129384389" EFFECT_SIZE="1.283558282208589" ESTIMABLE="YES" EVENTS_1="317" EVENTS_2="250" LOG_CI_END="0.15572725834084816" LOG_CI_START="0.06110392837047647" LOG_EFFECT_SIZE="0.10841559335566235" MODIFIED="2008-12-09 12:13:44 -0500" MODIFIED_BY="[Empty name]" ORDER="558" O_E="0.0" SE="0.05558221241763383" STUDY_ID="STD-Emery-1999" TOTAL_1="489" TOTAL_2="495" VAR="0.0030893823372389684" WEIGHT="16.213771431235525"/>
<DICH_DATA CI_END="1.5801794573018788" CI_START="0.8128471981515345" EFFECT_SIZE="1.1333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.1987064115684707" LOG_CI_START="-0.08999108692328527" LOG_EFFECT_SIZE="0.054357662322592676" MODIFIED="2008-12-09 12:15:53 -0500" MODIFIED_BY="[Empty name]" ORDER="559" O_E="0.0" SE="0.1695823396897228" STUDY_ID="STD-Jakez_x002d_Ocampo-2002" TOTAL_1="8" TOTAL_2="8" VAR="0.02875816993464053" WEIGHT="12.967386652367752"/>
<DICH_DATA CI_END="0.6265815684325445" CI_START="0.2863188904240985" EFFECT_SIZE="0.42355889724310775" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="60" LOG_CI_END="-0.2030223845034222" LOG_CI_START="-0.5431499976427272" LOG_EFFECT_SIZE="-0.3730861910730747" ORDER="34697" O_E="0.0" SE="0.19979264361686652" STUDY_ID="STD-Kremer-2002" TOTAL_1="133" TOTAL_2="130" VAR="0.03991710044341623" WEIGHT="11.92904815641647"/>
<DICH_DATA CI_END="0.7152113269311353" CI_START="0.3659560295851551" EFFECT_SIZE="0.5116013071895424" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="60" LOG_CI_END="-0.14556561615741917" LOG_CI_START="-0.4365710928998727" LOG_EFFECT_SIZE="-0.291068354528646" ORDER="34698" O_E="0.0" SE="0.1709380575388592" STUDY_ID="STD-Mladenovic-1995" TOTAL_1="102" TOTAL_2="101" VAR="0.02921981951515834" WEIGHT="12.920858649515916"/>
<DICH_DATA CI_END="1.0581971181918692" CI_START="0.731030750685526" EFFECT_SIZE="0.8795309168443497" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="112" LOG_CI_END="0.024566574475311027" LOG_CI_START="-0.1360643541335897" LOG_EFFECT_SIZE="-0.055748889829139364" ORDER="34699" O_E="0.0" SE="0.0943554026007887" STUDY_ID="STD-Poor-2004" TOTAL_1="201" TOTAL_2="198" VAR="0.008902941999956924" WEIGHT="15.343776780603186"/>
<DICH_DATA CI_END="1.0904522777924728" CI_START="0.716976130702748" EFFECT_SIZE="0.8842105263157894" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="95" LOG_CI_END="0.03760666400467908" LOG_CI_START="-0.1444953024586114" LOG_EFFECT_SIZE="-0.05344431922696612" ORDER="34700" O_E="0.0" SE="0.10696759651980872" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="182" VAR="0.011442066705224595" WEIGHT="14.99242171212325"/>
<DICH_DATA CI_END="1.3404215092468519" CI_START="0.9678911224714006" EFFECT_SIZE="1.1390268123138034" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="26" LOG_CI_END="0.12724138818163785" LOG_CI_START="-0.014173493486338486" LOG_EFFECT_SIZE="0.05653394734764969" MODIFIED="2008-12-09 12:15:15 -0500" MODIFIED_BY="[Empty name]" ORDER="560" O_E="0.0" SE="0.08306780150672324" STUDY_ID="STD-Wislowska-2007" TOTAL_1="18" TOTAL_2="30" VAR="0.006900259647160373" WEIGHT="15.632736617737896"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.167463145773603" CI_END="1.2275342667001699" CI_START="0.49308561244077775" DF="2" EFFECT_SIZE="0.7779970987657308" ESTIMABLE="YES" EVENTS_1="184" EVENTS_2="287" I2="80.32940988990595" ID="CMP-017.04.02" LOG_CI_END="0.08903362432338173" LOG_CI_START="-0.3070776693989734" LOG_EFFECT_SIZE="-0.10902202253779586" NO="2" P_CHI2="0.006196766461965986" P_Z="0.28063907788899556" STUDIES="3" TAU2="0.12224979954928675" TOTAL_1="384" TOTAL_2="509" WEIGHT="100.0" Z="1.078884854242845">
<NAME>Withdrawals =&gt; 50% patients randomized</NAME>
<DICH_DATA CI_END="1.0971285213405868" CI_START="0.8412749643541392" EFFECT_SIZE="0.9607219981257386" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="202" LOG_CI_END="0.040257505277219996" LOG_CI_START="-0.0750620351360119" LOG_EFFECT_SIZE="-0.017402264929395946" ORDER="34701" O_E="0.0" SE="0.06773926887966387" STUDY_ID="STD-Bao-2000" TOTAL_1="243" TOTAL_2="323" VAR="0.004588608548351399" WEIGHT="42.683386715518"/>
<DICH_DATA CI_END="1.8763265886990554" CI_START="0.4911724886012451" EFFECT_SIZE="0.96" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.27330843283054834" LOG_CI_START="-0.30876596675141155" LOG_EFFECT_SIZE="-0.017728766960431602" ORDER="34702" O_E="0.0" SE="0.3419133836291904" STUDY_ID="STD-Dougados-2005" TOTAL_1="50" TOTAL_2="56" VAR="0.11690476190476193" WEIGHT="22.637631455975413"/>
<DICH_DATA CI_END="0.7503402220134416" CI_START="0.36473353095230193" EFFECT_SIZE="0.5231388329979879" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="71" LOG_CI_END="-0.12474177255518132" LOG_CI_START="-0.43802430896984695" LOG_EFFECT_SIZE="-0.28138304076251414" ORDER="34703" O_E="0.0" SE="0.18402371266354045" STUDY_ID="STD-Smolen-1999" TOTAL_1="91" TOTAL_2="130" VAR="0.0338647268224733" WEIGHT="34.678981828506586"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-018" MODIFIED="2009-07-22 12:18:30 -0400" MODIFIED_BY="[Empty name]" NO="18">
<NAME>Summary of comparisons</NAME>
<DICH_OUTCOME CHI2="107.42276997219643" CI_END="0.9690245221883811" CI_START="0.7994928912083012" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8801864671171282" ESTIMABLE="YES" EVENTS_1="992" EVENTS_2="1114" I2="86.96738130693937" I2_Q="0.0" ID="CMP-018.01" LOG_CI_END="-0.013665232529890917" LOG_CI_START="-0.09718539348464246" LOG_EFFECT_SIZE="-0.05542531300726669" METHOD="MH" MODIFIED="2008-12-09 12:22:29 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.1102230246251565E-16" P_Q="0.0" P_Z="0.00928639386354839" Q="0.0" RANDOM="YES" SCALE="3.3" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.07634272990298822" TOTALS="SUB" TOTAL_1="1909" TOTAL_2="1980" WEIGHT="400.0" Z="2.6013268194000516">
<NAME>ACR20 Treatment responder</NAME>
<GROUP_LABEL_1>control</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.08164961887174922" CI_END="0.6157155876083914" CI_START="0.4164847767810528" DF="2" EFFECT_SIZE="0.5063952695925344" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="232" I2="0.0" ID="CMP-018.01.01" LOG_CI_END="-0.2106198515626207" LOG_CI_START="-0.38040086816070445" LOG_EFFECT_SIZE="-0.2955103598616626" MODIFIED="2008-12-08 09:07:13 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9599972985982314" P_Z="8.929242260979996E-12" STUDIES="3" TAU2="0.0" TOTAL_1="311" TOTAL_2="413" WEIGHT="100.0" Z="6.822784714011034">
<NAME>Lef vs placebo</NAME>
<DICH_DATA CI_END="0.7152113269311353" CI_START="0.3659560295851551" EFFECT_SIZE="0.5116013071895424" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="60" LOG_CI_END="-0.14556561615741917" LOG_CI_START="-0.4365710928998727" LOG_EFFECT_SIZE="-0.291068354528646" ORDER="484" O_E="0.0" SE="0.1709380575388592" STUDY_ID="STD-Mladenovic-1995" TOTAL_1="102" TOTAL_2="101" VAR="0.02921981951515834" WEIGHT="34.038932709942046"/>
<DICH_DATA CI_END="0.7503402220134416" CI_START="0.36473353095230193" EFFECT_SIZE="0.5231388329979879" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="71" LOG_CI_END="-0.12474177255518132" LOG_CI_START="-0.43802430896984695" LOG_EFFECT_SIZE="-0.28138304076251414" MODIFIED="2008-12-08 09:07:13 -0500" MODIFIED_BY="[Empty name]" ORDER="505" O_E="0.0" SE="0.18402371266354045" STUDY_ID="STD-Smolen-1999" TOTAL_1="91" TOTAL_2="130" VAR="0.0338647268224733" WEIGHT="29.37013121313834"/>
<DICH_DATA CI_END="0.67507969459288" CI_START="0.35373735584937394" EFFECT_SIZE="0.48867259607316665" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="101" LOG_CI_END="-0.1706449547557922" LOG_CI_START="-0.45131907481178224" LOG_EFFECT_SIZE="-0.3109820147837872" MODIFIED="2008-12-08 09:07:13 -0500" MODIFIED_BY="[Empty name]" ORDER="506" O_E="0.0" SE="0.1648693674801901" STUDY_ID="STD-Strand-1999a" TOTAL_1="118" TOTAL_2="182" VAR="0.027181908333317968" WEIGHT="36.59093607691961"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="16.525266278095494" CI_END="1.210605679309996" CI_START="0.956705350497594" DF="6" EFFECT_SIZE="1.0761937236105066" ESTIMABLE="YES" EVENTS_1="699" EVENTS_2="683" I2="63.6919617570514" ID="CMP-018.01.02" LOG_CI_END="0.08300270698542693" LOG_CI_START="-0.01922179718289659" LOG_EFFECT_SIZE="0.03189045490126515" MODIFIED="2008-12-08 10:02:53 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.011195827951246962" P_Z="0.22137510395071924" STUDIES="7" TAU2="0.014122396917643327" TOTAL_1="1128" TOTAL_2="1205" WEIGHT="99.99999999999999" Z="1.2228798479503273">
<NAME>Lef vs DMARDs</NAME>
<DICH_DATA CI_END="1.0885060370614963" CI_START="0.8409951695079767" EFFECT_SIZE="0.9567801832965548" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="207" LOG_CI_END="0.03683084206358449" LOG_CI_START="-0.07520649868729044" LOG_EFFECT_SIZE="-0.01918782831185299" MODIFIED="2008-12-08 09:17:01 -0500" MODIFIED_BY="[Empty name]" ORDER="507" O_E="0.0" SE="0.06581128855084503" STUDY_ID="STD-Bao-2003" TOTAL_1="243" TOTAL_2="323" VAR="0.004331125700722587" WEIGHT="19.539162644716612"/>
<DICH_DATA CI_END="1.431288752059266" CI_START="1.1510758129384389" EFFECT_SIZE="1.283558282208589" ESTIMABLE="YES" EVENTS_1="317" EVENTS_2="250" LOG_CI_END="0.15572725834084816" LOG_CI_START="0.06110392837047647" LOG_EFFECT_SIZE="0.10841559335566235" MODIFIED="2008-12-08 09:20:16 -0500" MODIFIED_BY="[Empty name]" ORDER="509" O_E="0.0" SE="0.05558221241763383" STUDY_ID="STD-Emery-1999" TOTAL_1="489" TOTAL_2="495" VAR="0.0030893823372389684" WEIGHT="20.948815021894386"/>
<DICH_DATA CI_END="1.5583062881943164" CI_START="0.8674953425438741" EFFECT_SIZE="1.1626794258373205" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="19" LOG_CI_END="0.19265282316915547" LOG_CI_START="-0.0617328481946391" LOG_EFFECT_SIZE="0.06545998748725818" MODIFIED="2008-12-08 09:20:26 -0500" MODIFIED_BY="[Empty name]" ORDER="510" O_E="0.0" SE="0.14942740258847476" STUDY_ID="STD-Karanikolas-2006" TOTAL_1="33" TOTAL_2="27" VAR="0.022328548644338114" WEIGHT="9.891825143331298"/>
<DICH_DATA CI_END="1.8132673198095044" CI_START="0.500218290237172" EFFECT_SIZE="0.9523809523809523" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.2584618344099575" LOG_CI_START="-0.3008404325498337" LOG_EFFECT_SIZE="-0.021189299069938095" MODIFIED="2008-12-08 09:20:37 -0500" MODIFIED_BY="[Empty name]" ORDER="511" O_E="0.0" SE="0.3285369202030541" STUDY_ID="STD-Reece-2002" TOTAL_1="21" TOTAL_2="18" VAR="0.10793650793650794" WEIGHT="2.954035842276733"/>
<DICH_DATA CI_END="1.2760288510455133" CI_START="0.8257053343849237" EFFECT_SIZE="1.0264618011096884" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="71" LOG_CI_END="0.10586049390568614" LOG_CI_START="-0.08317490967991055" LOG_EFFECT_SIZE="0.011342792112887806" MODIFIED="2008-12-08 09:20:45 -0500" MODIFIED_BY="[Empty name]" ORDER="492" O_E="0.0" SE="0.1110403318065187" STUDY_ID="STD-Smolen-1999" TOTAL_1="132" TOTAL_2="130" VAR="0.012329955287701769" WEIGHT="13.630787047185564"/>
<DICH_DATA CI_END="1.1173454932185867" CI_START="0.759177260501588" EFFECT_SIZE="0.921012101210121" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="101" LOG_CI_END="0.04818748161894343" LOG_CI_START="-0.11965680872958057" LOG_EFFECT_SIZE="-0.03573466355531858" MODIFIED="2008-12-08 09:21:21 -0500" MODIFIED_BY="[Empty name]" ORDER="489" O_E="0.0" SE="0.09859256699335987" STUDY_ID="STD-Strand-1999a" TOTAL_1="180" TOTAL_2="182" VAR="0.009720494266340154" WEIGHT="15.12259469818072"/>
<DICH_DATA CI_END="1.3397508337679778" CI_START="0.9887440768307858" EFFECT_SIZE="1.150943396226415" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="26" LOG_CI_END="0.12702403599049122" LOG_CI_START="-0.004916105170535247" LOG_EFFECT_SIZE="0.06105396540997798" MODIFIED="2008-12-08 09:21:40 -0500" MODIFIED_BY="[Empty name]" ORDER="512" O_E="0.0" SE="0.07750229203221896" STUDY_ID="STD-Wislowska-2007" TOTAL_1="30" TOTAL_2="30" VAR="0.0060066052702473505" WEIGHT="17.91277960241467"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.790046609940887" CI_END="1.231519280574565" CI_START="0.39064669568312155" DF="2" EFFECT_SIZE="0.6936057508603204" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="99" I2="81.4643988826017" ID="CMP-018.01.03" LOG_CI_END="0.09044121551056179" LOG_CI_START="-0.40821584485410023" LOG_EFFECT_SIZE="-0.15888731467176923" MODIFIED="2008-12-08 09:32:02 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.004539130084531329" P_Z="0.21166204657837162" STUDIES="3" TAU2="0.20311969299693494" TOTAL_1="210" TOTAL_2="217" WEIGHT="100.0" Z="1.2490083430452874">
<NAME>Lef+DMARD vs single agent</NAME>
<DICH_DATA CI_END="1.8763265886990554" CI_START="0.4911724886012451" EFFECT_SIZE="0.96" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.27330843283054834" LOG_CI_START="-0.30876596675141155" LOG_EFFECT_SIZE="-0.017728766960431602" MODIFIED="2008-12-08 09:31:40 -0500" MODIFIED_BY="[Empty name]" ORDER="513" O_E="0.0" SE="0.3419133836291904" STUDY_ID="STD-Dougados-2005" TOTAL_1="50" TOTAL_2="56" VAR="0.11690476190476193" WEIGHT="26.809948670345655"/>
<DICH_DATA CI_END="1.177181599753089" CI_START="0.6468142492264302" EFFECT_SIZE="0.8725925925925926" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="25" LOG_CI_END="0.07084346512639046" LOG_CI_START="-0.18922042121423702" LOG_EFFECT_SIZE="-0.059188478043923284" MODIFIED="2008-12-08 09:31:50 -0500" MODIFIED_BY="[Empty name]" ORDER="514" O_E="0.0" SE="0.15276281417348386" STUDY_ID="STD-Karanikolas-2006" TOTAL_1="27" TOTAL_2="31" VAR="0.02333647739420236" WEIGHT="37.88741633469584"/>
<DICH_DATA CI_END="0.6265815684325445" CI_START="0.2863188904240985" EFFECT_SIZE="0.42355889724310775" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="60" LOG_CI_END="-0.2030223845034222" LOG_CI_START="-0.5431499976427272" LOG_EFFECT_SIZE="-0.3730861910730747" MODIFIED="2008-12-08 09:32:02 -0500" MODIFIED_BY="[Empty name]" ORDER="515" O_E="0.0" SE="0.19979264361686652" STUDY_ID="STD-Kremer-2002" TOTAL_1="133" TOTAL_2="130" VAR="0.03991710044341623" WEIGHT="35.302634994958495"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.057058504430165" CI_END="1.4296285156288584" CI_START="0.6621089519034313" DF="1" EFFECT_SIZE="0.9729182072991963" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="100" I2="90.0567347842364" ID="CMP-018.01.04" LOG_CI_END="0.1552232021002402" LOG_CI_START="-0.17907054029270336" LOG_EFFECT_SIZE="-0.011923669096231533" MODIFIED="2008-12-08 09:35:28 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0015176628452696628" P_Z="0.8888046383992156" STUDIES="2" TAU2="0.06945780079941268" TOTAL_1="260" TOTAL_2="145" WEIGHT="100.0" Z="0.1398169276211998">
<NAME>Lef (+biologics) vs biologics</NAME>
<DICH_DATA CI_END="0.9918103452831513" CI_START="0.6919142832959375" EFFECT_SIZE="0.8284007147643512" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="74" LOG_CI_END="-0.003571366022773189" LOG_CI_START="-0.1599477040943204" LOG_EFFECT_SIZE="-0.0817595350585468" MODIFIED="2008-12-08 09:33:32 -0500" MODIFIED_BY="[Empty name]" ORDER="516" O_E="0.0" SE="0.09185623505858444" STUDY_ID="STD-Mariette-2004" TOTAL_1="242" TOTAL_2="115" VAR="0.008437567919137917" WEIGHT="49.50169397195965"/>
<DICH_DATA CI_END="1.3404215092468519" CI_START="0.9678911224714006" EFFECT_SIZE="1.1390268123138034" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="26" LOG_CI_END="0.12724138818163785" LOG_CI_START="-0.014173493486338486" LOG_EFFECT_SIZE="0.05653394734764969" MODIFIED="2008-12-08 09:33:44 -0500" MODIFIED_BY="[Empty name]" ORDER="517" O_E="0.0" SE="0.08306780150672324" STUDY_ID="STD-Wislowska-2007" TOTAL_1="18" TOTAL_2="30" VAR="0.006900259647160373" WEIGHT="50.49830602804036"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="104.73209521861051" CI_END="0.9608000502605667" CI_START="0.6022000738816256" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7606535750605414" ESTIMABLE="YES" EVENTS_1="471" EVENTS_2="565" I2="90.45182856398824" I2_Q="0.0" ID="CMP-018.02" LOG_CI_END="-0.017366982886700945" LOG_CI_START="-0.22025919554132606" LOG_EFFECT_SIZE="-0.11881308921401351" METHOD="MH" MODIFIED="2009-01-05 09:12:35 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="-4.440892098500626E-16" P_Q="0.0" P_Z="0.021704577440639687" Q="0.0" RANDOM="YES" SCALE="10.445158627577035" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.2822001032866803" TOTALS="SUB" TOTAL_1="1324" TOTAL_2="1286" WEIGHT="400.0" Z="2.295498409767107">
<NAME>ACR50 Treatment responder</NAME>
<GROUP_LABEL_1>control</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.273848408521499" CI_END="0.6101638342609053" CI_START="0.1661275771782467" DF="1" EFFECT_SIZE="0.3183787673001349" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="105" I2="56.021694487091175" ID="CMP-018.02.01" LOG_CI_END="-0.21455353751038533" LOG_CI_START="-0.7795582686791003" LOG_EFFECT_SIZE="-0.4970559030947428" MODIFIED="2008-12-08 09:50:49 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.13157293848638751" P_Z="5.636927668316989E-4" STUDIES="2" TAU2="0.1240528570972096" TOTAL_1="209" TOTAL_2="312" WEIGHT="100.0" Z="3.4485080022376655">
<NAME>Lef vs placebo</NAME>
<DICH_DATA CI_END="0.7557462440938899" CI_START="0.2468185041466534" EFFECT_SIZE="0.4318936877076412" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="43" LOG_CI_END="-0.12162400250059377" LOG_CI_START="-0.6076222840734193" LOG_EFFECT_SIZE="-0.36462314328700657" MODIFIED="2008-12-08 09:50:29 -0500" MODIFIED_BY="[Empty name]" ORDER="520" O_E="0.0" SE="0.2854777963261707" STUDY_ID="STD-Smolen-1999" TOTAL_1="91" TOTAL_2="130" VAR="0.08149757219524661" WEIGHT="53.58719008588058"/>
<DICH_DATA CI_END="0.4330306173112912" CI_START="0.11576087401642426" EFFECT_SIZE="0.2238928376161837" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="62" LOG_CI_END="-0.3634813958885386" LOG_CI_START="-0.9364382028714205" LOG_EFFECT_SIZE="-0.6499597993799796" MODIFIED="2008-12-08 09:50:40 -0500" MODIFIED_BY="[Empty name]" ORDER="518" O_E="0.0" SE="0.33655766460368075" STUDY_ID="STD-Strand-1999a" TOTAL_1="118" TOTAL_2="182" VAR="0.11327106160348367" WEIGHT="46.412809914119414"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.688292504451876" CI_END="1.1597581718837895" CI_START="0.6483416228142963" DF="3" EFFECT_SIZE="0.8671329167038221" ESTIMABLE="YES" EVENTS_1="354" EVENTS_2="345" I2="74.33329120692908" ID="CMP-018.02.02" LOG_CI_END="0.06436744132576855" LOG_CI_START="-0.18819609627722853" LOG_EFFECT_SIZE="-0.06191432747572999" MODIFIED="2008-12-08 10:03:43 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.00853094274513544" P_Z="0.3365797645738253" STUDIES="4" TAU2="0.059956653182635516" TOTAL_1="645" TOTAL_2="612" WEIGHT="100.00000000000001" Z="0.9609451398340684">
<NAME>Lef vs DMARDs</NAME>
<DICH_DATA CI_END="1.1257373270659237" CI_START="0.9791254726213775" EFFECT_SIZE="1.0498752746926412" ESTIMABLE="YES" EVENTS_1="259" EVENTS_2="226" LOG_CI_END="0.05143706661314671" LOG_CI_START="-0.009161650816443323" LOG_EFFECT_SIZE="0.021137707898351704" MODIFIED="2008-12-08 09:53:55 -0500" MODIFIED_BY="[Empty name]" ORDER="527" O_E="0.0" SE="0.03559598658663033" STUDY_ID="STD-Emery-1999" TOTAL_1="298" TOTAL_2="273" VAR="0.0012670742610755665" WEIGHT="35.94982172769838"/>
<DICH_DATA CI_END="1.3272070037888835" CI_START="0.4349022124072609" EFFECT_SIZE="0.7597402597402597" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.12293866483278922" LOG_CI_START="-0.3616083830133921" LOG_EFFECT_SIZE="-0.11933485909030142" MODIFIED="2008-12-08 09:54:09 -0500" MODIFIED_BY="[Empty name]" ORDER="522" O_E="0.0" SE="0.284625334451417" STUDY_ID="STD-Karanikolas-2006" TOTAL_1="33" TOTAL_2="27" VAR="0.08101158101158101" WEIGHT="15.61331955165334"/>
<DICH_DATA CI_END="1.307858292417658" CI_START="0.6417431228990629" EFFECT_SIZE="0.916138125440451" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="43" LOG_CI_END="0.11656069035289401" LOG_CI_START="-0.19263877665416845" LOG_EFFECT_SIZE="-0.03803904315063723" MODIFIED="2008-12-08 09:54:23 -0500" MODIFIED_BY="[Empty name]" ORDER="521" O_E="0.0" SE="0.1816252974819948" STUDY_ID="STD-Smolen-1999" TOTAL_1="132" TOTAL_2="130" VAR="0.032987748685423104" WEIGHT="23.680631031775995"/>
<DICH_DATA CI_END="0.9455529369516422" CI_START="0.4853213018295163" EFFECT_SIZE="0.6774193548387096" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="62" LOG_CI_END="-0.024314152083437502" LOG_CI_START="-0.3139706461172694" LOG_EFFECT_SIZE="-0.16914239910035345" MODIFIED="2008-12-08 09:54:44 -0500" MODIFIED_BY="[Empty name]" ORDER="525" O_E="0.0" SE="0.17014565841824272" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="182" VAR="0.028949545078577332" WEIGHT="24.7562276888723"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.53866861843872" CI_END="1.032789455805577" CI_START="0.11183957418547684" DF="2" EFFECT_SIZE="0.3398628149129381" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="64" I2="79.032713264261" ID="CMP-018.02.03" LOG_CI_END="0.0140117953807207" LOG_CI_START="-0.9514044951145756" LOG_EFFECT_SIZE="-0.46869634986692754" MODIFIED="2008-12-08 09:56:03 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.008486064737178167" P_Z="0.05703125634922631" STUDIES="3" TAU2="0.6397272272574541" TOTAL_1="210" TOTAL_2="217" WEIGHT="100.0" Z="1.9030711921243226">
<NAME>Lef+DMARD vs single agent</NAME>
<DICH_DATA CI_END="1.7925422602867989" CI_START="0.005759099549186115" EFFECT_SIZE="0.10160427807486631" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.25346940322017925" LOG_CI_START="-2.2396454143875193" LOG_EFFECT_SIZE="-0.9930880055836699" MODIFIED="2008-12-08 09:55:37 -0500" MODIFIED_BY="[Empty name]" ORDER="530" O_E="0.0" SE="1.4644679849801443" STUDY_ID="STD-Dougados-2005" TOTAL_1="50" TOTAL_2="56" VAR="2.144666479031804" WEIGHT="11.549782511563523"/>
<DICH_DATA CI_END="0.9614070940129974" CI_START="0.42999617364641957" EFFECT_SIZE="0.642962962962963" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="25" LOG_CI_END="-0.017092677631406993" LOG_CI_START="-0.3665354090056215" LOG_EFFECT_SIZE="-0.1918140433185142" MODIFIED="2008-12-08 09:55:41 -0500" MODIFIED_BY="[Empty name]" ORDER="531" O_E="0.0" SE="0.20526439017863124" STUDY_ID="STD-Karanikolas-2006" TOTAL_1="27" TOTAL_2="31" VAR="0.042133469875405366" WEIGHT="47.16380027391585"/>
<DICH_DATA CI_END="0.4778402312991523" CI_START="0.11069368633573407" EFFECT_SIZE="0.22998673153471916" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="34" LOG_CI_END="-0.32071728804015487" LOG_CI_START="-0.9558771493809662" LOG_EFFECT_SIZE="-0.6382972187105606" MODIFIED="2008-12-08 09:56:03 -0500" MODIFIED_BY="[Empty name]" ORDER="529" O_E="0.0" SE="0.37309604664361357" STUDY_ID="STD-Kremer-2002" TOTAL_1="133" TOTAL_2="130" VAR="0.13920066002109346" WEIGHT="41.286417214520625"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.59912678734681" CI_END="1.8655833324474997" CI_START="0.6231972575176502" DF="1" EFFECT_SIZE="1.0782515552745198" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="51" I2="78.2567420678374" ID="CMP-018.02.04" LOG_CI_END="0.2708146530090158" LOG_CI_START="-0.20537446651580635" LOG_EFFECT_SIZE="0.03272009324660478" MODIFIED="2008-12-08 09:56:51 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.03198830654694573" P_Z="0.7876621862346139" STUDIES="2" TAU2="0.12246003586298222" TOTAL_1="260" TOTAL_2="145" WEIGHT="100.0" Z="0.26934762557419023">
<NAME>Lef (+biologics) vs biologics</NAME>
<DICH_DATA CI_END="1.2033599689298338" CI_START="0.5796922523224403" EFFECT_SIZE="0.8352116203355873" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="33" LOG_CI_END="0.08039556012053263" LOG_CI_START="-0.23680250400407227" LOG_EFFECT_SIZE="-0.0782034719417698" MODIFIED="2008-12-08 09:56:38 -0500" MODIFIED_BY="[Empty name]" ORDER="533" O_E="0.0" SE="0.18632371302253348" STUDY_ID="STD-Mariette-2004" TOTAL_1="242" TOTAL_2="115" VAR="0.03471652603450341" WEIGHT="49.77902147079499"/>
<DICH_DATA CI_END="1.9864376237727512" CI_START="0.9710913257952325" EFFECT_SIZE="1.3888888888888888" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="18" LOG_CI_END="0.2980749323027265" LOG_CI_START="-0.012739925165263491" LOG_EFFECT_SIZE="0.14266750356873154" MODIFIED="2008-12-08 09:56:51 -0500" MODIFIED_BY="[Empty name]" ORDER="532" O_E="0.0" SE="0.18257418583505536" STUDY_ID="STD-Wislowska-2007" TOTAL_1="18" TOTAL_2="30" VAR="0.03333333333333333" WEIGHT="50.22097852920501"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.308217579919868" CI_END="0.5733742512360256" CI_START="0.32204653668596206" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.42971291792948085" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="136" I2="27.782343898871872" I2_Q="0.0" ID="CMP-018.03" LOG_CI_END="-0.24156181400061882" LOG_CI_START="-0.49208136692031457" LOG_EFFECT_SIZE="-0.3668215904604667" METHOD="MH" MODIFIED="2008-12-08 10:16:35 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.21638098760459668" P_Q="0.0" P_Z="9.482846711633694E-9" Q="0.0" RANDOM="NO" SCALE="18.206846781350126" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="705" TOTAL_2="768" WEIGHT="300.0" Z="5.7397284776783755">
<NAME>ACR70 Treatment responder</NAME>
<GROUP_LABEL_1>control</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5302098807937486" CI_START="0.08654977668955108" DF="0" EFFECT_SIZE="0.21421845574387946" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="36" I2="0.0" ID="CMP-018.03.01" LOG_CI_END="-0.275552183177393" LOG_CI_START="-1.0627340483272452" LOG_EFFECT_SIZE="-0.6691431157523191" MODIFIED="2008-12-08 10:10:47 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="8.618378786382169E-4" STUDIES="1" TAU2="0.0" TOTAL_1="118" TOTAL_2="182" WEIGHT="100.0" Z="3.332130643349612">
<NAME>Lef vs placebo</NAME>
<DICH_DATA CI_END="0.5302098807937486" CI_START="0.08654977668955108" EFFECT_SIZE="0.21421845574387946" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="36" LOG_CI_END="-0.275552183177393" LOG_CI_START="-1.0627340483272452" LOG_EFFECT_SIZE="-0.6691431157523191" MODIFIED="2008-12-08 10:10:47 -0500" MODIFIED_BY="[Empty name]" ORDER="534" O_E="0.0" SE="0.46239452420209937" STUDY_ID="STD-Strand-1999a" TOTAL_1="118" TOTAL_2="182" VAR="0.21380869601208585" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9851742862930724" CI_END="0.796926157932257" CI_START="0.39026265812053895" DF="3" EFFECT_SIZE="0.5576831723482707" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="66" I2="0.0" ID="CMP-018.03.02" LOG_CI_END="-0.09858191786141722" LOG_CI_START="-0.40864300174985646" LOG_EFFECT_SIZE="-0.25361245980563685" MODIFIED="2008-12-08 10:15:44 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5754895638873544" P_Z="0.0013446319641622234" STUDIES="4" TAU2="0.0" TOTAL_1="377" TOTAL_2="369" WEIGHT="100.0" Z="3.206279749886366">
<NAME>Lef vs DMARDs</NAME>
<DICH_DATA CI_END="1.3272070037888835" CI_START="0.4349022124072609" EFFECT_SIZE="0.7597402597402597" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.12293866483278922" LOG_CI_START="-0.3616083830133921" LOG_EFFECT_SIZE="-0.11933485909030142" ORDER="536" O_E="0.0" SE="0.284625334451417" STUDY_ID="STD-Karanikolas-2006" TOTAL_1="33" TOTAL_2="27" VAR="0.08101158101158101" WEIGHT="22.81765331282376"/>
<DICH_DATA CI_END="1.5534212824530211" CI_START="0.27750261068959475" EFFECT_SIZE="0.6565656565656566" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.1912892508562348" LOG_CI_START="-0.5567329267656235" LOG_EFFECT_SIZE="-0.18272183795469432" MODIFIED="2008-12-08 10:15:10 -0500" MODIFIED_BY="[Empty name]" ORDER="546" O_E="0.0" SE="0.43939192990457626" STUDY_ID="STD-Scott-2001" TOTAL_1="132" TOTAL_2="130" VAR="0.19306526806526805" WEIGHT="17.915714705815823"/>
<DICH_DATA CI_END="0.7717933546722152" CI_START="0.25593750322121295" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="36" LOG_CI_END="-0.11249896512923999" LOG_CI_START="-0.5918660710934851" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2008-12-08 10:15:31 -0500" MODIFIED_BY="[Empty name]" ORDER="537" O_E="0.0" SE="0.2815826109488418" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="182" VAR="0.0792887667887668" WEIGHT="53.33996878322438"/>
<DICH_DATA CI_END="2.5270106054871775" CI_START="0.09893112417381524" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.402607064593003" LOG_CI_START="-1.0046670559209654" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2008-12-08 10:15:44 -0500" MODIFIED_BY="[Empty name]" ORDER="547" O_E="0.0" SE="0.8266397845091497" STUDY_ID="STD-Wislowska-2007" TOTAL_1="30" TOTAL_2="30" VAR="0.6833333333333333" WEIGHT="5.926663198136042"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.956690320436272" CI_END="0.6274092227863568" CI_START="0.19772881414105722" DF="1" EFFECT_SIZE="0.35221709442147847" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="34" I2="0.0" ID="CMP-018.03.03" LOG_CI_END="-0.20244910155191245" LOG_CI_START="-0.7039300382704158" LOG_EFFECT_SIZE="-0.4531895699111642" MODIFIED="2008-12-08 10:16:22 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.3280223456214798" P_Z="3.9643058785275624E-4" STUDIES="3" TAU2="0.0" TOTAL_1="210" TOTAL_2="217" WEIGHT="100.0" Z="3.542448656203546">
<NAME>Lef+DMARD vs single agent</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-12-08 10:16:04 -0500" MODIFIED_BY="[Empty name]" ORDER="543" O_E="0.0" SE="0.0" STUDY_ID="STD-Dougados-2005" TOTAL_1="50" TOTAL_2="56" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.8212572315355353" CI_START="0.2329474909773524" EFFECT_SIZE="0.43738977072310403" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="21" LOG_CI_END="-0.08552079325907133" LOG_CI_START="-0.6327419628743093" LOG_EFFECT_SIZE="-0.3591313780666903" MODIFIED="2008-12-08 10:16:13 -0500" MODIFIED_BY="[Empty name]" ORDER="542" O_E="0.0" SE="0.32144042382046717" STUDY_ID="STD-Karanikolas-2006" TOTAL_1="27" TOTAL_2="31" VAR="0.10332394606588155" WEIGHT="59.79118134104241"/>
<DICH_DATA CI_END="0.7731649669816486" CI_START="0.06580623743385101" EFFECT_SIZE="0.22556390977443608" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" LOG_CI_END="-0.11172783259388039" LOG_CI_START="-1.1817329399009662" LOG_EFFECT_SIZE="-0.6467303862474234" MODIFIED="2008-12-08 10:16:22 -0500" MODIFIED_BY="[Empty name]" ORDER="541" O_E="0.0" SE="0.6285262966428862" STUDY_ID="STD-Kremer-2002" TOTAL_1="133" TOTAL_2="130" VAR="0.3950453055716213" WEIGHT="40.20881865895759"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="20.162151540158128" CI_END="2.256203200206711" CI_START="1.2989792559274265" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7119465979479593" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="120" I2="75.20105932126732" I2_Q="0.0" ID="CMP-018.04" LOG_CI_END="0.3533782108939326" LOG_CI_START="0.11360221565487123" LOG_EFFECT_SIZE="0.23349021327440192" METHOD="MH" MODIFIED="2009-07-22 12:18:30 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0011651248654556134" P_Q="0.0" P_Z="1.349932559121817E-4" Q="0.0" RANDOM="YES" SCALE="9.84" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.2054878361362257" TOTALS="SUB" TOTAL_1="405" TOTAL_2="489" WEIGHT="200.0" Z="3.8171661704845423">
<NAME>Reported adverse events</NAME>
<GROUP_LABEL_1>control</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.7587303767852003" CI_END="2.3629083268187494" CI_START="1.3462725219360314" DF="3" EFFECT_SIZE="1.783569048915664" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="65" I2="0.0" ID="CMP-018.04.01" LOG_CI_END="0.3734468727415284" LOG_CI_START="0.1291329817253322" LOG_EFFECT_SIZE="0.25128992723343024" MODIFIED="2009-07-22 12:18:30 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6239566933688774" P_Z="5.5338104709318714E-5" STUDIES="4" TAU2="0.0" TOTAL_1="323" TOTAL_2="401" WEIGHT="100.0" Z="4.031855945698674">
<NAME>Lef vs DMARDs</NAME>
<DICH_DATA CI_END="2.3349729377520285" CI_START="1.1985475274944921" EFFECT_SIZE="1.6728945099166428" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="49" LOG_CI_END="0.368281851474692" LOG_CI_START="0.07865526032990709" LOG_EFFECT_SIZE="0.22346855590229955" MODIFIED="2008-12-08 10:54:27 -0500" MODIFIED_BY="[Empty name]" ORDER="570" O_E="0.0" SE="0.1701280933131948" STUDY_ID="STD-Bao-2003" TOTAL_1="213" TOTAL_2="291" VAR="0.028943568134383126" WEIGHT="71.15729912771165"/>
<DICH_DATA CI_END="19.11103287056746" CI_START="1.0595973612282696" EFFECT_SIZE="4.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.281284159470821" LOG_CI_START="0.025140868079866426" LOG_EFFECT_SIZE="0.6532125137753437" MODIFIED="2008-12-08 10:54:51 -0500" MODIFIED_BY="[Empty name]" ORDER="571" O_E="0.0" SE="0.7378647873726218" STUDY_ID="STD-Jiang-2001" TOTAL_1="30" TOTAL_2="30" VAR="0.5444444444444445" WEIGHT="3.7828398408274335"/>
<DICH_DATA CI_END="3.7238395844736614" CI_START="0.9581243105755852" EFFECT_SIZE="1.8888888888888888" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="9" LOG_CI_END="0.5709909641786797" LOG_CI_START="-0.018578140300781705" LOG_EFFECT_SIZE="0.27620641193894907" MODIFIED="2008-12-08 10:55:03 -0500" MODIFIED_BY="[Empty name]" ORDER="572" O_E="0.0" SE="0.3463158103853704" STUDY_ID="STD-Lao-2001" TOTAL_1="40" TOTAL_2="40" VAR="0.11993464052287583" WEIGHT="17.172237533565408"/>
<DICH_DATA CI_END="4.900363059653602" CI_START="0.6611755007860642" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.690228257367919" LOG_CI_START="-0.17968324716130685" LOG_EFFECT_SIZE="0.25527250510330607" MODIFIED="2008-12-08 10:55:15 -0500" MODIFIED_BY="[Empty name]" ORDER="573" O_E="0.0" SE="0.510990323891863" STUDY_ID="STD-Shuai-2002" TOTAL_1="40" TOTAL_2="40" VAR="0.26111111111111107" WEIGHT="7.887623497895502"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.035239605127579" CI_END="2.469310940778274" CI_START="0.13890227607796182" DF="1" EFFECT_SIZE="0.5856559655790381" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="55" I2="87.55482040184758" ID="CMP-018.04.02" LOG_CI_END="0.39257578064136756" LOG_CI_START="-0.8572906377757006" LOG_EFFECT_SIZE="-0.23235742856716649" MODIFIED="2009-07-22 12:18:30 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.004587618866284782" P_Z="0.4661623263452339" STUDIES="2" TAU2="0.9560097820372365" TOTAL_1="82" TOTAL_2="88" WEIGHT="100.0" Z="0.7287373831657236">
<NAME>Lef+DMARD vs single agent</NAME>
<DICH_DATA CI_END="1.2962953575972698" CI_START="0.8312498107448969" EFFECT_SIZE="1.038048780487805" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="41" LOG_CI_END="0.11270396570149446" LOG_CI_START="-0.08026844056698192" LOG_EFFECT_SIZE="0.016217762567256287" MODIFIED="2008-12-08 10:57:13 -0500" MODIFIED_BY="[Empty name]" ORDER="556" O_E="0.0" SE="0.11335294667091976" STUDY_ID="STD-Dougados-2005" TOTAL_1="50" TOTAL_2="56" VAR="0.012848890518980378" WEIGHT="55.63421595453507"/>
<DICH_DATA CI_END="0.7745796254566185" CI_START="0.10538962087093581" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="14" LOG_CI_END="-0.11093393088225856" LOG_CI_START="-0.9772021578182927" LOG_EFFECT_SIZE="-0.5440680443502757" MODIFIED="2008-12-08 10:57:30 -0500" MODIFIED_BY="[Empty name]" ORDER="574" O_E="0.0" SE="0.5088502445991073" STUDY_ID="STD-Lao-2002" TOTAL_1="32" TOTAL_2="32" VAR="0.2589285714285714" WEIGHT="44.36578404546493"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="44.01980982859921" CI_END="0.8814260475187432" CI_START="0.5146765094679988" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6735349148270795" ESTIMABLE="YES" EVENTS_1="199" EVENTS_2="285" I2="68.1961370244168" I2_Q="0.0" ID="CMP-018.05" LOG_CI_END="-0.05481411955504494" LOG_CI_START="-0.28846565308504263" LOG_EFFECT_SIZE="-0.1716398863200438" METHOD="MH" MODIFIED="2008-12-08 11:09:15 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="5.876452767061835E-5" P_Q="0.0" P_Z="0.0039821764439815265" Q="0.0" RANDOM="YES" SCALE="367.2935247612345" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.2980067935076137" TOTALS="SUB" TOTAL_1="1782" TOTAL_2="2131" WEIGHT="300.0" Z="2.879570190834162">
<NAME>Withdrawals due to adverse events</NAME>
<GROUP_LABEL_1>control</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.0526681773282993" CI_END="0.6122157890760013" CI_START="0.22793750905504406" DF="2" EFFECT_SIZE="0.3735598238115978" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="70" I2="0.0" ID="CMP-018.05.01" LOG_CI_END="-0.21309547411771332" LOG_CI_START="-0.6421842020893632" LOG_EFFECT_SIZE="-0.4276398381035383" MODIFIED="2008-12-08 10:59:40 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5907667948708645" P_Z="9.356842378652117E-5" STUDIES="3" TAU2="0.0" TOTAL_1="311" TOTAL_2="416" WEIGHT="100.0" Z="3.9066916765655613">
<NAME>Lef vs placebo</NAME>
<DICH_DATA CI_END="0.8157420062109899" CI_START="0.04212967699463957" EFFECT_SIZE="0.18538324420677363" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.08844717334819857" LOG_CI_START="-1.3754118705665634" LOG_EFFECT_SIZE="-0.731929521957381" MODIFIED="2008-12-08 10:59:18 -0500" MODIFIED_BY="[Empty name]" ORDER="575" O_E="0.0" SE="0.755969433724062" STUDY_ID="STD-Mladenovic-1995" TOTAL_1="102" TOTAL_2="104" VAR="0.5714897847250789" WEIGHT="11.1163175391705"/>
<DICH_DATA CI_END="1.0853134177630805" CI_START="0.18751846815861128" EFFECT_SIZE="0.45112781954887216" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="19" LOG_CI_END="0.03555517223925074" LOG_CI_START="-0.7269559534061351" LOG_EFFECT_SIZE="-0.3457003905834422" MODIFIED="2008-12-08 10:59:27 -0500" MODIFIED_BY="[Empty name]" ORDER="560" O_E="0.0" SE="0.4479028096950458" STUDY_ID="STD-Smolen-1999" TOTAL_1="91" TOTAL_2="130" VAR="0.2006169269327164" WEIGHT="31.66662960362668"/>
<DICH_DATA CI_END="0.7409021041221611" CI_START="0.20067716199503816" EFFECT_SIZE="0.3855932203389831" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="40" LOG_CI_END="-0.1302391718428478" LOG_CI_START="-0.6975020494551781" LOG_EFFECT_SIZE="-0.4138706106490129" MODIFIED="2008-12-08 10:59:40 -0500" MODIFIED_BY="[Empty name]" ORDER="559" O_E="0.0" SE="0.3332130223060138" STUDY_ID="STD-Strand-1999a" TOTAL_1="118" TOTAL_2="182" VAR="0.11103091823430807" WEIGHT="57.217052857202816"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="23.36696730691288" CI_END="2.1906765919977245" CI_START="0.6326943156662769" DF="6" EFFECT_SIZE="1.1772971703100845" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="162" I2="74.32272694529358" ID="CMP-018.05.02" LOG_CI_END="0.3405782677122956" LOG_CI_START="-0.19880606736771844" LOG_EFFECT_SIZE="0.07088610017228864" MODIFIED="2008-12-08 11:05:09 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="6.824450624115519E-4" P_Z="0.6064422919206276" STUDIES="8" TAU2="0.36444079817716646" TOTAL_1="970" TOTAL_2="1250" WEIGHT="99.99999999999999" Z="0.5151584660743782">
<NAME>Lef vs DMARDs</NAME>
<DICH_DATA CI_END="134.72531882908612" CI_START="2.341338764877375" EFFECT_SIZE="17.760563380281692" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="1" LOG_CI_END="2.12944922003239" LOG_CI_START="0.3694642556756229" LOG_EFFECT_SIZE="1.2494567378540065" MODIFIED="2008-12-08 11:03:18 -0500" MODIFIED_BY="[Empty name]" ORDER="576" O_E="0.0" SE="1.0338238801292448" STUDY_ID="STD-Bao-2003" TOTAL_1="213" TOTAL_2="291" VAR="1.0687918151254872" WEIGHT="7.004145848150665"/>
<DICH_DATA CI_END="1.7315558733907392" CI_START="1.011612404411276" EFFECT_SIZE="1.3235042124803655" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="94" LOG_CI_END="0.23843650981200723" LOG_CI_START="0.0050141460325287875" LOG_EFFECT_SIZE="0.12172532792226802" MODIFIED="2008-12-08 11:03:43 -0500" MODIFIED_BY="[Empty name]" ORDER="562" O_E="0.0" SE="0.13711345194340133" STUDY_ID="STD-Emery-1999" TOTAL_1="298" TOTAL_2="501" VAR="0.01880009870383543" WEIGHT="26.19389094325946"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-12-08 11:03:53 -0500" MODIFIED_BY="[Empty name]" ORDER="577" O_E="0.0" SE="0.0" STUDY_ID="STD-Jiang-2001" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.0455425257222895" CI_START="0.006375362961899061" EFFECT_SIZE="0.11419753086419752" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3108085126755321" LOG_CI_START="-2.1954950849547665" LOG_EFFECT_SIZE="-0.9423432861396172" MODIFIED="2008-12-08 11:04:15 -0500" MODIFIED_BY="[Empty name]" ORDER="561" O_E="0.0" SE="1.4722151396509335" STUDY_ID="STD-Karanikolas-2006" TOTAL_1="35" TOTAL_2="36" VAR="2.1674174174174174" WEIGHT="3.9649022192739345"/>
<DICH_DATA CI_END="4.317746471024236" CI_START="0.36187858886243285" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6352571378898941" LOG_CI_START="-0.4414371118737813" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2008-12-08 11:04:30 -0500" MODIFIED_BY="[Empty name]" ORDER="578" O_E="0.0" SE="0.6324555320336759" STUDY_ID="STD-Lao-2001" TOTAL_1="40" TOTAL_2="40" VAR="0.39999999999999997" WEIGHT="13.131913265010454"/>
<DICH_DATA CI_END="100.96614901769104" CI_START="0.24760774024984902" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0041757920103214" LOG_CI_START="-0.6062357833382839" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2008-12-08 11:04:42 -0500" MODIFIED_BY="[Empty name]" ORDER="579" O_E="0.0" SE="1.5333686811054679" STUDY_ID="STD-Shuai-2002" TOTAL_1="40" TOTAL_2="40" VAR="2.351219512195122" WEIGHT="3.6965485777275755"/>
<DICH_DATA CI_END="2.2351751325642755" CI_START="0.7512770125732813" EFFECT_SIZE="1.29585326953748" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="19" LOG_CI_END="0.3493115570547387" LOG_CI_START="-0.12419989941434763" LOG_EFFECT_SIZE="0.11255582882019552" MODIFIED="2008-12-08 11:04:56 -0500" MODIFIED_BY="[Empty name]" ORDER="564" O_E="0.0" SE="0.2781429734494531" STUDY_ID="STD-Smolen-1999" TOTAL_1="132" TOTAL_2="130" VAR="0.07736351367930316" WEIGHT="22.72175709584105"/>
<DICH_DATA CI_END="0.787831201000368" CI_START="0.2863874897484476" EFFECT_SIZE="0.475" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="40" LOG_CI_END="-0.10356682353454019" LOG_CI_START="-0.5430459572157266" LOG_EFFECT_SIZE="-0.3233063903751334" MODIFIED="2008-12-08 11:05:09 -0500" MODIFIED_BY="[Empty name]" ORDER="563" O_E="0.0" SE="0.25815221858112597" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="182" VAR="0.06664256795835743" WEIGHT="23.286842050736855"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.5518958097556075" CI_END="1.1218871750879806" CI_START="0.5304313628630273" DF="4" EFFECT_SIZE="0.771416971073666" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="53" I2="0.0" ID="CMP-018.05.03" LOG_CI_END="0.049949183390299814" LOG_CI_START="-0.2753708052751069" LOG_EFFECT_SIZE="-0.11271081094240352" MODIFIED="2008-12-08 11:08:21 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6353678870203864" P_Z="0.17443080090700774" STUDIES="5" TAU2="0.0" TOTAL_1="501" TOTAL_2="465" WEIGHT="100.0" Z="1.3581036383388057">
<NAME>Lef+DMARD vs single agent</NAME>
<DICH_DATA CI_END="1.8134070754170961" CI_START="0.40514558893624897" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.2584953058951849" LOG_CI_START="-0.39238888515641135" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2008-12-08 11:07:19 -0500" MODIFIED_BY="[Empty name]" ORDER="580" O_E="0.0" SE="0.3823325957524159" STUDY_ID="STD-Amit-2006" TOTAL_1="233" TOTAL_2="233" VAR="0.1461782137747803" WEIGHT="24.981243367923526"/>
<DICH_DATA CI_END="37.45390297270346" CI_START="0.12456912710539954" EFFECT_SIZE="2.16" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.573497081079204" LOG_CI_START="-0.9045895787773421" LOG_EFFECT_SIZE="0.3344537511509309" MODIFIED="2008-12-08 11:07:32 -0500" MODIFIED_BY="[Empty name]" ORDER="581" O_E="0.0" SE="1.4556403707265366" STUDY_ID="STD-Antony-2006" TOTAL_1="49" TOTAL_2="11" VAR="2.118888888888889" WEIGHT="1.7234096382047843"/>
<DICH_DATA CI_END="1.3051716816045689" CI_START="0.42715538420639876" EFFECT_SIZE="0.7466666666666667" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="21" LOG_CI_END="0.1156676423022516" LOG_CI_START="-0.36941411507325084" LOG_EFFECT_SIZE="-0.1268732363854996" MODIFIED="2008-12-08 11:07:50 -0500" MODIFIED_BY="[Empty name]" ORDER="566" O_E="0.0" SE="0.2849394254757951" STUDY_ID="STD-Dougados-2005" TOTAL_1="50" TOTAL_2="56" VAR="0.08119047619047617" WEIGHT="44.977116833618126"/>
<DICH_DATA CI_END="9.947746479492718" CI_START="0.38007243201514196" EFFECT_SIZE="1.9444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9977247086485272" LOG_CI_START="-0.42013363015458816" LOG_EFFECT_SIZE="0.28879553924696955" MODIFIED="2008-12-08 11:08:05 -0500" MODIFIED_BY="[Empty name]" ORDER="565" O_E="0.0" SE="0.8328570067249201" STUDY_ID="STD-Karanikolas-2006" TOTAL_1="36" TOTAL_2="35" VAR="0.6936507936507936" WEIGHT="5.264484041280473"/>
<DICH_DATA CI_END="1.1994666622508223" CI_START="0.25202306819277515" EFFECT_SIZE="0.549812030075188" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="0.07898818177303656" LOG_CI_START="-0.5985597055267344" LOG_EFFECT_SIZE="-0.25978576187684893" MODIFIED="2008-12-08 11:08:21 -0500" MODIFIED_BY="[Empty name]" ORDER="567" O_E="0.0" SE="0.3979949829160189" STUDY_ID="STD-Kremer-2002" TOTAL_1="133" TOTAL_2="130" VAR="0.1584000064263222" WEIGHT="23.053746118973088"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-019" MODIFIED="2009-08-04 00:40:55 -0400" MODIFIED_BY="[Empty name]" NO="19">
<NAME>Treatment responder - ACR50 for SoF</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.051560086458611" CI_START="1.3231954611947305" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.3153846153846156" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-019.01" LOG_CI_END="0.6076222840734194" LOG_CI_START="0.1216240025005938" LOG_EFFECT_SIZE="0.3646231432870066" METHOD="MH" MODIFIED="2009-07-20 07:48:26 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.0032720775566547856" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="91" WEIGHT="100.0" Z="2.9409496118361576">
<NAME>leflunomide vs. placebo, at 6 months</NAME>
<GROUP_LABEL_1>placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.051560086458611" CI_START="1.3231954611947305" EFFECT_SIZE="2.3153846153846156" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="13" LOG_CI_END="0.6076222840734194" LOG_CI_START="0.1216240025005938" LOG_EFFECT_SIZE="0.3646231432870066" MODIFIED="2009-07-20 07:48:26 -0400" MODIFIED_BY="[Empty name]" ORDER="556" O_E="0.0" SE="0.2854777963261707" STUDY_ID="STD-Smolen-1999" TOTAL_1="130" TOTAL_2="91" VAR="0.08149757219524661" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.638497320416908" CI_START="2.3093055318098523" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.4664224664224665" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-019.02" LOG_CI_END="0.9364382028714207" LOG_CI_START="0.3634813958885386" LOG_EFFECT_SIZE="0.6499597993799796" METHOD="MH" MODIFIED="2009-04-09 23:16:32 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="8.71792563447997E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="182" TOTAL_2="118" WEIGHT="100.0" Z="4.446749851500408">
<NAME>leflunomide vs. placebo, at 12 months</NAME>
<GROUP_LABEL_1>placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.638497320416905" CI_START="2.3093055318098523" EFFECT_SIZE="4.4664224664224665" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="9" LOG_CI_END="0.9364382028714204" LOG_CI_START="0.3634813958885386" LOG_EFFECT_SIZE="0.6499597993799796" MODIFIED="2009-04-09 23:16:32 -0400" MODIFIED_BY="[Empty name]" ORDER="557" O_E="0.0" SE="0.33655766460368075" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="118" VAR="0.11327106160348367" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.155774045119458" CI_END="1.9373907353667723" CI_START="0.69462097854841" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1600656224675787" ESTIMABLE="YES" EVENTS_1="288" EVENTS_2="301" I2="89.07793054883157" I2_Q="0.0" ID="CMP-019.03" LOG_CI_END="0.2872172186026696" LOG_CI_START="-0.15825210451182314" LOG_EFFECT_SIZE="0.0644825570454232" METHOD="MH" MODIFIED="2009-04-09 23:17:36 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0024793534369175196" P_Q="0.0" P_Z="0.5704307346263607" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.12321995987079781" TOTALS="YES" TOTAL_1="455" TOTAL_2="480" WEIGHT="100.0" Z="0.5674172513450336">
<NAME>leflunomide vs. methotrexate, at 12 months</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0213195631840073" CI_START="0.8883066910523074" EFFECT_SIZE="0.9524940953512382" ESTIMABLE="YES" EVENTS_1="226" EVENTS_2="259" LOG_CI_END="0.009161650816443306" LOG_CI_START="-0.051437066613146794" LOG_EFFECT_SIZE="-0.02113770789835172" MODIFIED="2009-04-09 23:17:21 -0400" MODIFIED_BY="[Empty name]" ORDER="558" O_E="0.0" SE="0.03559598658663034" STUDY_ID="STD-Emery-1999" TOTAL_1="273" TOTAL_2="298" VAR="0.001267074261075567" WEIGHT="55.00303931174603"/>
<DICH_DATA CI_END="2.0604906403866856" CI_START="1.057582247297427" EFFECT_SIZE="1.4761904761904763" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="42" LOG_CI_END="0.3139706461172694" LOG_CI_START="0.02431415208343754" LOG_EFFECT_SIZE="0.16914239910035345" MODIFIED="2009-04-09 23:17:36 -0400" MODIFIED_BY="[Empty name]" ORDER="559" O_E="0.0" SE="0.17014565841824272" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="182" VAR="0.028949545078577332" WEIGHT="44.99696068825397"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6586348165775968" CI_START="0.9068264868137709" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2264150943396226" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="53" I2="0.0" I2_Q="0.0" ID="CMP-019.04" LOG_CI_END="0.21975077746305652" LOG_CI_START="-0.042475803378923524" LOG_EFFECT_SIZE="0.0886374870420665" METHOD="MH" MODIFIED="2009-04-09 23:17:53 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.18516818536033794" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="190" TOTAL_2="190" WEIGHT="100.0" Z="1.3250089424555709">
<NAME>leflunomide vs. methotrexate, at 2 years</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6586348165775968" CI_START="0.906826486813771" EFFECT_SIZE="1.2264150943396226" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="53" LOG_CI_END="0.21975077746305652" LOG_CI_START="-0.04247580337892347" LOG_EFFECT_SIZE="0.0886374870420665" MODIFIED="2009-04-09 23:17:53 -0400" MODIFIED_BY="[Empty name]" ORDER="560" O_E="0.0" SE="0.15403319162908877" STUDY_ID="STD-Cohen-2001" TOTAL_1="190" TOTAL_2="190" VAR="0.023726224123443586" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.558255888247806" CI_START="0.7646088309395029" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0915384615384616" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="40" I2="0.0" I2_Q="0.0" ID="CMP-019.05" LOG_CI_END="0.19263877665416848" LOG_CI_START="-0.11656069035289399" LOG_EFFECT_SIZE="0.03803904315063725" METHOD="MH" MODIFIED="2009-04-09 23:18:17 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.6296309678942538" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="132" WEIGHT="100.0" Z="0.48224633310840154">
<NAME>leflunomide vs. sulfasalazine, at 6 months</NAME>
<GROUP_LABEL_1>SSZ</GROUP_LABEL_1>
<GROUP_LABEL_2>leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.558255888247806" CI_START="0.7646088309395029" EFFECT_SIZE="1.0915384615384616" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="40" LOG_CI_END="0.19263877665416848" LOG_CI_START="-0.11656069035289399" LOG_EFFECT_SIZE="0.03803904315063725" MODIFIED="2009-04-09 23:18:17 -0400" MODIFIED_BY="[Empty name]" ORDER="561" O_E="0.0" SE="0.1816252974819948" STUDY_ID="STD-Smolen-1999" TOTAL_1="130" TOTAL_2="132" VAR="0.032987748685423104" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5854998288222428" CI_START="0.7350889909010503" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0795755968169762" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-019.06" LOG_CI_END="0.20016619947470676" LOG_CI_START="-0.1336600814358523" LOG_EFFECT_SIZE="0.033253059019427225" METHOD="MH" MODIFIED="2009-04-09 23:18:41 -0400" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.6961880430501224" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="78" TOTAL_2="74" WEIGHT="100.0" Z="0.3904713426162169">
<NAME>leflunomide vs. sulfasalazine, at 12 months</NAME>
<GROUP_LABEL_1>SSZ</GROUP_LABEL_1>
<GROUP_LABEL_2>Leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5854998288222428" CI_START="0.7350889909010503" EFFECT_SIZE="1.0795755968169762" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="29" LOG_CI_END="0.20016619947470676" LOG_CI_START="-0.1336600814358523" LOG_EFFECT_SIZE="0.033253059019427225" MODIFIED="2009-04-09 23:18:41 -0400" MODIFIED_BY="[Empty name]" ORDER="562" O_E="0.0" SE="0.19609120987360354" STUDY_ID="STD-Scott-2001" TOTAL_1="78" TOTAL_2="74" VAR="0.03845176258969363" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.526303597735187" CI_START="1.254858701883769" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.1035714285714286" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-019.07" LOG_CI_END="0.5473197002336059" LOG_CI_START="0.09859482665615896" LOG_EFFECT_SIZE="0.32295726344488246" METHOD="MH" MODIFIED="2009-04-09 23:19:03 -0400" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.0047835524443421325" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="57" WEIGHT="100.0" Z="2.821259271192752">
<NAME>leflunomide vs. sulfasalazine, at 24 months</NAME>
<GROUP_LABEL_1>SSZ</GROUP_LABEL_1>
<GROUP_LABEL_2>Leflunomide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.526303597735187" CI_START="1.254858701883769" EFFECT_SIZE="2.1035714285714286" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="14" LOG_CI_END="0.5473197002336059" LOG_CI_START="0.09859482665615896" LOG_EFFECT_SIZE="0.32295726344488246" MODIFIED="2009-04-09 23:19:03 -0400" MODIFIED_BY="[Empty name]" ORDER="563" O_E="0.0" SE="0.26358321196333995" STUDY_ID="STD-Scott-2001" TOTAL_1="60" TOTAL_2="57" VAR="0.06947610962891099" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.033938909279785" CI_START="2.092749698536683" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.348076923076923" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-019.08" LOG_CI_END="0.9558771493809662" LOG_CI_START="0.3207172880401548" LOG_EFFECT_SIZE="0.6382972187105606" METHOD="MH" MODIFIED="2009-04-09 23:19:26 -0400" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="8.17229757121533E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="133" WEIGHT="100.0" Z="3.9392903621581565">
<NAME>leflunomide+MTX vs MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.033938909279785" CI_START="2.092749698536683" EFFECT_SIZE="4.348076923076923" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="8" LOG_CI_END="0.9558771493809662" LOG_CI_START="0.3207172880401548" LOG_EFFECT_SIZE="0.6382972187105606" MODIFIED="2009-04-09 23:19:26 -0400" MODIFIED_BY="[Empty name]" ORDER="564" O_E="0.0" SE="0.37309604664361357" STUDY_ID="STD-Kremer-2002" TOTAL_1="130" TOTAL_2="133" VAR="0.13920066002109346" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8122053627261336" CI_START="0.8798871228131946" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.262749445676275" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-019.09" LOG_CI_END="0.2582074112464688" LOG_CI_START="-0.055573038172151604" LOG_EFFECT_SIZE="0.10131718653715861" METHOD="MH" MODIFIED="2009-04-09 23:19:51 -0400" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="0.20561578694068383" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="198" TOTAL_2="201" WEIGHT="100.0" Z="1.2657132526624095">
<NAME>leflunomide10mg vs leflunomide 20 mg, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef10</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef20</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef20</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef10</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8122053627261336" CI_START="0.8798871228131946" EFFECT_SIZE="1.262749445676275" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="41" LOG_CI_END="0.2582074112464688" LOG_CI_START="-0.055573038172151604" LOG_EFFECT_SIZE="0.10131718653715861" MODIFIED="2009-04-09 23:19:51 -0400" MODIFIED_BY="[Empty name]" ORDER="565" O_E="0.0" SE="0.18431618922677256" STUDY_ID="STD-Poor-2004" TOTAL_1="198" TOTAL_2="201" VAR="0.03397245761107943" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="173.63825567858458" CI_START="0.5578669034224076" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="9.842105263157896" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-019.10" LOG_CI_END="2.239645414387519" LOG_CI_START="-0.2534694032201793" LOG_EFFECT_SIZE="0.99308800558367" METHOD="MH" MODIFIED="2009-04-09 23:20:11 -0400" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="0.11842145995835247" Q="0.0" RANDOM="NO" SCALE="840.4349935842123" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="50" WEIGHT="100.0" Z="1.5614336818152768">
<NAME>leflunomide+SSZ vs. placebo+SSZ, at 24 weeks</NAME>
<GROUP_LABEL_1>Plc+SSZ</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef+SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="173.63825567858458" CI_START="0.5578669034224076" EFFECT_SIZE="9.842105263157896" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.239645414387519" LOG_CI_START="-0.2534694032201793" LOG_EFFECT_SIZE="0.99308800558367" MODIFIED="2009-04-09 23:20:11 -0400" MODIFIED_BY="[Empty name]" ORDER="566" O_E="0.0" SE="1.4644679849801443" STUDY_ID="STD-Dougados-2005" TOTAL_1="56" TOTAL_2="50" VAR="2.144666479031804" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.913872002955625" CI_START="0.828547509750549" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2592592592592593" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-019.11" LOG_CI_END="0.28191288941320325" LOG_CI_START="-0.08168258364666758" LOG_EFFECT_SIZE="0.10011515288326783" METHOD="MH" MODIFIED="2009-04-09 23:20:25 -0400" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="0.2804349171074324" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="96" TOTAL_2="96" WEIGHT="100.0" Z="1.0793428878891225">
<NAME>Lef/lef+MTX vs Plc/lef+MTX, at 48 weeks</NAME>
<GROUP_LABEL_1>Plc/lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef/lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef/Lef+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Plc/Lef+MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.913872002955625" CI_START="0.828547509750549" EFFECT_SIZE="1.2592592592592593" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="27" LOG_CI_END="0.28191288941320325" LOG_CI_START="-0.08168258364666758" LOG_EFFECT_SIZE="0.10011515288326783" MODIFIED="2009-04-09 23:20:25 -0400" MODIFIED_BY="[Empty name]" ORDER="567" O_E="0.0" SE="0.21357778070198705" STUDY_ID="STD-Kremer-2004" TOTAL_1="96" TOTAL_2="96" VAR="0.045615468409586066" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9046333031097766" CI_START="0.756051045442107" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-019.12" LOG_CI_END="0.27981137383551774" LOG_CI_START="-0.12144888174026804" LOG_EFFECT_SIZE="0.07918124604762482" METHOD="MH" MODIFIED="2009-04-09 23:20:35 -0400" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="0.0" P_Z="0.43921183149899656" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.7735248549929613">
<NAME>leflunomide vs. methotrexate, at 24 weeks</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9046333031097764" CI_START="0.756051045442107" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.2798113738355177" LOG_CI_START="-0.12144888174026804" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2009-04-09 23:20:35 -0400" MODIFIED_BY="[Empty name]" ORDER="568" O_E="0.0" SE="0.2357022603955158" STUDY_ID="STD-Wislowska-2007" TOTAL_1="30" TOTAL_2="30" VAR="0.055555555555555546" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.029769264163794" CI_START="0.5034137432922485" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.72" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-019.13" LOG_CI_END="0.012739925165263413" LOG_CI_START="-0.2980749323027266" LOG_EFFECT_SIZE="-0.14266750356873156" METHOD="MH" MODIFIED="2009-04-09 23:21:51 -0400" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="0.0" P_Z="0.0719726804349536" Q="0.0" RANDOM="NO" SCALE="4.554282434308712" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="18" WEIGHT="100.0" Z="1.79929087712772">
<NAME>leflunomide vs. anti-TNF+MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>anti-TNF+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours anti-TNF+MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.029769264163794" CI_START="0.5034137432922485" EFFECT_SIZE="0.72" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.012739925165263413" LOG_CI_START="-0.2980749323027266" LOG_EFFECT_SIZE="-0.14266750356873156" MODIFIED="2009-04-09 23:21:51 -0400" MODIFIED_BY="[Empty name]" ORDER="569" O_E="0.0" SE="0.18257418583505536" STUDY_ID="STD-Wislowska-2007" TOTAL_1="30" TOTAL_2="18" VAR="0.033333333333333326" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.299367470367241" CI_START="0.7534619672328584" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3162393162393162" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-019.14" LOG_CI_END="0.36160838301339204" LOG_CI_START="-0.12293866483278926" LOG_EFFECT_SIZE="0.1193348590903014" METHOD="MH" MODIFIED="2009-04-09 23:22:13 -0400" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="0.0" P_Z="0.3343421041787792" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="33" WEIGHT="99.99999999999999" Z="0.965404812419378">
<NAME>Lef vs. CsA, at 12 months</NAME>
<GROUP_LABEL_1>CsA</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CsA</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.299367470367241" CI_START="0.7534619672328584" EFFECT_SIZE="1.3162393162393162" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.36160838301339204" LOG_CI_START="-0.12293866483278926" LOG_EFFECT_SIZE="0.1193348590903014" MODIFIED="2009-04-09 23:22:13 -0400" MODIFIED_BY="[Empty name]" ORDER="570" O_E="0.0" SE="0.284625334451417" STUDY_ID="STD-Karanikolas-2006" TOTAL_1="27" TOTAL_2="33" VAR="0.08101158101158101" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9614070940129974" CI_START="0.4299961736464196" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.642962962962963" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-019.15" LOG_CI_END="-0.017092677631406993" LOG_CI_START="-0.3665354090056214" LOG_EFFECT_SIZE="-0.1918140433185142" METHOD="MH" MODIFIED="2009-04-09 23:22:38 -0400" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="1.0" P_Q="0.0" P_Z="0.031420695114990536" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="31" WEIGHT="100.0" Z="2.151703743585351">
<NAME>Lef vs. Lef+CsA, at 12 months</NAME>
<GROUP_LABEL_1>Lef+CsA</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef+CsA</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9614070940129974" CI_START="0.42999617364641957" EFFECT_SIZE="0.642962962962963" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="25" LOG_CI_END="-0.017092677631406993" LOG_CI_START="-0.3665354090056215" LOG_EFFECT_SIZE="-0.1918140433185142" MODIFIED="2009-04-09 23:22:38 -0400" MODIFIED_BY="[Empty name]" ORDER="571" O_E="0.0" SE="0.20526439017863124" STUDY_ID="STD-Karanikolas-2006" TOTAL_1="27" TOTAL_2="31" VAR="0.042133469875405366" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7250532433263799" CI_START="0.8310065365472603" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1973013493253373" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="58" I2="0.0" I2_Q="0.0" ID="CMP-019.16" LOG_CI_END="0.23680250400407216" LOG_CI_START="-0.08039556012053266" LOG_EFFECT_SIZE="0.07820347194176977" METHOD="MH" MODIFIED="2009-07-22 12:17:44 -0400" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Q="0.0" P_Z="0.33382551978988206" Q="0.0" RANDOM="NO" SCALE="2.77" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="115" TOTAL_2="242" WEIGHT="100.0" Z="0.9664370991346659">
<NAME>Lef+ADA vs. ADA, at 12 weeks</NAME>
<GROUP_LABEL_1>ADA</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef+ADA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ADA+Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ADA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.72505324332638" CI_START="0.8310065365472603" EFFECT_SIZE="1.1973013493253373" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="58" LOG_CI_END="0.2368025040040722" LOG_CI_START="-0.08039556012053266" LOG_EFFECT_SIZE="0.07820347194176977" MODIFIED="2009-04-09 23:23:10 -0400" MODIFIED_BY="[Empty name]" ORDER="572" O_E="0.0" SE="0.18632371302253348" STUDY_ID="STD-Mariette-2004" TOTAL_1="115" TOTAL_2="242" VAR="0.03471652603450341" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.670810720610725" CI_START="0.834284367430005" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-019.17" LOG_CI_END="0.5647619913921383" LOG_CI_START="-0.07868589401954952" LOG_EFFECT_SIZE="0.24303804868629442" METHOD="MH" MODIFIED="2009-07-22 12:17:44 -0400" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="1.0" P_Q="0.0" P_Z="0.13871207429144097" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0" Z="1.4806042046225885">
<NAME>Weekly Lef vs. daily Lef, at 6 months</NAME>
<GROUP_LABEL_1>Daily Lef</GROUP_LABEL_1>
<GROUP_LABEL_2>Weekly Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours weekly Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours daily Lef</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.670810720610725" CI_START="0.834284367430005" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.5647619913921383" LOG_CI_START="-0.07868589401954952" LOG_EFFECT_SIZE="0.24303804868629442" MODIFIED="2009-04-09 23:23:23 -0400" MODIFIED_BY="[Empty name]" ORDER="573" O_E="0.0" SE="0.3779644730092272" STUDY_ID="STD-Jakez_x002d_Ocampo-2002" TOTAL_1="8" TOTAL_2="8" VAR="0.14285714285714285" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.094238895478967E-31" CI_END="1.2938896225409886" CI_START="0.5917235803286195" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8749999999999999" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="99.99999999999999" I2_Q="0.0" ID="CMP-019.18" LOG_CI_END="0.11189722968201557" LOG_CI_START="-0.22788112363738916" LOG_EFFECT_SIZE="-0.0579919469776868" METHOD="MH" MODIFIED="2009-07-22 12:17:44 -0400" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.0" P_Q="0.0" P_Z="0.5034719463821811" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="7" TOTAL_2="6" WEIGHT="100.0" Z="0.6690368963132611">
<NAME>Weekly Lef vs. daily Lef, at 12 months</NAME>
<GROUP_LABEL_1>Daily Lef</GROUP_LABEL_1>
<GROUP_LABEL_2>Weekly Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours weekly Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours daily Lef</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2938896225409888" CI_START="0.5917235803286195" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.11189722968201565" LOG_CI_START="-0.22788112363738916" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2009-04-09 23:23:35 -0400" MODIFIED_BY="[Empty name]" ORDER="574" O_E="0.0" SE="0.19958748666979315" STUDY_ID="STD-Jakez_x002d_Ocampo-2002" TOTAL_1="7" TOTAL_2="6" VAR="0.03983516483516486" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-020" MODIFIED="2009-07-22 12:18:26 -0400" MODIFIED_BY="[Empty name]" NO="20">
<NAME>Adverse events-for SoF</NAME>
<DICH_OUTCOME CHI2="1.0526681773283" CI_END="4.4669497489174725" CI_START="1.6741828135487558" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.734682888128633" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-020.01" LOG_CI_END="0.6500110668907765" LOG_CI_START="0.22380287933256535" LOG_EFFECT_SIZE="0.4369069731116709" METHOD="MH" MODIFIED="2009-07-22 12:18:25 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5907667948708644" P_Q="0.0" P_Z="5.8612821475878024E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="416" TOTAL_2="311" WEIGHT="100.00000000000001" Z="4.018326990850354">
<NAME>Withdrawals due to adverse events in leflunomide vs. placebo</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="23.73623705036325" CI_START="1.2258777804576517" EFFECT_SIZE="5.394230769230769" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.3754118705665634" LOG_CI_START="0.08844717334819868" LOG_EFFECT_SIZE="0.731929521957381" ORDER="580" O_E="0.0" SE="0.755969433724062" STUDY_ID="STD-Mladenovic-1995" TOTAL_1="104" TOTAL_2="102" VAR="0.5714897847250789" WEIGHT="9.520356403085861"/>
<DICH_DATA CI_END="5.332808068558648" CI_START="0.9213928286826873" EFFECT_SIZE="2.216666666666667" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="6" LOG_CI_END="0.7269559534061351" LOG_CI_START="-0.03555517223925076" LOG_EFFECT_SIZE="0.3457003905834422" ORDER="578" O_E="0.0" SE="0.4479028096950458" STUDY_ID="STD-Smolen-1999" TOTAL_1="130" TOTAL_2="91" VAR="0.2006169269327164" WEIGHT="33.278168875039945"/>
<DICH_DATA CI_END="4.983128075255149" CI_START="1.3497059792869996" EFFECT_SIZE="2.5934065934065935" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="10" LOG_CI_END="0.6975020494551781" LOG_CI_START="0.1302391718428478" LOG_EFFECT_SIZE="0.413870610649013" ORDER="579" O_E="0.0" SE="0.3332130223060138" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="118" VAR="0.11103091823430807" WEIGHT="57.20147472187421"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3310669476958843" CI_START="0.44739223581678056" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7716923076923077" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-020.02" LOG_CI_END="0.12419989941434761" LOG_CI_START="-0.34931155705473865" LOG_EFFECT_SIZE="-0.11255582882019555" METHOD="MH" MODIFIED="2009-07-22 12:18:25 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.3514478021516" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="132" WEIGHT="100.0" Z="0.9317847233630395">
<NAME>Withdrawals due to adverse events in leflunomide vs. SSZ, at 6 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3310669476958843" CI_START="0.44739223581678045" EFFECT_SIZE="0.7716923076923077" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="25" LOG_CI_END="0.12419989941434761" LOG_CI_START="-0.34931155705473876" LOG_EFFECT_SIZE="-0.11255582882019555" ORDER="582" O_E="0.0" SE="0.2781429734494531" STUDY_ID="STD-Smolen-1999" TOTAL_1="130" TOTAL_2="132" VAR="0.07736351367930316" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.01625274446452" CI_END="1.828005843191186" CI_START="1.1255412823220534" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.43439744870019" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="93" I2="66.84627964830807" I2_Q="0.0" ID="CMP-020.03" LOG_CI_END="0.26197757961533613" LOG_CI_START="0.05136142857320873" LOG_EFFECT_SIZE="0.15666950409427247" METHOD="MH" MODIFIED="2009-07-22 12:18:25 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.08243394612372468" P_Q="0.0" P_Z="0.0035467745347199245" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="683" TOTAL_2="680" WEIGHT="99.99999999999999" Z="2.915888301834034">
<NAME>Withdrawals due to adverse events in leflunomide vs. MTX, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6676684767773293" CI_START="0.9560173675128808" EFFECT_SIZE="1.2626638614662566" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="74" LOG_CI_END="0.22210971955330044" LOG_CI_START="-0.0195342180309119" LOG_EFFECT_SIZE="0.10128775076119427" ORDER="586" O_E="0.0" SE="0.14194284509374872" STUDY_ID="STD-Emery-1999" TOTAL_1="501" TOTAL_2="498" VAR="0.020147771273307948" WEIGHT="79.61859356376638"/>
<DICH_DATA CI_END="3.491772636012711" CI_START="1.269307433788133" EFFECT_SIZE="2.1052631578947367" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="19" LOG_CI_END="0.5430459572157267" LOG_CI_START="0.10356682353454011" LOG_EFFECT_SIZE="0.3233063903751334" ORDER="585" O_E="0.0" SE="0.25815221858112597" STUDY_ID="STD-Strand-1999a" TOTAL_1="182" TOTAL_2="182" VAR="0.06664256795835743" WEIGHT="20.381406436233608"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.4738364992315516" CI_START="0.7746018723248527" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.384282624369142" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-020.04" LOG_CI_END="0.39337099285656785" LOG_CI_START="-0.11092145759603844" LOG_EFFECT_SIZE="0.1412247676302647" METHOD="MH" MODIFIED="2009-07-22 12:18:25 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.27231032749326545" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="292" TOTAL_2="320" WEIGHT="100.0" Z="1.0977576921166712">
<NAME>Withdrawals due to adverse events in leflunomide vs. MTX, at 2 years</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.4738364992315516" CI_START="0.7746018723248527" EFFECT_SIZE="1.384282624369142" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="19" LOG_CI_END="0.39337099285656785" LOG_CI_START="-0.11092145759603844" LOG_EFFECT_SIZE="0.1412247676302647" ORDER="640" O_E="0.0" SE="0.2962238816837503" STUDY_ID="STD-Emery-1999" TOTAL_1="292" TOTAL_2="320" VAR="0.0877485880797885" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9000985960898424" CI_START="0.0759960563610523" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.38" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-020.05" LOG_CI_END="0.27877613707218624" LOG_CI_START="-1.119208943838566" LOG_EFFECT_SIZE="-0.42021640338318983" METHOD="MH" MODIFIED="2009-07-22 12:18:25 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.23868497028504332" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="80" TOTAL_2="76" WEIGHT="100.00000000000001" Z="1.1782801227141093">
<NAME>Withdrawals due to adverse events in leflunomide vs. SSZ, at 12 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9000985960898424" CI_START="0.0759960563610523" EFFECT_SIZE="0.38" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.27877613707218624" LOG_CI_START="-1.119208943838566" LOG_EFFECT_SIZE="-0.42021640338318983" ORDER="642" O_E="0.0" SE="0.8211833566647329" STUDY_ID="STD-Scott-2001" TOTAL_1="80" TOTAL_2="76" VAR="0.6743421052631579" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7569283366188426" CI_START="0.25296674609948216" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-020.06" LOG_CI_END="0.24475404741121923" LOG_CI_START="-0.5969365655225818" LOG_EFFECT_SIZE="-0.17609125905568127" METHOD="MH" MODIFIED="2009-07-22 12:18:25 -0400" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.4121627807455758" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="60" WEIGHT="100.0" Z="0.8200935603605042">
<NAME>Withdrawals due to adverse events in leflunomide vs. SSZ, at 24 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7569283366188426" CI_START="0.25296674609948216" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.24475404741121923" LOG_CI_START="-0.5969365655225818" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="644" O_E="0.0" SE="0.4944132324730442" STUDY_ID="STD-Scott-2001" TOTAL_1="60" TOTAL_2="60" VAR="0.24444444444444446" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.639055582384503" CI_END="0.5749665946613316" CI_START="0.09805438299384726" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.23744050766790056" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="20" I2="64.5330681568794" I2_Q="0.0" ID="CMP-020.07" LOG_CI_END="-0.24035738692026365" LOG_CI_START="-1.0085329887631695" LOG_EFFECT_SIZE="-0.6244451878417165" METHOD="MH" MODIFIED="2009-07-22 12:18:25 -0400" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.05963415019965279" P_Q="0.0" P_Z="0.0014401287470472712" Q="0.0" RANDOM="NO" SCALE="249.81" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="401" TOTAL_2="323" WEIGHT="100.00000000000001" Z="3.186485161863817">
<NAME>Withdrawals due to adverse events in leflunomide vs. MTX, at 6 months</NAME>
<GROUP_LABEL_1>leflunomide</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.42710607068105066" CI_START="0.007422509805069453" EFFECT_SIZE="0.056304520222045996" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="13" LOG_CI_END="-0.3694642556756229" LOG_CI_START="-2.12944922003239" LOG_EFFECT_SIZE="-1.2494567378540062" ORDER="652" O_E="0.0" SE="1.0338238801292448" STUDY_ID="STD-Bao-2003" TOTAL_1="291" TOTAL_2="213" VAR="1.0687918151254872" WEIGHT="66.68429402432577"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="651" O_E="0.0" SE="0.0" STUDY_ID="STD-Jiang-2001" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.7633577414555113" CI_START="0.23160229687195705" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4414371118737813" LOG_CI_START="-0.6352571378898941" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="649" O_E="0.0" SE="0.6324555320336759" STUDY_ID="STD-Lao-2001" TOTAL_1="40" TOTAL_2="40" VAR="0.39999999999999997" WEIGHT="22.210470650449498"/>
<DICH_DATA CI_END="4.038645960707643" CI_START="0.009904309609993965" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6062357833382839" LOG_CI_START="-2.0041757920103214" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="650" O_E="0.0" SE="1.5333686811054679" STUDY_ID="STD-Shuai-2002" TOTAL_1="40" TOTAL_2="40" VAR="2.351219512195122" WEIGHT="11.105235325224749"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.9678907457593895" CI_START="0.8337038714552355" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8188034188034188" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-020.08" LOG_CI_END="0.5985597055267344" LOG_CI_START="-0.07898818177303658" LOG_EFFECT_SIZE="0.25978576187684893" METHOD="MH" MODIFIED="2009-07-22 12:18:25 -0400" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.13284399204088898" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="133" WEIGHT="100.0" Z="1.502980812187663">
<NAME>Withdrawals due to adverse events in leflunomide+MTX vs. MTX, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.9678907457593895" CI_START="0.8337038714552355" EFFECT_SIZE="1.8188034188034188" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="9" LOG_CI_END="0.5985597055267344" LOG_CI_START="-0.07898818177303658" LOG_EFFECT_SIZE="0.25978576187684893" ORDER="675" O_E="0.0" SE="0.3979949829160189" STUDY_ID="STD-Kremer-2002" TOTAL_1="130" TOTAL_2="133" VAR="0.1584000064263222" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.0995420659209487" CI_START="0.7789930377783005" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.278877887788779" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-020.09" LOG_CI_END="0.3221245804811394" LOG_CI_START="-0.10846642380109116" LOG_EFFECT_SIZE="0.10682907834002411" METHOD="MH" MODIFIED="2009-07-22 12:18:25 -0400" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="0.33078739581538674" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="202" TOTAL_2="200" WEIGHT="100.0" Z="0.972529123765979">
<NAME>Withdrawals due to adverse events in leflunomide10mg vs. leflunomide20mg, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef10</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef20</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef10</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef20</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0995420659209487" CI_START="0.7789930377783005" EFFECT_SIZE="1.278877887788779" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="24" LOG_CI_END="0.3221245804811394" LOG_CI_START="-0.10846642380109116" LOG_EFFECT_SIZE="0.10682907834002411" ORDER="677" O_E="0.0" SE="0.25293128737522913" STUDY_ID="STD-Poor-2004" TOTAL_1="202" TOTAL_2="200" VAR="0.06397423613329073" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.3410684658882968" CI_START="0.7661827283676634" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3392857142857142" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-020.10" LOG_CI_END="0.3694141150732508" LOG_CI_START="-0.11566764230225164" LOG_EFFECT_SIZE="0.1268732363854996" METHOD="MH" MODIFIED="2009-07-22 12:18:25 -0400" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="0.3052414864253755" Q="0.0" RANDOM="NO" SCALE="44.58914411375222" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="56" TOTAL_2="50" WEIGHT="100.0" Z="1.0252579905829051">
<NAME>Withdrawals due to adverse events in Lef+SSZ vs. Plc+SSZ, at 24 weeks</NAME>
<GROUP_LABEL_1>Lef+SSZ</GROUP_LABEL_1>
<GROUP_LABEL_2>Plc+SSZ</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3410684658882968" CI_START="0.7661827283676634" DF="0" EFFECT_SIZE="1.3392857142857142" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" I2="0.0" ID="CMP-020.10.01" LOG_CI_END="0.3694141150732508" LOG_CI_START="-0.11566764230225164" LOG_EFFECT_SIZE="0.1268732363854996" MODIFIED="2009-04-09 23:15:04 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3052414864253755" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="50" WEIGHT="100.0" Z="1.0252579905829051">
<NAME>Overall</NAME>
<DICH_DATA CI_END="2.3410684658882968" CI_START="0.7661827283676634" EFFECT_SIZE="1.3392857142857142" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" LOG_CI_END="0.3694141150732508" LOG_CI_START="-0.11566764230225164" LOG_EFFECT_SIZE="0.1268732363854996" ORDER="680" O_E="0.0" SE="0.2849394254757951" STUDY_ID="STD-Dougados-2005" TOTAL_1="56" TOTAL_2="50" VAR="0.08119047619047619" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.831228006100619" CI_START="0.20698671201964655" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-020.11" LOG_CI_END="0.6840575341651937" LOG_CI_START="-0.6840575341651937" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2009-07-22 12:18:25 -0400" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="161.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="96" TOTAL_2="96" WEIGHT="100.0" Z="0.0">
<NAME>Withdrawals due to adverse events, Lef/Lef+MTX vs. Plc/Lef+MTX, at 48 weeks</NAME>
<GROUP_LABEL_1>Plc/Lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef/Lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Plc/Lef+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef/Lef+MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.831228006100619" CI_START="0.20698671201964655" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6840575341651937" LOG_CI_START="-0.6840575341651937" LOG_EFFECT_SIZE="0.0" ORDER="693" O_E="0.0" SE="0.8036375634160796" STUDY_ID="STD-Kremer-2004" TOTAL_1="96" TOTAL_2="96" VAR="0.6458333333333334" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="156.85381459475747" CI_START="0.4888678614231671" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="8.756756756756756" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-020.12" LOG_CI_END="2.195495084954766" LOG_CI_START="-0.31080851267553233" LOG_EFFECT_SIZE="0.9423432861396172" METHOD="MH" MODIFIED="2009-07-22 12:18:25 -0400" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="0.0" P_Z="0.14052174116414637" Q="0.0" RANDOM="NO" SCALE="431.01" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="36" TOTAL_2="35" WEIGHT="100.0" Z="1.4738508963184394">
<NAME>Withdrawals due to adverse events, Lef vs. CsA, at 12 months</NAME>
<GROUP_LABEL_1>Lef</GROUP_LABEL_1>
<GROUP_LABEL_2>CsA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CsA</GRAPH_LABEL_2>
<DICH_DATA CI_END="156.85381459475747" CI_START="0.4888678614231671" EFFECT_SIZE="8.756756756756756" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.195495084954766" LOG_CI_START="-0.31080851267553233" LOG_EFFECT_SIZE="0.9423432861396172" ORDER="695" O_E="0.0" SE="1.4722151396509335" STUDY_ID="STD-Karanikolas-2006" TOTAL_1="36" TOTAL_2="35" VAR="2.1674174174174174" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.631077436208686" CI_START="0.10052527997788245" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5142857142857142" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-020.13" LOG_CI_END="0.42013363015458804" LOG_CI_START="-0.9977247086485272" LOG_EFFECT_SIZE="-0.2887955392469696" METHOD="MH" MODIFIED="2009-07-22 12:18:25 -0400" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="0.0" P_Z="0.42462220237766224" Q="0.0" RANDOM="NO" SCALE="431.01" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="36" WEIGHT="100.0" Z="0.7984279392787537">
<NAME>Withdrawals due to adverse events, Lef vs. Lef+CsA, at 12 months</NAME>
<GROUP_LABEL_1>Lef+CsA</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CsA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.631077436208686" CI_START="0.10052527997788245" EFFECT_SIZE="0.5142857142857142" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.42013363015458804" LOG_CI_START="-0.9977247086485272" LOG_EFFECT_SIZE="-0.2887955392469696" ORDER="697" O_E="0.0" SE="0.8328570067249201" STUDY_ID="STD-Karanikolas-2006" TOTAL_1="35" TOTAL_2="36" VAR="0.6936507936507936" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.817176968888557E-33" CI_END="8.02767124757876" CI_START="0.02669948711964154" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.462962962962963" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="100.0" I2_Q="0.0" ID="CMP-020.14" LOG_CI_END="0.9045895787773421" LOG_CI_START="-1.5734970810792037" LOG_EFFECT_SIZE="-0.33445375115093084" METHOD="MH" MODIFIED="2009-07-22 12:18:25 -0400" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.5967699651056404" Q="0.0" RANDOM="NO" SCALE="431.01" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="49" WEIGHT="100.0" Z="0.529051156579079">
<NAME>Withdrawals due to adverse events, Lef vs. Lef+MTX, at 3 months</NAME>
<GROUP_LABEL_1>Lef+MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lef+MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.02767124757876" CI_START="0.02669948711964154" EFFECT_SIZE="0.46296296296296297" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.9045895787773421" LOG_CI_START="-1.5734970810792037" LOG_EFFECT_SIZE="-0.3344537511509309" ORDER="698" O_E="0.0" SE="1.4556403707265366" STUDY_ID="STD-Antony-2006" TOTAL_1="11" TOTAL_2="49" VAR="2.118888888888889" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8134070754170961" CI_START="0.40514558893624897" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-020.15" LOG_CI_END="0.2584953058951849" LOG_CI_START="-0.39238888515641135" LOG_EFFECT_SIZE="-0.06694678963061322" METHOD="MH" MODIFIED="2009-07-22 12:18:25 -0400" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="1.0" P_Q="0.0" P_Z="0.6868123035416808" Q="0.0" RANDOM="NO" SCALE="431.01" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="233" TOTAL_2="233" WEIGHT="100.0" Z="0.40318477038008155">
<NAME>Withdrawals due to adverse events, Lef+MTX vs. MTX, at 36 months</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef+MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8134070754170961" CI_START="0.40514558893624897" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.2584953058951849" LOG_CI_START="-0.39238888515641135" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="700" O_E="0.0" SE="0.3823325957524159" STUDY_ID="STD-Amit-2006" TOTAL_1="233" TOTAL_2="233" VAR="0.1461782137747803" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="90.1806363901012" CI_START="0.2772213747955338" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-020.16" LOG_CI_END="1.9551132957269735" LOG_CI_START="-0.5571732870549357" LOG_EFFECT_SIZE="0.6989700043360189" METHOD="MH" MODIFIED="2009-07-22 12:18:26 -0400" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Q="0.0" P_Z="0.27544678733539196" Q="0.0" RANDOM="NO" SCALE="431.01" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0" Z="1.0906049048396544">
<NAME>Withdrawals due to adverse events, weekly Lef vs. daily Lef</NAME>
<GROUP_LABEL_1>daily Lef</GROUP_LABEL_1>
<GROUP_LABEL_2>weekly Lef</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours daily Lef</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours weekly Lef</GRAPH_LABEL_2>
<DICH_DATA CI_END="90.1806363901012" CI_START="0.2772213747955338" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9551132957269735" LOG_CI_START="-0.5571732870549357" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="702" O_E="0.0" SE="1.4757295747452437" STUDY_ID="STD-Jakez_x002d_Ocampo-2002" TOTAL_1="8" TOTAL_2="8" VAR="2.1777777777777776" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.233573242366921" CI_START="0.46296588904747427" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-020.17" LOG_CI_END="0.6267070776261904" LOG_CI_START="-0.3344510062697144" LOG_EFFECT_SIZE="0.14612803567823798" METHOD="MH" MODIFIED="2009-07-22 12:18:26 -0400" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="1.0" P_Q="0.0" P_Z="0.5512022282755797" Q="0.0" RANDOM="NO" SCALE="431.01" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="83" TOTAL_2="83" WEIGHT="100.0" Z="0.5959595863773619">
<NAME>Withdrawals due to adverse events, Lef+MTX vs. MTX, at 24 months</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Lef+MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lef+MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.233573242366921" CI_START="0.46296588904747427" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6267070776261904" LOG_CI_START="-0.3344510062697144" LOG_EFFECT_SIZE="0.14612803567823798" ORDER="704" O_E="0.0" SE="0.5645890162897027" STUDY_ID="STD-Amit-2004" TOTAL_1="83" TOTAL_2="83" VAR="0.3187607573149742" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.931409775025128" CI_START="0.046558835083477614" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4791666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-020.18" LOG_CI_END="0.6929710916891421" LOG_CI_START="-1.331997894405131" LOG_EFFECT_SIZE="-0.31951340135799433" METHOD="MH" MODIFIED="2009-07-22 12:18:26 -0400" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="1.0" P_Q="0.0" P_Z="0.5362372749139819" Q="0.0" RANDOM="NO" SCALE="431.01" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="23" WEIGHT="100.0" Z="0.6185129387560958">
<NAME>Withdrawals due to adverse events, weekly Lef200 vs. weekly Lef100, at 6 months</NAME>
<GROUP_LABEL_1>weekly Lef100</GROUP_LABEL_1>
<GROUP_LABEL_2>weekly Lef200</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours weekly Lef100</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours weekly Lef200</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.931409775025128" CI_START="0.046558835083477614" EFFECT_SIZE="0.4791666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6929710916891421" LOG_CI_START="-1.331997894405131" LOG_EFFECT_SIZE="-0.31951340135799433" ORDER="706" O_E="0.0" SE="1.1894768061899181" STUDY_ID="STD-Rozman-1994a" TOTAL_1="24" TOTAL_2="23" VAR="1.414855072463768" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2009-07-22 11:50:44 -0400" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2009-07-22 11:50:44 -0400" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-07-22 11:50:41 -0400" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-07-22 11:50:44 -0400" MODIFIED_BY="[Empty name]">
<P>1. exp "rheumatoid arthritis"/<BR/>2. (rheumat$ arthriti$).tw.<BR/>3. 1 or 2<BR/>4. exp "isoxazole"/<BR/>5. isoxazole$.tw.<BR/>6. isoxazole$.rw.<BR/>7. leflunomide$.tw.<BR/>8. leflunomide$.rn.<BR/>9. or/4-8<BR/>10. 3 and 9<BR/>11. clinical trial.pt.<BR/>12. randomized controlled trial.pt.<BR/>13. dt.fs.<BR/>14. tu.fs.<BR/>15. random$.tw.<BR/>16. (double adj blind$).tw.<BR/>17. placebo$.tw.<BR/>18. or/11-17<BR/>19. 10 and 18<BR/>20. limit 19 to human</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>